

WEST Search History

DATE: Tuesday, November 16, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L33	L32 AND CNS damage	24
<input type="checkbox"/>	L32	L31 AND tau	306
<input type="checkbox"/>	L31	L21 AND L28	4159
<input type="checkbox"/>	L30	L21 AND L28	4159
<input type="checkbox"/>	L29	L21 AND L28	4159
<input type="checkbox"/>	L28	anoxia OR ischemia	30628
<input type="checkbox"/>	L27	L26 AND L21	18
<input type="checkbox"/>	L26	L25 AND tau	37
<input type="checkbox"/>	L25	530/387.1.CCLS.	2128
<input type="checkbox"/>	L24	L22 AND ischemia	32
<input type="checkbox"/>	L23	L22 AND anoxia	8
<input type="checkbox"/>	L22	L20 AND L21	115
<input type="checkbox"/>	L21	CSF OR cerebrospinal fluid	45327
<input type="checkbox"/>	L20	L19 AND tau	294
<input type="checkbox"/>	L19	435/7.1,7.21.CCLS.	10729
<input type="checkbox"/>	L18	VanGool-Stefaan.IN.	0
<input type="checkbox"/>	L17	L16	0
<input type="checkbox"/>	L16	Van-Gool.IN.	0
<input type="checkbox"/>	L15	Van-Gool-S.IN.	2
<input type="checkbox"/>	L14	Van-Gool-Stefaan.IN.	1
<input type="checkbox"/>	L13	Van-de-Voorde.IN.	0
<input type="checkbox"/>	L12	Van-de-Voorde-A.IN.	8
<input type="checkbox"/>	L11	VandeVoorde-Andre.IN.	0
<input type="checkbox"/>	L10	Van-de-Voorde-Andre.IN.	19
<input type="checkbox"/>	L9	Vanderstichele.IN.	11
<input type="checkbox"/>	L8	Vanderstichele-H.IN.	4
<input type="checkbox"/>	L7	Vanderstichele-Hugo.IN.	6
<input type="checkbox"/>	L6	VanMechelen.IN.	40
<input type="checkbox"/>	L5	VanMechelen-E.IN.	9
<input type="checkbox"/>	L4	VanMechelen-Eugeen.IN.	27
<input type="checkbox"/>	L3	Hulstaert.IN.	10
<input type="checkbox"/>	L2	Hulstaert-F.IN.	3
<input type="checkbox"/>	L1	(Hulstaert-Frank.IN.)	3

END OF SEARCH HISTORY

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 20020019016 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 3

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Hulstaert, Frank	Gentbrugge		BE	

US-CL-CURRENT: [435/7.21](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 6670137 B2

L1: Entry 2 of 3

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137
DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

US-CL-CURRENT: [435/7.1](#); [435/7.21](#), [435/7.8](#), [436/501](#), [530/300](#), [530/350](#), [530/387.1](#)

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from

another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 6613535 B1

L1: Entry 3 of 3

File: USPT

Sep 2, 2003

US-PAT-NO: 6613535
DOCUMENT-IDENTIFIER: US 6613535 B1

TITLE: HLA-B27 assay

DATE-ISSUED: September 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrecht; Joachim	Heidelberg			DE
<u>Hulstaert; Frank</u>	Zwijnaarde			BE
Becker; Rosette	Palo Alto	CA		

US-CL-CURRENT: 435/7.24; 435/7.1, 435/967, 435/968, 436/10, 436/16, 436/172, 436/518, 436/529, 436/536, 436/546, 436/8, 436/805, 436/811, 530/388.7, 530/388.75, 530/391.3

ABSTRACT:

This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.

8 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
-------	-----------

Display Format: **Change Format**

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6613535 B1

Using default format because multiple data bases are involved.

L2: Entry 1 of 3

File: DWPI

Sep 2, 2003

DERWENT-ACC-NO: 2003-800186

DERWENT-WEEK: 200375

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Establishing decision point to determine if unknown sample of cells is positive or negative for marker utilizes fluorescence channel such that samples having median fluorescence channel that exceeds decision point are classed positive

INVENTOR: ALBRECHT, J; BECKER, R ; HULSTAERT, F

PRIORITY-DATA: 1992US-0968553 (October 29, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6613535 B1	September 2, 2003		009	G01N033/53

INT-CL (IPC): G01 N 33/53

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Footnote	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	----------

☐ 2. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

L2: Entry 2 of 3

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F ; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004502939 W	January 29, 2004		059	G01N033/53
<u>WO 200203073 A1</u>	January 10, 2002	E	037	G01N033/68
<u>US 20020019016 A1</u>	February 14, 2002		000	G01N033/567

AU 200179678 A	January 14, 2002		000	G01N033/68
EP 1295129 A1	March 26, 2003	E	000	G01N033/68
US 6670137 B2	December 30, 2003		000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: US20020019016A
BASIC-ABSTRACT:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

ABSTRACTED-PUB-NO:

WO 200203073A EQUIVALENT-ABSTRACTS:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an

individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

Full	Title	Citation	Front	Remew	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	-------	----------------	------	-----------	--------	------	----------

☐ 3. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L2: Entry 3 of 3

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F ; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69920487 E</u>	October 28, 2004		000	G01N033/68
<u>WO 200014546 A1</u>	March 16, 2000	E	040	G01N033/68
<u>AU 9959746 A</u>	March 27, 2000		000	G01N033/68
<u>BR 9913112 A</u>	May 8, 2001		000	G01N033/68
<u>EP 1112500 A1</u>	July 4, 2001	E	000	G01N033/68
<u>CN 1325491 A</u>	December 5, 2001		000	G01N033/68
<u>JP 2002524740 W</u>	August 6, 2002		042	G01N033/53
<u>AU 772151 B2</u>	April 8, 2004		000	G01N033/68
<u>EP 1112500 B1</u>	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator or early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Blwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Hulstaert-F.IN.	3

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 10 of 10 returned.

☐ 1. Document ID: US 20020019016 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 10

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Hulstaert, Frank	Gentbrugge		BE	

US-CL-CURRENT: 435/7.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 6670137 B2

L3: Entry 2 of 10

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137
DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.8, 436/501, 530/300, 530/350, 530/387.1

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.4&ref=3&dbname=PGPB,USPT,US...> 11/16/04

another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 3. Document ID: US 6613535 B1

L3: Entry 3 of 10

File: USPT

Sep 2, 2003

US-PAT-NO: 6613535
DOCUMENT-IDENTIFIER: US 6613535 B1

TITLE: HLA-B27 assay

DATE-ISSUED: September 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Albrecht; Joachim	Heidelberg			DE
Hulstaert; Frank	Zwijnaarde			BE
Becker; Rosette	Palo Alto	CA		

US-CL-CURRENT: 435/7.24; 435/7.1, 435/967, 435/968, 436/10, 436/16, 436/172, 436/518, 436/529, 436/536, 436/546, 436/8, 436/805, 436/811, 530/388.7, 530/388.75, 530/391.3

ABSTRACT:

This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.

8 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 4. Document ID: US 5225049 A

L3: Entry 4 of 10

File: USPT

Jul 6, 1993

US-PAT-NO: 5225049

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.4&ref=3&dbname=PGPB,USPT,US...> 11/16/04

DOCUMENT-IDENTIFIER: US 5225049 A

TITLE: Process for refining organic-solvent containing crude polyol fatty-acid polyester products

DATE-ISSUED: July 6, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Barmiento; Bart	Delft			NL
Van Buuren; Jan	Maasland			NL
Hulstaert; Alexander M.	Vlaardingen			NL

US-CL-CURRENT: 203/34; 203/71, 203/DIG.21, 203/DIG.6, 536/119, 536/127, 554/175, 554/176, 554/191

ABSTRACT:

A process for refining organic-solvent containing crude polyol fatty-acid polyester reaction product, including the steps of distilling the crude reaction product to substantially remove the organic solvent, and subsequently subjecting the distilled reaction product to a bleaching treatment. The process allows an economic use of bleaching agents while achieving good color and color stability of the refined product.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Publ	Draw Desc
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 5. Document ID: JP 04021656 A

L3: Entry 5 of 10

File: JPAB

Jan 24, 1992

PUB-NO: JP404021656A

DOCUMENT-IDENTIFIER: JP 04021656 A

TITLE: REFINING OF ORGANIC-SOLVENT CONTAINING CRUDE POLYOL FATTY-ACID POLYESTER PRODUCT

PUBN-DATE: January 24, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
BARMENTLO, BART	
VAN, BUUREN JAN	
HULSTAERT, ALEXANDER MARINUS M	

INT-CL (IPC): C07C 69/33; C07H 1/06; C07H 13/06; A23L 1/307

ABSTRACT:

PURPOSE: To prevent the dissoloration in the followed high temperature refining treatment by distilling the subject crude reaction product to remove the organic solvent, and subjecting the distilled reaction product to a bleaching treatment for reducing the coloring property and quantity of a discolouring component.

CONSTITUTION: A crude reaction product obtained by reacting a polyol such as monosaccharide or disaccharide with a fatty acid lower alkyl ester in the presence of an ester exchange catalyst and an emulsifier, is distilled preferably at 200-240

COPYRIGHT: (C)1992,JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	HMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 6. Document ID: EP 435364 A2

L3: Entry 6 of 10

File: EPAB

Jul 3, 1991

PUB-NO: EP000435364A2

DOCUMENT-IDENTIFIER: EP 435364 A2

TITLE: Process for refining organic-solvent containing crude polyol fatty-acid polyester products.

PUBN-DATE: July 3, 1991

INVENTOR-INFORMATION:

NAME

COUNTRY

BARMENTLO, BART

NL

VAN, BUUREN JAN

NL

HULSTAERT, ALEXANDER MARINUS MA

NL

INT-CL (IPC): C07H 13/06

EUR-CL (EPC): C07H013/06

ABSTRACT:

The present invention pertains to a process for refining organic-solvent containing crude polyol fatty-acid polyester reaction product, comprising the steps of distilling the crude reaction product to substantially remove the organic solvent, and subsequently subjecting the distilled reaction product to a bleaching treatment. The process allows an economic use of bleaching agents while achieving good colour and colour stability of the refined product.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	HMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 7. Document ID: US 6613535 B1

L3: Entry 7 of 10

File: DWPI

Sep 2, 2003

DERWENT-ACC-NO: 2003-800186

DERWENT-WEEK: 200375

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Establishing decision point to determine if unknown sample of cells is positive or negative for marker utilizes fluorescence channel such that samples having median fluorescence channel that exceeds decision point are classed positive

INVENTOR: ALBRECHT, J; BECKER, R ; HULSTAERT, F

PRIORITY-DATA: 1992US-0968553 (October 29, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 6613535 B1	September 2, 2003		009	G01N033/53

INT-CL (IPC): G01 N 33/53

ABSTRACTED-PUB-NO: US 6613535B

BASIC-ABSTRACT:

NOVELTY - Establishing a decision point to determine if an unknown sample of cells is positive or negative comprising utilizing a fluorescence channel such that samples having a median fluorescence channel that exceeds the decision point are classed positive for a marker, is new.

DETAILED DESCRIPTION - Establishing a decision point in order to determine if an unknown sample of cells is positive or negative for a marker comprises tagging sample of cells which are known to be positive or negative for the presence of the marker with a fluorescent marker that is specific for the marker of interest; analyzing the samples of tagged cells by flow cytometry and recording the median fluorescence channel for each sample; setting acceptance criteria for assay sensitivity and specificity; determining the fluorescence channel number at which the criteria are met; and utilizing the fluorescence channel number as the decision point such that samples having a median fluorescence channel that exceeds the decision point are classed positive for the marker.

USE - The method is useful for establishing a decision point in order to determine if an unknown sample of cells is positive or negative for a marker, e.g. is HLA-B27. It is used in the analysis of blood cells from patients having diseases, e.g. ankylosing spondylitis.

ADVANTAGE - The invention achieves a desired sensitivity and specificity.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 8. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

L3: Entry 8 of 10

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004502939 W	January 29, 2004		059	G01N033/53
WO 200203073 A1	January 10, 2002	E	037	G01N033/68

<u>US 20020019016 A1</u>	February 14, 2002	000	G01N033/567
<u>AU 200179678 A</u>	January 14, 2002	000	G01N033/68
<u>EP 1295129 A1</u>	March 26, 2003	E 000	G01N033/68
<u>US 6670137 B2</u>	December 30, 2003	000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: US20020019016A

BASIC-ABSTRACT:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

ABSTRACTED-PUB-NO:

WO 200203073A EQUIVALENT-ABSTRACTS:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from

Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 9. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L3: Entry 9 of 10

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69920487 E</u>	October 28, 2004		000	G01N033/68
<u>WO 200014546 A1</u>	March 16, 2000	E	040	G01N033/68
<u>AU 9959746 A</u>	March 27, 2000		000	G01N033/68
<u>BR 9913112 A</u>	May 8, 2001		000	G01N033/68
<u>EP 1112500 A1</u>	July 4, 2001	E	000	G01N033/68
<u>CN 1325491 A</u>	December 5, 2001		000	G01N033/68
<u>JP 2002524740 W</u>	August 6, 2002		042	G01N033/53
<u>AU 772151 B2</u>	April 8, 2004		000	G01N033/68
<u>EP 1112500 B1</u>	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.4&ref=3&dbname=PGPB,USPT,US...> 11/16/04

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator or early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 10. Document ID: EP 435364 A, AU 9068098 A, CA 2032676 A, DE 69018413 E, EP 435364 B1, JP 04021656 A, US 5225049 A

L3: Entry 10 of 10

File: DWPI

Jul 3, 1991

DERWENT-ACC-NO: 1991-194939

DERWENT-WEEK: 199127

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Refining organic solvent contg. poly-ol fatty acid polyester prods. - by distn. of polyester reaction prod. to remove organic solvent and subjecting distillate to bleaching treatment

INVENTOR: BARMENTLO, B; HULSTAERT, A M M ; VAN BUUREN, J ; VANBUUREN, J ; HULSTAERT, A M

PRIORITY-DATA: 1989EP-0203313 (December 21, 1989), 1990EP-0203229 (December 7, 1990)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 435364 A</u>	July 3, 1991		000	
<u>AU 9068098 A</u>	June 27, 1991		000	
<u>CA 2032676 A</u>	June 22, 1991		000	
<u>DE 69018413 E</u>	May 11, 1995		000	C07H013/06
<u>EP 435364 B1</u>	April 5, 1995	E	009	C07H013/06
<u>JP 04021656 A</u>	January 24, 1992		000	
<u>US 5225049 A</u>	July 6, 1993		006	B01D003/34

INT-CL (IPC): A23D 9/00; B01D 3/32; B01D 3/34; C07C 67/54; C07C 69/58; C07H 1/06; C07H 13/06; C11B 3/12

ABSTRACTED-PUB-NO: EP 435364A

BASIC-ABSTRACT:

Process (I) for refining an org. solvent-contg. crude polyol fatty-acid polyester reaction prod. (II) involves: (A) distilling the crude reaction prod. to remove (70% or more) the org. solvent at 200-240 deg. C and then (B) subjecting the distilled reaction prod. to a bleaching treatment. Pref. prior to (A) soap and metal ion components are removed from (II) pref. by a bleaching treatment. Pref. removal of

soap and metal ions also comprise contacting (II) with an acid to convert the soap into the corresp. free fatty acids. After (B), a further refining treatment at 180-260 deg.C takes place.

USE/ADVANTAGE - (I) provides a bleaching treatment used for refining (II) where a more efficient use of absorbent is obt'd. The refined (II) are used low-calorie fat-replacers in edible prods. e.g. cooking oil.

ABSTRACTED-PUB-NO:

EP 435364B EQUIVALENT-ABSTRACTS:

A process for refining a crude polyol fatty acid polyester reaction obtained by transesterification of a polyol and a fatty acid lower alkyl ester in the presence of a fatty acid soap emulsifier including alkali metal ions and a transesterification catalyst, comprising the steps of: (a) substantially removing alkali metals of said emulsifier and said transesterification catalyst from said crude reaction product including subjecting said reaction product to a bleaching step for removal of residual alkali metal ions; (b) distilling said crude reaction product resulting from step (a) to substantially remove organic solvent consisting essentially of said fatty acid lower alkyl ester; and (c) subjecting the distilled reaction product resulting from step (b) to a bleaching treatment.

US 5225049A

Crude polyol fatty acid polyester reaction prod. obt'd. by transesterification of polyol end fatty acid lower alkyl ester contg. fatty acid soap emulsifier and metal ions, is refined.

Process comprises (a) removing alkali metal ions of the emulsifier and catalyst from the reaction prod. including a bleaching step to remove residual alkali metal ions; (b) distilling to remove the fatty acid ester solvent; then (c) bleaching to remove coloured matter.

ADVANTAGE - Allows economic use of bleaching agents, while achieving good colour and colour stability of refined prod..

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Abstract	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Hulstaert.IN.	10

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 27 of 27 returned.

☐ 1. Document ID: US 20040091942 A1

Using default format because multiple data bases are involved.

L4: Entry 1 of 27

File: PGPB

May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091942

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040091942 A1

TITLE: Diagnosis of tauopathies

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Vanmechelen, Eugene</u>	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040072261 A1

L4: Entry 2 of 27

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072261

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072261 A1

TITLE: Method for the diagnosis and differential diagnosis of neurological diseases

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kostanjevecki, Vesna	Sint-Denijs-Westrem		BE	
<u>Vanmechelen, Eugene</u>	Nazareth-Eke		BE	
De Brabandere, Veronique	Gent		BE	

US-CL-CURRENT: 435/7.2

ABSTRACT:

A method is provided for the screening, diagnosis and/or prognosis of neurological diseases. More specifically, new biomarkers are provided for the screening, diagnosis

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.5&ref=4&dbname=PGPB,USPT,US...> 11/16/04

and/or prognosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression. The method further provides for the differential diagnosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040038430 A1

L4: Entry 3 of 27

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038430

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040038430 A1

TITLE: Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/518; 530/388.1

ABSTRACT:

The present invention relates more particularly to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau (PHF-tau) residing in the region spanning positions (143-254), and with said monoclonal antibody being characterized by the fact that it is capable of specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040014142 A1

L4: Entry 4 of 27

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014142

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014142 A1

TITLE: Differential diagnosis of neurodegeneration

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
VanMechelen, Eugeen	Nazareth Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to new methods for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and .alpha.-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and/or differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20030194742 A1

L4: Entry 5 of 27

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194742

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194742 A1

TITLE: DIAGNOSIS OF TAUOPATHIES

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugeen	Nazareth - Eke		BE	
Vanderstichele, Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/350

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20030143760 A1

L4: Entry 6 of 27

File: PGPB

Jul 31, 2003

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.5&ref=4&dbname=PGPB,USPT,US...> 11/16/04

PGPUB-DOCUMENT-NUMBER: 20030143760
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143760 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
<u>Vanmechelen, Eugene</u>	Nazareth-Eke		BE	
Mercken, Marc	Turnhout		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 436/543; 435/338, 435/70.21, 530/388.26

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 7. Document ID: US 20030138972 A1

L4: Entry 7 of 27

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138972
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138972 A1

TITLE: Monoclonal antibodies specific PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
<u>Vanmechelen, Eugene</u>	Nazareth		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/518; 435/338, 530/388.26

ABSTRACT:

A peptide from 6 to 100 amino acids long, including an amino acid sequence depicted by one of a) Val-Arg-Thr-Pro-Pro (amino acid 229-233; human tau numbering, SEQ ID NO 2) wherein the peptide is able to form an immunological complex with the monoclonal antibody AT180 produced by the hybridoma deposited at the ECACC on Dec. 22, 1992 under No.92122204 and b) Pro-Lys-Thr-Pro-Pro (amino acid 179-183; human tau numbering, SEQ ID NO 3) wherein the peptide is able to form an immunological complex with the monoclonal antibody AT270 produced by the hybridoma deposited at the ECACC on Jul. 7, 1993 under No.93070774, with Thr being phosphorylated. A method of detecting PHF-tau protein one of the peptides is also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20020019016 A1

L4: Entry 8 of 27

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
<u>Vanmechelen, Eugeen</u>	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Hulstaert, Frank	Gentbrugge		BE	

US-CL-CURRENT: 435/7.21

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 9. Document ID: US 20020001857 A1

L4: Entry 9 of 27

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001857

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001857 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
<u>Vanmechelen, Eugene</u>	Nazareth-Eke		BE	
Mercken, Marc	Turnhout		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/543; 435/70.21, 530/388.1

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 10. Document ID: US 20010018191 A1

L4: Entry 10 of 27

File: PGPB

Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018191

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010018191 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mercken, Marc	Somerville	MA	US	
Mandelkow, Eva-Maria	Hamburg		DE	
Vandermeeren, Marc	Geel		BE	
<u>Vanmechelen, Eugene</u>	Nazareth-Eke		BE	
Andre, Van De Voorde	Lokeren		BE	

US-CL-CURRENT: 435/7.2; 530/388.26

ABSTRACT:

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 6680173 B2

L4: Entry 11 of 27

File: USPT

Jan 20, 2004

US-PAT-NO: 6680173

DOCUMENT-IDENTIFIER: US 6680173 B2

TITLE: Diagnosis of tauopathies

DATE-ISSUED: January 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugeen	Nazareth-Eke			BE
Vanderstichele; Hugo	Ghent			BE

US-CL-CURRENT: 435/7.1; 436/8

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

7 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 12. Document ID: US 6670137 B2

L4: Entry 12 of 27

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugeen	Nazareth-Eke			BE
Vanderstichele; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 13. Document ID: US 6500674 B1

L4: Entry 13 of 27

File: USPT

Dec 31, 2002

US-PAT-NO: 6500674

DOCUMENT-IDENTIFIER: US 6500674 B1

**** See image for Certificate of Correction ****

TITLE: Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 436/518; 435/7.1, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 436/536, 436/63

ABSTRACT:

A method for the diagnosis of brain/neurological disease involving abnormally phosphorylated tau protein using at least one antibody chosen from the group consisting of monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

(SEQ ID NO 1) 143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile Ala Thr 160 Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys Gly Gln 170 Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro 180 Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro 190 200 Lys Ser Gly Asp Arg Ser Gly Tyr Ser Ser Pro Gly 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg Thr

Pro 220 Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys 230 Val Ala Val Val Arg Thr
Pro Pro Lys Ser Pro Ser 240 Ser Ala Lys Ser Arg Leu Gln Thr Ala Pro Val Pro 250 Met
Pro Asp Leu Lys COOH

with each monoclonal body specifically detecting abnormally phosphorylated tau
protein (PHF-tau) in cerebrospinal fluid (CSF).

32 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 14. Document ID: US 6238892 B1

L4: Entry 14 of 27

File: USPT

May 29, 2001

US-PAT-NO: 6238892

DOCUMENT-IDENTIFIER: US 6238892 B1

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mercken; Marc	Somerville	MA		
Mandelkow; Eva-Maria	Hamburg			DE
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/326, 435/331, 530/388.1

ABSTRACT:

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

3 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 15. Document ID: US 6232437 B1

L4: Entry 15 of 27

File: USPT

May 15, 2001

US-PAT-NO: 6232437

DOCUMENT-IDENTIFIER: US 6232437 B1

TITLE: Isolated human tau peptide epitope which specifically binds monoclonal antibody AT120.

DATE-ISSUED: May 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
<u>Vanmechelen; Eugene</u>	Nazareth-Eke			BE
Mercken; Marc	Sommerville	MA		
Van de Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 530/324; 530/327, 530/329, 530/402

ABSTRACT:

An isolated human tau peptide epitope which specifically binds monoclonal antibody AT120 consisting of the amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 3, 4, 15, 16, 17, 18, 19 and 20.

2 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Index	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	-------	----------

☐ 16. Document ID: US 6121003 A

L4: Entry 16 of 27

File: USPT

Sep 19, 2000

US-PAT-NO: 6121003

DOCUMENT-IDENTIFIER: US 6121003 A

TITLE: Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
<u>Vanmechelen; Eugene</u>	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/331, 435/7.92, 435/975, 436/503, 436/547, 436/548, 436/811, 530/387.9, 530/388.1

ABSTRACT:

The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which neurofibrillary tangle (NFT) is not a pathological

hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 17. Document ID: US 6010913 A

L4: Entry 17 of 27

File: USPT

Jan 4, 2000

US-PAT-NO: 6010913
DOCUMENT-IDENTIFIER: US 6010913 A

TITLE: Isolated human tau peptide

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
<u>Vanmechelen; Eugene</u>	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 436/543; 436/544, 436/545, 436/546, 530/300, 530/324

ABSTRACT:

The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 18. Document ID: US 6008024 A

L4: Entry 18 of 27

File: USPT

Dec 28, 1999

US-PAT-NO: 6008024
DOCUMENT-IDENTIFIER: US 6008024 A

TITLE: Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
<u>Vanmechelen; Eugeen</u>	Nazareth			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/331, 436/548, 530/387.9, 530/388.1

ABSTRACT:

Monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile - 160 Ala Thr Pro Arg Gly Ala Ala Pro Pro Gly - 170 Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile - 180 Pro Ala Lys Thr Pro Pro Ala Pro Lys Thr - 190 Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser - 200 Gly Asp Arg Ser Gly Tyr Ser Ser Pro Gly - 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg - 220 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg - 230 Glu Pro Lys Lys Val Ala Val Val Arg Thr - 240 Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser - 250 Arg Leu Gln Thr Ala Pro Val Pro Met Pro - Asp Leu Lys COOH

with each monoclonal antibody specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

8 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 19. Document ID: US 5861257 A

L4: Entry 19 of 27

File: USPT

Jan 19, 1999

US-PAT-NO: 5861257

DOCUMENT-IDENTIFIER: US 5861257 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Tokyo			JP
<u>Vanmechelen; Eugeen</u>	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.92, 435/7.95, 436/518, 436/63, 436/811

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

4 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 20. Document ID: US 5843779 A

L4: Entry 20 of 27

File: USPT

Dec 1, 1998

US-PAT-NO: 5843779
DOCUMENT-IDENTIFIER: US 5843779 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
<u>Vanmechelen; Eugene</u>	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/331; 435/70.21, 530/388.1

ABSTRACT:

The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 21. Document ID: JP 2004045417 A

L4: Entry 21 of 27

File: JPAB

Feb 12, 2004

PUB-NO: JP02004045417A

DOCUMENT-IDENTIFIER: JP 2004045417 A

TITLE: MONOCLONAL ANTIBODY SPECIFIC TO PHF-TAU, HYBRIDOMA SECRETING THE SAME, ANTIGEN RECOGNITION BY USING THE ANTIBODY, AND ITS APPLICATION

PUBN-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

VANDERMEEREN, MARC

VANMECHELEN, EUGEN

VOOR, DE ANDRE VAN DE

INT-CL (IPC): G01 N 33/53; C07 K 16/18; G01 N 33/577

ABSTRACT:

PROBLEM TO BE SOLVED: To provide a method for specifically detecting τ -protein (PHF- τ) being abnormally phosphorylated in cerebrospinal fluid (CSF), and to provide a method for using monoclonal antibodies or the like forming an immune complex in conjunction with a phosphorylated antigenic epitope belonging to the τ -protein (PHF- τ) existing in a region of (143-254) positions and being abnormally phosphorylated therein.

SOLUTION: The method for measuring the τ -protein phosphorylated abnormally includes step (a) in which a level of the abnormally phosphorylated τ -protein in the CSF is detected, step (b) in which the level obtained by the step (a) is compared to a level with a predetermined range, and step (c) in which the level obtained by the step (a) is determined whether it belongs to a level predetermined as an index of the CSF acquired from Alzheimer's patients.

COPYRIGHT: (C)2004,JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 22. Document ID: JP 2004043487 A

L4: Entry 22 of 27

File: JPAB

Feb 12, 2004

PUB-NO: JP02004043487A

DOCUMENT-IDENTIFIER: JP 2004043487 A

TITLE: MONOCLONAL ANTIBODY TO MICROTUBULAR ASSOCIATED PROTEIN TAU

PUBN-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

MERCKEN, MARC

MANDELKOW, EVA-MARIA

VANDERMEEREN, MARC

VANMECHELEN, EUGEN

VOOR, DE ANDRE VAN DE

INT-CL (IPC): C07 K 16/18; C07 K 14/47; C12 N 5/10; C12 N 15/02; C12 P 21/02; C12 P 21/08; G01 N 33/53; G01 N 33/577

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain a monoclonal antibody forming an immune complex with a phosphorylated epitope of an antigen belonging to a human abnormally-phosphorylated tau protein.

SOLUTION: This monoclonal antibody forms the immune complex with the phosphorylated epitope which exists in the human abnormally-phosphorylated tau protein obtained from a brain homogenate separated from the cerebral cortex of a patient who has Alzheimer's disease or died due to the Alzheimer's disease, but not exists in a normal human tau protein.

COPYRIGHT: (C)2004,JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 23. Document ID: WO 2004001421 A2

L4: Entry 23 of 27

File: EPAB

Dec 31, 2003

PUB-NO: WO2004001421A2

DOCUMENT-IDENTIFIER: WO 2004001421 A2

TITLE: METHOD FOR THE DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF NEUROLOGICAL DISEASES

PUBN-DATE: December 31, 2003

INVENTOR-INFORMATION:

NAME

COUNTRY

KOSTANJEVECKI, VESNA

BE

VANMECHELEN, EUGEN

BE

DE, BRABANDERE VERONIQUE

BE

INT-CL (IPC): G01 N 33/68

EUR-CL (EPC): G01N033/68

ABSTRACT:

CHG DATE=20040724 STATUS=O>A method is provided for the screening, diagnosis and/or prognosis of neurological diseases. More specifically, new biomarkers are provided for the screening, diagnosis and/or prognosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression. The method further provides for the differential diagnosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 24. Document ID: WO 9604309 A1

L4: Entry 24 of 27

File: EPAB

Feb 15, 1996

PUB-NO: WO009604309A1

DOCUMENT-IDENTIFIER: WO 9604309 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR AN EPITOPE OF A PARTICULAR SUBCLASS OR FORM

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.5&ref=4&dbname=PGPB,USPT,US...> 11/16/04

OF PHOSPHORYLATED TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION OF THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: February 15, 1996

INVENTOR-INFORMATION:

NAME

VANMECHELEN, EUGEN

VAN, DE VOORDE ANDRE

COUNTRY

BE

BE

INT-CL (IPC): C07 K 16/18; C12 N 5/20; C07 K 14/47; C12 N 15/06; C12 P 21/08; G01 N 33/577; G01 N 33/68; C12 N 9/12

EUR-CL (EPC): C07K016/18; C07K014/47, C12N009/12

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which NFT is not a pathological hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention. The invention also relates to kinases or phosphorylases which specifically react with the epitope recognized by these monoclonal antibodies as well as to a method for screening compounds which interfere with the activity of these kinases and phosphorylases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 25. Document ID: WO 9517429 A1

L4: Entry 25 of 27

File: EPAB

Jun 29, 1995

PUB-NO: WO009517429A1

DOCUMENT-IDENTIFIER: WO 9517429 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR PHF-TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION BY THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 29, 1995

INVENTOR-INFORMATION:

NAME

VANDERMEEREN, MARC

VANMECHELEN, EUGEN

VAN, DE VOORDE ANDRE

COUNTRY

BE

BE

BE

INT-CL (IPC): C07 K 16/18; C07 K 14/47; C12 N 5/20; G01 N 33/577; G01 N 33/68

EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates more particularly to a monoclonal antibody which forms an immunological complex with a phosphorylated

epitope of an antigen belonging to abnormally phosphorylated tau (PHF-tau) residing in the region spanning positions (143-254), and with said monoclonal antibody being characterized by the fact that it is capable of specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 26. Document ID: WO 9413795 A1

L4: Entry 26 of 27

File: EPAB

Jun 23, 1994

PUB-NO: WO009413795A1

DOCUMENT-IDENTIFIER: WO 9413795 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU, HYBRIDOMAS SECRETING THESE ANTIBODIES, ANTIGEN RECOGNITION BY THESE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 23, 1994

INVENTOR-INFORMATION:

NAME

COUNTRY

VANDERMEEREN, MARC

BE

MERCKEN, MARC

US

VANMECHELEN, EUGEN

BE

VAN, DE VOORDE ANDRE

BE

INT-CL (IPC): C12N 15/06; C12P 21/08; C12N 5/20; C07K 15/00; G01N 33/577; G01N 33/68
EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 27. Document ID: WO 9308302 A1

L4: Entry 27 of 27

File: EPAB

Apr 29, 1993

PUB-NO: WO009308302A1

DOCUMENT-IDENTIFIER: WO 9308302 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU

PUBN-DATE: April 29, 1993

INVENTOR-INFORMATION:

NAME	COUNTRY
MERCKEN, MARC	US
MANDELKOW, EVA-MARIA	US
VANDERMEEREN, MARC	US
VANMECHELEN, EUGEN	US
VAN, DE VOORDE ANDRE	US

US-CL-CURRENT: 435/332; 435/FOR.111, 530/328, 530/387.9, 530/388.2
 INT-CL (IPC): C07K 15/00; C07K 15/24; C12N 5/20; C12N 15/06; C12P 21/08; G01N 33/577
 EUR-CL (EPC): C07K014/47; C07K016/18

ABSTRACT:

CHG DATE=19990617 STATUS=O>A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	MMIC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate QACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
VanMechelen-Eugeen.IN.	27

Display Format: **Change Format**

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: AU 2003253014 A1, WO 2004001421 A2, US 20040072261 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 9

File: DWPI

Jan 6, 2004

DERWENT-ACC-NO: 2004-071781

DERWENT-WEEK: 200447

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Screening, diagnosing and/or prognosing a mammal with neurological disorders comprises detecting, in the mammal the level of at least one proteins, e.g. Apo E, alpha-1-antitrypsin, alpha-1-beta glycoprotein, antithrombin III, or Apo A-1

INVENTOR: DE BRABANDERE, V; KOSTANJEVECKI, V ; VANMECHELEN, E

PRIORITY-DATA: 2002US-396438P (July 17, 2002), 2002EP-0447121 (June 21, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003253014 A1</u>	January 6, 2004		000	G01N033/68
<u>WO 2004001421 A2</u>	December 31, 2003	E	106	G01N033/68
<u>US 20040072261 A1</u>	April 15, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/567; G01 N 33/68

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FWMC	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 2. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

L5: Entry 2 of 9

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004502939 W</u>	January 29, 2004		059	G01N033/53

<u>WO 200203073 A1</u>	January 10, 2002	E	037	G01N033/68
<u>US 20020019016 A1</u>	February 14, 2002		000	G01N033/567
<u>AU 200179678 A</u>	January 14, 2002		000	G01N033/68
<u>EP 1295129 A1</u>	March 26, 2003	E	000	G01N033/68
<u>US 6670137 B2</u>	December 30, 2003		000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: US20020019016A

BASIC-ABSTRACT:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

ABSTRACTED-PUB-NO:

WO 200203073A EQUIVALENT-ABSTRACTS:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.6&ref=5&dbname=PGPB,USPT,US...> 11/16/04

a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 3. Document ID: US 20040091942 A1, WO 200155725 A2, AU 200137319 A, EP 1250600 A2, BR 200107851 A, JP 2003521499 W, US 20030194742 A1, US 6680173 B2

L5: Entry 3 of 9

File: DWPI

May 13, 2004

DERWENT-ACC-NO: 2001-476242

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the ratio of phospho-tau / total tau is useful for diagnosing a tauopathy i.e. Alzheimer's disease or Pick's disease, versus a non tauopathy

INVENTOR: VANDERSTICHELE, H; VANMECHELEN, E

PRIORITY-DATA: 2000EP-0870280 (November 22, 2000), 2000EP-0870008 (January 24, 2000), 2000US-178391P (January 27, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040091942 A1</u>	May 13, 2004		000	G01N033/53
<u>WO 200155725 A2</u>	August 2, 2001	E	071	G01N033/68
<u>AU 200137319 A</u>	August 7, 2001		000	G01N033/68
<u>EP 1250600 A2</u>	October 23, 2002	E	000	G01N033/68
<u>BR 200107851 A</u>	October 29, 2002		000	G01N033/68
<u>JP 2003521499 W</u>	July 15, 2003		080	C07K007/06
<u>US 20030194742 A1</u>	October 16, 2003		000	G01N033/53
<u>US 6680173 B2</u>	January 20, 2004		000	G01N033/53

INT-CL (IPC): A61 K 38/17; A61 K 45/00; A61 P 25/28; A61 P 43/00; C07 K 7/06; C07 K 14/00; C07 K 14/47; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200155725A

BASIC-ABSTRACT:

NOVELTY - The diagnosis, (D1) of a tauopathy in an individual comprising determining the ratio of phospho-tau (181)/ total tau, is new.

DETAILED DESCRIPTION - Comparison of the phospho-tau of the patient to that in a control individual where alteration in the ratio indicates the condition. INDEPENDENT CLAIMS are included for the following:

(1) the use of tau and phospho-tau as neurological markers;

(2) a phospho-peptide liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270 comprising at least the minimal epitope of Ht 7: PPGQK in sequence (I) and AT270: PPAPKT(p)P in sequence (II). (I) is a 5 amino acid (aa) sequence and (II) a 7 aa sequence given in the specification;

(3) a kit for the diagnosis of a tauopathy in and individual and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising at least:

(i) an antibody specifically recognizing phospho-tau;

(ii) an antibody recognizing tau; and

(4) a kit for the diagnosis of a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising a peptide (2).

ACTIVITY - Nootropic; neuroprotective; cerebroprotective.

MECHANISM OF ACTION - None given.

USE - Tau and phospho tau are useful as neurological markers for the manufacture of a diagnostic kit for the diagnosis of a tauopathy and/or the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The phosphopeptide is useful to measure phospho-tau levels (claimed) and diagnose a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The

phosphopeptide is useful for the manufacture of a diagnostic kit for measuring phosphotau levels and/or diagnosing a tauopathy for the differential of a tauopathy versus a non tauopathy (claimed). The kit is useful for the diagnosis of Alzheimer's disease, Pick's disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 and or for the differential diagnosis of Alzheimer's disease, Picks's Disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 versus vascular dementia, Creutzfeldt Jacob disease, stroke and/or neurotoxicity in patients with leukemia (claimed). The phosphopeptide kits and methods are useful for therapeutic monitoring and for determining the effectiveness of a treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 4. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L5: Entry 4 of 9

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69920487 E	October 28, 2004		000	G01N033/68
WO 200014546 A1	March 16, 2000	E	040	G01N033/68

AU 9959746 A	March 27, 2000		000	G01N033/68
BR 9913112 A	May 8, 2001		000	G01N033/68
EP 1112500 A1	July 4, 2001	E	000	G01N033/68
CN 1325491 A	December 5, 2001		000	G01N033/68
JP 2002524740 W	August 6, 2002		042	G01N033/53
AU 772151 B2	April 8, 2004		000	G01N033/68
EP 1112500 B1	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator or early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 5. Document ID: AU 2003200041 A1, WO 200002053 A2, AU 9950290 A, EP 1095278 A2, BR 9911291 A, CN 1316055 A, JP 2002519702 W, AU 754062 B, US 20040014142 A1

L5: Entry 5 of 9

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2000-171031

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the level of three neurological markers using antibodies useful for detection, quantification and/or differential diagnosis of Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia

INVENTOR: VAN DE VOORDE, A; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 1999EP-0870069 (April 9, 1999), 1998EP-0870148 (July 3, 1998), 1998EP-

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.6&ref=5&dbname=PGPB,USPT,US...> 11/16/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003200041 A1	April 10, 2003		000	G01N033/68
WO 200002053 A2	January 13, 2000	E	112	G01N033/68
AU 9950290 A	January 24, 2000		000	G01N033/68
EP 1095278 A2	May 2, 2001	E	000	G01N033/68
BR 9911291 A	December 4, 2001		000	G01N033/68
CN 1316055 A	October 3, 2001		000	G01N033/68
JP 2002519702 W	July 2, 2002		115	G01N033/53
AU 754062 B	October 31, 2002		000	G01N033/68
US 20040014142 A1	January 22, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200002053A

BASIC-ABSTRACT:

NOVELTY - Detection, quantification and/or differential diagnosis of neurodegeneration in an individual, involves determining the level of three neurological markers in body fluid samples using antibodies, where the type and degree of neurodegeneration reflects a quantitative change in the levels of marker compared to a control sample.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a method for the detection of Rab3a in cerebrospinal fluid (CSF) comprising contacting a CSF sample with an antibody reactive with Rab3a, and detecting the immunological binding;
- (2) a method for detecting alpha -synuclein in CSF by contacting an antibody reactive with alpha -synuclein with CSF and detecting the immunological binding;
- (3) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual, comprising at least three antibodies each recognizing a different neurological marker;
- (4) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in individual, comprising
 - (a) a support, comprising together or separately, at least three antibodies (primary antibodies or capturing antibodies) each recognizing a different neurological marker;
 - (b) secondary antibodies (detector antibodies), each recognizing one of the neurological marker-primary antibody complexes;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibodies;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides which are specially recognized by the antibodies of the kit, used for the detection of the neurological marker;
- (5) a diagnostic kit for the detection of Rab3a in CSF, comprising at least one monoclonal antibody recognizing Rab3a;

- (6) a diagnostic kit for the detection of Rab3a in CSF, comprising
- (a) a support, comprising a monoclonal antibody recognizing Rab3a (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the Rab3a-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides, which are specifically recognized by the antibodies of the kit, used for the detection of Rab3a;
- (f) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising at least a monoclonal antibody recognizing alpha -synuclein; and
- (7) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising
- (a) a support comprising a monoclonal antibody recognizing alpha -synuclein (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the alpha -synuclein-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides that are specifically recognized by the antibodies of the kit, used for the detection of alpha -synuclein.

USE - The method is useful for detecting Rab3a and alpha -synuclein in cerebrospinal fluid (claimed). Neurodegeneration consists of conditions including Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia (claimed). The method is also useful for differential diagnosis of Alzheimer's disease versus any of the other diseases (claimed). The reagents of the method form diagnostic kits for detecting the diseases (claimed). The method or diagnostic kit is useful for therapeutic monitoring and/or determination of the effectiveness of a certain treatment (claimed).

ADVANTAGE - The method facilitates more specific diagnosis of neurodegeneration. Assaying for three neurological markers enables differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: DE 69529906 E, WO 9604309 A1, AU 9532234 A, EP 772634 A1, JP 10506381 W, AU 710952 B, US 6121003 A, EP 772634 B1

L5: Entry 6 of 9

File: DWPI

Apr 17, 2003

DERWENT-ACC-NO: 1996-129338

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.6&ref=5&dbname=PGPB,USPT,US...> 11/16/04

TITLE: Monoclonal antibodies specific for phosphorylated tau - for improved detection and diagnosis of e.g. Alzheimer's Disease

INVENTOR: VAN DE VOORDE, A; VANMECHELEN, E

PRIORITY-DATA: 1994EP-0870131 (July 29, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69529906 E</u>	April 17, 2003		000	C07K016/18
<u>WO 9604309 A1</u>	February 15, 1996	E	042	C07K016/18
<u>AU 9532234 A</u>	March 4, 1996		000	C07K016/18
<u>EP 772634 A1</u>	May 14, 1997	E	000	C07K016/18
<u>JP 10506381 W</u>	June 23, 1998		048	C07K016/18
<u>AU 710952 B</u>	September 30, 1999		000	C07K016/18
<u>US 6121003 A</u>	September 19, 2000		000	G01N033/53
<u>EP 772634 B1</u>	March 12, 2003	E	000	C07K016/18

INT-CL (IPC): C07 K 14/47; C07 K 16/00; C07 K 16/18; C12 N 5/10; C12 N 5/20; C12 N 9/12; C12 N 15/02; C12 N 15/06; C12 P 21/08; G01 N 33/53; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: US 6121003A

BASIC-ABSTRACT:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAbs can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MAbs of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

ABSTRACTED-PUB-NO:

WO 9604309A EQUIVALENT-ABSTRACTS:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated

epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAbs can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MAbs of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 7. Document ID: US 20040038430 A1, WO 9517429 A1, AU 9512736 A, EP 737208 A1, JP 09506771 W, AU 698383 B, US 6008024 A, US 6500674 B1, US 20030138972 A1, JP 2004045417 A

L5: Entry 7 of 9

File: DWPI

Feb 26, 2004

DERWENT-ACC-NO: 1995-240616

DERWENT-WEEK: 200416

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel monoclonal antibodies specific for abnormally phosphorylated paired helical filament tau protein (PHF-Tau) - useful for post mortem or in vitro detection of neurological diseases eg. Alzheimer's disease

INVENTOR: VAN DE VOORDE, A; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A V D

PRIORITY-DATA: 1993EP-0403133 (December 21, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040038430 A1</u>	February 26, 2004		000	G01N033/543
<u>WO 9517429 A1</u>	June 29, 1995	E	057	C07K016/18
<u>AU 9512736 A</u>	July 10, 1995		000	C07K016/18
<u>EP 737208 A1</u>	October 16, 1996	E	000	C07K016/18
<u>JP 09506771 W</u>	July 8, 1997		065	C12P021/08
<u>AU 698383 B</u>	October 29, 1998		000	C07K016/18
<u>US 6008024 A</u>	December 28, 1999		000	C12P021/04
<u>US 6500674 B1</u>	December 31, 2002		000	G01N033/543

INT-CL (IPC): C07 K 7/06; C07 K 14/47; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/20; C12 N 15/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68 ; C12 P 21/08; C12 R 1:91

ABSTRACTED-PUB-NO: US 6008024A

BASIC-ABSTRACT:

Novel monoclonal antibody (MAb) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

ABSTRACTED-PUB-NO:

WO 9517429A EQUIVALENT-ABSTRACTS:

Novel monoclonal antibody (MAb) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: WO 9413795 A1, AU 9458097 A, EP 673418 A1, JP 08502898 W, EP 673418 B1, AU 690092 B, DE 69318420 E, ES 2118373 T3, US 5843779 A, US 5861257 A, JP 2879975 B2, US 6010913 A, US 6232437 B1, US 20020001857 A1, US 20030143760 A1

L5: Entry 8 of 9

File: DWPI

Jun 23, 1994

DERWENT-ACC-NO: 1994-234211

DERWENT-WEEK: 200375

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibody reactive with tau protein - used to develop prods. for detection of brain diseases involving tau or paired helical filaments esp. Alzheimer's disease

INVENTOR: MERCKEN, M; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A
V D

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9413795 A1</u>	June 23, 1994	E	052	C12N015/06
<u>AU 9458097 A</u>	July 4, 1994		000	C12N015/06
<u>EP 673418 A1</u>	September 27, 1995	E	000	C12N015/06
<u>JP 08502898 W</u>	April 2, 1996		057	C12P021/08
<u>EP 673418 B1</u>	May 6, 1998	E	038	C12N015/06
<u>AU 690092 B</u>	April 23, 1998		000	C12P021/08
<u>DE 69318420 E</u>	June 10, 1998		000	C12N015/06
<u>ES 2118373 T3</u>	September 16, 1998		000	C12N015/06
<u>US 5843779 A</u>	December 1, 1998		000	C12N005/06
<u>US 5861257 A</u>	January 19, 1999		000	G01N033/53
<u>JP 2879975 B2</u>	April 5, 1999		024	C07K016/18
<u>US 6010913 A</u>	January 4, 2000		000	A61K038/00
<u>US 6232437 B1</u>	May 15, 2001		000	A61K038/00
<u>US 20020001857 A1</u>	January 3, 2002		000	G01N033/531
<u>US 20030143760 A1</u>	July 31, 2003		000	G01N033/531

INT-CL (IPC): A61 K 38/00; A61 K 39/00; A61 K 39/395; C07 K 7/06; C07 K 7/10; C07 K 13/00; C07 K 14/47; C07 K 15/00; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/10; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/531; G01 N 33/564; G01 N 33/577; G01 N 33/68; C12 P 21/08; C12 R 1:91; C12 P 21/08; C12 R 1:91; C12 N 5/00; C12 R 1:91

ABSTRACTED-PUB-NO: EP 673418B

BASIC-ABSTRACT:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

ABSTRACTED-PUB-NO:

US 5843779A EQUIVALENT-ABSTRACTS:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 5861257A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6010913A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6232437B

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain

homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US20020001857A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

WO 9413795A

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Publ. No.	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----------	------------

☐ 9. Document ID: JP 2004043487 A, WO 9308302 A1, AU 9228002 A, EP 610330 A1, JP 07502888 W, AU 662178 B, EP 610330 B1, DE 69220503 E, US 6238892 B1, US 20010018191 A1

L5: Entry 9 of 9

File: DWPI

Feb 12, 2004

DERWENT-ACC-NO: 1993-152493

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibodies binding abnormal micro-tubule-associated tau-protein - for diagnosing neurological disorders e.g. Alzheimer's disease, Downs syndrome, Picks disease, etc.

INVENTOR: MANDELKOW, E; MERCKEN, M ; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; ANDRE, V D V

PRIORITY-DATA: 1991EP-0402871 (October 25, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004043487 A	February 12, 2004		023	C07K016/18
WO 9308302 A1	April 29, 1993	E	047	C12P021/08

AU 9228002 A	May 21, 1993		000	C12P021/08
EP 610330 A1	August 17, 1994	E	000	C12P021/08
JP 07502888 W	March 30, 1995		000	C12P021/08
AU 662178 B	August 24, 1995		000	C12P021/08
EP 610330 B1	June 18, 1997	E	029	C12P021/08
DE 69220503 E	July 24, 1997		000	C12P021/08
US 6238892 B1	May 29, 2001		000	C12P021/04
US 20010018191 A1	August 30, 2001		000	G01N033/567

INT-CL (IPC): C07 K 2/00; C07 K 14/47; C07 K 15/00; C07 K 15/06; C07 K 15/24; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/06; C12 N 5/10; C12 N 5/12; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/564; G01 N 33/567; G01 N 33/577

ABSTRACTED-PUB-NO: EP 610330B

BASIC-ABSTRACT:

A monoclonal antibody (MAB) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAB as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAB as in (A), etc.

USE - The MAB is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAB can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

ABSTRACTED-PUB-NO:

US 6238892B EQUIVALENT-ABSTRACTS:

Monoclonal antibody which forms an immunological complex with a phosphorylated epitope specific for an antigen belonging to human abnormally phosphorylated tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from the cerebral cortex obtained from a patient having Alzheimer's disease or having died of Alzheimer's disease.

A monoclonal antibody (MAB) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAB as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAB as in (A), etc.

USE - The MAB is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAB can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

US20010018191A

A monoclonal antibody (MAB) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

WO 9308302A

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
VanMechelen-E.IN.	9

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 40 of 40 returned.

☐ 1. Document ID: US 20040091942 A1

Using default format because multiple data bases are involved.

L6: Entry 1 of 40

File: PGPB

May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091942

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040091942 A1

TITLE: Diagnosis of tauopathies

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040072261 A1

L6: Entry 2 of 40

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072261

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072261 A1

TITLE: Method for the diagnosis and differential diagnosis of neurological diseases

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kostanjevecki, Vesna	Sint-Denijs-Westrem		BE	
Vanmechelen, Eugene	Nazareth-Eke		BE	
De Brabandere, Veronique	Gent		BE	

US-CL-CURRENT: 435/7.2

ABSTRACT:

A method is provided for the screening, diagnosis and/or prognosis of neurological diseases. More specifically, new biomarkers are provided for the screening, diagnosis

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

and/or prognosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression. The method further provides for the differential diagnosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040038430 A1

L6: Entry 3 of 40

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040038430
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040038430 A1

TITLE: Monoclonal antibodies specific for PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
<u>Vanmechelen</u> , Eugene	Nazareth		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/518; 530/388.1

ABSTRACT:

The present invention relates more particularly to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau (PHF-tau) residing in the region spanning positions (143-254), and with said monoclonal antibody being characterized by the fact that it is capable of specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040014142 A1

L6: Entry 4 of 40

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014142
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040014142 A1

TITLE: Differential diagnosis of neurodegeneration

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

NAME	CITY	STATE	COUNTRY	RULE-47
VanMechelen, Eugene	Nazareth Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to new methods for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and .alpha.-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and/or differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20030194742 A1

L6: Entry 5 of 40

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194742

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194742 A1

TITLE: DIAGNOSIS OF TAUOPATHIES

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth - Eke		BE	
Vanderstichele, Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/350

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20030143760 A1

L6: Entry 6 of 40

File: PGPB

Jul 31, 2003

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

PGPUB-DOCUMENT-NUMBER: 20030143760
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030143760 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth-Eke		BE	
Mercken, Marc	Turnhout		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 436/543; 435/338, 435/70.21, 530/388.26

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20030138972 A1

L6: Entry 7 of 40

File: PGPB

Jul 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030138972
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030138972 A1

TITLE: Monoclonal antibodies specific PHF-TAU, hybridomas secreting them, antigen recognition by these antibodies and their applications

PUBLICATION-DATE: July 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/518; 435/338, 530/388.26

ABSTRACT:

A peptide from 6 to 100 amino acids long, including an amino acid sequence depicted by one of a) Val-Arg-Thr-Pro-Pro (amino acid 229-233; human tau numbering, SEQ ID NO 2) wherein the peptide is able to form an immunological complex with the monoclonal antibody AT180 produced by the hybridoma deposited at the ECACC on Dec. 22, 1992 under No.92122204 and b) Pro-Lys-Thr-Pro-Pro (amino acid 179-183; human tau numbering, SEQ ID NO 3) wherein the peptide is able to form an immunological complex with the monoclonal antibody AT270 produced by the hybridoma deposited at the ECACC on Jul. 7, 1993 under No.93070774, with Thr being phosphorylated. A method of detecting PHF-tau protein one of the peptides is also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20020019016 A1

L6: Entry 8 of 40

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Hulstaert, Frank	Gentbrugge		BE	

US-CL-CURRENT: 435/7.21

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 9. Document ID: US 20020001857 A1

L6: Entry 9 of 40

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001857

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001857 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth-Eke		BE	
Mercken, Marc	Turnhout		BE	
Voorde, Andre Van De	Lokeren		BE	

US-CL-CURRENT: 436/543; 435/70.21, 530/388.1

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: US 20010018191 A1

L6: Entry 10 of 40

File: PGPB

Aug 30, 2001

PGPUB-DOCUMENT-NUMBER: 20010018191

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010018191 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau

PUBLICATION-DATE: August 30, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mercken, Marc	Somerville	MA	US	
Mandelkow, Eva-Maria	Hamburg		DE	
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth-Eke		BE	
Andre, Van De Voorde	Lokeren		BE	

US-CL-CURRENT: 435/7.2; 530/388.26

ABSTRACT:

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 6680173 B2

L6: Entry 11 of 40

File: USPT

Jan 20, 2004

US-PAT-NO: 6680173

DOCUMENT-IDENTIFIER: US 6680173 B2

TITLE: Diagnosis of tauopathies

DATE-ISSUED: January 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Ghent			BE

US-CL-CURRENT: 435/7.1; 436/8

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

7 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 12. Document ID: US 6670137 B2

L6: Entry 12 of 40

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 13. Document ID: US 6500674 B1

L6: Entry 13 of 40

File: USPT

Dec 31, 2002

US-PAT-NO: 6500674

DOCUMENT-IDENTIFIER: US 6500674 B1

**** See image for Certificate of Correction ****

TITLE: Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 436/518; 435/7.1, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 436/536, 436/63

ABSTRACT:

A method for the diagnosis of brain/neurological disease involving abnormally phosphorylated tau protein using at least one antibody chosen from the group consisting of monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

(SEQ ID NO 1) 143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile Ala Thr 160 Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys Gly Gln 170 Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro 180 Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro 190 200 Lys Ser Gly Asp Arg Ser Gly Tyr Ser Ser Pro Gly 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg Thr

Pro 220 Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys 230 Val Ala Val Val Arg Thr
Pro Pro Lys Ser Pro Ser 240 Ser Ala Lys Ser Arg Leu Gln Thr Ala Pro Val Pro 250 Met
Pro Asp Leu Lys COOH

with each monoclonal body specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

32 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 14. Document ID: US 6238892 B1

L6: Entry 14 of 40

File: USPT

May 29, 2001

US-PAT-NO: 6238892

DOCUMENT-IDENTIFIER: US 6238892 B1

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mercken; Marc	Somerville	MA		
Mandelkow; Eva-Maria	Hamburg			DE
Vandermeeren; Marc	Geel			BE
<u>Vanmechelen</u> ; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/326, 435/331, 530/388.1

ABSTRACT:

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

3 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 15. Document ID: US 6232437 B1

L6: Entry 15 of 40

File: USPT

May 15, 2001

US-PAT-NO: 6232437

DOCUMENT-IDENTIFIER: US 6232437 B1

TITLE: Isolated human tau peptide epitope which specifically binds monoclonal antibody AT120.

DATE-ISSUED: May 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth-Eke			BE
Mercken; Marc	Sommerville	MA		
Van de Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 530/324; 530/327, 530/329, 530/402

ABSTRACT:

An isolated human tau peptide epitope which specifically binds monoclonal antibody AT120 consisting of the amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 3, 4, 15, 16, 17, 18, 19 and 20.

2 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 16. Document ID: US 6121003 A

L6: Entry 16 of 40

File: USPT

Sep 19, 2000

US-PAT-NO: 6121003

DOCUMENT-IDENTIFIER: US 6121003 A

TITLE: Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/331, 435/7.92, 435/975, 436/503, 436/547, 436/548, 436/811, 530/387.9, 530/388.1

ABSTRACT:

The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which neurofibrillary tangle (NFT) is not a pathological

hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 17. Document ID: US 6010913 A

L6: Entry 17 of 40

File: USPT

Jan 4, 2000

US-PAT-NO: 6010913
DOCUMENT-IDENTIFIER: US 6010913 A

TITLE: Isolated human tau peptide

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
<u>Vanmechelen</u> ; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 436/543; 436/544, 436/545, 436/546, 530/300, 530/324

ABSTRACT:

The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 18. Document ID: US 6008024 A

L6: Entry 18 of 40

File: USPT

Dec 28, 1999

US-PAT-NO: 6008024
DOCUMENT-IDENTIFIER: US 6008024 A

TITLE: Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
<u>Vanmechelen</u> ; Eugene	Nazareth			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/331, 436/548, 530/387.9, 530/388.1

ABSTRACT:

Monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile - 160 Ala Thr Pro Arg Gly Ala
 Ala Pro Pro Gly - 170 Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile - 180 Pro Ala Lys Thr
 Pro Pro Ala Pro Lys Thr - 190 Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser - 200 Gly Asp
 Arg Ser Gly Tyr Ser Ser Pro Gly - 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg - 220
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg - 230 Glu Pro Lys Lys Val Ala Val Val Arg Thr
 - 240 Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser - 250 Arg Leu Gln Thr Ala Pro Val Pro
 Met Pro - Asp Leu Lys COOH

with each monoclonal antibody specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

8 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 19. Document ID: US 5861257 A

L6: Entry 19 of 40

File: USPT

Jan 19, 1999

US-PAT-NO: 5861257

DOCUMENT-IDENTIFIER: US 5861257 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Tokyo			JP
<u>Vanmechelen</u> ; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.92, 435/7.95, 436/518, 436/63, 436/811

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

4 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 20. Document ID: US 5843779 A

L6: Entry 20 of 40

File: USPT

Dec 1, 1998

US-PAT-NO: 5843779
DOCUMENT-IDENTIFIER: US 5843779 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/331; 435/70.21, 530/388.1

ABSTRACT:

The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 21. Document ID: JP 2004045417 A

L6: Entry 21 of 40

File: JPAB

Feb 12, 2004

PUB-NO: JP02004045417A

DOCUMENT-IDENTIFIER: JP 2004045417 A

TITLE: MONOCLONAL ANTIBODY SPECIFIC TO PHF-TAU, HYBRIDOMA SECRETING THE SAME, ANTIGEN RECOGNITION BY USING THE ANTIBODY, AND ITS APPLICATION

PUBN-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

VANDERMEEREN, MARC

VANMECHELEN, EUGEN

VOOR, DE ANDRE VAN DE

INT-CL (IPC): G01 N 33/53; C07 K 16/18; G01 N 33/577

ABSTRACT:

PROBLEM TO BE SOLVED: To provide a method for specifically detecting τ -protein (PHF- τ) being abnormally phosphorylated in cerebrospinal fluid (CSF), and to provide a method for using monoclonal antibodies or the like forming an immune complex in conjunction with a phosphorylated antigenic epitope belonging to the τ -protein (PHF- τ) existing in a region of (143-254) positions and being abnormally phosphorylated therein.

SOLUTION: The method for measuring the τ -protein phosphorylated abnormally includes step (a) in which a level of the abnormally phosphorylated τ -protein in the CSF is detected, step (b) in which the level obtained by the step (a) is compared to a level with a predetermined range, and step (c) in which the level obtained by the step (a) is determined whether it belongs to a level predetermined as an index of the CSF acquired from Alzheimer's patients.

COPYRIGHT: (C)2004,JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 22. Document ID: JP 2004043487 A

L6: Entry 22 of 40

File: JPAB

Feb 12, 2004

PUB-NO: JP02004043487A

DOCUMENT-IDENTIFIER: JP 2004043487 A

TITLE: MONOCLONAL ANTIBODY TO MICROTUBULAR ASSOCIATED PROTEIN TAU

PUBN-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

MERCKEN, MARC

MANDELKOW, EVA-MARIA

VANDERMEEREN, MARC

VANMECHELEN, EUGEN

VOOR, DE ANDRE VAN DE

INT-CL (IPC): C07 K 16/18; C07 K 14/47; C12 N 5/10; C12 N 15/02; C12 P 21/02; C12 P 21/08; G01 N 33/53; G01 N 33/577

ABSTRACT:

PROBLEM TO BE SOLVED: To obtain a monoclonal antibody forming an immune complex with a phosphorylated epitope of an antigen belonging to a human abnormally-phosphorylated tau protein.

SOLUTION: This monoclonal antibody forms the immune complex with the phosphorylated epitope which exists in the human abnormally-phosphorylated tau protein obtained from a brain homogenate separated from the cerebral cortex of a patient who has Alzheimer's disease or died due to the Alzheimer's disease, but not exists in a normal human tau protein.

COPYRIGHT: (C)2004,JPO

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 23. Document ID: WO 2004060767 A1

L6: Entry 23 of 40

File: EPAB

Jul 22, 2004

PUB-NO: WO2004060767A1

DOCUMENT-IDENTIFIER: WO 2004060767 A1

TITLE: SHEET LIKE SEALING MEMBER FOR PACKAGING CONTAINERS AND SEALING METHOD

PUBN-DATE: July 22, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

DRIESSEN, JAN

BE

VANMECHELEN, LAURENT

BE

INT-CL (IPC): B65 D 55/08

EUR-CL (EPC): B65D043/02; B65D055/06, B65D055/08

ABSTRACT:

CHG DATE=20040802 STATUS=O>The invention relates to a packaging method comprising sealing two container halves (2, 3) by welding a peripheral sheet like sealing member (8) over adjacent peripheral rim surfaces (6, 7) on corresponding peripheral flanges (4, 5) of the container halves, wherein the sheet like sealing member comprises at least one first layer having a support function, and at least one second layer having a sealing function. The invention also relates to sealing members for such method and to packaging containers (1) sealed according to such method or designed to be sealed according to such method.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 24. Document ID: EP 1435330 A1

L6: Entry 24 of 40

File: EPAB

Jul 7, 2004

PUB-NO: EP001435330A1

DOCUMENT-IDENTIFIER: EP 1435330 A1

TITLE: Packaging container and method for sealing packaging containers

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

PUBN-DATE: July 7, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

DRIESSEN, JAN

BE

VANMECHELEN, LAURENT

BE

INT-CL (IPC): B65 D 55/08

EUR-CL (EPC): B29C065/00; B29C065/18, B29C065/50 , B65D043/02 , B65D055/06

ABSTRACT:

CHG DATE=20040904 STATUS=N>The invention relates to a packaging container comprising two container halves (2,3) with corresponding peripheral flanges, wherein said corresponding peripheral flanges each comprise at least one peripheral rim (6,7), shaped in such way that the surfaces of the respective rims of the corresponding flanges of the two container halves lie, in closed position of the container, substantially on one surface and allow the sealing of said container halves by means of a peripheral sheet like sealing member (8), and to such a packaging container, wherein said two container halves are sealed together by means of a peripheral sheet like sealing member (8) covering said respective rim surfaces (6,7) lying on one surface, as well as to a packaging method comprising sealing two container halves (2,3) via corresponding peripheral flanges on said container halves (2,3), by applying a peripheral sheet like sealing member (8) over adjacent peripheral rim surfaces (6,7) on the peripheral flanges of the container halves.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------	-----

☐ 25. Document ID: WO 2004001421 A2

L6: Entry 25 of 40

File: EPAB

Dec 31, 2003

PUB-NO: WO2004001421A2

DOCUMENT-IDENTIFIER: WO 2004001421 A2

TITLE: METHOD FOR THE DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS OF NEUROLOGICAL DISEASES

PUBN-DATE: December 31, 2003

INVENTOR-INFORMATION:

NAME

COUNTRY

KOSTANJEVECKI, VESNA

BE

VANMECHELEN, EUGEN

BE

DE, BRABANDERE VERONIQUE

BE

INT-CL (IPC): G01 N 33/68

EUR-CL (EPC): G01N033/68

ABSTRACT:

CHG DATE=20040724 STATUS=O>A method is provided for the screening, diagnosis and/or prognosis of neurological diseases. More specifically, new biomarkers are provided for the screening, diagnosis and/or prognosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular dementia and/or depression. The method further provides for the differential diagnosis in a mammal of Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, vascular

dementia and/or depression.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 26. Document ID: WO 9604309 A1

L6: Entry 26 of 40

File: EPAB

Feb 15, 1996

PUB-NO: WO009604309A1

DOCUMENT-IDENTIFIER: WO 9604309 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR AN EPITOPE OF A PARTICULAR SUBCLASS OR FORM OF PHOSPHORYLATED TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION OF THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: February 15, 1996

INVENTOR-INFORMATION:

NAME

COUNTRY

VANMECHELEN, EUGEN

BE

VAN, DE VOORDE ANDRE

BE

INT-CL (IPC): C07 K 16/18; C12 N 5/20; C07 K 14/47; C12 N 15/06; C12 P 21/08; G01 N 33/577; G01 N 33/68; C12 N 9/12

EUR-CL (EPC): C07K016/18; C07K014/47, C12N009/12

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which NFT is not a pathological hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention. The invention also relates to kinases or phosphorylases which specifically react with the epitope recognized by these monoclonal antibodies as well as to a method for screening compounds which interfere with the activity of these kinases and phosphorylases.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 27. Document ID: WO 9517429 A1

L6: Entry 27 of 40

File: EPAB

Jun 29, 1995

PUB-NO: WO009517429A1

DOCUMENT-IDENTIFIER: WO 9517429 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR PHF-TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION BY THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 29, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
VANDERMEEREN, MARC	BE
VANMECHELEN, EUGEN	BE
VAN, DE VOORDE ANDRE	BE

INT-CL (IPC): C07 K 16/18; C07 K 14/47; C12 N 5/20; G01 N 33/577; G01 N 33/68
 EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates more particularly to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau (PHF-tau) residing in the region spanning positions (143-254), and with said monoclonal antibody being characterized by the fact that it is capable of specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 28. Document ID: WO 9413795 A1

L6: Entry 28 of 40

File: EPAB

Jun 23, 1994

PUB-NO: WO009413795A1

DOCUMENT-IDENTIFIER: WO 9413795 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU, HYBRIDOMAS SECRETING THESE ANTIBODIES, ANTIGEN RECOGNITION BY THESE MONOCLONAL ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 23, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
VANDERMEEREN, MARC	BE
MERCKEN, MARC	US
VANMECHELEN, EUGEN	BE
VAN, DE VOORDE ANDRE	BE

INT-CL (IPC): C12N 15/06; C12P 21/08; C12N 5/20; C07K 15/00; G01N 33/577; G01N 33/68
 EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 29. Document ID: WO 9308302 A1

L6: Entry 29 of 40

File: EPAB

Apr 29, 1993

PUB-NO: WO009308302A1

DOCUMENT-IDENTIFIER: WO 9308302 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU

PUBN-DATE: April 29, 1993

INVENTOR-INFORMATION:

NAME	COUNTRY
MERCKEN, MARC	US
MANDELKOW, EVA-MARIA	US
VANDERMEEREN, MARC	US
VANMECHELEN, EUGEN	US
VAN, DE VOORDE ANDRE	US

US-CL-CURRENT: 435/332; 435/FOR.111, 530/328, 530/387.9, 530/388.2

INT-CL (IPC): C07K 15/00; C07K 15/24; C12N 5/20; C12N 15/06; C12P 21/08; G01N 33/577

EUR-CL (EPC): C07K014/47; C07K016/18

ABSTRACT:

CHG DATE=19990617 STATUS=O>A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMBO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 30. Document ID: WO 2004060767 A1

L6: Entry 30 of 40

File: DWPI

Jul 22, 2004

DERWENT-ACC-NO: 2004-543827

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Sheet like seal for closing packaging container involving container halves, comprises first layer(s) with support function, and second layer(s) with sealing function

INVENTOR: DRIESSEN, J; VANMECHELEN, L

PRIORITY-DATA: 2003EP-0447203 (July 31, 2003), 2003EP-0447001 (January 6, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004060767 A1</u>	July 22, 2004	E	031	B65D055/08

INT-CL (IPC): B65 D 55/08

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

NOVELTY - Sheet like seal for closing a packaging container involving two container halves, comprises first layer(s) having a support function, and second layer(s) having a sealing function. Each container half has corresponding peripheral flanges that provide, in closed position, adjacent peripheral rims to lie on one surface and covered by the sheet like seal.

DETAILED DESCRIPTION - Sheet like seal (8) for closing a packaging container involving two container halves (2, 3), comprises first layer(s) having a support function, and second layer(s) having a sealing function. Each container half comprises corresponding peripheral flanges (4, 5) shaped in such way that the corresponding flanges provide, in closed position of the container, adjacent peripheral rims lying substantially on one surface and allow the peripheral sealing of the container halves using the sheet like seal that covers the adjacent peripheral rims (13).

INDEPENDENT CLAIMS are also included for:

(a) a packaging container, comprising two container halves closed together via corresponding peripheral flanges, and sealed using the peripheral sheet like seal as above; and

(b) a packaging method, comprising sealing two container halves by welding a peripheral sheet like seal as above over adjacent peripheral rim surfaces of corresponding peripheral flanges of the container halves.

USE - For closing a packaging container involving two container halves.

ADVANTAGE - The inventive seal is tamper proof. It has tamper evident properties. It provides visibility of the product and allows reclosing of packaging. The seal is reusable and is easy to use. It provides ease of access to the product. It increases the freshness lifetime of the product and allows extended conservation of the product with opened packaging. The seal satisfies environmental aspects by using environmental friendly recyclable materials.

DESCRIPTION OF DRAWING(S) - The figure is a perspective elevation view of a packaging container.

Container halves 2, 3

Peripheral flanges 4, 5

Sealing rim 6, 7

Seal 8

Peripheral rims 13

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 31. Document ID: EP 1435330 A1

L6: Entry 31 of 40

File: DWPI

Jul 7, 2004

DERWENT-ACC-NO: 2004-501229

DERWENT-WEEK: 200452

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Packaging container for food market, has rigid units made of transparent material, peripheral sheet sealing unit welded to rims of flanges over their entire periphery to provide hermetically closed packaging

INVENTOR: DRIESSEN, J; VANMECHELEN, L

PRIORITY-DATA: 2003EP-0447001 (January 6, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1435330 A1</u>	July 7, 2004	E	016	B65D055/08

INT-CL (IPC): B65 D 55/08

ABSTRACTED-PUB-NO: EP 1435330A

BASIC-ABSTRACT:

NOVELTY - The container has two container halves (2, 3) with peripheral flanges (4, 5) with rims (6, 7), and rigid units made of transparent material. The container halves are sealed by a peripheral sheet sealing unit (8) that covers the respective rim surfaces lying on the surface. The sealing unit is welded to the rims over their entire periphery to provide hermetically closed packaging or only over part of the rims.

DETAILED DESCRIPTION - Surfaces of rims of the flanges lie in closed position of the container on one surface. An INDEPENDENT CLAIM is also included for a packaging method comprising sealing two container halves via corresponding peripheral flanges on the container halves.

USE - Used in food markets for packing food products e.g. fresh vegetables, fruit, fresh meat and meat preparations, fresh fish and fish preparations, prepared meals, salads, cheese, cookies chocolate ice-cream preparations and pastry e.g. pies, and for non-food applications.

ADVANTAGE - The sealing unit is welded to the peripheral rims over their entire periphery to provide hermetically closed packaging or only over part of the rims, so as to provide a sufficient, tamper proof and tamper evident sealing of the packaging, thus increasing the freshness and lifetime of the food product. The rigid units are made of entirely transparent material, thus visualizing the food product. The packaging is reclosable and reusable.

DESCRIPTION OF DRAWING(S) - The drawing shows a perspective elevation view of a packaging container.

Container halves 2, 3

Peripheral flanges 4, 5

Peripheral rims 6, 7

Sealing unit 8

Supporting units 11, 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

☐ 32. Document ID: AU 2003253014 A1, WO 2004001421 A2, US 20040072261 A1

L6: Entry 32 of 40

File: DWPI

Jan 6, 2004

DERWENT-ACC-NO: 2004-071781
DERWENT-WEEK: 200447
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Screening, diagnosing and/or prognosing a mammal with neurological disorders comprises detecting, in the mammal the level of at least one proteins, e.g. Apo E, alpha-1-antitrypsin, alpha-1-beta glycoprotein, antithrombin III, or Apo A-1

INVENTOR: DE BRABANDERE, V; KOSTANJEVECKI, V ; VANMECHELEN, E

PRIORITY-DATA: 2002US-396438P (July 17, 2002), 2002EP-0447121 (June 21, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003253014 A1</u>	January 6, 2004		000	G01N033/68
<u>WO 2004001421 A2</u>	December 31, 2003	E	106	G01N033/68
<u>US 20040072261 A1</u>	April 15, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: WO2004001421A

BASIC-ABSTRACT:

NOVELTY - Screening, diagnosing and/or prognosing a mammal with neurological disorders comprising detecting, in the mammal the level of at least one of Apo E, alpha -1-antitrypsin, alpha -1- beta glycoprotein, antithrombin III, Apo A-1, Apo A-IV, Apo J, gelsolin, haptoglobin, hemopexin Ig alpha -1 chain C region (heavy), kininogen, prostaglandin-H2 D-isomerase, transthyretin, vitamin D-binding protein, Zn- alpha -2-glycoprotein or its isoform, is new.

DETAILED DESCRIPTION - Screening, (differential) diagnosing and/or prognosing a mammal with, identifying a mammal at risk of or monitoring the effect of therapy administered to a mammal having Alzheimer's disease (AD), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), vascular dementia (VAD), and/or depression comprises:

(a) detecting, in the mammal, the level of at least one of: Apo E, alpha -1-antitrypsin, alpha -1- beta glycoprotein, antithrombin III, Apo A-1, Apo A-IV, Apo J, gelsolin, haptoglobin, hemopexin Ig alpha -1 chain C region (heavy), kininogen, prostaglandin-H2 D-isomerase, transthyretin, vitamin D-binding protein, Zn- alpha -2-glycoprotein or its isoform;

(b) comparing the level of the at least one protein or protein isoform detected with a range of levels of mammals suffering from AD, FTD, DLB, VAD or depression and with range of levels of control mammals; and

(c) concluding from the comparison whether the mammal is suffering from AD, FTD, DLB, VAD or depression

A level of the at least one protein or protein isoform indicates that the mammal is suffering from AD, FTD, DLB, VAD or depression.

INDEPENDENT CLAIMS are also included for:

(1) a composition comprising at least one of the following protein isoforms associated with AD, FTD, DLB, VAD or depression Apo E: NPI 11, NPI 34, NPI 35, NPI 41, NPI 52, NPI 60, NPI 66, NPI 72, NPI 73, NPI 74, NPI 75, NPI 76, NPI 77; alpha -1-antitrypsin: NPI 1, NPI 42, NPI 43, NPI 44, NPI 59, alpha -1- beta glycoprotein: NPI 2, NPI 3, NPI 31, NPI 48; Antithrombin-III: NPI 4; Apo A-I: NPI 5, NPI 6, NPI 7, NPI 37, NPI 69, NPI 70, NPI 71; Apo A-IV: NPI 8, NPI 9, NPI 10; Apo J: NPI 12, NPI 13, NPI 14, NPI 15, NPI 16; Gelsolin: NPI 17; Haptoglobin: NPI 18; Hemopexin: NPI 19, NPI

20; Ig alpha -1 chain C region (heavy): NPI 21, NPI 22; Ig alpha -1 chain C region (heavy): Npi 21, NPI 22; Kininogen: NPI 23; Prostaglandin-H2 D-isomerase: NPI 24, NPI 25; Transthyretin: NPI 26, NPI 27, NPI 28m; Vitamin D-binding protein: NPI 29, NPI 30; Zn- alpha -2-glycoprotein: NPI 33; or NPI 32, NPI36, NPI 39-40, NPI 45-47, NPI 49-51, NPI 53-58, NPI 61-65, NPI 67 or NPI 68;

(2) an antibody capable of specifically recognizing one of the protein isoforms of (1);

(3) a kit comprising the antibody of (2); and

(4) screening for agents that interact with and/or modulate the expression or activity of a protein or protein isoform.

USE - The method is useful in screening, diagnosing and/or prognosing a mammal with neurological disorders. The antibody is useful in preparing a kit for screening, (differential) diagnosing or prognosing a mammal with, identifying a mammal at risk of or monitoring the effect of therapy administered to a mammal having AD, FTD, DLB, VAD and/or depression. (All claimed.)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 33. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

L6: Entry 33 of 40

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004502939 W</u>	January 29, 2004		059	G01N033/53
<u>WO 200203073 A1</u>	January 10, 2002	E	037	G01N033/68
<u>US 20020019016 A1</u>	February 14, 2002		000	G01N033/567
<u>AU 200179678 A</u>	January 14, 2002		000	G01N033/68
<u>EP 1295129 A1</u>	March 26, 2003	E	000	G01N033/68
<u>US 6670137 B2</u>	December 30, 2003		000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: US20020019016A

BASIC-ABSTRACT:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

ABSTRACTED-PUB-NO:

WO 200203073A EQUIVALENT-ABSTRACTS:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 34. Document ID: US 20040091942 A1, WO 200155725 A2, AU 200137319 A, EP 1250600 A2, BR 200107851 A, JP 2003521499 W, US 20030194742 A1, US 6680173 B2

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

DERWENT-ACC-NO: 2001-476242
DERWENT-WEEK: 200432
COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the ratio of phospho-tau / total tau is useful for diagnosing a tauopathy i.e. Alzheimer's disease or Pick's disease, versus a non tauopathy

INVENTOR: VANDERSTICHELE, H; VANMECHELEN, E

PRIORITY-DATA: 2000EP-0870280 (November 22, 2000), 2000EP-0870008 (January 24, 2000),
2000US-178391P (January 27, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040091942 A1</u>	May 13, 2004		000	G01N033/53
<u>WO 200155725 A2</u>	August 2, 2001	E	071	G01N033/68
<u>AU 200137319 A</u>	August 7, 2001		000	G01N033/68
<u>EP 1250600 A2</u>	October 23, 2002	E	000	G01N033/68
<u>BR 200107851 A</u>	October 29, 2002		000	G01N033/68
<u>JP 2003521499 W</u>	July 15, 2003		080	C07K007/06
<u>US 20030194742 A1</u>	October 16, 2003		000	G01N033/53
<u>US 6680173 B2</u>	January 20, 2004		000	G01N033/53

INT-CL (IPC): A61 K 38/17; A61 K 45/00; A61 P 25/28; A61 P 43/00; C07 K 7/06; C07 K 14/00; C07 K 14/47; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200155725A
BASIC-ABSTRACT:

NOVELTY - The diagnosis, (D1) of a tauopathy in an individual comprising determining the ratio of phospho-tau (181)/ total tau, is new.

DETAILED DESCRIPTION - Comparison of the phospho-tau of the patient to that in a control individual where alteration in the ratio indicates the condition. INDEPENDENT CLAIMS are included for the following:

- (1) the use of tau and phospho-tau as neurological markers;
- (2) a phospho-peptide liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270 comprising at least the minimal epitope of Ht 7: PPGQK in sequence (I) and AT270: PPAPKT(p)P in sequence (II). (I) is a 5 amino acid (aa) sequence and (II) a 7 aa sequence given in the specification;
- (3) a kit for the diagnosis of a tauopathy in and individual and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising at least:
 - (i) an antibody specifically recognizing phospho-tau;
 - (ii) an antibody recognizing tau; and
- (4) a kit for the diagnosis of a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising a peptide (2).

ACTIVITY - Nootropic; neuroprotective; cerebroprotective.

MECHANISM OF ACTION - None given.

USE - Tau and phospho tau are useful as neurological markers for the manufacture of a diagnostic kit for the diagnosis of a tauopathy and/or the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The phosphopeptide is useful to measure phospho-tau levels (claimed) and diagnose a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The

phosphopeptide is useful for the manufacture of a diagnostic kit for measuring phosphotau levels and/or diagnosing a tauopathy for the differential of a tauopathy versus a non tauopathy (claimed). The kit is useful for the diagnosis of Alzheimer's disease, Pick's disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 and or for the differential diagnosis of Alzheimer's disease, Picks's Disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 versus vascular dementia, Creutzfeldt Jacob disease, stroke and/or neurotoxicity in patients with leukemia (claimed). The phosphopeptide kits and methods are useful for therapeutic monitoring and for determining the effectiveness of a treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 35. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L6: Entry 35 of 40

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69920487 E</u>	October 28, 2004		000	G01N033/68
<u>WO 200014546 A1</u>	March 16, 2000	E	040	G01N033/68
<u>AU 9959746 A</u>	March 27, 2000		000	G01N033/68
<u>BR 9913112 A</u>	May 8, 2001		000	G01N033/68
<u>EP 1112500 A1</u>	July 4, 2001	E	000	G01N033/68
<u>CN 1325491 A</u>	December 5, 2001		000	G01N033/68
<u>JP 2002524740 W</u>	August 6, 2002		042	G01N033/53
<u>AU 772151 B2</u>	April 8, 2004		000	G01N033/68
<u>EP 1112500 B1</u>	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator of early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 36. Document ID: AU 2003200041 A1, WO 200002053 A2, AU 9950290 A, EP 1095278 A2, BR 9911291 A, CN 1316055 A, JP 2002519702 W, AU 754062 B, US 20040014142 A1

L6: Entry 36 of 40

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2000-171031

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the level of three neurological markers using antibodies useful for detection, quantification and/or differential diagnosis of Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia

INVENTOR: VAN DE VOORDE, A; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 1999EP-0870069 (April 9, 1999), 1998EP-0870148 (July 3, 1998), 1998EP-0870236 (November 3, 1998), 2003AU-0200041 (January 8, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003200041 A1</u>	April 10, 2003		000	G01N033/68
<u>WO 200002053 A2</u>	January 13, 2000	E	112	G01N033/68
<u>AU 9950290 A</u>	January 24, 2000		000	G01N033/68
<u>EP 1095278 A2</u>	May 2, 2001	E	000	G01N033/68
<u>BR 9911291 A</u>	December 4, 2001		000	G01N033/68
<u>CN 1316055 A</u>	October 3, 2001		000	G01N033/68
<u>JP 2002519702 W</u>	July 2, 2002		115	G01N033/53
<u>AU 754062 B</u>	October 31, 2002		000	G01N033/68
<u>US 20040014142 A1</u>	January 22, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/567; G01 N 33/68

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.7&ref=6&dbname=PGPB,USPT,US...> 11/16/04

NOVELTY - Detection, quantification and/or differential diagnosis of neurodegeneration in an individual, involves determining the level of three neurological markers in body fluid samples using antibodies, where the type and degree of neurodegeneration reflects a quantitative change in the levels of marker compared to a control sample.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a method for the detection of Rab3a in cerebrospinal fluid (CSF) comprising contacting a CSF sample with an antibody reactive with Rab3a, and detecting the immunological binding;
- (2) a method for detecting alpha -synuclein in CSF by contacting an antibody reactive with alpha -synuclein with CSF and detecting the immunological binding;
- (3) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual, comprising at least three antibodies each recognizing a different neurological marker;
- (4) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in individual, comprising
 - (a) a support, comprising together or separately, at least three antibodies (primary antibodies or capturing antibodies) each recognizing a different neurological marker;
 - (b) secondary antibodies (detector antibodies), each recognizing one of the neurological marker-primary antibody complexes;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibodies;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides which are specially recognized by the antibodies of the kit, used for the detection of the neurological marker;
- (5) a diagnostic kit for the detection of Rab3a in CSF, comprising at least one monoclonal antibody recognizing Rab3a;
- (6) a diagnostic kit for the detection of Rab3a in CSF, comprising
 - (a) a support, comprising a monoclonal antibody recognizing Rab3a (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the Rab3a-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides, which are specifically recognized by the antibodies of the kit, used for the detection of Rab3a;

(f) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising at least a monoclonal antibody recognizing alpha -synuclein; and

(7) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising

(a) a support comprising a monoclonal antibody recognizing alpha -synuclein (primary antibody);

(b) a secondary antibody (or detector antibody) recognizing the alpha -synuclein-primary antibody complex;

(c) possibly, a marker either for specific tagging or coupling with the secondary antibody;

(d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and

(e) possibly, for standardization purposes, purified proteins or synthetic peptides that are specifically recognized by the antibodies of the kit, used for the detection of alpha -synuclein.

USE - The method is useful for detecting Rab3a and alpha -synuclein in cerebrospinal fluid (claimed). Neurodegeneration consists of conditions including Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia (claimed). The method is also useful for differential diagnosis of Alzheimer's disease versus any of the other diseases (claimed). The reagents of the method form diagnostic kits for detecting the diseases (claimed). The method or diagnostic kit is useful for therapeutic monitoring and/or determination of the effectiveness of a certain treatment (claimed).

ADVANTAGE - The method facilitates more specific diagnosis of neurodegeneration. Assaying for three neurological markers enables differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 37. Document ID: DE 69529906 E, WO 9604309 A1, AU 9532234 A, EP 772634 A1, JP 10506381 W, AU 710952 B, US 6121003 A, EP 772634 B1

L6: Entry 37 of 40

File: DWPI

Apr 17, 2003

DERWENT-ACC-NO: 1996-129338

DERWENT-WEEK: 200333

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibodies specific for phosphorylated tau - for improved detection and diagnosis of e.g. Alzheimer's Disease

INVENTOR: VAN DE VOORDE, A; VANMECHELEN, E

PRIORITY-DATA: 1994EP-0870131 (July 29, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69529906 E</u>	April 17, 2003		000	C07K016/18
<u>WO 9604309 A1</u>	February 15, 1996	E	042	C07K016/18
<u>AU 9532234 A</u>	March 4, 1996		000	C07K016/18

EP 772634 A1	May 14, 1997	E	000	C07K016/18
JP 10506381 W	June 23, 1998		048	C07K016/18
AU 710952 B	September 30, 1999		000	C07K016/18
US 6121003 A	September 19, 2000		000	G01N033/53
EP 772634 B1	March 12, 2003	E	000	C07K016/18

INT-CL (IPC): C07 K 14/47; C07 K 16/00; C07 K 16/18; C12 N 5/10; C12 N 5/20; C12 N 9/12; C12 N 15/02; C12 N 15/06; C12 P 21/08; G01 N 33/53; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: US 6121003A

BASIC-ABSTRACT:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAbs can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MAbs of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

ABSTRACTED-PUB-NO:

WO 9604309A EQUIVALENT-ABSTRACTS:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAbs can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's

disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MABs of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	----------

☐ 38. Document ID: US 20040038430 A1, WO 9517429 A1, AU 9512736 A, EP 737208 A1, JP 09506771 W, AU 698383 B, US 6008024 A, US 6500674 B1, US 20030138972 A1, JP 2004045417 A

L6: Entry 38 of 40

File: DWPI

Feb 26, 2004

DERWENT-ACC-NO: 1995-240616

DERWENT-WEEK: 200416

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel monoclonal antibodies specific for abnormally phosphorylated paired helical filament tau protein (PHF-Tau) - useful for post mortem or in vitro detection of neurological diseases eg. Alzheimer's disease

INVENTOR: VAN DE VOORDE, A; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A V D

PRIORITY-DATA: 1993EP-0403133 (December 21, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040038430 A1</u>	February 26, 2004		000	G01N033/543
<u>WO 9517429 A1</u>	June 29, 1995	E	057	C07K016/18
<u>AU 9512736 A</u>	July 10, 1995		000	C07K016/18
<u>EP 737208 A1</u>	October 16, 1996	E	000	C07K016/18
<u>JP 09506771 W</u>	July 8, 1997		065	C12P021/08
<u>AU 698383 B</u>	October 29, 1998		000	C07K016/18
<u>US 6008024 A</u>	December 28, 1999		000	C12P021/04
<u>US 6500674 B1</u>	December 31, 2002		000	G01N033/543
<u>US 20030138972 A1</u>	July 24, 2003		000	G01N033/543
<u>JP 2004045417 A</u>	February 12, 2004		041	G01N033/53

INT-CL (IPC): C07 K 7/06; C07 K 14/47; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/20; C12 N 15/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68 ; C12 P 21/08; C12 R 1:91

ABSTRACTED-PUB-NO: US 6008024A

BASIC-ABSTRACT:

Novel monoclonal antibody (MAB) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form

and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

ABSTRACTED-PUB-NO:

WO 9517429A EQUIVALENT-ABSTRACTS:

Novel monoclonal antibody (MAb) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 39. Document ID: WO 9413795 A1, AU 9458097 A, EP 673418 A1, JP 08502898 W, EP 673418 B1, AU 690092 B, DE 69318420 E, ES 2118373 T3, US 5843779 A, US 5861257 A, JP 2879975 B2, US 6010913 A, US 6232437 B1, US 20020001857 A1, US 20030143760 A1

L6: Entry 39 of 40

File: DWPI

Jun 23, 1994

DERWENT-ACC-NO: 1994-234211

DERWENT-WEEK: 200375

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibody reactive with tau protein - used to develop prods. for detection of brain diseases involving tau or paired helical filaments esp. Alzheimer's disease

INVENTOR: MERCKEN, M; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A
V D

PRIORITY-DATA: 1992EP-0403403 (December 14, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9413795 A1</u>	June 23, 1994	E	052	C12N015/06
<u>AU 9458097 A</u>	July 4, 1994		000	C12N015/06
<u>EP 673418 A1</u>	September 27, 1995	E	000	C12N015/06
<u>JP 08502898 W</u>	April 2, 1996		057	C12P021/08
<u>EP 673418 B1</u>	May 6, 1998	E	038	C12N015/06
<u>AU 690092 B</u>	April 23, 1998		000	C12P021/08
<u>DE 69318420 E</u>	June 10, 1998		000	C12N015/06
<u>ES 2118373 T3</u>	September 16, 1998		000	C12N015/06
<u>US 5843779 A</u>	December 1, 1998		000	C12N005/06
<u>US 5861257 A</u>	January 19, 1999		000	G01N033/53

JP 2879975 B2	April 5, 1999	024	C07K016/18
US 6010913 A	January 4, 2000	000	A61K038/00
US 6232437 B1	May 15, 2001	000	A61K038/00
US 20020001857 A1	January 3, 2002	000	G01N033/531
US 20030143760 A1	July 31, 2003	000	G01N033/531

INT-CL (IPC): A61 K 38/00; A61 K 39/00; A61 K 39/395; C07 K 7/06; C07 K 7/10; C07 K 13/00; C07 K 14/47; C07 K 15/00; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/10; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/531; G01 N 33/564; G01 N 33/577; G01 N 33/68; C12 P 21/08; C12 R 1:91; C12 P 21/08; C12 R 1:91; C12 N 5/00; C12 R 1:91

ABSTRACTED-PUB-NO: EP 673418B
BASIC-ABSTRACT:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

ABSTRACTED-PUB-NO:

US 5843779A EQUIVALENT-ABSTRACTS:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally

phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 5861257A

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6010913A

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6232437B

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US20020001857A

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain

homogenate, itself isolated from the human cerebral cortex, characterised in that:
 (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

WO 9413795A

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 40. Document ID: JP 2004043487 A, WO 9308302 A1, AU 9228002 A, EP 610330 A1, JP 07502888 W, AU 662178 B, EP 610330 B1, DE 69220503 E, US 6238892 B1, US 20010018191 A1

L6: Entry 40 of 40

File: DWPI

Feb 12, 2004

DERWENT-ACC-NO: 1993-152493

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibodies binding abnormal micro-tubule-associated tau-protein - for diagnosing neurological disorders e.g. Alzheimer's disease, Downs syndrome, Picks disease, etc.

INVENTOR: MANDELKOW, E; MERCKEN, M ; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; ANDRE, V D V

PRIORITY-DATA: 1991EP-0402871 (October 25, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>JP 2004043487 A</u>	February 12, 2004		023	C07K016/18
<u>WO 9308302 A1</u>	April 29, 1993	E	047	C12P021/08
<u>AU 9228002 A</u>	May 21, 1993		000	C12P021/08
<u>EP 610330 A1</u>	August 17, 1994	E	000	C12P021/08
<u>JP 07502888 W</u>	March 30, 1995		000	C12P021/08
<u>AU 662178 B</u>	August 24, 1995		000	C12P021/08
<u>EP 610330 B1</u>	June 18, 1997	E	029	C12P021/08
<u>DE 69220503 E</u>	July 24, 1997		000	C12P021/08
<u>US 6238892 B1</u>	May 29, 2001		000	C12P021/04
<u>US 20010018191 A1</u>	August 30, 2001		000	G01N033/567

INT-CL (IPC): C07 K 2/00; C07 K 14/47; C07 K 15/00; C07 K 15/06; C07 K 15/24; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/06; C12 N 5/10; C12 N 5/12; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/564; G01 N 33/567; G01 N 33/577

ABSTRACTED-PUB-NO: EP 610330B

BASIC-ABSTRACT:

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

ABSTRACTED-PUB-NO:

US 6238892B EQUIVALENT-ABSTRACTS:

Monoclonal antibody which forms an immunological complex with a phosphorylated epitope specific for an antigen belonging to human abnormally phosphorylated tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from the cerebral cortex obtained from a patient having Alzheimer's disease or having died of Alzheimer's disease.

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

US20010018191A

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

WO 9308302A

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	-----	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
VanMechelen.IN.	40

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040091942 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 6

File: PGPB

May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091942

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040091942 A1

TITLE: Diagnosis of tauopathies

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
<u>Vanderstichele, Hugo</u>	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040014142 A1

L7: Entry 2 of 6

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014142

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014142 A1

TITLE: Differential diagnosis of neurodegeneration

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
VanMechelen, Eugene	Nazareth Eke		BE	
<u>Vanderstichele, Hugo</u>	Gent		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to new methods for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.8&ref=7&dbname=PGPB,USPT,US...> 11/16/04

making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and .alpha.-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and/or differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HTML	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 3. Document ID: US 20030194742 A1

L7: Entry 3 of 6

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194742
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194742 A1

TITLE: DIAGNOSIS OF TAUOPATHIES

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth - Eke		BE	
<u>Vanderstichele, Hugo</u>	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/350

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HTML	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 4. Document ID: US 20020019016 A1

L7: Entry 4 of 6

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Vanmechelen, Eugene	Nazareth-Eke	BE
Vanderstichele, Hugo	Gent	BE
Hulstaert, Frank	Gentbrugge	BE

US-CL-CURRENT: 435/7.21

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 5. Document ID: US 6680173 B2

L7: Entry 5 of 6

File: USPT

Jan 20, 2004

US-PAT-NO: 6680173

DOCUMENT-IDENTIFIER: US 6680173 B2

TITLE: Diagnosis of tauopathies

DATE-ISSUED: January 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Ghent			BE

US-CL-CURRENT: 435/7.1; 436/8

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

7 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugene	Nazareth-Eke			BE
<u>Vanderstichele; Hugo</u>	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.8, 436/501, 530/300, 530/350, 530/387.1

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Vanderstichele-Hugo.IN.	6

Display Format: Change Format

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

Using default format because multiple data bases are involved.

L8: Entry 1 of 4

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004502939 W	January 29, 2004		059	G01N033/53
WO 200203073 A1	January 10, 2002	E	037	G01N033/68
US 20020019016 A1	February 14, 2002		000	G01N033/567
AU 200179678 A	January 14, 2002		000	G01N033/68
EP 1295129 A1	March 26, 2003	E	000	G01N033/68
US 6670137 B2	December 30, 2003		000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 2. Document ID: US 20040091942 A1, WO 200155725 A2, AU 200137319 A, EP 1250600 A2, BR 200107851 A, JP 2003521499 W, US 20030194742 A1, US 6680173 B2

L8: Entry 2 of 4

File: DWPI

May 13, 2004

DERWENT-ACC-NO: 2001-476242

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the ratio of phospho-tau / total tau is useful for diagnosing a tauopathy i.e. Alzheimer's disease or Pick's disease, versus a non tauopathy

INVENTOR: VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000EP-0870280 (November 22, 2000), 2000EP-0870008 (January 24, 2000),

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.9&ref=8&dbname=PGPB,USPT,US...> 11/16/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20040091942 A1	May 13, 2004		000	G01N033/53
WO 200155725 A2	August 2, 2001	E	071	G01N033/68
AU 200137319 A	August 7, 2001		000	G01N033/68
EP 1250600 A2	October 23, 2002	E	000	G01N033/68
BR 200107851 A	October 29, 2002		000	G01N033/68
JP 2003521499 W	July 15, 2003		080	C07K007/06
US 20030194742 A1	October 16, 2003		000	G01N033/53
US 6680173 B2	January 20, 2004		000	G01N033/53

INT-CL (IPC): A61 K 38/17; A61 K 45/00; A61 P 25/28; A61 P 43/00; C07 K 7/06; C07 K 14/00; C07 K 14/47; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200155725A
BASIC-ABSTRACT:

NOVELTY - The diagnosis, (D1) of a tauopathy in an individual comprising determining the ratio of phospho-tau (181)/ total tau, is new.

DETAILED DESCRIPTION - Comparison of the phospho-tau of the patient to that in a control individual where alteration in the ratio indicates the condition. INDEPENDENT CLAIMS are included for the following:

- (1) the use of tau and phospho-tau as neurological markers;
- (2) a phospho-peptide liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270 comprising at least the minimal epitope of Ht 7: PPGQK in sequence (I) and AT270: PPAPKT(p)P in sequence (II). (I) is a 5 amino acid (aa) sequence and (II) a 7 aa sequence given in the specification;
- (3) a kit for the diagnosis of a tauopathy in an individual and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising at least:
 - (i) an antibody specifically recognizing phospho-tau;
 - (ii) an antibody recognizing tau; and
- (4) a kit for the diagnosis of a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising a peptide (2).

ACTIVITY - Nootropic; neuroprotective; cerebroprotective.

MECHANISM OF ACTION - None given.

USE - Tau and phospho tau are useful as neurological markers for the manufacture of a diagnostic kit for the diagnosis of a tauopathy and/or the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The phosphopeptide is useful to measure phospho-tau levels (claimed) and diagnose a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The

phosphopeptide is useful for the manufacture of a diagnostic kit for measuring phosphotau levels and/or diagnosing a tauopathy for the differential of a tauopathy versus a non tauopathy (claimed). The kit is useful for the diagnosis of Alzheimer's disease, Pick's disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 and or for the differential diagnosis of Alzheimer's disease, Pick's Disease, sporadic Frontotemporal dementia

and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 versus vascular dementia, Creutzfeldt Jacob disease, stroke and/or neurotoxicity in patients with leukemia (claimed). The phosphopeptide kits and methods are useful for therapeutic monitoring and for determining the effectiveness of a treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 3. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L8: Entry 3 of 4

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H; VANMECHELEN, E; VAN DE VOORDE, A; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69920487 E</u>	October 28, 2004		000	G01N033/68
<u>WO 200014546 A1</u>	March 16, 2000	E	040	G01N033/68
<u>AU 9959746 A</u>	March 27, 2000		000	G01N033/68
<u>BR 9913112 A</u>	May 8, 2001		000	G01N033/68
<u>EP 1112500 A1</u>	July 4, 2001	E	000	G01N033/68
<u>CN 1325491 A</u>	December 5, 2001		000	G01N033/68
<u>JP 2002524740 W</u>	August 6, 2002		042	G01N033/53
<u>AU 772151 B2</u>	April 8, 2004		000	G01N033/68
<u>EP 1112500 B1</u>	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.9&ref=8&dbname=PGPB,USPT,US...> 11/16/04

(malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator of early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	Form	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------	-----

☐ 4. Document ID: AU 2003200041 A1, WO 200002053 A2, AU 9950290 A, EP 1095278 A2, BR 9911291 A, CN 1316055 A, JP 2002519702 W, AU 754062 B, US 20040014142 A1

L8: Entry 4 of 4

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2000-171031

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the level of three neurological markers using antibodies useful for detection, quantification and/or differential diagnosis of Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia

INVENTOR: VAN DE VOORDE, A; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 1999EP-0870069 (April 9, 1999), 1998EP-0870148 (July 3, 1998), 1998EP-0870236 (November 3, 1998), 2003AU-0200041 (January 8, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003200041 A1</u>	April 10, 2003		000	G01N033/68
<u>WO 200002053 A2</u>	January 13, 2000	E	112	G01N033/68
<u>AU 9950290 A</u>	January 24, 2000		000	G01N033/68
<u>EP 1095278 A2</u>	May 2, 2001	E	000	G01N033/68
<u>BR 9911291 A</u>	December 4, 2001		000	G01N033/68
<u>CN 1316055 A</u>	October 3, 2001		000	G01N033/68
<u>JP 2002519702 W</u>	July 2, 2002		115	G01N033/53
<u>AU 754062 B</u>	October 31, 2002		000	G01N033/68
<u>US 20040014142 A1</u>	January 22, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200002053A

BASIC-ABSTRACT:

NOVELTY - Detection, quantification and/or differential diagnosis of neurodegeneration in an individual, involves determining the level of three neurological markers in body fluid samples using antibodies, where the type and degree of neurodegeneration reflects a quantitative change in the levels of marker compared to a control sample.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method for the detection of Rab3a in cerebrospinal fluid (CSF) comprising

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.9&ref=8&dbname=PGPB,USPT,US...> 11/16/04

contacting a CSF sample with an antibody reactive with Rab3a, and detecting the immunological binding;

(2) a method for detecting alpha -synuclein in CSF by contacting an antibody reactive with alpha -synuclein with CSF and detecting the immunological binding;

(3) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual, comprising at least three antibodies each recognizing a different neurological marker;

(4) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in individual, comprising

(a) a support, comprising together or separately, at least three antibodies (primary antibodies or capturing antibodies) each recognizing a different neurological marker;

(b) secondary antibodies (detector antibodies), each recognizing one of the neurological marker-primary antibody complexes;

(c) possibly, a marker either for specific tagging or coupling with the secondary antibodies;

(d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and

(e) possibly, for standardization purposes, purified proteins or synthetic peptides which are specially recognized by the antibodies of the kit, used for the detection of the neurological marker;

(5) a diagnostic kit for the detection of Rab3a in CSF, comprising at least one monoclonal antibody recognizing Rab3a;

(6) a diagnostic kit for the detection of Rab3a in CSF, comprising

(a) a support, comprising a monoclonal antibody recognizing Rab3a (primary antibody);

(b) a secondary antibody (or detector antibody) recognizing the Rab3a-primary antibody complex;

(c) possibly, a marker either for specific tagging or coupling with the secondary antibody;

(d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and

(e) possibly, for standardization purposes, purified proteins or synthetic peptides, which are specifically recognized by the antibodies of the kit, used for the detection of Rab3a;

(f) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising at least a monoclonal antibody recognizing alpha -synuclein; and

(7) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising

(a) a support comprising a monoclonal antibody recognizing alpha -synuclein (primary antibody);

(b) a secondary antibody (or detector antibody) recognizing the alpha -synuclein-primary antibody complex;

(c) possibly, a marker either for specific tagging or coupling with the secondary

antibody;

(d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and

(e) possibly, for standardization purposes, purified proteins or synthetic peptides that are specifically recognized by the antibodies of the kit, used for the detection of alpha -synuclein.

USE - The method is useful for detecting Rab3a and alpha -synuclein in cerebrospinal fluid (claimed). Neurodegeneration consists of conditions including Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia (claimed). The method is also useful for differential diagnosis of Alzheimer's disease versus any of the other diseases (claimed). The reagents of the method form diagnostic kits for detecting the diseases (claimed). The method or diagnostic kit is useful for therapeutic monitoring and/or determination of the effectiveness of a certain treatment (claimed).

ADVANTAGE - The method facilitates more specific diagnosis of neurodegeneration. Assaying for three neurological markers enables differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Vanderstichele-H.IN.	4

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 11 of 11 returned.

☐ 1. Document ID: US 20040091942 A1

Using default format because multiple data bases are involved.

L9: Entry 1 of 11

File: PGPB

May 13, 2004

PGPUB-DOCUMENT-NUMBER: 20040091942

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040091942 A1

TITLE: Diagnosis of tauopathies

PUBLICATION-DATE: May 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth-Eke		BE	
<u>Vanderstichele</u> , Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/324

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040014142 A1

L9: Entry 2 of 11

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014142

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014142 A1

TITLE: Differential diagnosis of neurodegeneration

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
VanMechelen, Eugene	Nazareth Eke		BE	
<u>Vanderstichele</u> , Hugo	Gent		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

ABSTRACT:

The present invention relates to new methods for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.10&ref=9&dbname=PGPB,USPT,U...> 11/16/04

making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and .alpha.-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and/or differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20030194742 A1

L9: Entry 3 of 11

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194742
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030194742 A1

TITLE: DIAGNOSIS OF TAUOPATHIES

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vanmechelen, Eugene	Nazareth - Eke		BE	
<u>Vanderstichele</u> , Hugo	Gent		BE	

US-CL-CURRENT: 435/7.1; 530/350

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20020019016 A1

L9: Entry 4 of 11

File: PGPB

Feb 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020019016
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020019016 A1

TITLE: Differential diagnosis of neurological diseases

PUBLICATION-DATE: February 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Vanmechelen, Eugene	Nazareth-Eke	BE
<u>Vanderstichele</u> , Hugo	Gent	BE
Hulstaert, Frank	Gentbrugge	BE

US-CL-CURRENT: 435/7.21

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 6680173 B2

L9: Entry 5 of 11

File: USPT

Jan 20, 2004

US-PAT-NO: 6680173

DOCUMENT-IDENTIFIER: US 6680173 B2

TITLE: Diagnosis of tauopathies

DATE-ISSUED: January 20, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugene	Nazareth-Eke			BE
<u>Vanderstichele</u> ; Hugo	Ghent			BE

US-CL-CURRENT: 435/7.1; 436/8

ABSTRACT:

The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.

7 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 6. Document ID: US 6670137 B2

L9: Entry 6 of 11

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugeen	Nazareth-Eke			BE
<u>Vanderstichele</u> ; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.8, 436/501, 530/300, 530/350, 530/387.1

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	Form	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 7. Document ID: FR 2666909 A1

L9: Entry 7 of 11

File: EPAB

Mar 20, 1992

PUB-NO: FR002666909A1

DOCUMENT-IDENTIFIER: FR 2666909 A1

TITLE: Method for the projection, with or without sound, of 360 DEG panoramic views on to a circular screen

PUBN-DATE: March 20, 1992

INVENTOR-INFORMATION:

NAME	COUNTRY
GILLES, VANDERSTICHELE	

US-CL-CURRENT: 352/69

INT-CL (IPC): G03B 31/00; G03B 37/04; H04N 5/74


EUR-CL (EPC): G03B037/04

ABSTRACT:

A method for projecting panoramic views covering filming angles up to 360 DEG , with or without sound messages.

The method uses an opaque or translucent circular screen (A) and whatever number of image generators (B) are required to reconstitute, in projection, the angles corresponding to the filming.

In particular, the method enables the perspective in a three-dimensional space to be created or reproduced.

Its aim is to integrate spectators (C) with the messages by placing them at the very centre of the means used for broadcasting. 

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 8. Document ID: JP 2004502939 W, WO 200203073 A1, US 20020019016 A1, AU 200179678 A, EP 1295129 A1, US 6670137 B2

L9: Entry 8 of 11

File: DWPI

Jan 29, 2004

DERWENT-ACC-NO: 2002-171654

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease involves use of phospho-tau as a neurological marker

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 2000US-218907P (July 18, 2000), 2000EP-0870151 (June 30, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004502939 W	January 29, 2004		059	G01N033/53
WO 200203073 A1	January 10, 2002	E	037	G01N033/68
US 20020019016 A1	February 14, 2002		000	G01N033/567
AU 200179678 A	January 14, 2002		000	G01N033/68
EP 1295129 A1	March 26, 2003	E	000	G01N033/68
US 6670137 B2	December 30, 2003		000	G01N033/53

INT-CL (IPC): A61 K 45/00; A61 P 21/00; A61 P 25/16; A61 P 25/28; C07 K 1/00; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/566; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: US20020019016A

BASIC-ABSTRACT:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

ABSTRACTED-PUB-NO:

WO 200203073A EQUIVALENT-ABSTRACTS:

NOVELTY - Method for differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from neurological disease involves use of phospho-tau (I) as a neurological marker.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) a diagnostic kit for use in the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease; and

(2) use of an antibody that specifically recognizes (I) for the manufacture of the diagnostic kit.

ACTIVITY - Neuroprotective; Nootropic.

MECHANISM OF ACTION - None given.

USE - As neurological marker in the differential diagnosis and in the manufacture of a diagnostic kit for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from Alzheimer's disease versus an individual suffering from another neurological disease such as dementics with Lewy bodies, Parkinson's disease without dementia, multi - system atrophy and/or progressive supranuclear palsy; and for screening or monitoring the effect on an individual of compounds which prevent or treat Alzheimer's disease and the other neurological diseases. (all claimed).

ADVANTAGE - The method is effective in the differential diagnosis of Alzheimer's disease versus another neurological disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	HOME	Draws	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	-------	-----

☐ 9. Document ID: US 20040091942 A1, WO 200155725 A2, AU 200137319 A, EP 1250600 A2, BR 200107851 A, JP 2003521499 W, US 20030194742 A1, US 6680173 B2

DERWENT-ACC-NO: 2001-476242

DERWENT-WEEK: 200432

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the ratio of phospho-tau / total tau is useful for diagnosing a tauopathy i.e. Alzheimer's disease or Pick's disease, versus a non tauopathy

INVENTOR: VANDERSTICHELE, H; VANMECHELEN, E

PRIORITY-DATA: 2000EP-0870280 (November 22, 2000), 2000EP-0870008 (January 24, 2000), 2000US-178391P (January 27, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040091942 A1</u>	May 13, 2004		000	G01N033/53
<u>WO 200155725 A2</u>	August 2, 2001	E	071	G01N033/68
<u>AU 200137319 A</u>	August 7, 2001		000	G01N033/68
<u>EP 1250600 A2</u>	October 23, 2002	E	000	G01N033/68
<u>BR 200107851 A</u>	October 29, 2002		000	G01N033/68
<u>JP 2003521499 W</u>	July 15, 2003		080	C07K007/06
<u>US 20030194742 A1</u>	October 16, 2003		000	G01N033/53
<u>US 6680173 B2</u>	January 20, 2004		000	G01N033/53

INT-CL (IPC): A61 K 38/17; A61 K 45/00; A61 P 25/28; A61 P 43/00; C07 K 7/06; C07 K 14/00; C07 K 14/47; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200155725A

BASIC-ABSTRACT:

NOVELTY - The diagnosis, (D1) of a tauopathy in an individual comprising determining the ratio of phospho-tau (181)/ total tau, is new.

DETAILED DESCRIPTION - Comparison of the phospho-tau of the patient to that in a control individual where alteration in the ratio indicates the condition. INDEPENDENT CLAIMS are included for the following:

- (1) the use of tau and phospho-tau as neurological markers;
- (2) a phospho-peptide liable to form an immunological complex with monoclonal antibody HT7 and monoclonal antibody AT270 comprising at least the minimal epitope of Ht 7: PPGQK in sequence (I) and AT270: PPAPKT(p)P in sequence (II). (I) is a 5 amino acid (aa) sequence and (II) a 7 aa sequence given in the specification;
- (3) a kit for the diagnosis of a tauopathy in and individual and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising at least:
 - (i) an antibody specifically recognizing phospho-tau;
 - (ii) an antibody recognizing tau; and
- (4) a kit for the diagnosis of a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy comprising a peptide (2).

ACTIVITY - Nootropic; neuroprotective; cerebroprotective.

MECHANISM OF ACTION - None given.

USE - Tau and phospho tau are useful as neurological markers for the manufacture of a diagnostic kit for the diagnosis of a tauopathy and/or the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The phosphopeptide is useful to measure phospho-tau levels (claimed) and diagnose a tauopathy and/or for the differential diagnosis of a tauopathy versus a non tauopathy (claimed). The

phosphopeptide is useful for the manufacture of a diagnostic kit for measuring phosphotau levels and/or diagnosing a tauopathy for the differential of a tauopathy versus a non tauopathy (claimed). The kit is useful for the diagnosis of Alzheimer's disease, Pick's disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 and or for the differential diagnosis of Alzheimer's disease, Picks's Disease, sporadic Frontotemporal dementia and/or Frontotemporal dementia with Parkinsonism linked to chromosome 17 versus vascular dementia, Creutzfeldt Jacob disease, stroke and/or neurotoxicity in patients with leukemia (claimed). The phosphopeptide kits and methods are useful for therapeutic monitoring and for determining the effectiveness of a treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 10. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L9: Entry 10 of 11

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69920487 E	October 28, 2004		000	G01N033/68
WO 200014546 A1	March 16, 2000	E	040	G01N033/68
AU 9959746 A	March 27, 2000		000	G01N033/68
BR 9913112 A	May 8, 2001		000	G01N033/68
EP 1112500 A1	July 4, 2001	E	000	G01N033/68
CN 1325491 A	December 5, 2001		000	G01N033/68
JP 2002524740 W	August 6, 2002		042	G01N033/53
AU 772151 B2	April 8, 2004		000	G01N033/68
EP 1112500 B1	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A

BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.10&ref=9&dbname=PGPB,USPT,U...> 11/16/04

with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator of early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 11. Document ID: AU 2003200041 A1, WO 200002053 A2, AU 9950290 A, EP 1095278 A2, BR 9911291 A, CN 1316055 A, JP 2002519702 W, AU 754062 B, US 20040014142 A1

L9: Entry 11 of 11

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2000-171031

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the level of three neurological markers using antibodies useful for detection, quantification and/or differential diagnosis of Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia

INVENTOR: VAN DE VOORDE, A; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 1999EP-0870069 (April 9, 1999), 1998EP-0870148 (July 3, 1998), 1998EP-0870236 (November 3, 1998), 2003AU-0200041 (January 8, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003200041 A1</u>	April 10, 2003		000	G01N033/68
<u>WO 200002053 A2</u>	January 13, 2000	E	112	G01N033/68
<u>AU 9950290 A</u>	January 24, 2000		000	G01N033/68
<u>EP 1095278 A2</u>	May 2, 2001	E	000	G01N033/68
<u>BR 9911291 A</u>	December 4, 2001		000	G01N033/68
<u>CN 1316055 A</u>	October 3, 2001		000	G01N033/68
<u>JP 2002519702 W</u>	July 2, 2002		115	G01N033/53
<u>AU 754062 B</u>	October 31, 2002		000	G01N033/68
<u>US 20040014142 A1</u>	January 22, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/567; G01 N 33/68

<http://westbtrs.9000/bin/gate.exe?f=TOC&state=ikvmks.10&ref=9&dbname=PGPB,USPT,U...> 11/16/04

NOVELTY - Detection, quantification and/or differential diagnosis of neurodegeneration in an individual, involves determining the level of three neurological markers in body fluid samples using antibodies, where the type and degree of neurodegeneration reflects a quantitative change in the levels of marker compared to a control sample.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a method for the detection of Rab3a in cerebrospinal fluid (CSF) comprising contacting a CSF sample with an antibody reactive with Rab3a, and detecting the immunological binding;
- (2) a method for detecting alpha -synuclein in CSF by contacting an antibody reactive with alpha -synuclein with CSF and detecting the immunological binding;
- (3) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual, comprising at least three antibodies each recognizing a different neurological marker;
- (4) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in individual, comprising
 - (a) a support, comprising together or separately, at least three antibodies (primary antibodies or capturing antibodies) each recognizing a different neurological marker;
 - (b) secondary antibodies (detector antibodies), each recognizing one of the neurological marker-primary antibody complexes;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibodies;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides which are specially recognized by the antibodies of the kit, used for the detection of the neurological marker;
- (5) a diagnostic kit for the detection of Rab3a in CSF, comprising at least one monoclonal antibody recognizing Rab3a;
- (6) a diagnostic kit for the detection of Rab3a in CSF, comprising
 - (a) a support, comprising a monoclonal antibody recognizing Rab3a (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the Rab3a-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides, which are specifically recognized by the antibodies of the kit, used for the detection of Rab3a;

- (f) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising at least a monoclonal antibody recognizing alpha -synucelin; and
- (7) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising
- (a) a support comprising a monoclonal antibody recognizing alpha -synuclein (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the alpha -synuclein-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides that are specifically recognized by the antibodies of the kit, used for the detection of alpha -synuclein.

USE - The method is useful for detecting Rab3a and alpha -synuclein in cerebrospinal fluid (claimed). Neurodegeneration consists of conditions including Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia (claimed). The method is also useful for differential diagnosis of Alzheimer's disease versus any of the other diseases (claimed). The reagents of the method form diagnostic kits for detecting the diseases (claimed). The method or diagnostic kit is useful for therapeutic monitoring and/or determination of the effectiveness of a certain treatment (claimed).

ADVANTAGE - The method facilitates more specific diagnosis of neurodegeneration. Assaying for three neurological markers enables differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Summary	Claims	FIGS	Draws Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	---------	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Vanderstichele.IN.	11

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 19 of 19 returned.

☐ 1. Document ID: US 20040014142 A1

Using default format because multiple data bases are involved.

L10: Entry 1 of 19

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014142

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014142 A1

TITLE: Differential diagnosis of neurodegeneration

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
VanMechelen, Eugene	Nazareth Eke		BE	
Vanderstichele, Hugo	Gent		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 435/7.1; 435/7.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20030143760 A1

L10: Entry 2 of 19

File: PGPB

Jul 31, 2003

PGPUB-DOCUMENT-NUMBER: 20030143760

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030143760 A1

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

PUBLICATION-DATE: July 31, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Vandermeeren, Marc	Geel		BE	
Vanmechelen, Eugene	Nazareth-Eke		BE	
Mercken, Marc	Turnhout		BE	
Van De Voorde, Andre	Lokeren		BE	

US-CL-CURRENT: 436/543; 435/338, 435/70.21, 530/388.26

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20020069422 A1

L10: Entry 3 of 19

File: PGPB

Jun 6, 2002

PGPUB-DOCUMENT-NUMBER: 20020069422

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020069422 A1

TITLE: NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY

PUBLICATION-DATE: June 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
FRANSEN, LUCIA	NAZARETH-EKE		BE	
DEVOS, KATHLEEN	DESTELBERGEN		BE	
<u>VAN DE VOORDE, ANDRE</u>	LOKEREN		BE	
VAN HEUVERSWYN, HUGO	KALKEN		BE	

US-CL-CURRENT: 800/8; 435/320.1, 435/325, 435/455, 800/14, 800/3

ABSTRACT:

The invention relates:

to a polypeptide containing in its peptidic chain

the amino acid sequence of 311 amino acids of FIG. 3,

or a fragment of this sequence, with said fragment being such that it is liable to produce antibodies capable of forming a complex with the amino acid sequence of FIG. 3,

or an amino acid sequence having a percentage of homology of at least 50%, preferably 75%, and advantageously 90% with the amino acid sequence of FIG. 3,

and to pharmaceutical compositions containing, as active substance, at least one of the polypeptides of the invention or of the antagonists of the polypeptides of the invention as antitumor compounds, or antiinflammatory compounds or as growth activators of T-cells and B-cells, as bone repair compounds as inducer of immunosuppressive cells, as inhibitors of anti-colony stimulating factor; or as trypanocidal agents; or part of the polypeptides of the invention, capable of binding to the above-defined receptor.

☐ 4. Document ID: US 6500674 B1

L10: Entry 4 of 19

File: USPT

Dec 31, 2002

US-PAT-NO: 6500674

DOCUMENT-IDENTIFIER: US 6500674 B1

**** See image for Certificate of Correction ****

TITLE: Method for the diagnosis of brain/neurological disease using monoclonal antibodies specific for PHF-tau, hybridomas secreting them, and antigen recognition by these antibodies and their applications

DATE-ISSUED: December 31, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 436/518; 435/7.1, 435/7.92, 435/7.93, 435/7.94, 435/7.95, 436/536, 436/63

ABSTRACT:

A method for the diagnosis of brain/neurological disease involving abnormally phosphorylated tau protein using at least one antibody chosen from the group consisting of monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

(SEQ ID NO 1) 143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile Ala Thr 160 Pro Arg Gly Ala Ala Pro Pro Gly Gln Lys Gly Gln 170 Ala Asn Ala Thr Arg Ile Pro Ala Lys Thr Pro Pro 180 Ala Pro Lys Thr Pro Pro Ser Ser Gly Glu Pro Pro 190 200 Lys Ser Gly Asp Arg Ser Gly Tyr Ser Ser Pro Gly 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg Thr Pro 220 Ser Leu Pro Thr Pro Pro Thr Arg Glu Pro Lys Lys 230 Val Ala Val Val Arg Thr Pro Pro Lys Ser Pro Ser 240 Ser Ala Lys Ser Arg Leu Gln Thr Ala Pro Val Pro 250 Met Pro Asp Leu Lys COOH

with each monoclonal body specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

32 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

☐ 5. Document ID: US 6238892 B1

L10: Entry 5 of 19

File: USPT

May 29, 2001

US-PAT-NO: 6238892

DOCUMENT-IDENTIFIER: US 6238892 B1

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mercken; Marc	Somerville	MA		
Mandelkow; Eva-Maria	Hamburg			DE
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/326, 435/331, 530/388.1

ABSTRACT:

A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

3 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 6. Document ID: US 6232437 B1

L10: Entry 6 of 19

File: USPT

May 15, 2001

US-PAT-NO: 6232437

DOCUMENT-IDENTIFIER: US 6232437 B1

TITLE: Isolated human tau peptide epitope which specifically binds monoclonal antibody AT120.

DATE-ISSUED: May 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth-Eke			BE
Mercken; Marc	Somerville	MA		
Van de Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 530/324; 530/327, 530/329, 530/402

ABSTRACT:

An isolated human tau peptide epitope which specifically binds monoclonal antibody AT120 consisting of the amino acid sequence selected from the group consisting of SEQ ID Nos. 2, 3, 4, 15, 16, 17, 18, 19 and 20.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: US 6121003 A

L10: Entry 7 of 19

File: USPT

Sep 19, 2000

US-PAT-NO: 6121003

DOCUMENT-IDENTIFIER: US 6121003 A

TITLE: Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vanmechelen; Eugene	Nazareth-Eke			BE
<u>Van De Voorde; Andre</u>	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/331, 435/7.92, 435/975, 436/503, 436/547, 436/548,
436/811, 530/387.9, 530/388.1

ABSTRACT:

The present invention relates to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which neurofibrillary tangle (NFT) is not a pathological hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: US 6010913 A

L10: Entry 8 of 19

File: USPT

Jan 4, 2000

US-PAT-NO: 6010913
DOCUMENT-IDENTIFIER: US 6010913 A

TITLE: Isolated human tau peptide

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
Vanmechelen; Eugene	Nazareth-Eke			BE
<u>Van De Voorde; Andre</u>	Lokeren			BE

US-CL-CURRENT: 436/543; 436/544, 436/545, 436/546, 530/300, 530/324

ABSTRACT:

The invention deals with isolated human tau peptide epitopes of SEQ ID Nos: 1 to 4, 7 and 15 to 20 which have the capability of binding AT120 monoclonal antibody.

2 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 9. Document ID: US 6008024 A

L10: Entry 9 of 19

File: USPT

Dec 28, 1999

US-PAT-NO: 6008024
DOCUMENT-IDENTIFIER: US 6008024 A

TITLE: Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Vanmechelen; Eugene	Nazareth			BE
<u>Van De Voorde; Andre</u>	Lokeren			BE

US-CL-CURRENT: 435/70.21; 435/331, 436/548, 530/387.9, 530/388.1

ABSTRACT:

Monoclonal antibody AT180 secreted by the hybridoma deposited at ECACC on Dec. 22, 1992 under No. 92122204, and monoclonal antibody AT270 secreted by the hybridoma deposited at ECACC on Jul. 7, 1993 under 93070774, each of which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau protein (PHF-tau) residing in the region spanning positions 143-254 with the following amino acid sequence:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.11&ref=10&dbname=PGPB,USPT,...> 11/16/04

143 150 NH.sub.2 - Lys Gly Ala Asp Gly Lys Thr Lys Ile - 160 Ala Thr Pro Arg Gly Ala
 Ala Pro Pro Gly - 170 Gln Lys Gly Gln Ala Asn Ala Thr Arg Ile - 180 Pro Ala Lys Thr
 Pro Pro Ala Pro Lys Thr - 190 Pro Pro Ser Ser Gly Glu Pro Pro Lys Ser - 200 Gly Asp
 Arg Ser Gly Tyr Ser Ser Pro Gly - 210 Ser Pro Gly Thr Pro Gly Ser Arg Ser Arg - 220
 Thr Pro Ser Leu Pro Thr Pro Pro Thr Arg - 230 Glu Pro Lys Lys Val Ala Val Val Arg Thr
 - 240 Pro Pro Lys Ser Pro Ser Ser Ala Lys Ser - 250 Arg Leu Gln Thr Ala Pro Val Pro
 Met Pro - Asp Leu Lys COOH

with each monoclonal antibody specifically detecting abnormally phosphorylated tau
 protein (PHF-tau) in cerebrospinal fluid (CSF).

8 Claims, 4 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 10. Document ID: US 5981277 A

L10: Entry 10 of 19

File: USPT

Nov 9, 1999

US-PAT-NO: 5981277

DOCUMENT-IDENTIFIER: US 5981277 A

TITLE: Polypeptides and peptides, nucleic acids coding for them, and their use in the
 field of tumor therapy, inflammation or immunology

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fransen; Lucia	Nazareth-Eke			BE
Devos; Kathleen	Destelbergen			BE
Van De Voorde; Andre	Lokeren			BE
Van Heuverswyn; Hugo	Kalken			BE

US-CL-CURRENT: 435/325; 435/252.3, 435/252.33, 435/254.11, 435/320.1, 435/364,
435/367, 435/455, 536/23.1, 536/23.5, 536/24.1, 536/24.33

ABSTRACT:

An isolated and purified nucleic acid comprising:

a nucleotide sequence which has at least 50% sequence identity, with any of the
 nucleotide sequences coding for polypeptides containing in their pepridic chains:

the amino acid sequence of 311 amino acids of FIGS. 2 or 3,

or a fragment of this sequence being such that it is able to produce antibodies
 capable of forming a complex with the amino acid sequence of FIG. 2 or 3,

or an amino acid sequence having a percentage of homology of at least 50%, with the
 amino acid sequence of FIG. 2 or 3,

or a sequence able to form a complex with antibodies raised against the amino acid
 sequence of FIG. 2 or 3,

or against pep1(m) or pep1(h)

or against pep2(m) or pep2(h)

or against pep3(m) or pep3(h)

a nucleotide sequence which hybridizes with nucleotide sequence coding for said polypeptides,

or the above-indicated nucleotide sequences wherein T is replaced by U,

or the complementary sequences of the above-mentioned nucleotide sequences and vectors containing necessary elements to promote the expression in a cellular host of polypeptides coated by nucleic acids thereof.

5 Claims, 34 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Notes	Drawing Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	--------------

☐ 11. Document ID: US 5861257 A

L10: Entry 11 of 19

File: USPT

Jan 19, 1999

US-PAT-NO: 5861257

DOCUMENT-IDENTIFIER: US 5861257 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Tokyo			JP
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.92, 435/7.95, 436/518, 436/63, 436/811

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

4 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

☐ 12. Document ID: US 5843779 A

L10: Entry 12 of 19

File: USPT

Dec 1, 1998

US-PAT-NO: 5843779

DOCUMENT-IDENTIFIER: US 5843779 A

TITLE: Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vandermeeren; Marc	Geel			BE
Mercken; Marc	Somerville	MA		
Vanmechelen; Eugene	Nazareth-Eke			BE
Van De Voorde; Andre	Lokeren			BE

US-CL-CURRENT: 435/331; 435/70.21, 530/388.1

ABSTRACT:

The invention relates to a monoclonal antibody AT 120 which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

2 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

☐ 13. Document ID: WO 9900670 A1

L10: Entry 13 of 19

File: EPAB

Jan 7, 1999

PUB-NO: WO009900670A1

DOCUMENT-IDENTIFIER: WO 9900670 A1

TITLE: METHODS FOR COVALENT IMMOBILISATION OF BIOMOLECULES TO A CARRIER BY MEANS OF A HIS-TAG

PUBN-DATE: January 7, 1999

INVENTOR-INFORMATION:

NAME	COUNTRY
BOSMAN, ALFONS	BE

VAN, WIJNENDAELE FRANS
VAN, DEN BROECK DIRK
VAN, DE VOORDE ANDRE

BE
BE
BE

INT-CL (IPC): G01 N 33/547; C07 K 17/06; C12 N 11/06
EUR-CL (EPC): C12N011/00; G01N033/543, G01N033/543

ABSTRACT:

CHG DATE=19990905 STATUS=O>The present invention relates to methods for covalent immobilisation of biomolecules to carriers and membranes, wherein the presence of a His-tag is exploited, and wherein the amino acid residues that comprise said His-tag are directly involved in the covalent bond. The present invention also provides several strategies that further augment the probability of covalent immobilisation through said His-tags, such as improving the presentation of said His-tag, choosing the appropriate reaction conditions such as pH, temperature, concentration of reagent and kinetics, increasing contact between His-tag and reactive groups of said carrier or membrane, by for instance the use of IDA or anti-His antibodies or increasing the hydrophobicity of the membrane, or shielding the rest of the biomolecule from reaction by for instance increasing the hydrophobicity of said carrier or membrane or addition of substrate or competitors or blocking otherwise reactive groups, or by choosing chemical reactions that have a high selectivity for histidine residues. A carrier can also be another biomolecule. The present invention thus also relates to a method that allows covalent cross-linking between identical or different biomolecules. When such biomolecules have a natural tendency to interact with each other to form homo- or heterodimers, a strategy of increasing contact between the reactive groups (two His-tags or one His-tag and another reactive group) can be exploited. The present invention also relates to a method of providing a simultaneous and universal system for detection of biomolecules through said His-tag.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 14. Document ID: WO 9604309 A1

L10: Entry 14 of 19

File: EPAB

Feb 15, 1996

PUB-NO: WO009604309A1

DOCUMENT-IDENTIFIER: WO 9604309 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR AN EPITOPE OF A PARTICULAR SUBCLASS OR FORM OF PHOSPHORYLATED TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION OF THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: February 15, 1996

INVENTOR-INFORMATION:

NAME

COUNTRY

VANMECHELEN, EUGEN

BE

VAN, DE VOORDE ANDRE

BE

INT-CL (IPC): C07 K 16/18; C12 N 5/20; C07 K 14/47; C12 N 15/06; C12 P 21/08; G01 N 33/577; G01 N 33/68; C12 N 9/12
EUR-CL (EPC): C07K016/18; C07K014/47, C12N009/12

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates to a monoclonal antibody

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.11&ref=10&dbname=PGPB,USPT,...> 11/16/04

which forms an immunological complex with a phosphorylated epitope of a particular subclass or form of phosphorylated tau protein without forming an immunological complex with (i) fetal tau or (ii) biopsy or autopsy derived brain material from patients having died or suffering from diseases in which NFT is not a pathological hallmark. The invention also relates to a process for diagnosing brain diseases involving monoclonal antibodies of the invention. The invention also relates to a region of the tau molecule which is specifically recognized by the monoclonal antibodies of the invention. The invention also relates to kinases or phosphorylases which specifically react with the epitope recognized by these monoclonal antibodies as well as to a method for screening compounds which interfere with the activity of these kinases and phosphorylases.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 15. Document ID: WO 9517429 A1

L10: Entry 15 of 19

File: EPAB

Jun 29, 1995

PUB-NO: WO009517429A1

DOCUMENT-IDENTIFIER: WO 9517429 A1

TITLE: MONOCLONAL ANTIBODIES SPECIFIC FOR PHF-TAU, HYBRIDOMAS SECRETING THEM, ANTIGEN RECOGNITION BY THESE ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 29, 1995

INVENTOR-INFORMATION:

NAME	COUNTRY
VANDERMEEREN, MARC	BE
VANMECHELEN, EUGEN	BE
VAN, DE VOORDE ANDRE	BE

INT-CL (IPC): C07 K 16/18; C07 K 14/47; C12 N 5/20; G01 N 33/577; G01 N 33/68
EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

CHG DATE=19990617 STATUS=O>The present invention relates more particularly to a monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated tau (PHF-tau) residing in the region spanning positions (143-254), and with said monoclonal antibody being characterized by the fact that it is capable of specifically detecting abnormally phosphorylated tau protein (PHF-tau) in cerebrospinal fluid (CSF).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 16. Document ID: WO 9413795 A1

L10: Entry 16 of 19

File: EPAB

Jun 23, 1994

PUB-NO: WO009413795A1

DOCUMENT-IDENTIFIER: WO 9413795 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU, HYBRIDOMAS SECRETING THESE ANTIBODIES, ANTIGEN RECOGNITION BY THESE MONOCLONAL

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.11&ref=10&dbname=PGPB,USPT,...> 11/16/04

ANTIBODIES AND THEIR APPLICATIONS

PUBN-DATE: June 23, 1994

INVENTOR-INFORMATION:

NAME	COUNTRY
VANDERMEEREN, MARC	BE
MERCKEN, MARC	US
VANMECHELEN, EUGEN	BE
VAN, DE VOORDE ANDRE	BE

INT-CL (IPC): C12N 15/06; C12P 21/08; C12N 5/20; C07K 15/00; G01N 33/577; G01N 33/68
 EUR-CL (EPC): C07K016/18; C07K014/47

ABSTRACT:

The invention relates to a monoclonal antibody which forms an immunological complex with an epitope of an antigen belonging to normal human tau protein as well as abnormally phosphorylated human tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from human cerebral cortex. The monoclonal antibodies of the invention can be used to detect tau and abnormally phosphorylated tau in brain extracts and in unconcentrated cerebrospinal fluid.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 17. Document ID: WO 9322437 A1

L10: Entry 17 of 19

File: EPAB

Nov 11, 1993

PUB-NO: WO009322437A1

DOCUMENT-IDENTIFIER: WO 9322437 A1

TITLE: NEW POLYPEPTIDES AND PEPTIDES, NUCLEIC ACIDS CODING FOR THEM, AND THEIR USE IN THE FIELD OF TUMOR THERAPY, INFLAMMATION OR IMMUNOLOGY

PUBN-DATE: November 11, 1993

INVENTOR-INFORMATION:

NAME	COUNTRY
FRANSEN, LUCIA	BE
DEVOS, KATHLEEN	BE
VAN, DE VOORDE ANDRE	BE
VAN, HEUVERSWYN HUGO	BE

US-CL-CURRENT: 530/350; 530/351

INT-CL (IPC): C12N 15/19; C12P 21/02; A61K 37/02; C12N 15/11; C07K 13/00; C12N 15/00; C12P 21/08; A01K 67/027

EUR-CL (EPC): C07K014/52; C07K014/525

ABSTRACT:

The invention relates: to a polypeptide containing in its peptidic chain the amino acid sequence of 311 amino acids of figure 3, or a fragment of this sequence, with said fragment being such that it is liable to produce antibodies capable of forming a complex with the amino acid sequence of figure 3, or an amino acid sequence having a

percentage of homology of at least 50 %, preferably 75 %, and advantageously 90 % with the amino acid sequence of figure 3, and to pharmaceutical compositions containing, as active substance, at least one of the polypeptides of the invention or of the antagonists of the polypeptides of the invention as antitumor compounds, or antiinflammatory compounds or as growth activators of T-cells and B-cells, as bone repair compounds as inducer of immunosuppressive cells, as inhibitors of anti-colony stimulating factor; or as trypanocidal agents; or part of the polypeptides of the invention, capable of binding to the above-defined receptor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 18. Document ID: WO 9308302 A1

L10: Entry 18 of 19

File: EPAB

Apr 29, 1993

PUB-NO: WO009308302A1

DOCUMENT-IDENTIFIER: WO 9308302 A1

TITLE: MONOCLONAL ANTIBODIES DIRECTED AGAINST THE MICROTUBULE-ASSOCIATED PROTEIN TAU

PUBN-DATE: April 29, 1993

INVENTOR-INFORMATION:

NAME	COUNTRY
MERCKEN, MARC	US
MANDELKOW, EVA-MARIA	US
VANDERMEEREN, MARC	US
VANMECHELEN, EUGEN	US
VAN, DE VOORDE ANDRE	US

US-CL-CURRENT: 435/332; 435/FOR.111, 530/328, 530/387.9, 530/388.2

INT-CL (IPC): C07K 15/00; C07K 15/24; C12N 5/20; C12N 15/06; C12P 21/08; G01N 33/577

EUR-CL (EPC): C07K014/47; C07K016/18

ABSTRACT:

CHG DATE=19990617 STATUS=O>A monoclonal antibody which forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau proteine. The tau protein can be obtained from a brain homogenate, itself isolated from the cerebral cortex of a patient having Alzheimer's disease.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 19. Document ID: EP 408463 A1

L10: Entry 19 of 19

File: EPAB

Jan 16, 1991

PUB-NO: EP000408463A1

DOCUMENT-IDENTIFIER: EP 408463 A1

TITLE: Chemiluminescent compositions, chemiluminescent processes and their uses in analytical assays.

PUBN-DATE: January 16, 1991

INVENTOR-INFORMATION:

NAME

COUNTRY

ROELANT, CHRIS

BE

VAN, DE VOORDE ANDRE

BE

VAN, HEUVERSWYN HUGO

BE

INT-CL (IPC): C12Q 1/42; C12Q 1/58; C12Q 1/68; G01N 31/22; G01N 33/52; G01N 33/543; G01N 33/577; G01N 33/58; G01N 33/68

EUR-CL (EPC): C12Q001/42; C12Q001/58, G01N033/52 , G01N033/58 , C12Q001/68 , G01N033/58

ABSTRACT:

CHG DATE=19990617 STATUS=O> The invention relates to an homogeneous hydroalcoholic chemiluminescent composition which can comprise: - a solution containing an acridine derivative, - a water-miscible alcohol, - a reducing agent. The chemiluminescent compositions of the invention are used particularly for the determination and quantification of reducing agents, pH variations in small samples, antigens or antibodies, and hybridization reactions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Summary	Claims	Form	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	---------	--------	------	------------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms

Documents

Van-de-Voorde-Andre.IN.

19

Display Format:

[Change Format](#)[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

Using default format because multiple data bases are involved.

L12: Entry 1 of 8

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 69920487 E	October 28, 2004		000	G01N033/68
WO 200014546 A1	March 16, 2000	E	040	G01N033/68
AU 9959746 A	March 27, 2000		000	G01N033/68
BR 9913112 A	May 8, 2001		000	G01N033/68
EP 1112500 A1	July 4, 2001	E	000	G01N033/68
CN 1325491 A	December 5, 2001		000	G01N033/68
JP 2002524740 W	August 6, 2002		042	G01N033/53
AU 772151 B2	April 8, 2004		000	G01N033/68
EP 1112500 B1	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 2. Document ID: AU 2003200041 A1, WO 200002053 A2, AU 9950290 A, EP 1095278 A2, BR 9911291 A, CN 1316055 A, JP 2002519702 W, AU 754062 B, US 20040014142 A1

L12: Entry 2 of 8

File: DWPI

Apr 10, 2003

DERWENT-ACC-NO: 2000-171031

DERWENT-WEEK: 200433

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Determining the level of three neurological markers using antibodies useful for detection, quantification and/or differential diagnosis of Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia

<http://westbrs.9000/bin/gate.exe?f=TOC&state=ikvmks.13&ref=12&dbname=PGPB,USPT,...> 11/16/04

INVENTOR: VAN DE VOORDE, A ; VANDERSTICHELE, H ; VANMECHELEN, E

PRIORITY-DATA: 1999EP-0870069 (April 9, 1999), 1998EP-0870148 (July 3, 1998), 1998EP-0870236 (November 3, 1998), 2003AU-0200041 (January 8, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>AU 2003200041 A1</u>	April 10, 2003		000	G01N033/68
<u>WO 200002053 A2</u>	January 13, 2000	E	112	G01N033/68
<u>AU 9950290 A</u>	January 24, 2000		000	G01N033/68
<u>EP 1095278 A2</u>	May 2, 2001	E	000	G01N033/68
<u>BR 9911291 A</u>	December 4, 2001		000	G01N033/68
<u>CN 1316055 A</u>	October 3, 2001		000	G01N033/68
<u>JP 2002519702 W</u>	July 2, 2002		115	G01N033/53
<u>AU 754062 B</u>	October 31, 2002		000	G01N033/68
<u>US 20040014142 A1</u>	January 22, 2004		000	G01N033/53

INT-CL (IPC): G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/567; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200002053A

BASIC-ABSTRACT:

NOVELTY - Detection, quantification and/or differential diagnosis of neurodegeneration in an individual, involves determining the level of three neurological markers in body fluid samples using antibodies, where the type and degree of neurodegeneration reflects a quantitative change in the levels of marker compared to a control sample.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a method for the detection of Rab3a in cerebrospinal fluid (CSF) comprising contacting a CSF sample with an antibody reactive with Rab3a, and detecting the immunological binding;
- (2) a method for detecting alpha -synuclein in CSF by contacting an antibody reactive with alpha -synuclein with CSF and detecting the immunological binding;
- (3) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual, comprising at least three antibodies each recognizing a different neurological marker;
- (4) a diagnostic kit for the specific detection, quantification and/or differential diagnosis of neurodegeneration in individual, comprising
 - (a) a support, comprising together or separately, at least three antibodies (primary antibodies or capturing antibodies) each recognizing a different neurological marker;
 - (b) secondary antibodies (detector antibodies), each recognizing one of the neurological marker-primary antibody complexes;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibodies;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides which are specially recognized by the antibodies of the kit, used for the detection of the neurological marker;

- (5) a diagnostic kit for the detection of Rab3a in CSF, comprising at least one monoclonal antibody recognizing Rab3a;
- (6) a diagnostic kit for the detection of Rab3a in CSF, comprising
 - (a) a support, comprising a monoclonal antibody recognizing Rab3a (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the Rab3a-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides, which are specifically recognized by the antibodies of the kit, used for the detection of Rab3a;
- (f) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising at least a monoclonal antibody recognizing alpha -synuclein; and
- (7) a diagnostic kit for the detection of alpha -synuclein in CSF, comprising
 - (a) a support comprising a monoclonal antibody recognizing alpha -synuclein (primary antibody);
 - (b) a secondary antibody (or detector antibody) recognizing the alpha -synuclein-primary antibody complex;
 - (c) possibly, a marker either for specific tagging or coupling with the secondary antibody;
 - (d) possibly, appropriate buffer solutions for carrying out the immunological reactions; and
 - (e) possibly, for standardization purposes, purified proteins or synthetic peptides that are specifically recognized by the antibodies of the kit, used for the detection of alpha -synuclein.

USE - The method is useful for detecting Rab3a and alpha -synuclein in cerebrospinal fluid (claimed). Neurodegeneration consists of conditions including Alzheimer's disease, Lewy Body disease, Parkinson's disease and Frontal Temporal Lobe dementia (claimed). The method is also useful for differential diagnosis of Alzheimer's disease versus any of the other diseases (claimed). The reagents of the method form diagnostic kits for detecting the diseases (claimed). The method or diagnostic kit is useful for therapeutic monitoring and/or determination of the effectiveness of a certain treatment (claimed).

ADVANTAGE - The method facilitates more specific diagnosis of neurodegeneration. Assaying for three neurological markers enables differential diagnosis of neurodegeneration.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 3. Document ID: DE 69825896 E, WO 9900670 A1, AU 9887290 A, EP 991944 A1, AU 746325 B, EP 991944 B1

DERWENT-ACC-NO: 1999-120361
 DERWENT-WEEK: 200465
 COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for covalent conjugation of bio-molecules to carrier - is achieved by exploiting presence of His-tag to use as covalent linkage

INVENTOR: BOSMAN, A; VAN DE VOORDE, A ; VAN DEN BROECK, D ; VAN WIJNENDAELE, F

PRIORITY-DATA: 1997EP-0870095 (June 25, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69825896 E</u>	September 30, 2004		000	G01N033/547
<u>WO 9900670 A1</u>	January 7, 1999	E	034	G01N033/547
<u>AU 9887290 A</u>	January 19, 1999		000	G01N033/547
<u>EP 991944 A1</u>	April 12, 2000	E	000	G01N033/547
<u>AU 746325 B</u>	April 18, 2002		000	G01N033/547
<u>EP 991944 B1</u>	August 25, 2004	E	000	G01N033/547

INT-CL (IPC): C07 K 17/00; C07 K 17/06; C12 N 11/00; C12 N 11/06; G01 N 33/547; C07 K 17/00; C12 N 11/00; C07 K 17/00; C12 N 11/00

ABSTRACTED-PUB-NO: WO 9900670A

BASIC-ABSTRACT:

A method for covalent immobilisation and/or conjugation of proteins, peptides or biomolecules to a support or carrier exploits the presence of His-tag, which is used as the covalent linkage.

USE - The method is used for purification of biomolecules.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: DE 69529906 E, WO 9604309 A1, AU 9532234 A, EP 772634 A1, JP 10506381 W, AU 710952 B, US 6121003 A, EP 772634 B1

L12: Entry 4 of 8

File: DWPI

Apr 17, 2003

DERWENT-ACC-NO: 1996-129338
 DERWENT-WEEK: 200333
 COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibodies specific for phosphorylated tau - for improved detection and diagnosis of e.g. Alzheimer's Disease

INVENTOR: VAN DE VOORDE, A ; VANMECHELEN, E

PRIORITY-DATA: 1994EP-0870131 (July 29, 1994)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69529906 E</u>	April 17, 2003		000	C07K016/18

WO 9604309 A1	February 15, 1996	E	042	C07K016/18
AU 9532234 A	March 4, 1996		000	C07K016/18
EP 772634 A1	May 14, 1997	E	000	C07K016/18
JP 10506381 W	June 23, 1998		048	C07K016/18
AU 710952 B	September 30, 1999		000	C07K016/18
US 6121003 A	September 19, 2000		000	G01N033/53
EP 772634 B1	March 12, 2003	E	000	C07K016/18

INT-CL (IPC): C07 K 14/47; C07 K 16/00; C07 K 16/18; C12 N 5/10; C12 N 5/20; C12 N 9/12; C12 N 15/02; C12 N 15/06; C12 P 21/08; G01 N 33/53; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: US 6121003A

BASIC-ABSTRACT:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAbs can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MAbs of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

ABSTRACTED-PUB-NO:

WO 9604309A EQUIVALENT-ABSTRACTS:

A new monoclonal antibody (MAb), forms an immunological complex with a phosphorylated epitope of an antigen present in a particular subclass or form of phosphorylated tau protein without forming such a complex with either foetal tau or biopsy/autopsy derived brain material from individuals suffering or having died from diseases in which neurofibrillary tangles (NFT) is not a pathological hallmark. Also claimed are: (1) a hybridoma which secretes MAb; (2) a phosphorylated peptide capable of forming an immunological complex with MAb, the peptide comprising phosphorylated parts or derivatives of a sequence (I) spanning residues 146-251 of phosphorylated tau provided in the specification; (3) a kinase which acts upon non-phosphorylated-tau to specifically introduce a phosphorylation in a region of (I), giving rise to an epitope recognised by MAb; (4) a phosphorylase which reacts specifically with an epitope provided in (I) which is recognised by MAb; and (5) a method of screening for cpds. which interfere with the activity of the kinase of (3) or the phosphorylase of (4), comprising carrying out the phosphorylation/dephosphorylation in the presence of the suspect compound, and measuring the amt. of activity which occurs. A diagnostic kit is also claimed.

USE - The MAb's can be used in a process for the in vitro detection or diagnosis of brain/neurological disease, e.g. Alzheimer's disease (AD), Down syndrome, Pick's disease, subacute sclerosing panencephalitis (SSPE) or other neurological diseases in which NFT are a pathological hallmark.

ADVANTAGE - Previously identified monoclonal antibodies that react with PHF-tau appear to be not truly PHF-tau specific when tested on fresh biopsy-derived and foetal samples from normal individuals or non-AD patients. The MAb's of the present invention detect only a subset of phosphorylated tau proteins which are truly indicative of AD in fresh biopsy samples.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawings	Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------	-----

☐ 5. Document ID: US 20040038430 A1, WO 9517429 A1, AU 9512736 A, EP 737208 A1, JP 09506771 W, AU 698383 B, US 6008024 A, US 6500674 B1, US 20030138972 A1, JP 2004045417 A

L12: Entry 5 of 8

File: DWPI

Feb 26, 2004

DERWENT-ACC-NO: 1995-240616

DERWENT-WEEK: 200416

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel monoclonal antibodies specific for abnormally phosphorylated paired helical filament tau protein (PHF-Tau) - useful for post mortem or in vitro detection of neurological diseases eg. Alzheimer's disease

INVENTOR: VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A V D

PRIORITY-DATA: 1993EP-0403133 (December 21, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040038430 A1</u>	February 26, 2004		000	G01N033/543
<u>WO 9517429 A1</u>	June 29, 1995	E	057	C07K016/18
<u>AU 9512736 A</u>	July 10, 1995		000	C07K016/18
<u>EP 737208 A1</u>	October 16, 1996	E	000	C07K016/18
<u>JP 09506771 W</u>	July 8, 1997		065	C12P021/08
<u>AU 698383 B</u>	October 29, 1998		000	C07K016/18
<u>US 6008024 A</u>	December 28, 1999		000	C12P021/04
<u>US 6500674 B1</u>	December 31, 2002		000	G01N033/543
<u>US 20030138972 A1</u>	July 24, 2003		000	G01N033/543
<u>JP 2004045417 A</u>	February 12, 2004		041	G01N033/53

INT-CL (IPC): C07 K 7/06; C07 K 14/47; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/20; C12 N 15/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/537; G01 N 33/543; G01 N 33/577; G01 N 33/68 ; C12 P 21/08; C12 R 1:91

ABSTRACTED-PUB-NO: US 6008024A

BASIC-ABSTRACT:

Novel monoclonal antibody (MAb) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is

characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

ABSTRACTED-PUB-NO:

WO 9517429A EQUIVALENT-ABSTRACTS:

Novel monoclonal antibody (MAb) which forms an immunological complex with a phosphorylated epitope of an antigen belonging to abnormally phosphorylated paired helical filament tau protein (PHF-tau) residing in the region spanning positions 143-254 with the amino acid sequence of 112 residues as given in the specification, is characterised by the fact that it is capable of specifically detecting PHF-tau in cerebrospinal fluid. Also claimed is a peptide (I) of 6-100 amino acids which specifically complexes with the novel antibodies, (I) being in phosphorylated form and comprising phosphorylated parts of the above amino acid sequence.

USE - The monoclonal antibodies are useful for post mortem or in vitro diagnosis of brain/neurological disease, eg. Alzheimer's disease, Down's syndrome, Pick's disease and other neurological disorders in which abnormally phosphorylated protein or paired helical filaments are implicated (claimed).

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: WO 9413795 A1, AU 9458097 A, EP 673418 A1, JP 08502898 W, EP 673418 B1, AU 690092 B, DE 69318420 E, ES 2118373 T3, US 5843779 A, US 5861257 A, JP 2879975 B2, US 6010913 A, US 6232437 B1, US 20020001857 A1, US 20030143760 A1

L12: Entry 6 of 8

File: DWPI

Jun 23, 1994

DERWENT-ACC-NO: 1994-234211

DERWENT-WEEK: 200375

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibody reactive with tau protein - used to develop prods. for detection of brain diseases involving tau or paired helical filaments esp. Alzheimer's disease

INVENTOR: MERCKEN, M; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; VOORDE, A
V D

PRIORITY-DATA: 1992EP-0403403 (December 14, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9413795 A1	June 23, 1994	E	052	C12N015/06
AU 9458097 A	July 4, 1994		000	C12N015/06
EP 673418 A1	September 27, 1995	E	000	C12N015/06
JP 08502898 W	April 2, 1996		057	C12P021/08
EP 673418 B1	May 6, 1998	E	038	C12N015/06
AU 690092 B	April 23, 1998		000	C12P021/08
DE 69318420 E	June 10, 1998		000	C12N015/06

<u>ES 2118373 T3</u>	September 16, 1998	000	C12N015/06
<u>US 5843779 A</u>	December 1, 1998	000	C12N005/06
<u>US 5861257 A</u>	January 19, 1999	000	G01N033/53
<u>JP 2879975 B2</u>	April 5, 1999	024	C07K016/18
<u>US 6010913 A</u>	January 4, 2000	000	A61K038/00
<u>US 6232437 B1</u>	May 15, 2001	000	A61K038/00
<u>US 20020001857 A1</u>	January 3, 2002	000	G01N033/531
<u>US 20030143760 A1</u>	July 31, 2003	000	G01N033/531

INT-CL (IPC): A61 K 38/00; A61 K 39/00; A61 K 39/395; C07 K 7/06; C07 K 7/10; C07 K 13/00; C07 K 14/47; C07 K 15/00; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/00; C12 N 5/06; C12 N 5/10; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/531; G01 N 33/564; G01 N 33/577; G01 N 33/68 ; C12 P 21/08; C12 R 1:91; C12 P 21/08; C12 R 1:91; C12 N 5/00; C12 R 1:91

ABSTRACTED-PUB-NO: EP 673418B
BASIC-ABSTRACT:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

ABSTRACTED-PUB-NO:

US 5843779A EQUIVALENT-ABSTRACTS:

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MAbs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

(A) A monoclonal antibody (MAb) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as

low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 5861257A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6010913A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US 6232437B

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

US20020001857A

(A) A monoclonal antibody (MAB) is claimed which forms an immunological complex (IC) with an epitope of an antigen belonging to human normal as well as abnormally phosphorylated tau protein, where the tau protein is obtainable from a brain homogenate, itself isolated from the human cerebral cortex, characterised in that: (i) it does not form an IC with other phosphorylated proteins such as MAP-1, MAP-2, and neurofilaments which share part of their sequence with tau protein, as determined by ELISA, (ii) it is able to detect human normal as well as abnormally phosphorylated tau protein in cerebrospinal fluid (CSF), with the tau protein being at a concn. as low as 1 pg/ml, (iii) it is able to detect the tau proteins with 100% recovery upon the addn. of a fixed amt. of tau proteins in tau-protein-negative CSF.

USE - The MABs allow the reliable and sensitive detection of normal and abnormally phosphorylated tau present in brain extracts and in unconcentrated CSF. They can be used for the detection or diagnosis of brain diseases involving tau protein and/or PHF (claimed).

WO 9413795A

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------	-----

☐ 7. Document ID: ES 2185630 T3, WO 9322437 A1, EP 639225 A1, JP 07502171 W, US 5981277 A, US 20020069422 A1, EP 639225 B1, DE 69332406 E

Il2: Entry 7 of 8

File: DWPI

May 1, 2003

DERWENT-ACC-NO: 1993-368796

DERWENT-WEEK: 200341

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New polypeptide induced in macrophage(s) by lipo-polysaccharide - useful e.g. as antitumour, antiinflammatory or trypanocidal agent, also related nucleic acid, antibodies, anti-sense cpds. etc.

INVENTOR: DEVOS, K; FRANSEN, L ; VAN DE VOORDE, A ; VAN HEUVERSWYN, H

PRIORITY-DATA: 1992EP-0401231 (April 30, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>ES 2185630 T3</u>	May 1, 2003		000	C12N015/19
<u>WO 9322437 A1</u>	November 11, 1993	E	108	C12N015/19
<u>EP 639225 A1</u>	February 22, 1995	E	000	C12N015/19
<u>JP 07502171 W</u>	March 9, 1995		000	C12N015/11
<u>US 5981277 A</u>	November 9, 1999		000	C12N005/02
<u>US 20020069422 A1</u>	June 6, 2002		000	A01K067/27
<u>EP 639225 B1</u>	October 16, 2002	E	000	C12N015/19
<u>DE 69332406 E</u>	November 21, 2002		000	C12N015/19

INT-CL (IPC): A01 K 67/00; A01 K 67/027; A01 K 67/27; A61 K 37/02; A61 K 38/00; C07 K 13/00; C07 K 14/00; C12 N 5/02; C12 N 5/06; C12 N 15/00; C12 N 15/11; C12 N 15/19; C12 P 21/02; C12 P 21/04; C12 P 21/08

ABSTRACTED-PUB-NO: US 5981277A

BASIC-ABSTRACT:

New polypeptide (I) contains in its chain (a) either of two 331 aminoacid sequences

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.13&ref=12&dbname=PGPB,USPT,...> 11/16/04

(A); (b) fragments of (A) able to generate antibodies which form a complex with (A); (c) a sequence at least 50 (best 90)% homologous with (A), or (d) a sequence able to form a complex with antibodies raised against (A) or specific fragment of it.

Also new are (1) muteins of (I) in which aminoacids are substd. deleted and/or added provided the hydropathicity profile is not altered; (2) nucleic acid (NA) encoding (A) or able to hybridise with, or complementary to, (A)-encoding NA; (3) recombinant NA contg. NA of (2) plus heterologous NA; (4) recombinant vectors contg. this NH; (5) host cells contg. these vectors; (6) antibodies (Ab) against (I); (7) nucleotide probes with hybridise with NA; (8) antisense oligonucleotides and mRNA derived from the specified NA and (9) transgenic animals contg. such NA. (A), which are reproduced in the specification together with the DNA encoding them, are gene products of mouse and human origin, induced by treating macrophages or pre-monocytic cells with lipopolysaccharide (LPS).

USE/ADVANTAGE - (I) (a) stimulate cell proliferation (esp. when costimulated with IL-4); (b) promote activation, cytotoxicity and mobilisation of LAK cells; (c) promote recruitment of suppressive peritoneal exudate cells; (d) promote generation of immunocompetent lymph node cells (LNC) and (e) have trypanocidal and trypanolytic activity. They are useful as antitumour and antiinflammatory agents; as T- and B-cell growth activators; for bone repair, to induce immunosuppressive cells; to inhibit anti-colony stimulating factors and for control of trypanosome infections. (I) can also be used as immunogens and diagnostic reagents. Ab can be used to neutralise activity of (I) and to produce anti-idiotypic (and anti-anti-idiotypic) antibodies, or as diagnostic reagents. Antisense cpds. can be used to block (I) expression while the transgenic animals (partic. those in which the homologous (I) gene is inactivated) are used for pharmacological studies and to produce various types of cells with constitutive or induced expression of (I). Transformed cells, apart from producing (I), can also be used to screen cpds. which act as ligand or receptor for (I).

ABSTRACTED-PUB-NO:

US20020069422A EQUIVALENT-ABSTRACTS:

New polypeptide (I) contains in its chain (a) either of two 331 aminoacid sequences (A); (b) fragments of (A) able to generate antibodies which form a complex with (A); (c) a sequence at least 50 (best 90)% homologous with (A), or (d) a sequence able to form a complex with antibodies raised against (A) or specific fragment of it.

Also new are (1) muteins of (I) in which aminoacids are substd. deleted and/or added provided the hydropathicity profile is not altered; (2) nucleic acid (NA) encoding (A) or able to hybridise with, or complementary to, (A)-encoding NA; (3) recombinant NA contg. NA of (2) plus heterologous NA; (4) recombinant vectors contg. this NH; (5) host cells contg. these vectors; (6) antibodies (Ab) against (I); (7) nucleotide probes with hybridise with NA; (8) antisense oligonucleotides and mRNA derived from the specified NA and (9) transgenic animals contg. such NA. (A), which are reproduced in the specification together with the DNA encoding them, are gene products of mouse and human origin, induced by treating macrophages or pre-monocytic cells with lipopolysaccharide (LPS).

USE/ADVANTAGE - (I) (a) stimulate cell proliferation (esp. when costimulated with IL-4); (b) promote activation, cytotoxicity and mobilisation of LAK cells; (c) promote recruitment of suppressive peritoneal exudate cells; (d) promote generation of immunocompetent lymph node cells (LNC) and (e) have trypanocidal and trypanolytic activity. They are useful as antitumour and antiinflammatory agents; as T- and B-cell growth activators; for bone repair, to induce immunosuppressive cells; to inhibit anti-colony stimulating factors and for control of trypanosome infections. (I) can also be used as immunogens and diagnostic reagents. Ab can be used to neutralise activity of (I) and to produce anti-idiotypic (and anti-anti-idiotypic) antibodies, or as diagnostic reagents. Antisense cpds. can be used to block (I) expression while the transgenic animals (partic. those in which the homologous (I) gene is inactivated) are used for pharmacological studies and to produce various types of cells with constitutive or induced expression of (I). Transformed cells,

apart from producing (I), can also be used to screen cpds. which act as ligand or receptor for (I).

New polypeptide (I) contains in its chain (a) either of two 331 aminoacid sequences (A); (b) fragments of (A) able to generate antibodies which form a complex with (A); (c) a sequence at least 50 (best 90)% homologous with (A), or (d) a sequence able to form a complex with antibodies raised against (A) or specific fragment of it.

Also new are (1) muteins of (I) in which aminoacids are substd. deleted and/or added provided the hydropathicity profile is not altered; (2) nucleic acid (NA) encoding (A) or able to hybridise with, or complementary to, (A)-encoding NA; (3) recombinant NA contg. NA of (2) plus heterologous NA; (4) recombinant vectors contg. this NH; (5) host cells contg. these vectors; (6) antibodies (Ab) against (I); (7) nucleotide probes with hybridise with NA; (8) antisense oligonucleotides and mRNA derived from the specified NA and (9) transgenic animals contg. such NA. (A), which are reproduced in the specification together with the DNA encoding them, are gene products of mouse and human origin, induced by treating macrophages or pre-monocytic cells with lipopolysaccharide (LPS).

USE/ADVANTAGE - (I) (a) stimulate cell proliferation (esp. when costimulated with IL-4); (b) promote activation, cytotoxicity and mobilisation of LAK cells; (c) promote recruitment of suppressive peritoneal exudate cells; (d) promote generation of immunocompetent lymph node cells (LNC) and (e) have trypanocidal and trypanolytic activity. They are useful as antitumour and antiinflammatory agents; as T- and B-cell growth activators; for bone repair, to induce immunosuppressive cells; to inhibit anti-colony stimulating factors and for control of trypanosome infections. (I) can also be used as immunogens and diagnostic reagents. Ab can be used to neutralise activity of (I) and to produce anti-idiotypic (and anti-anti-idiotypic) antibodies, or as diagnostic reagents. Antisense cpds. can be used to block (I) expression while the transgenic animals (partic. those in which the homologous (I) gene is inactivated) are used for pharmacological studies and to produce various types of cells with constitutive or induced expression of (I). Transformed cells, apart from producing (I), can also be used to screen cpds. which act as ligand or receptor for (I).

WO 9322437A

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FORM	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 8. Document ID: JP 2004043487 A, WO 9308302 A1, AU 9228002 A, EP 610330 A1, JP 07502888 W, AU 662178 B, EP 610330 B1, DE 69220503 E, US 6238892 B1, US 20010018191 A1

L12: Entry 8 of 8

File: DWPI

Feb 12, 2004

DERWENT-ACC-NO: 1993-152493

DERWENT-WEEK: 200413

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Monoclonal antibodies binding abnormal micro-tubule-associated tau-protein - for diagnosing neurological disorders e.g. Alzheimer's disease, Downs syndrome, Picks disease, etc.

INVENTOR: MANDELKOW, E; MERCKEN, M ; VAN DE VOORDE, A ; VANDERMEEREN, M ; VANMECHELEN, E ; ANDRE, V D V

PRIORITY-DATA: 1991EP-0402871 (October 25, 1991)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2004043487 A	February 12, 2004		023	C07K016/18
WO 9308302 A1	April 29, 1993	E	047	C12P021/08
AU 9228002 A	May 21, 1993		000	C12P021/08
EP 610330 A1	August 17, 1994	E	000	C12P021/08
JP 07502888 W	March 30, 1995		000	C12P021/08
AU 662178 B	August 24, 1995		000	C12P021/08
EP 610330 B1	June 18, 1997	E	029	C12P021/08
DE 69220503 E	July 24, 1997		000	C12P021/08
US 6238892 B1	May 29, 2001		000	C12P021/04
US 20010018191 A1	August 30, 2001		000	G01N033/567

INT-CL (IPC): C07 K 2/00; C07 K 14/47; C07 K 15/00; C07 K 15/06; C07 K 15/24; C07 K 16/00; C07 K 16/18; C07 K 16/40; C12 N 5/06; C12 N 5/10; C12 N 5/12; C12 N 5/20; C12 N 15/02; C12 N 15/06; C12 P 21/02; C12 P 21/04; C12 P 21/08; G01 N 33/53; G01 N 33/564; G01 N 33/567; G01 N 33/577

ABSTRACTED-PUB-NO: EP 610330B
BASIC-ABSTRACT:

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

ABSTRACTED-PUB-NO:

US 6238892B EQUIVALENT-ABSTRACTS:

Monoclonal antibody which forms an immunological complex with a phosphorylated epitope specific for an antigen belonging to human abnormally phosphorylated tau protein, with said tau protein being liable to be obtained from a brain homogenate, itself isolated from the cerebral cortex obtained from a patient having Alzheimer's disease or having died of Alzheimer's disease.

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

US20010018191A

A monoclonal antibody (MAb) forms an immunological complex with a phosphorylated

epitope of an antigen belonging to human abnormally phosphorylated tau protein which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient having Alzheimer's disease (AD) or having died from AD.

Also claimed are e.g. (B) a hybridoma which secretes a MAb as in (a); (C) peptides which can be obtd. from a brain homogenate isolated from the cerebral cortex obtd. from a patient with a MAb as in (A), etc.

USE - The MAb is able to specifically detect only abnormally phosphorylated tau protein and not react with normal tau protein. The MAb can be used for the detection or diagnosis of neurological diseases such as AD, Down's syndrome, Pick's disease or SSPE

WO 9308302A

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Van-de-Voorde-A.IN.	8

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: WO 2004067697 A2

Using default format because multiple data bases are involved.

L14: Entry 1 of 1

File: EPAB

Aug 12, 2004

PUB-NO: WO2004067697A2

DOCUMENT-IDENTIFIER: WO 2004067697 A2

TITLE: ICOS+ SUPPRESSER T CELLS

PUBN-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME

COUNTRY

VAN, GOOL STEFAAN

BE

INT-CL (IPC): C12 N 0/

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw	Desc
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------	------

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Terms	Documents
Van-Gool-Stefaan.IN.	1

Display Format: [Change Format](#)

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: WO 2004067697 A2

Using default format because multiple data bases are involved.

L15: Entry 1 of 2

File: DWPI

Aug 12, 2004

DERWENT-ACC-NO: 2004-580983

DERWENT-WEEK: 200456

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Generating suppresser T cells for controlling immune responses comprises allogeneically activating T cells in the absence of co-stimulatory signals and identifying the T cells by expression of ICOS after activation

INVENTOR: VAN GOOL, S

PRIORITY-DATA: 2003GB-0002167 (January 30, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 2004067697 A2</u>	August 12, 2004	E	030	C12N000/00

INT-CL (IPC): C12 N 0/00

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	Form	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 2. Document ID: DE 69920487 E, WO 200014546 A1, AU 9959746 A, BR 9913112 A, EP 1112500 A1, CN 1325491 A, JP 2002524740 W, AU 772151 B2, EP 1112500 B1

L15: Entry 2 of 2

File: DWPI

Oct 28, 2004

DERWENT-ACC-NO: 2000-257071

DERWENT-WEEK: 200471

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Early detection of central nervous system damage, useful e.g. for assessing treatment of brain tumors, by detecting high levels of tau protein

INVENTOR: HULSTAERT, F; VANDERSTICHELE, H ; VANMECHELEN, E ; VAN DE VOORDE, A ; VAN GOOL, S

PRIORITY-DATA: 1998EP-0870190 (September 8, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 69920487 E</u>	October 28, 2004		000	G01N033/68
<u>WO 200014546 A1</u>	March 16, 2000	E	040	G01N033/68
<u>AU 9959746 A</u>	March 27, 2000		000	G01N033/68

BR 9913112 A	May 8, 2001		000	G01N033/68
EP 1112500 A1	July 4, 2001	E	000	G01N033/68
CN 1325491 A	December 5, 2001		000	G01N033/68
JP 2002524740 W	August 6, 2002		042	G01N033/53
AU 772151 B2	April 8, 2004		000	G01N033/68
EP 1112500 B1	September 22, 2004	E	000	G01N033/68

INT-CL (IPC): C07 K 16/18; G01 N 33/15; G01 N 33/50; G01 N 33/53; G01 N 33/574; G01 N 33/577; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200014546A
BASIC-ABSTRACT:

NOVELTY - Early detection and/or quantitation of central nervous system (CNS) damage comprises determining the level of tau protein (I) in a subject and comparing this with levels in healthy controls. The damage may be caused by space-occupying lesions; invasion or metastasis; organisms; anoxia or ischemia, and/or chemical or physical agents.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(A) a kit for early diagnosis of CNS damage, containing a reagent for detecting (I); and

(B) screening or monitoring the effect of compounds used to prevent or treat CNS damage from their effect on levels of (I).

USE - The method is used to detect damage caused by particularly primary brain tumors (malignant or benign), brain metastases or subdural hematoma; metastatic leukemia, lymphoma or breast cancer; bacterial or viral encephalitis or meningitis; stroke, cerebral infarction or hemorrhage, thrombosis, perinatal asphyxia, Binswager disease or vasculitis; chemotherapeutic agents; or trauma, stroke, intracranial pressure or radiation. Especially the method is used to evaluate the effect of treatments for CNS damage.

ADVANTAGE - An elevated level of (I), a microtubule-associated protein, is a non-specific indicator of early CNS damage, i.e. long before this damage can be detected by current methods.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Van-Gool-S.IN.	2

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 8 of 8 returned.

☐ 1. Document ID: US 20040175754 A1

Using default format because multiple data bases are involved.

L23: Entry 1 of 8

File: PGPB

Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175754

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040175754 A1

TITLE: Diagnosis and monitoring of inflammation, ischemia and appendicitis

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bar-Or, David	Englewood	CO	US	
Bar-Or, Raphael	Denver	CO	US	
Winkler, James V.	Denver	CO	US	
Yukl, Richard L.	Denver	CO	US	

US-CL-CURRENT: 435/7.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20030215874 A1

L23: Entry 2 of 8

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215874

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030215874 A1

TITLE: Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gewirth, Daniel T.	Durham	NC	US	
Nicchitta, Christopher V.	Durham	NC	US	

US-CL-CURRENT: 435/7.1; 435/189, 702/19

ABSTRACT:

An isolated GRP94 ligand binding domain polypeptide, a three-dimensional crystal structure of the same, and methods of using the same to design modulators of Hsp90 proteins.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20030149997 A1

L23: Entry 3 of 8

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149997

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030149997 A1

TITLE: Diagnostics and therapeutics for arterial wall disruptive disorders

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hageman, Gregory S.	Coralville	IA	US	

US-CL-CURRENT: 800/8; 435/6, 435/7.1, 800/9

ABSTRACT:

The invention provides diagnostics, therapeutics and drug screening assays for arterial wall disruptive disorders, based on the discovery of a high level of correlation between the incidence of arterial wall disruptive disorders and the incidence of Age Related Macular Degeneration (AMD). In one embodiment, the arterial wall disruptive disorder is an aortic aneurysm.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 6635743 B1

L23: Entry 4 of 8

File: USPT

Oct 21, 2003

US-PAT-NO: 6635743

DOCUMENT-IDENTIFIER: US 6635743 B1

TITLE: Apoptosis inducing molecule II and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ebner; Reinhard	Gaithersburg	MD		
Yu; Guo-Liang	Berkeley	CA		
Ruben; Steven M.	Olney	MD		
Ullrich; Stephen	Rockville	MD		
Zhai; Yifan	Guilford	CT		

US-CL-CURRENT: 530/388.23; 435/7.1, 530/387.1, 530/387.3, 530/388.1, 530/389.1,
530/389.2, 930/144

ABSTRACT:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

39 Claims, 80 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 5. Document ID: US 6596701 B1

L23: Entry 5 of 8

File: USPT

Jul 22, 2003

US-PAT-NO: 6596701
DOCUMENT-IDENTIFIER: US 6596701 B1

TITLE: S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwartz; Dennis E.	Redmond	WA		
Vermeulen; Nicolaas M. J.	Woodinville	WA		
O'Day; Christine L.	Mountlake Terrace	WA		

US-CL-CURRENT: 514/46; 435/7.1, 528/338, 528/340

ABSTRACT:

A new paradigm of disease centers around the metabolic pathways of S-adenosyl-L-methionine (SAM), the intermediates of these pathways and other metabolic pathways influenced by the SAM pathways. Methods are provided to analyze and modulate SAM pathways associated with a disease or condition. Such methods permit identification and utilization of diagnostic and therapeutic protocols and agents for such disease states and conditions.

21 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 6. Document ID: US 6455040 B1

L23: Entry 6 of 8

File: USPT

Sep 24, 2002

US-PAT-NO: 6455040

DOCUMENT-IDENTIFIER: US 6455040 B1

TITLE: Tumor necrosis factor receptor 5

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wei; Ying-Fei	Berkeley	CA		
Ni; Jian	Rockville	MD		
Gentz; Reiner L.	Rockville	MD		
Ruben; Steven M.	Odenton	MD		

US-CL-CURRENT: 424/134.1; 424/138.1, 424/139.1, 424/143.1, 424/178.1, 435/328,
435/334, 435/7.21, 530/387.3, 530/387.9, 530/388.22

ABSTRACT:

The present invention relates to a novel human gene encoding a polypeptide which is a member of the TNF receptor family, and has now been found to bind TRAIL. More specifically, an isolated nucleic acid molecule is provided encoding a human polypeptide named tumor necrosis factor receptor-5, sometimes referred to as "TNFR-5" or "TR5," and now referred to hereinafter as "TRAIL receptor without intracellular domain" or "TRID." TRID polypeptides are also provided, as are vectors, host cells, and recombinant methods for producing the same as well as anti-TRID antibodies. The invention further relates to screening methods for identifying agonists or antagonists of TRAIL polypeptide activity. Also provided are diagnostic and therapeutic methods utilizing such compositions.

31 Claims, 24 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	----------

☐ 7. Document ID: US 6433145 B1

L23: Entry 7 of 8

File: USPT

Aug 13, 2002

US-PAT-NO: 6433145

DOCUMENT-IDENTIFIER: US 6433145 B1

**** See image for Certificate of Correction ****

TITLE: Keratinocyte derived interferon

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
LaFleur; David W.	Washington	DC		
Moore; Paul A.	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 530/351; 424/85.4, 435/7.1, 530/350

ABSTRACT:

The present invention relates to a novel KDI protein which is a member of the interferon family. In particular, isolated nucleic acid molecules are provided encoding a human interferon polypeptide, called "KDI". KDI polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of KDI activity. Also provided are therapeutic methods for treating immune system-related disorders.

92 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 8. Document ID: US 6020139 A

L23: Entry 8 of 8

File: USPT

Feb 1, 2000

US-PAT-NO: 6020139
DOCUMENT-IDENTIFIER: US 6020139 A

TITLE: S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy

DATE-ISSUED: February 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwartz; Dennis E.	Redmond	WA		
Vermeulen; Nicolaas M. J.	Woodinville	WA		
O'Day; Christine L.	Mountlake Terrace	WA		

US-CL-CURRENT: 435/7.1; 435/192, 514/556

ABSTRACT:

A new paradigm of disease centers around the metabolic pathways of S-adenosyl-L-methionine (SAM), the intermediates of these pathways and other metabolic pathways influenced by the SAM pathways. Methods are provided to analyze and modulate SAM pathways associated with a disease or condition. Such methods permit identification and utilization of diagnostic and therapeutic protocols and agents for such disease states and conditions.

18 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L22 AND anoxia	8

Display Format: [Change Format](#)

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 37 of 37 returned.

☐ 1. Document ID: US 20030224367 A1

Using default format because multiple data bases are involved.

L26: Entry 1 of 37

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224367

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224367 A1

TITLE: Novel polypeptides and nucleic acids encoding same

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Majumder, Kumud	Stamford	CT	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/69.1, 435/7.1, 514/12,
530/350, 530/387.1, 536/23.2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HOWC	Drawn Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-----------

☐ 2. Document ID: US 20020002270 A1

L26: Entry 2 of 37

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020002270

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020002270 A1

TITLE: PURIFIED ANTIGEN FOR ALZHEIMER'S DISEASE, AND METHODS OF OBTAINING AND USING SAME

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
ZINKOWSKI, RAYMOND P.	NORTHBROOK	IL	US	
KERKMAN, DANIEL J.	LAKE VILLA	IL	US	
KOHNKEN, RUSSELL E.	SKOKIE	IL	US	
DEBERNARDIS, JOHN F.	LINDENHURST	IL	US	
DAVIES, PETER	RYE	NY	US	

US-CL-CURRENT: 530/387.1; 435/7.1, 436/501

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.27&ref=26&dbname=PGPB,USPT,...> 11/16/04

The invention relates, among other things, a preparation comprising Alzheimer's disease antigen (A68), as well as methods of obtaining this purified antigen, and methods of using this purified antigen, for instance, for diagnosing Alzheimer's disease and for detecting human autoantibodies to the Alzheimer disease antigen. The antigen preparation according to the invention is purified in that it is substantially free of immunoglobulin G. The invention further relates to methods of making Alzheimer disease antigens that can be used instead of or along with the A68 antigen preparation (e.g., for diagnosing AD), such as recombinant human tau, tau isolated from various species including human, and phosphorylated recombinant human tau or isolated tau, as well as A68 anti-idiotypic antibodies.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20010024650 A1

L26: Entry 3 of 37

File: PGPB

Sep 27, 2001

PGPUB-DOCUMENT-NUMBER: 20010024650

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010024650 A1

TITLE: Artery - and vein-specific proteins and uses therefor

PUBLICATION-DATE: September 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Wang, Hai U.	Pasadena	CA	US	
Chen, Zhoufeng	Pasadena	CA	US	
Anderson, David J.	Altadena	CA	US	

US-CL-CURRENT: 424/185.1; 435/325, 435/6, 435/7.1, 435/7.2, 530/387.1, 536/23.5, 800/13

ABSTRACT:

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 6787637 B1

L26: Entry 4 of 37

File: USPT

Sep 7, 2004

US-PAT-NO: 6787637

DOCUMENT-IDENTIFIER: US 6787637 B1

TITLE: N-Terminal amyloid-.beta. antibodies

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.27&ref=26&dbname=PGPB,USPT,...> 11/16/04

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of A.beta. and antibodies binding to the same.

7 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 5. Document ID: US 6761888 B1

L26: Entry 5 of 37

File: USPT

Jul 13, 2004

US-PAT-NO: 6761888

DOCUMENT-IDENTIFIER: US 6761888 B1

TITLE: Passive immunization treatment of Alzheimer's disease

DATE-ISSUED: July 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

36 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 6. Document ID: US 6750324 B1

L26: Entry 6 of 37

File: USPT

Jun 15, 2004

US-PAT-NO: 6750324

DOCUMENT-IDENTIFIER: US 6750324 B1

TITLE: Humanized and chimeric N-terminal amyloid beta-antibodies

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		
Bard; Frederique	Pacifica	CA		
Yednock; Theodore	Forest Knolls	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

12 Claims, 25 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: US 6743427 B1

L26: Entry 7 of 37

File: USPT

Jun 1, 2004

US-PAT-NO: 6743427

DOCUMENT-IDENTIFIER: US 6743427 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 8. Document ID: US 6692930 B2

L26: Entry 8 of 37

File: USPT

Feb 17, 2004

US-PAT-NO: 6692930

DOCUMENT-IDENTIFIER: US 6692930 B2

**** See image for Certificate of Correction ****

TITLE: Monoclonal antibodies specific to cooked meats

DATE-ISSUED: February 17, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hsieh; Y. H. Peggy	Auburn	AL		

US-CL-CURRENT: 435/7.92; 424/141.1, 424/152.1, 435/332, 435/7.1, 435/7.94, 436/548, 530/387.1

ABSTRACT:

Monoclonal antibodies are provided which bind to heat-treated proteins of meats. The antibodies are useful in detecting the presence of an exogenous meat in a cooked or raw meat sample. Furthermore, the antibodies can be used to determine the end point temperature of a meat sample.

10 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 9. Document ID: US 6689607 B2

L26: Entry 9 of 37

File: USPT

Feb 10, 2004

US-PAT-NO: 6689607

DOCUMENT-IDENTIFIER: US 6689607 B2

TITLE: Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

DATE-ISSUED: February 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/331; 435/326, 435/328, 435/330, 435/334, 435/343.2, 435/344.1,
435/7.1, 530/387.1, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.15,
530/388.22, 530/388.75, 530/388.8, 530/388.85, 530/389.1, 530/389.7, 530/391.1,
530/391.3

ABSTRACT:

The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. The present invention further relates to antibodies that specifically bind TR11, TR11SV1, and/or TR11SV2. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.

60 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 10. Document ID: US 6673902 B2

L26: Entry 10 of 37

File: USPT

Jan 6, 2004

US-PAT-NO: 6673902

DOCUMENT-IDENTIFIER: US 6673902 B2

TITLE: Cyclin D binding factor, and uses thereof

DATE-ISSUED: January 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sherr; Charles J.	Memphis	TN		
Hirai; Hiroshi	Ibaraki			JP
Bodner; Sara M.	New Haven	CT		
Inoue; Kazushi	Memphis	TN		

US-CL-CURRENT: 530/387.1; 530/387.9

ABSTRACT:

The invention discloses a direct interaction between D-type cyclins and a novel myb-

like transcription factor, DMP1, which specifically interacts with cyclin D2. The present invention also provides evidence that D-type cyclins regulate gene expression in an RB-independent manner. Also included is DMP1, the transcription factor composed of a central DNA-binding domain containing three atypical myb repeats flanked by highly acidic segments located at its amino- and carboxyterminal ends. The invention includes amino acid sequences coding for DMP1, and DNA and RNA nucleotide sequences that encode the amino acid sequences. A use of DMP1 as a transcription factor is disclosed due to its specificity in binding to oligonucleotides containing the nonamer consensus sequence CCCG(G/T)ATGT. In this aspect of the invention, DMP1 when transfected into mammalian cells, activates the transcription of a reporter gene driven by a minimal promoter containing concatamerized DMP1 binding sites.

4 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 11. Document ID: US 6670137 B2

L26: Entry 11 of 37

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
VanMechelen; Eugene	Nazareth-Eke			BE
Vanderstichele; Hugo	Gent			BE
Hulstaert; Frank	Gentbrugge			BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.8, 436/501, 530/300, 530/350, 530/387.1

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 12. Document ID: US 6635743 B1

L26: Entry 12 of 37

File: USPT

Oct 21, 2003

US-PAT-NO: 6635743

DOCUMENT-IDENTIFIER: US 6635743 B1

TITLE: Apoptosis inducing molecule II and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ebner; Reinhard	Gaithersburg	MD		
Yu; Guo-Liang	Berkeley	CA		
Ruben; Steven M.	Olney	MD		
Ullrich; Stephen	Rockville	MD		
Zhai; Yifan	Guilford	CT		

US-CL-CURRENT: 530/388.23; 435/7.1, 530/387.1, 530/387.3, 530/388.1, 530/389.1, 530/389.2, 930/144

ABSTRACT:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as tumor cell growth.

39 Claims, 80 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 13. Document ID: US 6635482 B1

L26: Entry 13 of 37

File: USPT

Oct 21, 2003

US-PAT-NO: 6635482

DOCUMENT-IDENTIFIER: US 6635482 B1

TITLE: Monoclonal antibodies to membrane neutrokin-.alpha.

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		

Ni; Jian Rockville MD
Rosen; Craig A. Laytonsville MD

US-CL-CURRENT: 435/326; 435/328, 435/331, 435/4, 530/387.1, 530/387.3, 530/387.9,
530/388.1, 530/388.15

ABSTRACT:

The present invention relates to a novel Neutrokin- α , and a splice variant thereof designated Neutrokin- α SV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokin- α and/or Neutrokin- α SV polypeptides, including soluble forms of the extracellular domain. Neutrokin- α and/or Neutrokin- α SV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokin- α and/or Neutrokin- α SV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

32 Claims, 34 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 14. Document ID: US 6566495 B1

L26: Entry 14 of 37

File: USPT

May 20, 2003

US-PAT-NO: 6566495

DOCUMENT-IDENTIFIER: US 6566495 B1

TITLE: Very large scale immobilized polymer synthesis

DATE-ISSUED: May 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fodor; Stephen P. A.	Palo Alto	CA		
Stryer; Lubert	Stanford	CA		
Read; J. Leighton	Palo Alto	CA		
Pirrung; Michael C.	Durham	NC		

US-CL-CURRENT: 530/334; 435/6, 435/7.1, 530/300, 530/335, 530/336, 530/337, 530/350,
530/387.1, 536/24.3, 536/25.3, 536/25.31

ABSTRACT:

A synthetic strategy for the creation of large scale chemical diversity. Solid-phase chemistry, photolabile protecting groups, and photolithography are used to achieve light-directed spatially-addressable parallel chemical synthesis. Binary masking techniques are utilized in one embodiment. A reactor system, photoremovable protective groups, and improved data collection and handling techniques are also disclosed. A technique for screening linker molecules is also provided.

44 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 17

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 15. Document ID: US 6555110 B1

L26: Entry 15 of 37

File: USPT

Apr 29, 2003

US-PAT-NO: 6555110
DOCUMENT-IDENTIFIER: US 6555110 B1

TITLE: Microencapsulated compounds and method of preparing same

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
D'Souza; Martin J.	Sugar Hill	GA		

US-CL-CURRENT: 424/130.1; 424/145.1, 424/158.1, 424/491, 424/499, 514/2, 530/350,
530/387.1, 530/388.24, 530/389.2

ABSTRACT:

Compositions useful in treating immune modulated disease comprising an anticytokine antibody or immune active drug capable of modifying cytokine activity or modulating the immune system microencapsulated with a biodegradable nonantigenic material, such as albumin or PLGA. When the composition is introduced into a subject, it is phagocytosed by the target organ, the target organ digests the microsphere, releasing the drug or an active form or fragment thereof intracellularly. The drug then modifies the target organ function, thereby modulating it's activity. A method is disclosed for preparation of the microencapsulated composition.

29 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 16. Document ID: US 6413755 B1

L26: Entry 16 of 37

File: USPT

Jul 2, 2002

US-PAT-NO: 6413755
DOCUMENT-IDENTIFIER: US 6413755 B1
**** See image for Certificate of Correction ****

TITLE: Human checkpoint kinase, HCDS1, compositions and methods

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.27&ref=26&dbname=PGPB,USPT,...> 11/16/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Luyten; Walter H. M. L.	Beerse			BE
Parker; Andrew E.	Cheshire			GB
McGowan; Clare	Del Mar	CA		
Blasina; Alessandra	San Diego	CA		

US-CL-CURRENT: 435/194; 435/183, 435/69.1, 530/350, 530/387.1, 536/23.1

ABSTRACT:

The invention provides for a novel human checkpoint kinase gene, hCDS 1, translated protein, compositions, methods, and kits.

1 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 17. Document ID: US 6410687 B1

L26: Entry 17 of 37

File: USPT

Jun 25, 2002

US-PAT-NO: 6410687

DOCUMENT-IDENTIFIER: US 6410687 B1

TITLE: Polypeptides for the detection of microtubule depolymerization inhibitors

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vale; Ronald D.	San Francisco	CA		
Hartman; James J.	San Francisco	CA		

US-CL-CURRENT: 530/350; 530/386, 530/387.1

ABSTRACT:

This invention provides methods for the screening and identification of agents having potent effects on the progression of the cell cycle. In one embodiment, the methods involve contacting a polymerized microtubule with a microtubule severing protein or a microtubule depolymerizing protein in the presence of an ATP or a GTP and a test agent; and detecting the formation of tubulin monomers, dimers or oligomers. The p60 subunit of katanin provides a particularly preferred microtubule severing protein possessing both ATPase and microtubule severing activities.

4 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 18. Document ID: US 6406867 B1

L26: Entry 18 of 37

File: USPT

Jun 18, 2002

US-PAT-NO: 6406867

DOCUMENT-IDENTIFIER: US 6406867 B1

**** See image for Certificate of Correction ****

TITLE: Antibody to human endokine alpha and methods of use

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.2; 424/130.1, 424/139.1, 424/141.1, 424/142.1, 424/158.1,
530/387.1, 530/387.9, 530/388.1, 530/388.15, 530/388.24, 530/389.2

ABSTRACT:

The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Antibodies and antibody fragments which specifically bind the polypeptides of the invention are also provided, as well as methods for detecting the polypeptides of the invention using said antibodies and antibody fragments. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

56 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

☐ 19. Document ID: US 6372215 B1

L26: Entry 19 of 37

File: USPT

Apr 16, 2002

US-PAT-NO: 6372215

DOCUMENT-IDENTIFIER: US 6372215 B1

TITLE: Monoclonal antibodies to human CD6

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Starling; Gary C.	Lawrenceville	NJ		
Siadak; Anthony W.	Seattle	WA		
Bowen; Michael A.	Princeton	NJ		
Aruffo; Alejandro A.	Belle Mead	NJ		

Bajorath; Jurgen	Lynnwood	WA
Bodian; Dale L.	Paoli	PA
Skonier; John E.	Seattle	WA

US-CL-CURRENT: 424/141.1; 424/130.1, 424/133.1, 424/134.1, 424/178.1, 424/801,
435/7.1, 435/7.2, 435/7.25, 435/70.1, 435/70.2, 436/548, 530/350, 530/386, 530/387.1,
530/388.1, 530/391.1, 530/808, 530/864

ABSTRACT:

The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.

16 Claims, 25 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 20. Document ID: US 6365716 B1

L26: Entry 20 of 37

File: USPT

Apr 2, 2002

US-PAT-NO: 6365716

DOCUMENT-IDENTIFIER: US 6365716 B1

TITLE: Antibodies to lipocalin homologs

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Conklin; Darrell C.	Seattle	WA		

US-CL-CURRENT: 530/387.9; 530/350, 530/387.1, 530/388.1, 530/388.2, 530/389.1,
530/391.1, 530/391.3, 530/391.7

ABSTRACT:

The present invention is directed to antibodies to polypeptides for a member of the lipocalin family. The expression of the polypeptide is restricted to testis and mammary gland, particularly breast tumor tissue. The polypeptide has been designated zlipol.

4 Claims, 5 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 21. Document ID: US 6261535 B1

L26: Entry 21 of 37

File: USPT

Jul 17, 2001

US-PAT-NO: 6261535

DOCUMENT-IDENTIFIER: US 6261535 B1

**** See image for Certificate of Correction ****

TITLE: Diagnostic methods for targeting the vasculature of solid tumors

DATE-ISSUED: July 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	San Diego	CA		

US-CL-CURRENT: 424/1.49; 424/130.1, 424/133.1, 424/142.1, 424/145.1, 424/155.1,
424/156.1, 424/178.1, 424/179.1, 424/181.1, 424/183.1, 424/186.1, 424/9.32,
424/9.323, 424/9.34, 424/9.341, 424/9.36, 424/9.42, 530/387.1 , 530/388.1,
530/388.15, 530/388.22, 530/391.3, 530/391.7

ABSTRACT:

The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.

27 Claims, 37 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------------

☐ 22. Document ID: US 6245899 B1

L26: Entry 22 of 37

File: USPT

Jun 12, 2001

US-PAT-NO: 6245899

DOCUMENT-IDENTIFIER: US 6245899 B1

TITLE: Composition for detection of cell density signal molecule

DATE-ISSUED: June 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schwarz; Richard I.	Oakland	CA		

US-CL-CURRENT: 530/389.2; 530/387.1, 530/388.1

ABSTRACT:

Disclosed herein is a novel proteinaceous cell density signal molecule (CDS), which is secreted by fibroblastic cells in culture, preferably tendon cells, and which provides a means by which the cells self-regulate their proliferation and the expression of differentiated function. CDS, and the antibodies which recognize them, are important for the development of diagnostics and treatments for injuries and diseases involving connective tissues, particularly tendon. Also disclosed are methods of production and use.

13 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----

☐ 23. Document ID: US 6210905 B1

L26: Entry 23 of 37

File: USPT

Apr 3, 2001

US-PAT-NO: 6210905
DOCUMENT-IDENTIFIER: US 6210905 B1

TITLE: Tumor necrosis factor stimulated gene 6 (TSG-6) binding molecules

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae Ho	Seoul			KR
Wisniewski; Hans-Georg	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 435/7.1; 436/501, 530/387.1, 530/388.1

ABSTRACT:

TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as plasmids, and host cells transformed or transfected with the DNA molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

5 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----

☐ 24. Document ID: US 6207815 B1

L26: Entry 24 of 37

File: USPT

Mar 27, 2001

US-PAT-NO: 6207815

DOCUMENT-IDENTIFIER: US 6207815 B1

TITLE: Family of high affinity, modified antibodies for cancer treatment

DATE-ISSUED: March 27, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mezes; Peter S.	Midland	MI		
Gourlie; Brian B.	Midland	MI		
Rixon; Mark W.	Midland	MI		
Schlom; Jeffrey	Potomac	MD		
Kaplan; Donald A.	Cincinnati	OH		
Anderson; W. H. Kerr	Midland	MI		

US-CL-CURRENT: 536/23.53; 435/326, 435/328, 435/69.1, 435/70.21, 530/387.1,
530/387.3, 530/388.8, 530/391.1

ABSTRACT:

This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal V.sub.H and V.sub.L sequences which mediate TAG-72 binding and (2) human C.sub.H and C.sub.L regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human C.sub.H and C.sub.L antibody domains. The nucleotide and amino acid sequences of V.sub.H.alpha.TAG V.sub.H, CC46 V.sub.H, CC49.sub.H, CC83 V.sub.H, and CC92 V.sub.H, and CC49.sub.L, CC83 V.sub.L, and CC92 V.sub.L idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.

7 Claims, 46 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 62

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 25. Document ID: US 6172199 B1

L26: Entry 25 of 37

File: USPT

Jan 9, 2001

US-PAT-NO: 6172199

DOCUMENT-IDENTIFIER: US 6172199 B1

**** See image for Certificate of Correction ****

TITLE: Human ubiquitin-conjugating enzyme

DATE-ISSUED: January 9, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Au-Young; Janice	Berkeley	CA		
Goli; Surya K.	Sunnyvale	CA		
Hillman; Jennifer L.	San Jose	CA		

US-CL-CURRENT: 530/387.9; 424/134.1, 424/139.1, 424/141.1, 424/146.1, 435/326,
435/331, 435/338, 435/346, 435/69.1, 435/69.2, 435/7.1, 530/350, 530/387.1,
530/388.1, 530/388.26, 536/23.2, 536/23.5

ABSTRACT:

The present invention provides a polynucleotide (ubcp) which identifies and encodes a novel ubiquitin-conjugating enzyme (UBCP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding UBCP. The invention also provides for the use of substantially purified UBCP and its agonists, antagonists, or inhibitors in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of UBCP. Additionally, the invention provides for the use of antisense molecules to ubcp in pharmaceutical compositions for treatment of diseases associated with the expression of UBCP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of ubcp or anti-UBCP antibodies which specifically bind to UBCP.

11 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 26. Document ID: US 6086900 A

L26: Entry 26 of 37

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900

DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3,
435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 27. Document ID: US 6063905 A

L26: Entry 27 of 37

File: USPT

May 16, 2000

US-PAT-NO: 6063905

DOCUMENT-IDENTIFIER: US 6063905 A

**** See image for Certificate of Correction ****

TITLE: Recombinant human IGA-J. chain dimer

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capra; J. Donald	Dallas	TX		
Hexham; Jonathan M.	Dallas	TX		
Carayannopoulos; Leon N.	St Louis	MO		
Max; Edward E.	Bethesda	MD		

US-CL-CURRENT: 530/387.3; 424/130.1, 424/133.1, 435/328, 530/387.1, 530/390.1

ABSTRACT:

Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.

102 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 28. Document ID: US 6051230 A

L26: Entry 28 of 37

File: USPT

Apr 18, 2000

US-PAT-NO: 6051230

DOCUMENT-IDENTIFIER: US 6051230 A

**** See image for Certificate of Correction ****

TITLE: Compositions for targeting the vasculature of solid tumors

DATE-ISSUED: April 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	San Diego	CA		

US-CL-CURRENT: 424/178.1; 424/179.1, 424/180.1, 424/181.1, 424/182.1, 424/183.1,
530/387.1, 530/387.7, 530/388.1, 530/388.2

ABSTRACT:

The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.

61 Claims, 37 Drawing figures
Exemplary Claim Number: 1,11,40
Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 29. Document ID: US 6025197 A

L26: Entry 29 of 37

File: USPT

Feb 15, 2000

US-PAT-NO: 6025197

DOCUMENT-IDENTIFIER: US 6025197 A

TITLE: Secreted salivary zsig32 polypeptides

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 435/325; 435/320.1, 530/350, 530/387.1, 536/23.4, 536/23.5, 536/24.1

ABSTRACT:

The present invention relates to polynucleotide and polypeptide molecules for secreted salivary zsig32 polypeptides. The polypeptides, and polynucleotides encoding them modulate adhesion or modulate or indicate salivary gland function. The present invention also includes antibodies and binding proteins for the zsig32 polypeptides.

20 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 30. Document ID: US 5976816 A

L26: Entry 30 of 37

File: USPT

Nov 2, 1999

US-PAT-NO: 5976816

DOCUMENT-IDENTIFIER: US 5976816 A

TITLE: Cell tests for alzheimer's disease

DATE-ISSUED: November 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alkon; Daniel L.	Bethesda	MD		
Etcheberrigaray; Rene	Rockville	MD		
Kim; Christopher S.	Silver Spring	MD		
Han; Yi-Fan	Shanghai			CN
Nelson; Tom J.	Silver Spring	MD		

US-CL-CURRENT: 435/7.21; 435/7.1, 435/7.92, 436/548, 530/300, 530/387.1

ABSTRACT:

The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.

9 Claims, 49 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 30

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 31. Document ID: US 5958684 A

L26: Entry 31 of 37

File: USPT

Sep 28, 1999

US-PAT-NO: 5958684

DOCUMENT-IDENTIFIER: US 5958684 A

TITLE: Diagnosis of neurodegenerative disease

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Leeuwen; Frederik Willem	3063CL Maarssen			NL
Burbach; Johannes Peter Henri	3981 SB Bunnik			NL
Grosveld; Franklin G.	3065 NH Rotterdam			NL

US-CL-CURRENT: 435/6; 435/7.1, 435/91.2, 530/350, 530/387.1, 536/23.1, 536/23.5,
536/24.3, 536/24.33

ABSTRACT:

The invention encompasses methods and reagents for the diagnosis of a disease caused by or associated with a gene having a somatic mutation giving rise to a frameshift mutation. The methods include the steps of providing a body fluid or tissue sample from a patient; and analyzing the sample for the presence of a gene having a frameshift mutation or a protein encoded thereby, wherein the presence of the mutated gene or encoded protein is indicative of the disease.

12 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 32. Document ID: US 5914111 A

L26: Entry 32 of 37

File: USPT

Jun 22, 1999

US-PAT-NO: 5914111
DOCUMENT-IDENTIFIER: US 5914111 A

TITLE: CD2-binding domain of lymphocyte function associated antigen-3

DATE-ISSUED: June 22, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wallner; Barbara P.	Cambridge	MA		
Miller; Glenn T.	Haverhill	MA		
Rosa; Margaret D.	Winchester	MA		

US-CL-CURRENT: 424/134.1; 424/153.1, 424/173.1, 424/182.1, 424/185.1, 424/192.1,
435/69.7, 514/12, 530/324, 530/387.1

ABSTRACT:

Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed.

6 Claims, 47 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 31

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 33. Document ID: US 5864018 A

L26: Entry 33 of 37

File: USPT

Jan 26, 1999

US-PAT-NO: 5864018

DOCUMENT-IDENTIFIER: US 5864018 A

**** See image for Certificate of Correction ****

TITLE: Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor

DATE-ISSUED: January 26, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morser; Michael John	San Francisco	CA		
Nagashima; Mariko	Belmont	CA		

US-CL-CURRENT: 530/387.1; 530/387.3, 530/388.1, 530/388.22, 530/391.3

ABSTRACT:

It is a general object of the present invention to provide compositions that specifically interact with advanced glycosylation end products (AGEs) or their receptors. Such compositions may be used in a variety of applications including therapeutic applications, e.g., as blocking agents to inhibit or otherwise reduce the AGE/RAGE interaction, screening applications, e.g., as models of the AGE/RAGE interaction, and diagnostic applications, e.g., to identify abnormal levels of AGE or RAGE in a given system.

10 Claims, 27 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 34. Document ID: US 5855866 A

L26: Entry 34 of 37

File: USPT

Jan 5, 1999

US-PAT-NO: 5855866

DOCUMENT-IDENTIFIER: US 5855866 A

**** See image for Certificate of Correction ****

TITLE: Methods for treating the vasculature of solid tumors

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	Dallas	TX		

US-CL-CURRENT: 424/1.49; 424/142.1, 424/155.1, 424/156.1, 424/178.1, 424/181.1,

424/183.1, 530/387.1, 530/388.15, 530/388.22, 530/388.8, 530/391.3, 530/391.7,
530/391.9

ABSTRACT:

The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunologically-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.

26 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 35. Document ID: US 5698426 A

L26: Entry 35 of 37

File: USPT

Dec 16, 1997

US-PAT-NO: 5698426

DOCUMENT-IDENTIFIER: US 5698426 A

**** See image for Certificate of Correction ****

TITLE: Surface expression libraries of heteromeric receptors

DATE-ISSUED: December 16, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Huse; William D.	Del Mar	CA		

US-CL-CURRENT: 435/91.41; 435/320.1, 435/475, 435/69.1, 435/69.7, 530/387.1

ABSTRACT:

A composition of matter comprising a plurality of procaryotic cells containing diverse combinations of first and second DNA sequences encoding first and second polypeptides which form a heteromeric receptor exhibiting binding activity toward a preselected molecule, said heteromeric receptors being expressed on the surface of filamentous bacteriophage.

10 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 36. Document ID: US 5660827 A

L26: Entry 36 of 37

File: USPT

Aug 26, 1997

US-PAT-NO: 5660827

DOCUMENT-IDENTIFIER: US 5660827 A

**** See image for Certificate of Correction ****

TITLE: Antibodies that bind to endoglin

DATE-ISSUED: August 26, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Thorpe; Philip E.	Dallas	TX		
Burrows; Francis J.	San Diego	CA		

US-CL-CURRENT: 424/152.1; 424/130.1, 424/138.1, 424/141.1, 530/387.1, 530/388.1

ABSTRACT:

Disclosed are antibodies that specifically bind to endoglin. Conjugates of the antibodies linked to diagnostic or therapeutic agents are also provided. Methods of using the antibodies and conjugates are also disclosed, including methods of targeting the vasculature of solid tumors through recognition of the tumor vasculature-associated antigen, endoglin.

30 Claims, 37 Drawing figures

Exemplary Claim Number: 1,16

Number of Drawing Sheets: 25

Full	Title	Crstion	Front	Review	Classification	Date	Reference				Claims	FIGS	Draw Des
------	-------	---------	-------	--------	----------------	------	-----------	--	--	--	--------	------	----------

☐ 37. Document ID: US 5585244 A

L26: Entry 37 of 37

File: USPT

Dec 17, 1996

US-PAT-NO: 5585244

DOCUMENT-IDENTIFIER: US 5585244 A

**** See image for Certificate of Correction ****

TITLE: Detection of retinoid X receptor subtype .gamma. proteins

DATE-ISSUED: December 17, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Allegretto; Elizabeth A.	La Jolla	CA		
Pike; J. Wesley	Encinitas	CA		

US-CL-CURRENT: 435/7.1; 435/7.2, 435/7.21, 435/7.23, 530/387.1, 530/387.9, 530/388.1, 530/388.2, 530/388.22, 530/389.1

ABSTRACT:

The present invention features peptides derived from RXRX, and antibodies elicited by the peptides. These antibodies bind specifically to RXRX subtypes in its native, functional conformation. Methods are disclosed for detection of RXRX with the antibodies in immunological assays. In addition, this invention describes a hormone-

binding immunoprecipitation assay which utilizes both the retinoid receptor subtype specific antibodies and retinoid receptor ligands to detect and measure RXR and RAR subtypes in a sample. A method is also disclosed for determining the profile of retinoid receptor subfamily members with the retinoid receptor ligands.

11 Claims, 24 Drawing figures

Exemplary Claim Number: 8

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	HWDC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L25 AND tau	37

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 18 of 18 returned.

☐ 1. Document ID: US 20020002270 A1

Using default format because multiple data bases are involved.

L27: Entry 1 of 18

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020002270

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020002270 A1

TITLE: PURIFIED ANTIGEN FOR ALZHEIMER'S DISEASE, AND METHODS OF OBTAINING AND USING SAME

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
ZINKOWSKI, RAYMOND P.	NORTHBROOK	IL	US	
KERKMAN, DANIEL J.	LAKE VILLA	IL	US	
KOHNKEN, RUSSELL E.	SKOKIE	IL	US	
DEBERNARDIS, JOHN F.	LINDENHURST	IL	US	
DAVIES, PETER	RYE	NY	US	

US-CL-CURRENT: 530/387.1; 435/7.1, 436/501

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: US 6787637 B1

L27: Entry 2 of 18

File: USPT

Sep 7, 2004

US-PAT-NO: 6787637

DOCUMENT-IDENTIFIER: US 6787637 B1

TITLE: N-Terminal amyloid-.beta. antibodies

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.28&ref=27&dbname=PGPB,USPT,...> 11/16/04

associated with amyloid deposits of A.beta. in the brain of a patient Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred including N-terminal fragments of A.beta. and antibodies binding to the same.

7 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 3. Document ID: US 6761888 B1

L27: Entry 3 of 18

File: USPT

Jul 13, 2004

US-PAT-NO: 6761888
DOCUMENT-IDENTIFIER: US 6761888 B1

TITLE: Passive immunization treatment of Alzheimer's disease

DATE-ISSUED: July 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

36 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 6750324 B1

L27: Entry 4 of 18

File: USPT

Jun 15, 2004

US-PAT-NO: 6750324
DOCUMENT-IDENTIFIER: US 6750324 B1

TITLE: Humanized and chimeric N-terminal amyloid beta-antibodies

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		
Bard; Frederique	Pacifica	CA		
Yednock; Theodore	Forest Knolls	CA		

US-CL-CURRENT: 530/387.1; 424/130.1, 530/300, 530/350

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

12 Claims, 25 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 5. Document ID: US 6743427 B1

L27: Entry 5 of 18

File: USPT

Jun 1, 2004

US-PAT-NO: 6743427

DOCUMENT-IDENTIFIER: US 6743427 B1

TITLE: Prevention and treatment of amyloidogenic disease

DATE-ISSUED: June 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schenk; Dale B.	Burlingame	CA		

US-CL-CURRENT: 424/130.1; 530/300, 530/350, 530/387.1

ABSTRACT:

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A.beta. in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A.beta. and antibodies binding to the same.

19 Claims, 0 Drawing figures
 Exemplary Claim Number: 1
 Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 6. Document ID: US 6689607 B2

L27: Entry 6 of 18

File: USPT

Feb 10, 2004

US-PAT-NO: 6689607

DOCUMENT-IDENTIFIER: US 6689607 B2

TITLE: Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2

DATE-ISSUED: February 10, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ni; Jian	Germantown	MD		
Ruben; Steven M.	Olney	MD		

US-CL-CURRENT: 435/331; 435/326, 435/328, 435/330, 435/334, 435/343.2, 435/344.1,
435/7.1, 530/387.1, 530/387.3, 530/387.7, 530/387.9, 530/388.1, 530/388.15,
530/388.22, 530/388.75, 530/388.8, 530/388.85, 530/389.1, 530/389.7, 530/391.1,
530/391.3

ABSTRACT:

The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. The present invention further relates to antibodies that specifically bind TR11, TR11SV1, and/or TR11SV2. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.

60 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 11

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	EMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 7. Document ID: US 6670137 B2

L27: Entry 7 of 18

File: USPT

Dec 30, 2003

US-PAT-NO: 6670137

DOCUMENT-IDENTIFIER: US 6670137 B2

TITLE: Differential diagnosis of neurological diseases

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

VanMechelen; Eugene	Nazareth-Eke	BE
Vanderstichele; Hugo	Gent	BE
Hulstaert; Frank	Gentbrugge	BE

US-CL-CURRENT: 435/7.1; 435/7.21, 435/7.8, 436/501, 530/300, 530/350, 530/387.1

ABSTRACT:

The present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus and individual suffering from another neurological disease. More specifically, the present invention provides a method for the differential diagnosis of an individual suffering from Alzheimer's disease versus an individual suffering from dementia with Lewy bodies, versus an individual suffering from Parkinson's disease without dementia, versus an individual suffering from multi-system atrophy and/or versus an individual suffering from progressive supranuclear palsy, said method characterized that phospho-tau is used as a neurological marker.

5 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 8. Document ID: US 6635743 B1

L27: Entry 8 of 18

File: USPT

Oct 21, 2003

US-PAT-NO: 6635743

DOCUMENT-IDENTIFIER: US 6635743 B1

TITLE: Apoptosis inducing molecule II and methods of use

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ebner; Reinhard	Gaithersburg	MD		
Yu; Guo-Liang	Berkeley	CA		
Ruben; Steven M.	Olney	MD		
Ullrich; Stephen	Rockville	MD		
Zhai; Yifan	Guilford	CT		

US-CL-CURRENT: 530/388.23; 435/7.1, 530/387.1, 530/387.3, 530/388.1, 530/389.1, 530/389.2, 930/144

ABSTRACT:

The present invention relates to a novel member of the TNF-Ligand superfamily. More specifically, isolated nucleic acid molecules are provided encoding a human Apoptosis Inducing Molecule II (AIM II). AIM II polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of AIM II activity. Also provided are therapeutic methods for treating lymphadenopathy, aberrant bone development, autoimmune and other immune system diseases, graft versus host disease, rheumatoid arthritis, osteoarthritis and to inhibit neoplasia, such as

tumor cell growth.

39 Claims, 80 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 9. Document ID: US 6635482 B1

L27: Entry 9 of 18

File: USPT

Oct 21, 2003

US-PAT-NO: 6635482
DOCUMENT-IDENTIFIER: US 6635482 B1

TITLE: Monoclonal antibodies to membrane neutrokin-.alpha.

DATE-ISSUED: October 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ebner; Reinhard	Gaithersburg	MD		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/326, 435/328, 435/331, 435/4, 530/387.1, 530/387.3, 530/387.9,
530/388.1, 530/388.15

ABSTRACT:

The present invention relates to a novel Neutrokin-.alpha, and a splice variant thereof designated Neutrokin-.alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokin-.alpha and/or Neutrokin-.alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokin-.alpha and/or Neutrokin-.alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokin-.alpha and/or Neutrokin-.alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

32 Claims, 34 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 10. Document ID: US 6555110 B1

L27: Entry 10 of 18

File: USPT

Apr 29, 2003

US-PAT-NO: 6555110

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.28&ref=27&dbname=PGPB,USPT,...> 11/16/04

DOCUMENT-IDENTIFIER: US 6555110 B1

TITLE: Microencapsulated compounds and method of preparing same

DATE-ISSUED: April 29, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
D'Souza; Martin J.	Sugar Hill	GA		

US-CL-CURRENT: 424/130.1; 424/145.1, 424/158.1, 424/491, 424/499, 514/2, 530/350,
530/387.1, 530/388.24, 530/389.2

ABSTRACT:

Compositions useful in treating immune modulated disease comprising an anticytokine antibody or immune active drug capable of modifying cytokine activity or modulating the immune system microencapsulated with a biodegradable nonantigenic material, such as albumin or PLGA. When the composition is introduced into a subject, it is phagocytosed by the target organ, the target organ digests the microsphere, releasing the drug or an active form or fragment thereof intracellularly. The drug then modifies the target organ function, thereby modulating it's activity. A method is disclosed for preparation of the microencapsulated composition.

29 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 48

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 11. Document ID: US 6406867 B1

L27: Entry 11 of 18

File: USPT

Jun 18, 2002

US-PAT-NO: 6406867

DOCUMENT-IDENTIFIER: US 6406867 B1

**** See image for Certificate of Correction ****

TITLE: Antibody to human endokine alpha and methods of use

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Yu; Guo-Liang	Berkeley	CA		
Ni; Jian	Rockville	MD		
Rosen; Craig A.	Laytonsville	MD		

US-CL-CURRENT: 435/7.2; 424/130.1, 424/139.1, 424/141.1, 424/142.1, 424/158.1,
530/387.1, 530/387.9, 530/388.1, 530/388.15, 530/388.24, 530/389.2

ABSTRACT:

The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided

encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Antibodies and antibody fragments which specifically bind the polypeptides of the invention are also provided, as well as methods for detecting the polypeptides of the invention using said antibodies and antibody fragments. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

56 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 12. Document ID: US 6372215 B1

L27: Entry 12 of 18

File: USPT

Apr 16, 2002

US-PAT-NO: 6372215
DOCUMENT-IDENTIFIER: US 6372215 B1

TITLE: Monoclonal antibodies to human CD6

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Starling; Gary C.	Lawrenceville	NJ		
Siadak; Anthony W.	Seattle	WA		
Bowen; Michael A.	Princeton	NJ		
Aruffo; Alejandro A.	Belle Mead	NJ		
Bajorath; Jurgen	Lynnwood	WA		
Bodian; Dale L.	Paoli	PA		
Skonier; John E.	Seattle	WA		

US-CL-CURRENT: 424/141.1; 424/130.1, 424/133.1, 424/134.1, 424/178.1, 424/801,
435/7.1, 435/7.2, 435/7.25, 435/70.1, 435/70.2, 436/548, 530/350, 530/386, 530/387.1,
530/388.1, 530/391.1, 530/808, 530/864

ABSTRACT:

The invention provides antibodies and other binding agents that bind specifically to SRCR domains of human CD6 (hCD6) and have advantageous properties, including the capacity to substantially inhibit binding of activated leukocyte adhesion molecule (ALCAM) to hCD6. The binding agents of the invention are useful, inter alia, in methods for screening peptides and drugs that also bind to hCD6 and/or modulate ALCAM binding to hCD6, as well as in diagnostic and therapeutic methods for management and treatment of inflammatory and autoimmune diseases.

16 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 13. Document ID: US 6365716 B1

L27: Entry 13 of 18

File: USPT

Apr 2, 2002

US-PAT-NO: 6365716

DOCUMENT-IDENTIFIER: US 6365716 B1

TITLE: Antibodies to lipocalin homologs

DATE-ISSUED: April 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Conklin; Darrell C.	Seattle	WA		

US-CL-CURRENT: 530/387.9; 530/350, 530/387.1, 530/388.1, 530/388.2, 530/389.1,
530/391.1, 530/391.3, 530/391.7

ABSTRACT:

The present invention is directed to antibodies to polypeptides for a member of the lipocalin family. The expression of the polypeptide is restricted to testis and mammary gland, particularly breast tumor tissue. The polypeptide has been designated zlipol.

4 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 14. Document ID: US 6210905 B1

L27: Entry 14 of 18

File: USPT

Apr 3, 2001

US-PAT-NO: 6210905

DOCUMENT-IDENTIFIER: US 6210905 B1

TITLE: Tumor necrosis factor stimulated gene 6 (TSG-6) binding molecules

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tae Ho	Seoul			KR
Wisniewski; Hans-Georg	New York	NY		
Vilcek; Jan	New York	NY		

US-CL-CURRENT: 435/7.1; 436/501, 530/387.1, 530/388.1

ABSTRACT:

TSG-6 protein and functional derivatives thereof, DNA coding therefor, expression vehicles, such as plasmids, and host cells transformed or transfected with the DNA

molecule, and methods for producing the protein and the DNA are provided, as well as antibodies specific for the TSG-6 protein; a method for detecting the presence of TSG-6 protein in a biological sample; a method for detecting the presence of nucleic acid encoding a normal or mutant TSG-6 protein; a method for measuring induction of expression of TSG-6 in a cell using either nucleic acid hybridization or immunoassay; a method for identifying a compound capable of inducing the expression of TSG-6 in a cell; and a method for measuring the ability of a cell to respond to TNF.

5 Claims, 48 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 28

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 15. Document ID: US 6086900 A

L27: Entry 15 of 18

File: USPT

Jul 11, 2000

US-PAT-NO: 6086900

DOCUMENT-IDENTIFIER: US 6086900 A

TITLE: Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Draper; Rockford	Plano	TX		

US-CL-CURRENT: 424/282.1; 435/320.1, 435/357, 435/358, 435/367, 435/372.2, 435/372.3, 435/455, 514/2, 514/44, 530/350, 530/387.1, 536/23.1, 536/23.4, 536/23.5, 536/23.7

ABSTRACT:

The present invention provides methods and compositions delivery of agents into the cytoplasm of cells. Particularly, it concerns the use of membrane-penetrating toxin proteins to deliver drugs to the cytoplasm of target cells.

62 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 16. Document ID: US 6063905 A

L27: Entry 16 of 18

File: USPT

May 16, 2000

US-PAT-NO: 6063905

DOCUMENT-IDENTIFIER: US 6063905 A

**** See image for Certificate of Correction ****

TITLE: Recombinant human IGA-J. chain dimer

DATE-ISSUED: May 16, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capra; J. Donald	Dallas	TX		
Hexham; Jonathan M.	Dallas	TX		
Carayannopoulos; Leon N.	St Louis	MO		
Max; Edward E.	Bethesda	MD		

US-CL-CURRENT: 530/387.3; 424/130.1, 424/133.1, 435/328, 530/387.1, 530/390.1

ABSTRACT:

Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.

102 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 17. Document ID: US 6025197 A

L27: Entry 17 of 18

File: USPT

Feb 15, 2000

US-PAT-NO: 6025197

DOCUMENT-IDENTIFIER: US 6025197 A

TITLE: Secreted salivary zsig32 polypeptides

DATE-ISSUED: February 15, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sheppard; Paul O.	Redmond	WA		

US-CL-CURRENT: 435/325; 435/320.1, 530/350, 530/387.1, 536/23.4, 536/23.5, 536/24.1

ABSTRACT:

The present invention relates to polynucleotide and polypeptide molecules for secreted salivary zsig32 polypeptides. The polypeptides, and polynucleotides encoding them modulate adhesion or modulate or indicate salivary gland function. The present invention also includes antibodies and binding proteins for the zsig32 polypeptides.

20 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 18. Document ID: US 5958684 A

L27: Entry 18 of 18

File: USPT

Sep 28, 1999

US-PAT-NO: 5958684

DOCUMENT-IDENTIFIER: US 5958684 A

TITLE: Diagnosis of neurodegenerative disease

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Van Leeuwen; Frederik Willem	3063CL Maarssen			NL
Burbach; Johannes Peter Henri	3981 SB Bunnik			NL
Grosveld; Franklin G.	3065 NH Rotterdam			NL

US-CL-CURRENT: 435/6; 435/7.1, 435/91.2, 530/350, 530/387.1, 536/23.1, 536/23.5, 536/24.3, 536/24.33

ABSTRACT:

The invention encompasses methods and reagents for the diagnosis of a disease caused by or associated with a gene having a somatic mutation giving rise to a frameshift mutation. The methods include the steps of providing a body fluid or tissue sample from a patient; and analyzing the sample for the presence of a gene having a frameshift mutation or a protein encoded thereby, wherein the presence of the mutated gene or encoded protein is indicative of the disease.

12 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 25

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	FWMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	-------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L26 AND L21	18

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 24 of 24 returned.

☐ 1. Document ID: US 20040219509 A1

Using default format because multiple data bases are involved.

L33: Entry 1 of 24

File: PGPB

Nov 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040219509

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040219509 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: November 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars E.	Escondido	CA	US	
Dahlen, Jeffrey R.	San Diego	CA	US	
Kirchick, Howard J.	San Diego	CA	US	
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	

US-CL-CURRENT: 435/4; 435/7.21

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 20040209307 A1

L33: Entry 2 of 24

File: PGPB

Oct 21, 2004

PGPUB-DOCUMENT-NUMBER: 20040209307

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040209307 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 21, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Valkirs, Gunars	Escondido	CA	US	
Dahlen, Jeffrey	San Diego	CA	US	
Kirchick, Howard	San Diego	CA	US	
Buechler, Kenneth F.	San Diego	CA	US	

US-CL-CURRENT: 435/7.1

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20040203083 A1

L33: Entry 3 of 24

File: PGPB

Oct 14, 2004

PGPUB-DOCUMENT-NUMBER: 20040203083

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040203083 A1

TITLE: Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases

PUBLICATION-DATE: October 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	
Maisel, Alan	Solana Beach	CA	US	

US-CL-CURRENT: 435/7.92

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040203014 A1

L33: Entry 4 of 24

File: PGPB

Oct 14, 2004

PGPUB-DOCUMENT-NUMBER: 20040203014
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040203014 A1

TITLE: Neurotransmission-associated proteins

PUBLICATION-DATE: October 14, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Honchell, Cynthia D.	San Francisco	CA	US	
Warren, Bridget A.	San Marcos	CA	US	
Borowsky, Mark L.	Needham	MA	US	
Griffin, Jennifer A.	Fremont	CA	US	
Li, Joana X.	Millbrae	CA	US	
Lee, Soo Yeun	Mountain View	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Forsythe, Ian J.	Edmonton	CA	CA	
Marquis, Joseph P.	San Jose	CA	US	
Gietzen, Kimberly J.	San Jose	CA	US	
Baughn, Mariah R.	Los Angeles	CA	US	
Tran, Uyen K.	San Jose	CA	US	
Lehr-Mason, Patricia M.	Morgan Hill	CA	US	
Tang, Y. Tom	San Jose	CA	US	
Ramkumar, Jayalaxmi	Fremont	IL	US	
Emerling, Brooke M.	Chicago	CA	US	
Lee, Ernestine A.	Kensington	CA	US	
Elliott, Vicki S.	San Jose	CA	US	
Hafalia, April J.A.	Daly City	CA	US	
Duggan, Brendan M.	Sunnyvale	CA	US	
Chawla, Narinder K.	Union City	MD	US	
Kable, Amy E.	Silver Spring	CA	US	
Chang, Hsin-Ru	Belmont	CA	US	
Khare, Reena	Saratoga	CA	US	
Becha, Shanya D.	San Francisco	CA	US	
Jin, Pei	Palo Alto	CA	US	
Lee, Sally	San Jose		US	

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

Various embodiments of the invention provide human neurotransmission-associated proteins (NTRAN) and polynucleotides which identify and encode NTRAN. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of NTRAN.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 5. Document ID: US 20040121343 A1

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.34&ref=33&dbname=PGPB,USPT,...> 11/16/04

PGPUB-DOCUMENT-NUMBER: 20040121343
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040121343 A1

TITLE: Markers for differential diagnosis and methods of use thereof

PUBLICATION-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Buechler, Kenneth F.	Rancho Santa Fe	CA	US	
Maisel, Alan	Del Mar	CA	US	

US-CL-CURRENT: 435/6; 435/7.2

ABSTRACT:

The present invention provides methods for the identification and use of diagnostic markers, for differential diagnosis of diseases. In a various aspects, the invention relates to methods and compositions able to determine the presence or absence of one, and preferably a plurality, of diseases that exhibit one or more similar or identical symptoms. Such methods and compositions can be used to provide assays and assay devices for use in determining the disease underlying one or more non-specific symptoms exhibited in a clinical setting.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 6. Document ID: US 20040105847 A1

L33: Entry 6 of 24

File: PGPB

Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040105847
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040105847 A1

TITLE: Promoting Recovery from Damage to the Central Nervous System

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Finklestein, Seth P.	Needham	MA	US	
Snyder, Evan Y.	Jamaica Plain	MA	US	

US-CL-CURRENT: 424/93.7; 514/12

ABSTRACT:

Methods, kits and compositions for improving a subject's recovery from CNS injury are disclosed. In certain aspects, a method may include administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech

capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 7. Document ID: US 20040014660 A1

L33: Entry 7 of 24

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014660

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040014660 A1

TITLE: Insulin-associated peptides with effects on cerebral health

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
During, Matthew J.	Philadelphia	PA	US	
Haile, Colin N.	Katy	TX	US	

US-CL-CURRENT: 514/12; 530/350

ABSTRACT:

The present invention provides compositions and methods for ameliorating neurological, attention, or memory disorders and improving learning and cognition through the delivery of insulin A-chain and analogs thereof to a subject. Insulin A-chain, peptides comprising the 21 amino acid sequence GIVEQ CCASV CSLYQ LENYC N (SEQ ID NO:1), and functional analogs thereof are disclosed to modulate neurological activity when administered to a subject. The methods of the invention can be used to prevent or treat neurological disorders as well as improve memory retention and acquisition. The invention includes pharmaceutical compositions comprising a therapeutically or prophylactically effective amount of insulin A-chain peptide or a functional analogs thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 8. Document ID: US 20030199000 A1

L33: Entry 8 of 24

File: PGPB

Oct 23, 2003

PGPUB-DOCUMENT-NUMBER: 20030199000

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030199000 A1

TITLE: Diagnostic markers of stroke and cerebral injury and methods of use thereof

PUBLICATION-DATE: October 23, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Valkirs, Gunars E.	Escondido	CA	US
Dahlen, Jeffery	San Diego	CA	US
Kirchick, Howard J.	San Diego	CA	US
Buechler, Kenneth F.	Rancho Santa Fe	CA	US

US-CL-CURRENT: 435/7.1; 435/287.2

ABSTRACT:

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20030129134 A1

L33: Entry 9 of 24

File: PGPB

Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129134

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030129134 A1

TITLE: Method of monitoring neuroprotective treatment

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenard, Bertrand L.	Waterford	CT	US	
Friedman, David L.	Madison	CT	US	
Kimmel, Lida	Chester	CT	US	
Nelms, Linda F.	Gales Ferry	CT	US	
Silber, B. Michael	Madison	CT	US	
Soares, Holly D.	Noank	CT	US	
Frost White, Walter JR.	Ledyard	CT	US	

US-CL-CURRENT: 424/9.3; 435/7.92

ABSTRACT:

Methods for monitoring and evaluating the efficacy of neuroprotective treatment of a patient suffering from neurological damage by measuring the amount of at least one biomarker in a biological sample taken from the patient during or after treatment.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: US 20030109008 A1

L33: Entry 10 of 24

File: PGPB

Jun 12, 2003

PGPUB-DOCUMENT-NUMBER: 20030109008
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030109008 A1

TITLE: Methods of making CDNA libraries

PUBLICATION-DATE: June 12, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weiss, Samuel	Alberta	RI	CA	
Reynolds, Brent	Alberta	RI	CA	
Hamman, Joseph P.	Barrington		US	
Baetge, E. Edward	Barrington		US	

US-CL-CURRENT: 435/91.1; 435/368

ABSTRACT:

The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGs	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 11. Document ID: US 20030095956 A1

L33: Entry 11 of 24

File: PGPB

May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030095956
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030095956 A1

TITLE: Methods of proliferating undifferentiated neural cells

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weiss, Samuel	Alberta	RI	CA	
Reynolds, Brent	Alberta	RI	CA	
Hamman, Joseph P.	Barrington		US	
Baetge, E. Edward	Barrington		US	

US-CL-CURRENT: 424/93.21; 435/368

ABSTRACT:

The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 12. Document ID: US 20030082515 A1

L33: Entry 12 of 24

File: PGPB

May 1, 2003

PGPUB-DOCUMENT-NUMBER: 20030082515

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030082515 A1

TITLE: Methods of screening biological agents

PUBLICATION-DATE: May 1, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weiss, Samuel	Alberta	RI	CA	
Reynolds, Brent	Alberta	RI	CA	
Hammang, Joseph P.	Barrington		US	
Baetge, E. Edward	Barrington		US	

US-CL-CURRENT: 435/4; 435/368

ABSTRACT:

The invention discloses methods of proliferation and differentiation of multipotent neural stem cells. Also provided are methods of making cDNA libraries and methods of screening biological agents which affect proliferation differentiation survival phenotype or function of CNS cells.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20030077641 A1

L33: Entry 13 of 24

File: PGPB

Apr 24, 2003

PGPUB-DOCUMENT-NUMBER: 20030077641

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030077641 A1

TITLE: Methods of suppressing microglial activation and systemic inflammatory responses

PUBLICATION-DATE: April 24, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Laskowitz, Daniel T.	Chapel Hill	NC	US
Matthew, William D.	Durham	NC	US
McMillian, Michael	Rareton	NJ	US

US-CL-CURRENT: 435/6; 424/186.1, 435/235.1, 435/325, 514/13

ABSTRACT:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. ApoE receptor binding peptides that may be used in the methods of the invention are also described, as are methods of using such peptides to treat peripheral inflammatory conditions such as sepsis. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20030049837 A1

L33: Entry 14 of 24

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030049837

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030049837 A1

TITLE: In vitro and in vivo proliferation and use of multipotent neural stem cells and their progeny

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Weiss, Samuel	Alberta	RI	CA	
Reynolds, Brent	Alberta	RI	CA	
Hammang, Joseph P.	Barrington		US	
Baetge, E. Edward	Barrington		US	

US-CL-CURRENT: 435/368; 435/384

ABSTRACT:

Nucleic acids may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The resultant progeny may be passaged repeatedly to produce a sufficient number of cells to obtain representative nucleic acid samples. Clonal cultures may be produced. Nucleic acids may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acids derived from dysfunctional tissue can be compared with that of normal tissue to identify genetic material which may be the cause of the dysfunction. This information could then be used in the design of therapies to treat

the neurological disorder. A further use of the technology would be in the diagnosis of genetic disorders or for use in identifying neural cells at a particular stage in development.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------	-----

☐ 15. Document ID: US 20020169102 A1

L33: Entry 15 of 24

File: PGPB

Nov 14, 2002

PGPUB-DOCUMENT-NUMBER: 20020169102

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020169102 A1

TITLE: Intranasal delivery of agents for regulating development of implanted cells in the CNS

PUBLICATION-DATE: November 14, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Frey, William H. II	White Bear	MN	US	

US-CL-CURRENT: 514/1; 435/368

ABSTRACT:

The present invention provides a method of regulating the development of a donor cell in the central nervous system of a mammal. The method comprises administering a composition comprising a therapeutically effective amount of at least one regulatory agent, preferably a growth factor such as bFGF, NGF, or IGF-I, or an agent that modulates the immune response to a tissue of the mammal innervated by the trigeminal nerve and/or the olfactory nerve. The methods find use in improving the clinical outcome of a mammal having undergone a neural regenerative strategy. Hence, the present invention is directed to the treatment and/or prevention of CNS disorders, such as, epilepsy, stroke, ischemia, Huntington disease, Parkinson's disease, ALS, Alzheimer's disease, brain and spinal cord injuries and demyelinating or dysmyelinating disorders, such as Pelizaeus-Merzbacher disease and multiple sclerosis.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------	-----

☐ 16. Document ID: US 20020164789 A1

L33: Entry 16 of 24

File: PGPB

Nov 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020164789

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020164789 A1

TITLE: Methods of suppressing microglial activation

PUBLICATION-DATE: November 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Laskowitz, Daniel T.	Chapel Hill	NC	US	
Matthew, William D.	Durham	NC	US	
McMillian, Michael	Rareton	NJ	US	

US-CL-CURRENT: 435/343; 435/5, 514/12, 514/44

ABSTRACT:

Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or reduces microglial activation are described. Also described are methods of screening compounds for the ability to suppress or reduce microglial activation.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 17. Document ID: US 6749850 B1

L33: Entry 17 of 24

File: USPT

Jun 15, 2004

US-PAT-NO: 6749850

DOCUMENT-IDENTIFIER: US 6749850 B1

TITLE: Methods, compositions and kits for promoting recovery from damage to the central nervous system

DATE-ISSUED: June 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Finkelstein; Seth P.	Needham	MA		
Snyder; Evan Y.	Jamaica Plain	MA		

US-CL-CURRENT: 424/93.7; 424/93.1, 514/12

ABSTRACT:

The present application relates to methods, kits and compositions for improving a subject's recovery from CNS injury. In certain aspects, methods of the invention comprise administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.

7 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 18. Document ID: US 6497872 B1

L33: Entry 18 of 24

File: USPT

Dec 24, 2002

US-PAT-NO: 6497872

DOCUMENT-IDENTIFIER: US 6497872 B1

TITLE: Neural transplantation using proliferated multipotent neural stem cells and their progeny

DATE-ISSUED: December 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Alberta			CA
Reynolds; Brent	Alberta			CA
Hammang; Joseph P.	Barrington	RI		
Baetge; E. Edward	Barrington	RI		

US-CL-CURRENT: 424/93.1; 424/93.2, 424/93.21

ABSTRACT:

The invention provides methods of transplanting multipotent neural stem cell progeny to a host by obtaining a population of cells derived from mammalian neural tissue containing at least one multipotent CNS multipotent neural stem cell; culturing the neural stem cell in a culture medium containing one or more growth factors which induce multipotent neural stem cell proliferation; inducing proliferation of the multipotent neural stem cell to produce neural stem cell progeny which includes multipotent neural stem cell progeny cells; and transplanting the multipotent neural stem cell progeny to the host. Also provided are methods of transplanting neural stem cell progeny to a host by obtaining an in vitro cell culture containing CNS neural stem cells where one or more cells in the culture (i) proliferates in a culture medium supplemented with one or more mitogens, (ii) retains the capacity for renewed proliferation, and (iii) maintains the multipotential capacity, under suitable culture conditions, to differentiate into neurons, astrocytes, and oligodendrocytes; and transplanting the one or more cells to the host.

32 Claims, 9 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 19. Document ID: US 6399369 B1

L33: Entry 19 of 24

File: USPT

Jun 4, 2002

US-PAT-NO: 6399369

DOCUMENT-IDENTIFIER: US 6399369 B1

TITLE: Multipotent neural stem cell cDNA libraries

DATE-ISSUED: June 4, 2002

<http://westbrs:9000/bin/gate.exe?f=TOC&state=ikvmks.34&ref=33&dbname=PGPB,USPT,...> 11/16/04

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Calgary			CA
Reynolds; Brent	Saltspring			CA

US-CL-CURRENT: 435/320.1; 435/368, 435/6, 435/91.1, 536/23.1, 536/23.5

ABSTRACT:

CDNA libraries may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The libraries may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acid derived from dysfunctional tissue can be compared with that of normal tissue to identify genetic material which may be a cause of the dysfunction. This information could then be used in the design of therapies to treat the neurological disorder. A further use of the technology would be in the diagnosis of genetic disorders or for use in identifying neural cells at a particular stage in development.

5 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 20. Document ID: US 6294346 B1

L33: Entry 20 of 24

File: USPT

Sep 25, 2001

US-PAT-NO: 6294346

DOCUMENT-IDENTIFIER: US 6294346 B1

**** See image for Certificate of Correction ****

TITLE: Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Calgary			CA
Reynolds; Brent	Calgary			CA
Hammang; Joseph P.	Barrington	RI		
Baetge; E. Edward	Barrington	RI		

US-CL-CURRENT: 435/7.21; 435/368, 435/375, 435/377

ABSTRACT:

A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a

disease such as Alzheimer's Disease, Parkinson's Disease or Down's Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions. The disclosed cultures provide an optimal source of normal and diseased neural cells at various developmental stages, which can be screened for potential side effects in addition to testing the action and efficacy of different biological agents.

12 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 21. Document ID: US 6071889 A

L33: Entry 21 of 24

File: USPT

Jun 6, 2000

US-PAT-NO: 6071889
DOCUMENT-IDENTIFIER: US 6071889 A

TITLE: In vivo genetic modification of growth factor-responsive neural precursor cells

DATE-ISSUED: June 6, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Alberta			CA
Reynolds; Brent	Alberta			CA
Hammang; Joseph P.	Barrington	RI		
Baetge; E. Edward	Barrington	RI		

US-CL-CURRENT: 514/44; 424/93.1, 424/93.2, 424/93.21, 435/440, 435/455

ABSTRACT:

Methods for administering genetic material to dividing neural precursor cell populations in vivo are provided. The genetic material may comprise useful genes for neurotransmitters, growth factors, growth factor receptors, and the like. The genetic material is administered to the brain with one or more growth factors. The growth factors induce proliferation of neural precursor cells, thereby facilitating the incorporation of the genetic material into the cell progeny.

14 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 22. Document ID: US 5980885 A

L33: Entry 22 of 24

File: USPT

Nov 9, 1999

US-PAT-NO: 5980885

DOCUMENT-IDENTIFIER: US 5980885 A

TITLE: Growth factor-induced proliferation of neural precursor cells in vivo

DATE-ISSUED: November 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Alberta			CA
Reynolds; Brent	Alberta			CA

US-CL-CURRENT: 424/93.21; 424/93.1, 424/93.2, 435/325, 435/360, 435/366, 435/368,
435/377, 435/383, 435/384, 435/440, 435/455, 435/456, 435/457, 514/2, 514/44

ABSTRACT:

A method is described for inducing in vivo proliferation of precursor cells located in mammalian neural tissue by administering to the mammal a fibroblast growth factor and at least one additional growth factor selected from the group consisting of epidermal growth factor, transforming growth factor alpha, and amphiregulin. The method can be used to replace damaged or missing neurons and/or glia. Another method is described for transplanting multipotent neural stem cell progeny into a mammal. The method comprises the steps of administering growth factors to a mammal to induce in vivo proliferation of neural precursor cells, removing the precursor cell progeny from the mammal, culturing the removed cells in vitro in the presence of one or more growth factors that induces multipotent neural stem cell proliferation, and implanting the multipotent neural stem cell progeny into the mammal.

11 Claims, 3 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 23. Document ID: US 5851832 A

L33: Entry 23 of 24

File: USPT

Dec 22, 1998

US-PAT-NO: 5851832

DOCUMENT-IDENTIFIER: US 5851832 A

TITLE: In vitro growth and proliferation of multipotent neural stem cells and their progeny

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Alberta			CA
Reynolds; Brent	Alberta			CA

Hamming; Joseph P. Barrington RI
Baetge; E. Edward Barrington RI

US-CL-CURRENT: 435/368; 435/325, 435/366, 435/377, 435/383, 435/384

ABSTRACT:

A method for the in vitro proliferation and differentiation of neural stem cells and stem cell progeny comprising the steps of (a) isolating the cells from a mammal, (b) exposing the cells to a culture medium containing a growth factor, (c) inducing the cells to proliferate, and (d) inducing the cells to differentiate is provided.

80 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 24. Document ID: US 5750376 A

L33: Entry 24 of 24

File: USPT

May 12, 1998

US-PAT-NO: 5750376

DOCUMENT-IDENTIFIER: US 5750376 A

TITLE: In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Alberta			CA
Reynolds; Brent	Alberta			CA
Hamming; Joseph P.	Barrington	RI		
Baetge; E. Edward	Barrington	RI		

US-CL-CURRENT: 435/69.52; 435/325, 435/368, 435/377, 435/384, 435/392, 435/395,
435/455, 435/456, 435/458, 435/461, 435/69.1

ABSTRACT:

A method for producing genetically modified neural cells comprises culturing cells derived from embryonic, juvenile, or adult mammalian neural tissue with one or more growth factors that induce multipotent neural stem cells to proliferate and produce multipotent neural stem cell progeny which include more daughter multipotent neural stem cells and undifferentiated progeny that are capable of differentiating into neurons, astrocytes, and oligodendrocytes. The proliferating neural cells can be transfected with exogenous DNA to produce genetically modified neural stem cell progeny. The genetic modification can be for the production of biologically useful proteins such as growth factor products, growth factor receptors, neurotransmitters, neurotransmitter receptors, neuropeptides and neurotransmitter synthesizing genes. The multipotent neural stem cell progeny can be continuously passaged and proliferation reinitiated in the presence of growth factors to result in an unlimited supply of neural cells for transplantation and other purposes. Culture conditions can be provided that induce the genetically modified multipotent neural stem cell progeny

to differentiate into neurons, astrocytes, and oligodendrocytes in vitro.

40 Claims, 9 Drawing figures
Exemplary Claim Number: 1,8,9
Number of Drawing Sheets: 3

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------


Terms	Documents
L32 AND CNS damage	24

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for tau AND CSF Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts










ClinicalTrials.gov





PubMed Central

Items 1 - 328 of 328

One p:

- ☐ 1: [Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA.](#) Related Articles, Li
Effects of Processing and Storage Conditions on Amyloid {beta}(1-42) and T Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice. Clin Chem. 2004 Nov 11 [Epub ahead of print]
PMID: 15539465 [PubMed - as supplied by publisher]
- ☐ 2: [Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.](#) Related Articles, Li
Cerebrospinal fluid beta-amyloid(1-42) and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol Psychiatry. 2004 Nov 1;56(9):670-6.
PMID: 15522251 [PubMed - in process]
- ☐ 3: [Murayama S, Saito Y.](#) Related Articles, Li
Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology. 2004 Sep;24(3):254-60.
PMID: 15484705 [PubMed - in process]
- ☐ 4: [Hartmann AP, Almeida SM, Livramento JA, Nitrini R, Takahashi D, Caramelli P.](#) Related Articles, Li
Hyperphosphorylated tau protein in the cerebrospinal fluid of patients with Alzheimer's disease and other dementias: preliminary findings. Arq Neuropsiquiatr. 2004 Sep;62(3B):751-5. Epub 2004 Oct 05.
PMID: 15476062 [PubMed - in process]
- ☐ 5: [Colucci M, Roccatagliata L, Capello E, Narciso E, Latronico N, Tabaton M, Mancardi GL.](#) Related Articles, Li
The 14-3-3 protein in multiple sclerosis: a marker of disease severity. Mult Scler. 2004 Oct;10(5):477-81.
PMID: 15471360 [PubMed - in process]
- ☐ 6: [Zetterberg H, Andreasen N, Blennow K.](#) Related Articles, Li
Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. Neurosci Lett. 2004 Sep 2;367(2):194-6.
PMID: 15331151 [PubMed - indexed for MEDLINE]
- ☐ 7: [Blennow K.](#) Related Articles, Li
CSF biomarkers for mild cognitive impairment. J Intern Med. 2004 Sep;256(3):224-34.
PMID: 15324365 [PubMed - in process]
- ☐ 8: [de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.](#) Related Articles, Li
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med. 2004 Sep;256(3):205-23.

- ☐ **9:** Iqbal K, Grundke-Iqbal I. Related Articles, Li
 Inhibition of neurofibrillary degeneration: a promising approach to Alzheimer disease and other tauopathies.
 Curr Drug Targets. 2004 Aug;5(6):495-502. Review.
 PMID: 15270196 [PubMed - indexed for MEDLINE]
- ☐ **10:** Wada-Isoe K, Wakutani Y, Urakami K, Nakashima K. Related Articles, Li
 Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients.
 Acta Neurol Scand. 2004 Aug;110(2):124-7.
 PMID: 15242421 [PubMed - indexed for MEDLINE]
- ☐ **11:** Tomita I, Sato K, Shirabe S, Nagasato K, Satoh A, Tsujihata M. Related Articles, Li
 [Serial diffusion-weighted MRI (DWI) in a patient with sporadic Creutzfeldt Jakob disease]
 Rinsho Shinkeigaku. 2004 Mar;44(3):182-6. Japanese.
 PMID: 15233271 [PubMed - indexed for MEDLINE]
- ☐ **12:** Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Related Articles, Li
 Proteins released from degenerating neurons are surrogate markers for acute brain damage.
 Neurobiol Dis. 2004 Jul;16(2):311-20.
 PMID: 15193288 [PubMed - indexed for MEDLINE]
- ☐ **13:** Hampel H, Teipel SJ. Related Articles, Li
 Total and phosphorylated tau proteins: evaluation as core biomarker candidate in frontotemporal dementia.
 Dement Geriatr Cogn Disord. 2004;17(4):350-4. Review.
 PMID: 15178952 [PubMed - indexed for MEDLINE]
- ☐ **14:** Maruyama M, Matsui T, Tanji H, Ootsuki M, Nemoto M, Tomita N, Okamura N, Matsushita S, Higuchi S, Kodama M, Arai H, Sasaki H. Related Articles, Li
 [Diagnosing the mild cognitive impairment stage of Alzheimer's disease]
 Seishin Shinkeigaku Zasshi. 2004;106(3):269-80. Review. Japanese.
 PMID: 15164576 [PubMed - indexed for MEDLINE]
- ☐ **15:** Martinez-Yelamos A, Saiz A, Bas J, Hernandez JJ, Graus F, Arbizu T. Related Articles, Li
 Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.
 Neurosci Lett. 2004 Jun 3;363(1):14-7.
 PMID: 15157986 [PubMed - indexed for MEDLINE]
- ☐ **16:** Shiga Y, Miyazawa K, Takeda A, Arai H, Doh-ura K, Itoyama Y. Related Articles, Li
 [Laboratory and imaging studies for the diagnosis of prion disease]
 Rinsho Shinkeigaku. 2003 Nov;43(11):810-2. Japanese.
 PMID: 15152471 [PubMed - indexed for MEDLINE]
- ☐ **17:** Pijnenburg YA, Schoonenboom NS, Rosso SM, Mulder C, Van Kamp GJ, Van Swieten JC, Scheltens P. Related Articles, Li
 CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration.
 Neurology. 2004 May 11;62(9):1649. No abstract available.
 PMID: 15136709 [PubMed - indexed for MEDLINE]
- ☐ **18:** Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P. Related Articles, Li

-  Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.
Neurology. 2004 May 11;62(9):1580-4.
PMID: 15136685 [PubMed - indexed for MEDLINE]
- ☐ 19: Abdo WF, De Jong D, Hendriks JC, Horstink MW, Kremer BP, Bloem BR, Verbeek MM. Related Articles, Li
Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
Mov Disord. 2004 May;19(5):571-9.
PMID: 15133823 [PubMed - indexed for MEDLINE]
- ☐ 20: Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J. Related Articles, Li
Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature.
J Mol Neurosci. 2004;23(1-2):115-22.
PMID: 15126697 [PubMed - indexed for MEDLINE]
- ☐ 21: Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. Related Articles, Li
Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.
Neurobiol Aging. 2004 Mar;25(3):273-81.
PMID: 15123331 [PubMed - indexed for MEDLINE]
- ☐ 22: Silverberg GD. Related Articles, Li
Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both.
Brain. 2004 May;127(Pt 5):947-8. No abstract available.
PMID: 15111447 [PubMed - indexed for MEDLINE]
- ☐ 23: Bartosik-Psujek H, Archelos JJ. Related Articles, Li
Tau protein and 14-3-3 are elevated in the cerebrospinal fluid of patients with multiple sclerosis and correlate with intrathecal synthesis of IgG.
J Neurol. 2004 Apr;251(4):414-20.
PMID: 15083285 [PubMed - in process]
- ☐ 24: Trysberg E, Hoglund K, Svenungsson E, Blennow K, Tarkowski A. Related Articles, Li
 Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus.
Arthritis Res Ther. 2004;6(2):R129-36. Epub 2004 Jan 22.
PMID: 15059276 [PubMed - in process]
- ☐ 25: Blomqvist ME, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA. Related Articles, Li
 Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease.
Neurosci Lett. 2004 Apr 1;358(3):220-2.
PMID: 15039120 [PubMed - indexed for MEDLINE]
- ☐ 26: Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Related Articles, Li
 Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease.
Hum Genet. 2004 May;114(6):581-7. Epub 2004 Mar 18.
PMID: 15034781 [PubMed - indexed for MEDLINE]
- Van Gool SW, De Meyer G, Van de Voorde A, Vanmechelen E, Related Articles, Li

☐ 27: Vanderstichele H.



Neurotoxicity marker profiles in the CSF are not age-dependent but show variation in children treated for acute lymphoblastic leukemia.

Neurotoxicology. 2004 Mar;25(3):471-80.

PMID: 15019310 [PubMed - indexed for MEDLINE]

☐ 28: Quinn JF, Montine KS, Moore M, Morrow JD, Kaye JA, Montine TJ. Related Articles, Li



Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.

J Alzheimers Dis. 2004 Feb;6(1):93-7.

PMID: 15004331 [PubMed - indexed for MEDLINE]

☐ 29: Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Moller HJ. Related Articles, Li



Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.

J Neural Transm. 2004 Mar;111(3):247-72. Epub 2003 Dec 03. Review.

PMID: 14991453 [PubMed - indexed for MEDLINE]

☐ 30: Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. Related Articles, Li



Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.

Arch Gen Psychiatry. 2004 Jan;61(1):95-102.

PMID: 14706948 [PubMed - indexed for MEDLINE]

☐ 31: Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Moller HJ, Blennow K, Buerger K. Related Articles, Li



Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease patients with mild cognitive impairment.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID: 14699432 [PubMed - in process]

☐ 32: Tisell M, Tullberg M, Mansson JE, Fredman P, Blennow K, Wikkelso C. Related Articles, Li



Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and idiopathic normal pressure hydrocephalus.

Eur J Neurol. 2004 Jan;11(1):17-23.

PMID: 14692883 [PubMed - indexed for MEDLINE]

☐ 33: Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr, Farlow M, Weitlauf SL, Quinn J, Kaye J, Knopman D, Arai H, Doody RS, DeCarli C, Leight S, Lee VM, Trojanowski JQ. Related Articles, Li



Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?

Arch Neurol. 2003 Dec;60(12):1696-702.

PMID: 14676043 [PubMed - indexed for MEDLINE]

☐ 34: Sussmuth SD, Tumani H, Ecker D, Ludolph AC. Related Articles, Li












Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum.

Neurosci Lett. 2003 Dec 15;353(1):57-60.







PMID: 14642437 [PubMed - indexed for MEDLINE]











☐ 35: Wagner M, Teichner G, Bachman DL. Related Articles, Li










Diagnostic challenges of using CSF assay of tau and beta-amyloid(42) in










-  atypical degenerative dementias of the Alzheimer type.
Arch Clin Neuropsychol. 2003 Dec;18(8):893-903.
PMID: 14609583 [PubMed - indexed for MEDLINE]
- ☐ **36:** Andreasen N, Sjogren M, Blennow K. Related Articles, Li
 CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
World J Biol Psychiatry. 2003 Oct;4(4):147-55. Review.
PMID: 14608585 [PubMed - indexed for MEDLINE]
- ☐ **37:** Kay A, Petzold A, Kerr M, Keir G, Thompson E, Nicoll J. Related Articles, Li
 Temporal alterations in cerebrospinal fluid amyloid beta-protein and apolipoprotein E after subarachnoid hemorrhage.
Stroke. 2003 Dec;34(12):e240-3. Epub 2003 Nov 06.
PMID: 14605321 [PubMed - indexed for MEDLINE]
- ☐ **38:** Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V. Related Articles, Li
 Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.
Neurol Sci. 2003 Oct;24(3):199-200.
PMID: 14598086 [PubMed - indexed for MEDLINE]
- ☐ **39:** Kay AD, Petzold A, Kerr M, Keir G, Thompson E, Nicoll JA. Related Articles, Li
 Alterations in cerebrospinal fluid apolipoprotein E and amyloid beta-protein after traumatic brain injury.
J Neurotrauma. 2003 Oct;20(10):943-52.
PMID: 14588111 [PubMed - indexed for MEDLINE]
- ☐ **40:** Leszek J, Malyszczak K, Janicka B, Kiejna A, Wiak A. Related Articles, Li
 Total tau in cerebrospinal fluid differentiates Alzheimer's disease from vascular dementia.
Med Sci Monit. 2003 Nov;9(11):CR484-8.
PMID: 14586274 [PubMed - indexed for MEDLINE]
- ☐ **41:** Schonknecht P, Pantel J, Hartmann T, Werle E, Volkmann M, Essig M, Amann M, Zanabali N, Bardenheuer H, Hunt A, Schroder J. Related Articles, Li
 Cerebrospinal fluid tau levels in Alzheimer's disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy.
Psychiatry Res. 2003 Oct 15;120(3):231-8.
PMID: 14561434 [PubMed - indexed for MEDLINE]
- ☐ **42:** Ganzer S, Arlt S, Schoder V, Buhmann C, Mandelkow EM, Finckh U, Beisiegel U, Naber D, Muller-Thomsen T. Related Articles, Li
 CSF-tau, CSF-Abeta1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity.
J Neural Transm. 2003 Oct;110(10):1149-60.
PMID: 14523627 [PubMed - indexed for MEDLINE]
- ☐ **43:** Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, Brookes AJ. Related Articles, Li
 Genetic variation in a haplotype block spanning IDE influences Alzheimer disease.
Hum Mutat. 2003 Nov;22(5):363-71.
PMID: 14517947 [PubMed - indexed for MEDLINE]
- ☐ **44:** Wallin A, Sjogren M, Blennow K, Davidsson P. Related Articles, Li

Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical

-  ischemic vascular dementia.
Dement Geriatr Cogn Disord. 2003;16(4):200-7.
PMID: 14512714 [PubMed - indexed for MEDLINE]
- ☐ 45: Pea F, Pavan F, Nascimben E, Benetton C, Scotton PG, Vaglia A, Furlanut M. Related Articles, Li
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.
Antimicrob Agents Chemother. 2003 Oct;47(10):3104-8.
PMID: 14506016 [PubMed - indexed for MEDLINE]
-  ☐ 46: Blennow K, Hampel H. Related Articles, Li
CSF markers for incipient Alzheimer's disease.
Lancet Neurol. 2003 Oct;2(10):605-13. Review.
PMID: 14505582 [PubMed - indexed for MEDLINE]
- ☐ 47: Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R. Related Articles, Li
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.
J Mol Neurosci. 2003;20(3):349-56. Review.
PMID: 14501019 [PubMed - indexed for MEDLINE]
-  ☐ 48: Emond V, MacLaren LA, Kimmins S, Arosh JA, Fortier MA, Lambert RD. Related Articles, Li
Expression of cyclooxygenase-2 and granulocyte-macrophage colony-stimulating factor in the endometrial epithelium of the cow is up-regulated during early pregnancy and in response to intrauterine infusions of interferon tau.
Biol Reprod. 2004 Jan;70(1):54-64. Epub 2003 Sep 17.
PMID: 13679318 [PubMed - indexed for MEDLINE]
- ☐ 49: Gomez-Tortosa E, Gonzalo I, Fanjul S, Sainz MJ, Cantarero S, Cemillan C, Yebenes JG, del Ser T. Related Articles, Li
Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Arch Neurol. 2003 Sep;60(9):1218-22.
PMID: 12975286 [PubMed - indexed for MEDLINE]
-  ☐ 50: Rosso SM, van Herpen E, Pijnenburg YA, Schoonenboom NS, Scheltens P, Heutink P, van Swieten JC. Related Articles, Li
Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutation.
Arch Neurol. 2003 Sep;60(9):1209-13.
PMID: 12975285 [PubMed - indexed for MEDLINE]
- ☐ 51: Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C. Related Articles, Li
Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.
Arch Neurol. 2003 Sep;60(9):1202-6.
PMID: 12975284 [PubMed - indexed for MEDLINE]
-  ☐ 52: Pei JJ, Gong CX, An WL, Winblad B, Cowburn RF, Grundke-Iqbal I, Iqbal K. Related Articles, Li
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.
Am J Pathol. 2003 Sep;163(3):845-58.
PMID: 12937126 [PubMed - indexed for MEDLINE]
- 

- ☐ **53:** Van Everbroeck B, Quoilin S, Boons J, Martin JJ, Cras P. Related Articles, Li
 **A prospective study of CSF markers in 250 patients with possible Creutzfeldt Jakob disease.**
 J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1210-4.
 PMID: 12933920 [PubMed - indexed for MEDLINE]
- ☐ **54:** Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Related Articles, Li
 **Intrathecal inflammation precedes development of Alzheimer's disease.**
 J Neurol Neurosurg Psychiatry. 2003 Sep;74(9):1200-5.
 PMID: 12933918 [PubMed - indexed for MEDLINE]
- ☐ **55:** Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC. Related Articles, Li
 **A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease.**
 Proteomics. 2003 Aug;3(8):1486-94.
 PMID: 12923774 [PubMed - indexed for MEDLINE]
- ☐ **56:** Hampel H, Goernitz A, Buerger K. Related Articles, Li
 **Advances in the development of biomarkers for Alzheimer's disease: from C total tau and Abeta(1-42) proteins to phosphorylated tau protein.**
 Brain Res Bull. 2003 Aug 15;61(3):243-53. Review.
 PMID: 12909294 [PubMed - indexed for MEDLINE]
- ☐ **57:** Blennow K, Vanmechelen E. Related Articles, Li
 **CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry.**
 Brain Res Bull. 2003 Aug 15;61(3):235-42. Review.
 PMID: 12909293 [PubMed - indexed for MEDLINE]
- ☐ **58:** Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M. Related Articles, Li
 **Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jak disease.**
 Ann Neurol. 2003 Aug;54(2):263-7.
 PMID: 12891683 [PubMed - indexed for MEDLINE]
- ☐ **59:** Ransmayr G. Related Articles, Li
 **[Cholesterol and statins in Alzheimer disease]**
 Wien Med Wochenschr. 2003;153(11-12):258-9. German.
 PMID: 12879635 [PubMed - indexed for MEDLINE]
- ☐ **60:** Burn DJ, Lees AJ. Related Articles, Li
 **Progressive supranuclear palsy: where are we now?**
 Lancet Neurol. 2002 Oct;1(6):359-69. Review.
 PMID: 12849397 [PubMed - indexed for MEDLINE]
- ☐ **61:** Lehmann M, Regland B, Blennow K, Gottfries CG. Related Articles, Li
 **Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment.**
 Dement Geriatr Cogn Disord. 2003;16(3):145-50.
 PMID: 12826740 [PubMed - indexed for MEDLINE]
- ☐ **62:** Urakami K, Ito N, Arai H, Ishiguro K, Ohno H, Nakashima K. Related Articles, Li
 **[The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease]**

- ☐ **63:** Tanaka T, Wada K, Yamamori H, Tanaka S, Kudo T, Takeda M. Related Articles, Li
 [Biological markers for Alzheimer disease]
Seishin Shinkeigaku Zasshi. 2003;105(4):387-92. Review. Japanese.
PMID: 12806899 [PubMed - indexed for MEDLINE]
- ☐ **64:** Schonknecht P, Hempel A, Hunt A, Seidl U, Volkmann M, Pantel J, Schroder J. Related Articles, Li
 Cerebrospinal fluid tau protein levels in schizophrenia.
Eur Arch Psychiatry Clin Neurosci. 2003 Apr;253(2):100-2.
PMID: 12799749 [PubMed - indexed for MEDLINE]
- ☐ **65:** Urakami K, Nakashima K. Related Articles, Li
 [Corticobasal degeneration and progressive supranuclear palsy--biochemical marker]
Rinsho Shinkeigaku. 2002 Nov;42(11):1162-4. Japanese.
PMID: 12784694 [PubMed - indexed for MEDLINE]
- ☐ **66:** Gadoth N. Related Articles, Li
 Multiple sclerosis in children.
Brain Dev. 2003 Jun;25(4):229-32. Review.
PMID: 12767451 [PubMed - indexed for MEDLINE]
- ☐ **67:** Mitchell A, Brindle N. Related Articles, Li
 CSF phosphorylated tau--does it constitute an accurate biological test for Alzheimer's disease?
Int J Geriatr Psychiatry. 2003 May;18(5):407-11. Review.
PMID: 12766916 [PubMed - indexed for MEDLINE]
- ☐ **68:** Sjogren M, Andreasen N, Blennow K. Related Articles, Li
 Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.
Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.
PMID: 12763273 [PubMed - indexed for MEDLINE]
- ☐ **69:** Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, Deisenhammer F. Related Articles, Li
 Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury.
Neurology. 2003 May 13;60(9):1457-61.
PMID: 12743231 [PubMed - indexed for MEDLINE]
- ☐ **70:** Sjogren M, Gustafsson K, Syversen S, Olsson A, Edman A, Davidsson P, Wallin A, Blennow K. Related Articles, Li
 Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein.
Dement Geriatr Cogn Disord. 2003;16(1):25-30.
PMID: 12714796 [PubMed - indexed for MEDLINE]
- ☐ **71:** Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM. Related Articles, Li
 Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid c patients with Alzheimer disease.
JAMA. 2003 Apr 23-30;289(16):2094-103.
PMID: 12709467 [PubMed - indexed for MEDLINE]

- ☐ **72:** Saez-Valero J, Fodero LR, Sjogren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Related Articles, Li
-  Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer's disease.
J Neurosci Res. 2003 May 15;72(4):520-6.
PMID: 12704813 [PubMed - indexed for MEDLINE]
- ☐ **73:** Serot JM, Bene MC, Faure GC. Related Articles, Li
-  Choroid plexus, aging of the brain, and Alzheimer's disease.
Front Biosci. 2003 May 01;8:s515-21. Review.
PMID: 12700093 [PubMed - indexed for MEDLINE]
- ☐ **74:** Michikawa M. Related Articles, Li
-  Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?
J Neurosci Res. 2003 Apr 15;72(2):141-6. Review.
PMID: 12671988 [PubMed - indexed for MEDLINE]
- ☐ **75:** Riemenschneider M, Wagenpfeil S, Vanderstichele H, Otto M, Wiltfang J, Kretzschmar H, Vanmechelen E, Forstl H, Kurz A. Related Articles, Li
-  Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.
Mol Psychiatry. 2003 Mar;8(3):343-7.
PMID: 12660807 [PubMed - indexed for MEDLINE]
- ☐ **76:** Arai H. Related Articles, Li
-  [Biomarkers, mild cognitive impairment and early diagnosis of Alzheimer's disease]
Nippon Ronen Igakkai Zasshi. 2003 Jan;40(1):22-6. Japanese.
PMID: 12649841 [PubMed - indexed for MEDLINE]
- ☐ **77:** Wahlund LO, Blennow K. Related Articles, Li
-  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients.
Neurosci Lett. 2003 Mar 20;339(2):99-102.
PMID: 12614904 [PubMed - indexed for MEDLINE]
- ☐ **78:** Kapaki E, Paraskevas GP, Zalonis I, Zournas C. Related Articles, Li
-  CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.
Eur J Neurol. 2003 Mar;10(2):119-28.
PMID: 12603286 [PubMed - indexed for MEDLINE]
- ☐ **79:** Almkvist O, Axelman K, Basun H, Jensen M, Viitanen M, Wahlund LO, Lannfelt L. Related Articles, Li
-  Clinical findings in nondemented mutation carriers predisposed to Alzheimer's disease: a model of mild cognitive impairment.
Acta Neurol Scand Suppl. 2003;179:77-82.
PMID: 12603253 [PubMed - indexed for MEDLINE]
- ☐ **80:** Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Related Articles, Li
-  Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Acta Neurol Scand Suppl. 2003;179:47-51.
PMID: 12603251 [PubMed - indexed for MEDLINE]

- ☐ **81:** Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A. Related Articles, Li
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
 Neurosci Lett. 2003 Feb 27;338(2):159-63.
 PMID: 12566177 [PubMed - indexed for MEDLINE]
- ☐ **82:** Buerger K, Zinkowski R, Teipel SJ, Arai H, DeBernardis J, Kerkman D, McCulloch C, Padberg F, Faltraco F, Goernitz A, Tapiola T, Rapoport SI, Pirttila T, Moller HJ, Hampel H. Related Articles, Li
Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231.
 Am J Psychiatry. 2003 Feb;160(2):376-9.
 PMID: 12562590 [PubMed - indexed for MEDLINE]
- ☐ **83:** Pijnenburg YA, Schoonenboom NS, Scheltens P. Related Articles, Li
Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration
 Neurology. 2003 Jan 28;60(2):353-4; author reply 353-4. No abstract available.
 PMID: 12552068 [PubMed - indexed for MEDLINE]
- ☐ **84:** Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Andreasen N, Minthon L, Davidsson P, Pottel H, Blennow K, Gallai V. Related Articles, Li
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
 Neurol Sci. 2002 Sep;23 Suppl 2:S95-6.
 PMID: 12548360 [PubMed - indexed for MEDLINE]
- ☐ **85:** Verbeek MM, De Jong D, Kremer HP. Related Articles, Li
Brain-specific proteins in cerebrospinal fluid for the diagnosis of neurodegenerative diseases.
 Ann Clin Biochem. 2003 Jan;40(Pt 1):25-40. Review.
 PMID: 12542908 [PubMed - indexed for MEDLINE]
- ☐ **86:** Chatfield DA, Zemlan FP, Day DJ, Menon DK. Related Articles, Li
Discordant temporal patterns of S100beta and cleaved tau protein elevation after head injury: a pilot study.
 Br J Neurosurg. 2002 Oct;16(5):471-6.
 PMID: 12498491 [PubMed - indexed for MEDLINE]
- ☐ **87:** Mulder C, Schoonenboom SN, Wahlund LO, Scheltens P, van Kamp GJ, Veerhuis R, Hack CE, Blomberg M, Schutgens RB, Eikelenboom P. Related Articles, Li
CSF markers related to pathogenetic mechanisms in Alzheimer's disease.
 J Neural Transm. 2002 Dec;109(12):1491-8.
 PMID: 12486489 [PubMed - indexed for MEDLINE]
- ☐ **88:** Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G. Related Articles, Li
Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer's disease.
 Neurobiol Dis. 2002 Oct;11(1):106-10.
 PMID: 12460550 [PubMed - indexed for MEDLINE]
- ☐ **89:** Jimenez-Jimenez FJ, Zurdo JM, Hernanz A, Medina-Acebron S, de Bustos F, Barcenilla B, Sayed Y, Ayuso-Peralta L. Related Articles, Li
Tau protein concentrations in cerebrospinal fluid of patients with multiple sclerosis.
 Acta Neurol Scand. 2002 Dec;106(6):351-4.

- ☐ **90:** Fisher A, Brandeis R, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. Related Articles, Li



Impact of muscarinic agonists for successful therapy of Alzheimer's disease. J Neural Transm Suppl. 2002(62):189-202. Review. PMID: 12456063 [PubMed - indexed for MEDLINE]

- ☐ **91:** Green AJ.

Related Articles, Li



Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol. 2002 Dec;28(6):427-40. Review. PMID: 12445159 [PubMed - indexed for MEDLINE]

- ☐ **92:** de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, Convit A, Caraos C, Rusinek H, Tsui W, Saint Louis LA, DeBernardis J, Kerkman D, Qadri F, Gary A, Lesbre P, Wisniewski T, Poirier J, Davies P. Related Articles, Li



Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett. 2002 Nov 29;333(3):183-6. PMID: 12429378 [PubMed - indexed for MEDLINE]

- ☐ **93:** Bonelli RM, Aschoff A, Jirikowski G.

Related Articles, Li



Cerebrospinal fluid tissue transglutaminase in vascular dementia. J Neurol Sci. 2002 Nov 15;203-204:207-9. Review. PMID: 12417385 [PubMed - indexed for MEDLINE]

- ☐ **94:** Nagga K, Gottfries J, Blennow K, Marcusson J.

Related Articles, Li



Cerebrospinal fluid phospho-tau, total tau and beta-amyloid(1-42) in the differentiation between Alzheimer's disease and vascular dementia. Dement Geriatr Cogn Disord. 2002;14(4):183-90. PMID: 12411760 [PubMed - indexed for MEDLINE]

- ☐ **95:** Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, Maruyama M, Iwatsubo T, Higuchi S. Related Articles, Li



Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry. 2002 Nov 1;52(9):907-10. PMID: 12399144 [PubMed - indexed for MEDLINE]

- ☐ **96:** Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, Flitman S, Winn R, Marciano F, Saul T, Huhn S, Mayo M, McGuire D. Related Articles, Li



Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology. 2002 Oct 22;59(8):1139-45. PMID: 12391340 [PubMed - indexed for MEDLINE]

- ☐ **97:** McGuire WJ, Imakawa K, Tamura K, Meka CS, Christenson RK.

Related Articles, Li












Regulation of endometrial granulocyte macrophage-colony stimulating factor (GM-CSF) in the ewe. Domest Anim Endocrinol. 2002 Oct;23(3):383-96. PMID: 12206872 [PubMed - indexed for MEDLINE]










- ☐ **98:** Csernansky JG, Miller JP, McKeel D, Morris JC.

Related Articles, Li



Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type.

- ☐ **99:** Matsuda K, Tashiro K, Hayashi Y, Monji A, Yoshida I, Mitsuyama Y. Related Articles, Li
 Measurement of laminins in the cerebrospinal fluid obtained from patients w Alzheimer's disease and vascular dementia using a modified enzyme-linked immunosorbent assay.
Dement Geriatr Cogn Disord. 2002;14(3):113-22.
PMID: 12218253 [PubMed - indexed for MEDLINE]
- ☐ **100:** Eschweiler GW, Wormstall H, Widmann U, Naegele T, Bartels M. Related Articles, Li
 [Correlation of diffusion-weighted magnetic resonance imaging with neurological deficits in sporadic Creutzfeldt-Jakob Disease]
Nervenarzt. 2002 Sep;73(9):883-6. German.
PMID: 12215882 [PubMed - indexed for MEDLINE]
- ☐ **101:** Trojanowski JQ, Clark CM, Arai H, Lee VM. Related Articles, Li
 Elevated levels of tau in cerebrospinal fluid: implications for the antemortem diagnosis of Alzheimer's disease elevated levels of tau in cerebrospinal fluid implications for the antemortem diagnosis of Alzheimer's disease.
J Alzheimers Dis. 1999 Nov;1(4-5):297-305.
PMID: 12214127 [PubMed]
- ☐ **102:** Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K. Related Articles, Li
 Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke.
J Alzheimers Dis. 2000 Nov;2(3-4):199-206.
PMID: 12214084 [PubMed]
- ☐ **103:** De La Monte SM, Wands JR. Related Articles, Li
 The AD7c-NTP neuronal thread protein biomarker for detecting Alzheimer disease.
J Alzheimers Dis. 2001 Jun;3(3):345-353.
PMID: 12214056 [PubMed - as supplied by publisher]
- ☐ **104:** Saez-Valero J, Small DH. Related Articles, Li
 Acetylcholinesterase and butyrylcholinesterase glycoforms are biomarkers Alzheimer's disease.
J Alzheimers Dis. 2001 Jun;3(3):323-328.
PMID: 12214053 [PubMed - as supplied by publisher]
- ☐ **105:** Shoji M, Kanai M. Related Articles, Li
 Cerebrospinal fluid Abeta40 and Abeta42: Natural course and clinical usefulness.
J Alzheimers Dis. 2001 Jun;3(3):313-321.
PMID: 12214052 [PubMed - as supplied by publisher]
- ☐ **106:** Growdon JH. Related Articles, Li
 Incorporating biomarkers into clinical drug trials in Alzheimer's disease.
J Alzheimers Dis. 2001 Jun;3(3):287-292.
PMID: 12214049 [PubMed - as supplied by publisher]
- ☐ **107:** Mulder C, Wahlund LO, Blomberg M, de Jong S, van Kamp GJ, Scheltens P, Teerlink T. Related Articles, Li
 Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid
J Neural Transm. 2002 Sep;109(9):1203-8.

- ☐ **108:** Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptak U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H. Related Articles, Li
 CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects.
 Neurology. 2002 Aug 27;59(4):627-9.
 PMID: 12196665 [PubMed - indexed for MEDLINE]
- ☐ **109:** Nussinovitch M, Prais D, Finkelstein Y, Harel D, Amir J, Volovitz B. Related Articles, Li
 Lactic dehydrogenase isoenzymes in cerebrospinal fluid of children with Guillain-Barre syndrome.
 Arch Dis Child. 2002 Sep;87(3):255-6.
 PMID: 12193446 [PubMed - indexed for MEDLINE]
- ☐ **110:** Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Moller HJ, Davies P, Hampel H. Related Articles, Li
 Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.
 Arch Neurol. 2002 Aug;59(8):1267-72.
 PMID: 12164722 [PubMed - indexed for MEDLINE]
- ☐ **111:** Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M. Related Articles, Li
 C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome.
 Brain Res. 2002 Aug 23;947(1):131-9.
 PMID: 12144861 [PubMed - indexed for MEDLINE]
- ☐ **112:** Van Everbroeck B, Green AJ, Vanmechelen E, Vanderstichele H, Pals P, Sanchez-Valle R, Corrales NC, Martin JJ, Cras P. Related Articles, Li
 Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease.
 J Neurol Neurosurg Psychiatry. 2002 Jul;73(1):79-81.
 PMID: 12082054 [PubMed - indexed for MEDLINE]
- ☐ **113:** Riemenschneider M, Wagenpfeil S, Diehl J, Lautenschlager N, Thiemel T, Heldmann B, Drzezga A, Jahn T, Forstl H, Kurz A. Related Articles, Li
 Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration.
 Neurology. 2002 Jun 11;58(11):1622-8.
 PMID: 12058089 [PubMed - indexed for MEDLINE]
- ☐ **114:** Fishman P, Bar-Yehuda S, Madi L, Cohn I. Related Articles, Li
 A3 adenosine receptor as a target for cancer therapy.
 Anticancer Drugs. 2002 Jun;13(5):437-43. Review.
 PMID: 12045454 [PubMed - indexed for MEDLINE]
- ☐ **115:** Green A. Related Articles, Li
 Biochemical investigations in patients with dementia.
 Ann Clin Biochem. 2002 May;39(Pt 3):211-20. Review.
 PMID: 12038595 [PubMed - indexed for MEDLINE]
- ☐ **116:** Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Related Articles, Li
 Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid.

Neurobiol Aging. 2002 Jul-Aug;23(4):485-508. Review.
PMID: 12009495 [PubMed - indexed for MEDLINE]

- ☐ 117: Shoji M, Matsubara E, Murakami T, Manabe Y, Abe K, Kanai M, Ikeda M, Tomidokoro Y, Shizuka M, Watanabe M, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Nishimura T, Nakamura Y, Takeda M, Urakami K, Adachi Y, Nakashima K, Arai H, Sasaki H, Kanemaru K, Yamanouchi H, Yoshida Y, Ichise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Yoshida H, Toji H, Nakamura S, Hirai S. Related Articles, Li



Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group.
Neurobiol Aging. 2002 May-Jun;23(3):363-70.
PMID: 11959397 [PubMed - indexed for MEDLINE]

- ☐ 118: Briani C, Ruggero S, Naccarato M, Cagnin A, Ricchieri GL, Pasqui L, Pizzolato G, Battistin L. Related Articles, Li



Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data.
J Neural Transm. 2002 Mar;109(3):393-8.
PMID: 11956959 [PubMed - indexed for MEDLINE]

- ☐ 119: Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, Wang J. Related Articles, Li



Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.
Am J Pathol. 2002 Apr;160(4):1269-78.
PMID: 11943712 [PubMed - indexed for MEDLINE]

- ☐ 120: Torreilles F, Touchon J. Related Articles, Li



Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease.
Prog Neurobiol. 2002 Feb;66(3):191-203. Review.
PMID: 11943451 [PubMed - indexed for MEDLINE]

- ☐ 121: Hu Y, He S, Wang J. Related Articles, Li



[Diagnostic value of tau in cerebrospinal fluid in alzheimer disease]
Zhonghua Yi Xue Za Zhi. 2001 Nov 25;81(22):1377-9. Chinese.
PMID: 11930632 [PubMed - indexed for MEDLINE]

- ☐ 122: Shoji M. Related Articles, Li



Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.
Front Biosci. 2002 Apr 01;7:d997-1006. Review.
PMID: 11897565 [PubMed - indexed for MEDLINE]

- ☐ 123: de la Monte SM, Wands JR. Related Articles, Li





















The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease.
Front Biosci. 2002 Apr 01;7:d989-96. Review.
PMID: 11897561 [PubMed - indexed for MEDLINE]

- ☐ 124: Savion S, Zeldich E, Orenstein H, Shepshelovich J, Torchinsky A, Carp H, Toder V, Fein A. Related Articles, Li



Cytokine expression in the uterus of mice with pregnancy loss: effect of maternal immunopotentiality with GM-CSF.
Reproduction. 2002 Mar;123(3):399-409.
PMID: 11882017 [PubMed - indexed for MEDLINE]

- 125: Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H. Related Articles, Li
 Combined Analysis of CSF Tau Levels and [(123)I]Iodoamphetamine SPE in Mild Cognitive Impairment: Implications for a Novel Predictor of Alzheimer's Disease.
 Am J Psychiatry. 2002 Mar;159(3):474-6.
 PMID: 11870015 [PubMed - indexed for MEDLINE]
- 126: Hu YY, He SS, Wang XC, Duan QH, Khatoun S, Iqbal K, Grundke-Iqbal I, Wang JZ. Related Articles, Li
 Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients.
 Neurosci Lett. 2002 Mar 8;320(3):156-60.
 PMID: 11852185 [PubMed - indexed for MEDLINE]
- 127: Sanchez-Valle R, Saiz A, Graus F. Related Articles, Li
 14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease.
 Neurosci Lett. 2002 Mar 1;320(1-2):69-72.
 PMID: 11849766 [PubMed - indexed for MEDLINE]
- 128: Tumani H, Windl O, Kretschmar HA, Ludolph AC. Related Articles, Li
 [Clinically atypical CJD: diagnostic relevance of cerebrospinal fluid markers and molecular genetic analysis?]
 Dtsch Med Wochenschr. 2002 Feb 15;127(7):318-20. German.
 PMID: 11845387 [PubMed - indexed for MEDLINE]
- 129: Sjogren M, Davidsson P, Wallin A, Granerus AK, Grundstrom E, Askmark H, Vanmechelen E, Blennow K. Related Articles, Li
 Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms.
 Dement Geriatr Cogn Disord. 2002;13(2):112-8.
 PMID: 11844893 [PubMed - indexed for MEDLINE]
- 130: Blennow K, Vanmechelen E, Hampel H. Related Articles, Li
 CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.
 Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.
 PMID: 11831556 [PubMed - indexed for MEDLINE]
- 131: Jauss M, Herholz K, Kracht L, Pantel J, Hartmann T, Jensen M, Essig M, Schroder J. Related Articles, Li
 Frontotemporal dementia: clinical, neuroimaging, and molecular biological findings in 6 patients.
 Eur Arch Psychiatry Clin Neurosci. 2001 Oct;251(5):225-31.
 PMID: 11829209 [PubMed - indexed for MEDLINE]
- 132: Galasko D. Related Articles, Li
 Biological markers and the treatment of Alzheimer's disease.
 J Mol Neurosci. 2001 Oct;17(2):119-25. Review.
 PMID: 11816785 [PubMed - indexed for MEDLINE]
- 133: Otto M, Wiltfang J, Cepek L, Neumann M, Mollenhauer B, Steinacker P, Ciesielczyk B, Schulz-Schaeffer W, Kretschmar HA, Poser S. Related Articles, Li
 Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease.
 Neurology. 2002 Jan 22;58(2):192-7.

- ☐ **134:** Hattori H, Matsumoto M, Iwai K, Tsuchiya H, Miyauchi E, Takasaki M, Kamino K, Munehira J, Kimura Y, Kawanishi K, Hoshino T, Murai H, Ogata H, Maruyama H, Yoshida H. Related Articles, Li
-  The tau protein of oral epithelium increases in Alzheimer's disease.
J Gerontol A Biol Sci Med Sci. 2002 Jan;57(1):M64-70.
PMID: 11773216 [PubMed - indexed for MEDLINE]
- ☐ **135:** Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A. Related Articles, Li
-  Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.
J Neurosci Res. 2001 Nov 1;66(3):510-6.
PMID: 11746370 [PubMed - indexed for MEDLINE]
- ☐ **136:** Fodero LR, Saez-Valero J, Barquero MS, Marcos A, McLean CA, Small DH. Related Articles, Li
-  Wheat germ agglutinin-binding glycoproteins are decreased in Alzheimer's disease cerebrospinal fluid.
J Neurochem. 2001 Dec;79(5):1022-6.
PMID: 11739614 [PubMed - indexed for MEDLINE]
- ☐ **137:** Potemkowski A, Lehmitz R, Koziarska D. Related Articles, Li
-  [Present condition and prospects of cerebrospinal fluid diagnostics]
Neurol Neurochir Pol. 2001 Mar-Apr;35(3):471-81. Review. Polish.
PMID: 11732269 [PubMed - indexed for MEDLINE]
- ☐ **138:** Maruyama M, Arai H, Sugita M, Tanji H, Higuchi M, Okamura N, Matsui T, Higuchi S, Matsushita S, Yoshida H, Sasaki H. Related Articles, Li
-  Cerebrospinal fluid amyloid beta(1-42) levels in the mild cognitive impairment stage of Alzheimer's disease.
Exp Neurol. 2001 Dec;172(2):433-6.
PMID: 11716567 [PubMed - indexed for MEDLINE]
- ☐ **139:** Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjogren M, Wallin A, Xilinas M, Gottfries CG. Related Articles, Li
-  Treatment of Alzheimer's disease with clioquinol.
Dement Geriatr Cogn Disord. 2001 Nov-Dec;12(6):408-14.
PMID: 11598313 [PubMed - indexed for MEDLINE]
- ☐ **140:** Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K. Related Articles, Li
-  Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
Mech Ageing Dev. 2001 Nov;122(16):2005-11. Review.
PMID: 11589918 [PubMed - indexed for MEDLINE]
- ☐ **141:** Wallin A, Sjogren M. Related Articles, Li
-  Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia.
Mech Ageing Dev. 2001 Nov;122(16):1937-49.
PMID: 11589912 [PubMed - indexed for MEDLINE]
- ☐ **142:** Sjogren M, Wallin A. Related Articles, Li
-  Pathophysiological aspects of frontotemporal dementia--emphasis on cytoskeleton proteins and autoimmunity.
Mech Ageing Dev. 2001 Nov;122(16):1923-35.
PMID: 11589911 [PubMed - indexed for MEDLINE]
- ☐ **143:** Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbacke M. Related Articles, Li

Wikkelso C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nagga K, Andreassen N, Davidsson P, Vanmechelen E, Blennow K.



Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values.

Clin Chem. 2001 Oct;47(10):1776-81.

PMID: 11568086 [PubMed - indexed for MEDLINE]

- ☐ **144:** Chelmonska-Soyta A, Katska L, Kurpisz M, Stefaniak T, Zimecki M. Related Articles, Li



The effect of Ureaplasma diversum activated mononuclear leukocytes on the development and interferon-tau production by bovine IVF-derived embryos

J Reprod Immunol. 2001 Aug;51(2):145-58.

PMID: 11543853 [PubMed - indexed for MEDLINE]

- ☐ **145:** Soderstrom H, Blennow K, Manhem A, Forsman A. Related Articles, Li



CSF studies in violent offenders. II. Blood-brain barrier dysfunction without concurrent inflammation or structure degeneration.

J Neural Transm. 2001;108(7):879-86.

PMID: 11515753 [PubMed - indexed for MEDLINE]

- ☐ **146:** Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E. Related Articles, Li



Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?

J Neurol Neurosurg Psychiatry. 2001 Sep;71(3):401-3.

PMID: 11511720 [PubMed - indexed for MEDLINE]

- ☐ **147:** Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, Buerger K, Wiltfang J, Otto M, Kretschmar H, Moeller HJ, Imagawa M, Kohno H, Nakashima K, Kuzuhara S, Sasaki H, Imahori K. Related Articles, Li



Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease.

Ann Neurol. 2001 Aug;50(2):150-6.

PMID: 11506396 [PubMed - indexed for MEDLINE]

- ☐ **148:** Reiber H. Related Articles, Li



Dynamics of brain-derived proteins in cerebrospinal fluid.

Clin Chim Acta. 2001 Aug 20;310(2):173-86.

PMID: 11498083 [PubMed - indexed for MEDLINE]

- ☐ **149:** Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F; Related Articles, Li
Phospho-Tau International Study Group.



CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group.

Neurol Sci. 2001 Feb;22(1):77-8.

PMID: 11487210 [PubMed - indexed for MEDLINE]

- ☐ **150:** Shoji M. Related Articles, Li



[The progress of Alzheimer's disease research biomarkers--sensitivity and specificity]

Rinsho Shinkeigaku. 2000 Dec;40(12):1234-6. Review. Japanese.










PMID: 11464465 [PubMed - indexed for MEDLINE]

- ☐ **151:** Tarkowski E, Liljeroth AM, Nilsson A, Minthon L, Blennow K. Related Articles, Li



Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease.

Dement Geriatr Cogn Disord. 2001 Sep-Oct;12(5):314-7.

- ☐ **152:** Blennow K, Lind B, Andersson E, Andreasen N. Related Articles, Li
 [CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. A literature review and three cases from routine clinical practice]
 Lakartidningen. 2001 May 16;98(20):2446-51. Swedish.
 PMID: 11433975 [PubMed - indexed for MEDLINE]
- ☐ **153:** Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A. Related Articles, Li
 Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.
 Am J Alzheimers Dis Other Dement. 2001 Jan-Feb;16(1):21-31.
 PMID: 11416945 [PubMed - indexed for MEDLINE]
- ☐ **154:** Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, Ironside JW, Will RG, Knight RS. Related Articles, Li
 Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease.
 J Neurol Neurosurg Psychiatry. 2001 Jun;70(6):744-8.
 PMID: 11385008 [PubMed - indexed for MEDLINE]
- ☐ **155:** Sjogren M, Davidsson P, Gottfries J, Vanderstichele H, Edman A, Vanmechelen E, Wallin A, Blennow K. Related Articles, Li
 The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process.
 Dement Geriatr Cogn Disord. 2001 Jul-Aug;12(4):257-64.
 PMID: 11351137 [PubMed - indexed for MEDLINE]
- ☐ **156:** Sjogren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkelso C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K. Related Articles, Li
 Both total and phosphorylated tau are increased in Alzheimer's disease.
 J Neurol Neurosurg Psychiatry. 2001 May;70(5):624-30.
 PMID: 11309456 [PubMed - indexed for MEDLINE]
- ☐ **157:** Tapiola T, Soininen H, Pirttila T. Related Articles, Li
 CSF tau and Abeta42 levels in patients with Down's syndrome.
 Neurology. 2001 Apr 10;56(7):979-80. No abstract available.
 PMID: 11294944 [PubMed - indexed for MEDLINE]
- ☐ **158:** Saez-Valero J, Mok SS, Small DH. Related Articles, Li
 An unusually glycosylated form of acetylcholinesterase is a CSF biomarker for Alzheimer's disease.
 Acta Neurol Scand Suppl. 2000;176:49-52.
 PMID: 11261805 [PubMed - indexed for MEDLINE]
- ☐ **159:** Montine TJ, Kaye JA, Montine KS, McFarland L, Morrow JD, Quinn JF. Related Articles, Li
 Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls.
 Arch Pathol Lab Med. 2001 Apr;125(4):510-2.
 PMID: 11260625 [PubMed - indexed for MEDLINE]
- ☐ **160:** Fabre SF, Forsell C, Viitanen M, Sjogren M, Wallin A, Blennow K, Blomberg M, Andersen C, Wahlund LO, Lannfelt L. Related Articles, Li
 Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon4 frequency, but no

tau gene mutations.

Exp Neurol. 2001 Apr;168(2):413-8.

PMID: 11259129 [PubMed - indexed for MEDLINE]

- ☐ **161:** Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Related Articles, Li



Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID: 11255440 [PubMed - indexed for MEDLINE]

- ☐ **162:** Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A. Related Articles, Li



Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia.

Acta Neurol Scand. 2001 Mar;103(3):166-74.

PMID: 11240564 [PubMed - indexed for MEDLINE]

- ☐ **163:** Green AJ, Giovannoni G, Hall-Craggs MA, Thompson EJ, Miller RF. Related Articles, Li



Cerebrospinal fluid tau concentrations in HIV infected patients with suspected neurological disease.

Sex Transm Infect. 2000 Dec;76(6):443-6.

PMID: 11221126 [PubMed - indexed for MEDLINE]

- ☐ **164:** Tschampa HJ, Schulz-Schaeffer W, Wiltfang J, Poser S, Otto M, Neumann M, Kretschmar HA. Related Articles, Li



Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.

Neurology. 2001 Feb 27;56(4):576. No abstract available.

PMID: 11222819 [PubMed - indexed for MEDLINE]

- ☐ **165:** Paradowski B, Szczepaniak M, Dobosz T, Sasiadek M. Related Articles, Li



[Apolipoprotein E(ApoE) and tau protein in Alzheimer type dementia]

Pol Merkuriusz Lek. 2000 Nov;9(53):758-9. Polish.

PMID: 11204323 [PubMed - indexed for MEDLINE]

- ☐ **166:** Van Gool SW, Van Kerschaver E, Brock P, Pottel H, Hulstaert F, Vanmechelen E, Uyttebroeck A, Van De Voorde A, Vanderstichele H. Related Articles, Li



Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies.

Leukemia. 2000 Dec;14(12):2076-84.

PMID: 11187896 [PubMed - indexed for MEDLINE]

- ☐ **167:** Sussmuth SD, Reiber H, Tumani H. Related Articles, Li



Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.

Neurosci Lett. 2001 Mar 9;300(2):95-8.

PMID: 11207383 [PubMed - indexed for MEDLINE]

- ☐ **168:** Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Related Articles, Li



Cerebrospinal fluid tau levels increase with age in healthy individuals.

Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):127-32.










PMID: 11173885 [PubMed - indexed for MEDLINE]










- ☐ **169:** Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M, Ishizu H, Kashihara K, Yamamoto M, Tsuchiya-Ikemoto K, Morimatsu M, Related Articles, Li





Takashima H, Nakagawa M, Kurokawa K, Maruyama H, Kaseda Y, Nakamura S, Hasegawa K, Oono H, Hikasa C, Ikeda K, Yamagata K,











Wakutani Y, Takeshima T, Nakashima K.









Diagnostic significance of tau protein in cerebrospinal fluid from patients










-  with corticobasal degeneration or progressive supranuclear palsy.
J Neurol Sci. 2001 Jan 15;183(1):95-8.
PMID: 11166802 [PubMed - indexed for MEDLINE]
- ☐ 170: Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Related Articles, Li
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.
Neurosci Lett. 2001 Jan 19;297(3):187-90.
PMID: 11137759 [PubMed - indexed for MEDLINE]
-  ☐ 171: Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Related Articles, Li
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Dement Geriatr Cogn Disord. 2001 Jan-Feb;12(1):22-32.
PMID: 11125238 [PubMed - indexed for MEDLINE]
- ☐ 172: Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Related Articles, Li
 Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain.
FEBS Lett. 2000 Nov 17;485(1):87-93.
PMID: 11086171 [PubMed - indexed for MEDLINE]
- ☐ 173: Sjogren M, Minthon L, Davidsson P, Granerus A-K, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. Related Articles, Li
 CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging.
J Neural Transm. 2000;107(5):563-79.
PMID: 11072752 [PubMed - indexed for MEDLINE]
- ☐ 174: Andersen C, Froelich Fabre S, Ostberg P, Lannfelt L, Wahlund L. Related Articles, Li
 Tau protein in cerebrospinal fluid from semantic dementia patients.
Neurosci Lett. 2000 Nov 24;294(3):155-8.
PMID: 11072138 [PubMed - indexed for MEDLINE]
- ☐ 175: Zachrisson OC, Balldin J, Ekman R, Naesh O, Rosengren L, Agren H, Blennow K. Related Articles, Li
 No evident neuronal damage after electroconvulsive therapy.
Psychiatry Res. 2000 Oct 30;96(2):157-65.
PMID: 11063788 [PubMed - indexed for MEDLINE]
- ☐ 176: Averback P. Related Articles, Li
 Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF.
Neurology. 2000 Oct 10;55(7):1068-9. No abstract available.
PMID: 11061282 [PubMed - indexed for MEDLINE]
- ☐ 177: Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H, Imahori K. Related Articles, Li
 CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
Exp Neurol. 2000 Nov;166(1):201-3.
PMID: 11031097 [PubMed - indexed for MEDLINE]
- ☐ 178: Tapiola T, Pirttila T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H. Related Articles, Li
 Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau patients with probable and definite Alzheimer's disease.









- ☐ **179:** Fagan AM, Holtzman DM. Related Articles, Li
 Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo.
Microsc Res Tech. 2000 Aug 15;50(4):297-304. Review.
PMID: 10936884 [PubMed - indexed for MEDLINE]
- ☐ **180:** Kropp S, Schlimme J, Bleich S, Wiltfang J, Dietrich DE, Emrich HM. Related Articles, Li
 [Diagnostic steps in Alzheimer dementia before treatment with new antidementives]
Fortschr Neurol Psychiatr. 2000 Jun;68(6):257-61. Review. German.
PMID: 10923250 [PubMed - indexed for MEDLINE]
- ☐ **181:** Arai H, Suzuki T, Sasaki H, Hanawa T, Toriizuka K, Yamada H. Related Articles, Li
 [A new interventional strategy for Alzheimer's disease by Japanese herbal medicine]
Nippon Ronen Igakkai Zasshi. 2000 Mar;37(3):212-5. Review. Japanese.
PMID: 10879069 [PubMed - indexed for MEDLINE]
- ☐ **182:** Kapaki E, Paraskevas GP, Michalopoulou M, Kilidireas K. Related Articles, Li
 Increased cerebrospinal fluid tau protein in multiple sclerosis.
Eur Neurol. 2000;43(4):228-32.
PMID: 10828654 [PubMed - indexed for MEDLINE]
- ☐ **183:** Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Related Articles, Li
 Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Neurology. 2000 May 23;54(10):1960-4.
PMID: 10822437 [PubMed - indexed for MEDLINE]
- ☐ **184:** Emond V, Asselin E, Fortier MA, Murphy BD, Lambert RD. Related Articles, Li
 Interferon-tau stimulates granulocyte-macrophage colony-stimulating factor gene expression in bovine lymphocytes and endometrial stromal cells.
Biol Reprod. 2000 Jun;62(6):1728-37.
PMID: 10819777 [PubMed - indexed for MEDLINE]
- ☐ **185:** Emmerling MR, Morganti-Kossmann MC, Kossmann T, Stahel PF, Watson MD, Evans LM, Mehta PD, Spiegel K, Kuo YM, Rohrer AE, Raby CA. Related Articles, Li
 Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury.
Ann N Y Acad Sci. 2000 Apr;903:118-22.
PMID: 10818496 [PubMed - indexed for MEDLINE]
- ☐ **186:** Kudo T, Mima T, Hashimoto R, Nakao K, Morihara T, Tanimukai H, Tsujio I, Koike Y, Tagami S, Mori H, Nakamura Y, Tanaka T, Mori K, Takeda M. Related Articles, Li
 Tau protein is a potential biological marker for normal pressure hydrocephalus.
Psychiatry Clin Neurosci. 2000 Apr;54(2):199-202.
PMID: 10803815 [PubMed - indexed for MEDLINE]
- ☐ **187:** Kanemaru K, Kameda N, Yamanouchi H. Related Articles, Li
 Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.
Neurology. 2000 May 9;54(9):1875-6. No abstract available.
PMID: 10802808 [PubMed - indexed for MEDLINE]

- ☐ **188:** Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreassen N, Blennow K. Related Articles, Li
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. *Neurosci Lett.* 2000 May 5;285(1):49-52.
PMID: 10788705 [PubMed - indexed for MEDLINE]
-  **189:** Kahle PJ, Jakowec M, Teipel SJ, Hampel H, Petzinger GM, Di Monte DA, Silverberg GD, Moller HJ, Yesavage JA, Tinklenberg JR, Shooter EM, Murphy GM Jr. Related Articles, Li
Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. *Neurology.* 2000 Apr 11;54(7):1498-504.
PMID: 10751266 [PubMed - indexed for MEDLINE]
- ☐ **190:** Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, Soininen H. Related Articles, Li
Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. *Neurosci Lett.* 2000 Feb 18;280(2):119-22.
PMID: 10686392 [PubMed - indexed for MEDLINE]
-  **191:** Burger nee Buch K, Padberg F, Nolde T, Teipel SJ, Stubner S, Haslinger A, Schwarz MJ, Sunderland T, Arai H, Rapoport SI, Moller HJ, Hampel H. Related Articles, Li
Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. *Neurosci Lett.* 1999 Dec 17;277(1):21-4.
PMID: 10643888 [PubMed - indexed for MEDLINE]
- ☐ **192:** Molina L, Touchon J, Herpe M, Lefranc D, Duplan L, Cristol JP, Sabatier R, Vermersch P, Pau B, Mourtou-Gilles C. Related Articles, Li
Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias. *Neuroreport.* 1999 Nov 26;10(17):3491-5.
PMID: 10619631 [PubMed - indexed for MEDLINE]
-  **193:** Wallin A, Blennow K, Rosengren L. Related Articles, Li
Cerebrospinal fluid markers of pathogenetic processes in vascular dementia with special reference to the subcortical subtype. *Alzheimer Dis Assoc Disord.* 1999 Oct-Dec;13 Suppl 3:S102-5. Review.
PMID: 10609688 [PubMed - indexed for MEDLINE]
- ☐ **194:** Moricarty PL, Seubert P, Galasko D, Markwell S, Unni L, Vicari S, Becker RE. Related Articles, Li
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. *Methods Find Exp Clin Pharmacol.* 1999 Oct;21(8):549-54.
PMID: 10599054 [PubMed - indexed for MEDLINE]
-  **195:** Tang YW, Hibbs JR, Tau KR, Qian Q, Skarhus HA, Smith TF, Persing DH. Related Articles, Li
Effective use of polymerase chain reaction for diagnosis of central nervous system infections. *Clin Infect Dis.* 1999 Oct;29(4):803-6.
PMID: 10589893 [PubMed - indexed for MEDLINE]
- ☐ **196:** Andersson L, Blennow K, Fuchs D, Svennerholm B, Gisslen M. Related Articles, Li

-  **Increased cerebrospinal fluid protein tau concentration in neuro-AIDS.**
J Neurol Sci. 1999 Dec 15;171(2):92-6.
PMID: 10581374 [PubMed - indexed for MEDLINE]
- ☐ **197:** Martinez M, Fernandez E, Frank A, Guaza C, de la Fuente M, Hernanz A. Related Articles, Li
Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.
Brain Res. 1999 Nov 6;846(2):265-7.
PMID: 10556645 [PubMed - indexed for MEDLINE]
-  **Increased cerebrospinal fluid cAMP levels in Alzheimer's disease.**
Brain Res. 1999 Nov 6;846(2):265-7.
PMID: 10556645 [PubMed - indexed for MEDLINE]
- ☐ **198:** Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Related Articles, Li
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.
Neurology. 1999 Oct 22;53(7):1488-94.
PMID: 10534256 [PubMed - indexed for MEDLINE]
-  **Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.**
Neurology. 1999 Oct 22;53(7):1488-94.
PMID: 10534256 [PubMed - indexed for MEDLINE]
- ☐ **199:** Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Itoh M, Iwatsubo T, Tomita T, Sasaki H. Related Articles, Li
Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans.
Neurosci Lett. 1999 Oct 8;273(3):203-7.
PMID: 10515194 [PubMed - indexed for MEDLINE]
-  **Cerebrospinal fluid levels of amyloid beta-peptide1-42, but not tau have positive correlation with brain glucose metabolism in humans.**
Neurosci Lett. 1999 Oct 8;273(3):203-7.
PMID: 10515194 [PubMed - indexed for MEDLINE]
- ☐ **200:** Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K. Related Articles, Li
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.
Neurosci Lett. 1999 Sep 24;273(1):5-8.
PMID: 10505638 [PubMed - indexed for MEDLINE]
-  **Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.**
Neurosci Lett. 1999 Sep 24;273(1):5-8.
PMID: 10505638 [PubMed - indexed for MEDLINE]
- ☐ **201:** Kimura M, Asada T, Uno M, Machida N, Kasuya K, Taniguchi Y, Fujita T, Nishiyama E, Iwamoto N, Arai H. Related Articles, Li
Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease.
Neurosci Lett. 1999 Oct 1;273(2):137-9.
PMID: 10505635 [PubMed - indexed for MEDLINE]
-  **Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease.**
Neurosci Lett. 1999 Oct 1;273(2):137-9.
PMID: 10505635 [PubMed - indexed for MEDLINE]
- ☐ **202:** Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimaki T, Seubert P. Related Articles, Li
Longitudinal stability of CSF tau levels in Alzheimer patients.
Biol Psychiatry. 1999 Sep 15;46(6):750-5.
PMID: 10494442 [PubMed - indexed for MEDLINE]
-  **Longitudinal stability of CSF tau levels in Alzheimer patients.**
Biol Psychiatry. 1999 Sep 15;46(6):750-5.
PMID: 10494442 [PubMed - indexed for MEDLINE]
- ☐ **203:** Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K, Park JM, Sato K, Kohno H, Imahori K. Related Articles, Li
Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.
Neurosci Lett. 1999 Jul 30;270(2):91-4.
PMID: 10462105 [PubMed - indexed for MEDLINE]
-  **Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.**
Neurosci Lett. 1999 Jul 30;270(2):91-4.
PMID: 10462105 [PubMed - indexed for MEDLINE]
- ☐ **204:** Kanai M, Shizuka M, Urakami K, Matsubara E, Harigaya Y, Okamoto K, Shoji M. Related Articles, Li
Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.
Neurosci Lett. 1999 May 21;267(1):65-8.
PMID: 10400250 [PubMed - indexed for MEDLINE]
-  **Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease.**
Neurosci Lett. 1999 May 21;267(1):65-8.
PMID: 10400250 [PubMed - indexed for MEDLINE]
- ☐ **205:** Kanemaru K, Tajika T. Related Articles, Li
Antibodies to CSF tau.
-  **Antibodies to CSF tau.**

- ☐ **206:** Savion S, Brengauz-Breitmann M, Torchinsky A, Toder V. Related Articles, Li
 A possible role for granulocyte macrophage-colony stimulating factor in modulating teratogen-induced effects.
Teratog Carcinog Mutagen. 1999;19(3):171-82.
PMID: 10379842 [PubMed - indexed for MEDLINE]
- ☐ **207:** Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H. Related Articles, Li
 Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.
Neurology. 1999 May 12;52(8):1555-62.
PMID: 10331678 [PubMed - indexed for MEDLINE]
- ☐ **208:** Morikawa Y, Arai H, Matsushita S, Kato M, Higuchi S, Miura M, Kawakami H, Higuchi M, Okamura N, Tashiro M, Matsui T, Sasaki H. Related Articles, Li
 Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics.
Alcohol Clin Exp Res. 1999 Apr;23(4):575-7.
PMID: 10235290 [PubMed - indexed for MEDLINE]
- ☐ **209:** Hampel H, Teipel SJ, Padberg F, Haslinger A, Riemenschneider M, Schwarz MJ, Kotter HU, Scheloske M, Buch K, Stubner S, Dukoff R, Lasser R, Muller N, Sunderland T, Rapoport SI, Moller HJ. Related Articles, Li
 Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.
Brain Res. 1999 Mar 27;823(1-2):104-12.
PMID: 10095017 [PubMed - indexed for MEDLINE]
- ☐ **210:** Kropp S, Zerr I, Schulz-Schaeffer WJ, Riedemann C, Bodemer M, Laske C, Kretzschmar HA, Poser S. Related Articles, Li
 Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease.
Neurosci Lett. 1999 Feb 12;261(1-2):124-6.
PMID: 10081943 [PubMed - indexed for MEDLINE]
- ☐ **211:** Green AJ, Harvey RJ, Thompson EJ, Rossor MN. Related Articles, Li
 Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.
Neurosci Lett. 1999 Jan 8;259(2):133-5.
PMID: 10025576 [PubMed - indexed for MEDLINE]
- ☐ **212:** Urakami K, Mori M, Wada K, Kowa H, Takeshima T, Arai H, Sasaki H, Kanai M, Shoji M, Ikemoto K, Morimatsu M, Hikasa C, Nakashima K. Related Articles, Li
 A comparison of tau protein in cerebrospinal fluid between corticobasal degeneration and progressive supranuclear palsy.
Neurosci Lett. 1999 Jan 8;259(2):127-9.
PMID: 10025574 [PubMed - indexed for MEDLINE]
- ☐ **213:** Zemlan FP, Rosenberg WS, Luebke PA, Campbell TA, Dean GE, Weiner NE, Cohen JA, Rudick RA, Woo D. Related Articles, Li
 Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins.
J Neurochem. 1999 Feb;72(2):741-50.
PMID: 9930748 [PubMed - indexed for MEDLINE]











- ☐ **214:** Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Muller U, Guder W. Related Articles, Li
 Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.
 Alzheimer Dis Assoc Disord. 1998 Dec;12(4):372-7.
 PMID: 9876968 [PubMed - indexed for MEDLINE]
- ☐ **215:** Arai H, Satoh-Nakagawa T, Higuchi M, Morikawa Y, Miura M, Kawakami H, Seki H, Takase S, Sasaki H. Related Articles, Li
 No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia.
 Neurosci Lett. 1998 Nov 13;256(3):174-6.
 PMID: 9855368 [PubMed - indexed for MEDLINE]
- ☐ **216:** Lasser RA, Dukoff R, Levy J, Levin R, Lehtimaki T, Seubert P, Sunderland T. Related Articles, Li
 Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.
 Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.
 PMID: 9850873 [PubMed - indexed for MEDLINE]
- ☐ **217:** Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I, Iqbal K. Related Articles, Li
 Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK.
 FEBS Lett. 1998 Oct 9;436(3):471-5.
 PMID: 9801171 [PubMed - indexed for MEDLINE]
- ☐ **218:** Ellis RJ, Seubert P, Motter R, Galasko D, Deutsch R, Heaton RK, Heyes MP, McCutchan JA, Atkinson JH, Grant I. Related Articles, Li
 Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC).
 Neurosci Lett. 1998 Sep 18;254(1):1-4.
 PMID: 9780077 [PubMed - indexed for MEDLINE]
- ☐ **219:** Mecocci P, Cherubini A, Bregnocchi M, Chionne F, Cecchetti R, Lowenthal DT, Senin U. Related Articles, Li
 Tau protein in cerebrospinal fluid: a new diagnostic and prognostic marker Alzheimer disease?
 Alzheimer Dis Assoc Disord. 1998 Sep;12(3):211-4.
 PMID: 9772026 [PubMed - indexed for MEDLINE]
- ☐ **220:** Delacourte A. Related Articles, Li
 [Diagnosis of Alzheimer's disease]
 Ann Biol Clin (Paris). 1998 Mar-Apr;56(2):133-42. Review. French.
 PMID: 9754238 [PubMed - indexed for MEDLINE]
- ☐ **221:** Kano S, Watanabe M, Kanai M, Koike R, Onodera O, Tsuji S, Okamoto K, Shoji M. Related Articles, Li
 A Japanese family with adrenoleukodystrophy with a codon 291 deletion: a clinical, biochemical, pathological, and genetic report.
 J Neurol Sci. 1998 Jun 30;158(2):187-92.
 PMID: 9702690 [PubMed - indexed for MEDLINE]
- ☐ **222:** Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S. Related Articles, Li
 Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

- ☐ **223:** Blennow K, Vanmechelen E. Related Articles, Li
 **Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.**
J Neural Transm Suppl. 1998;53:223-35. Review.
PMID: 9700660 [PubMed - indexed for MEDLINE]
- ☐ **224:** Galasko D. Related Articles, Li
 **Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.**
J Neural Transm Suppl. 1998;53:209-21. Review.
PMID: 9700659 [PubMed - indexed for MEDLINE]
- ☐ **225:** Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I. Related Articles, Li
 **Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles.**
J Neural Transm Suppl. 1998;53:169-80. Review.
PMID: 9700655 [PubMed - indexed for MEDLINE]
- ☐ **226:** Morihara T, Kudo T, Ikura Y, Kashiwagi Y, Miyamae Y, Nakamura Y, Tanaka T, Shinozaki K, Nishikawa T, Takeda M. Related Articles, Li
 **Increased tau protein level in postmortem cerebrospinal fluid.**
Psychiatry Clin Neurosci. 1998 Feb;52(1):107-10.
PMID: 9682942 [PubMed - indexed for MEDLINE]
- ☐ **227:** Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P. Related Articles, Li
 **High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.**
Arch Neurol. 1998 Jul;55(7):937-45.
PMID: 9678311 [PubMed - indexed for MEDLINE]
- ☐ **228:** Kanai M, Matsubara E, Ise K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M. Related Articles, Li
 **Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.**
Ann Neurol. 1998 Jul;44(1):17-26.
PMID: 9667589 [PubMed - indexed for MEDLINE]
- ☐ **229:** Nishimura T, Takeda M, Nakamura Y, Yoshida Y, Arai H, Sasaki H, Shouji M, Hirai S, Khise K, Tanaka K, Hamamoto M, Yamamoto H, Matsubayashi T, Urakami K, Adachi Y, Nakashima K, Toji H, Nakamura S, Yoshida H. Related Articles, Li
 **Basic and clinical studies on the measurement of tau protein in cerebrospinal fluid as a biological marker for Alzheimer's disease and related disorders: multicenter study in Japan.**
Methods Find Exp Clin Pharmacol. 1998 Apr;20(3):227-35.
PMID: 9646285 [PubMed - indexed for MEDLINE]
- ☐ **230:** Buch K, Riemenschneider M, Bartenstein P, Willoch F, Muller U, Schmolke M, Nolde T, Steinmann C, Guder WG, Kurz A. Related Articles, Li
 **[Tau protein. A potential biological indicator for early detection of Alzheimer disease]**

Nervenarzt. 1998 May;69(5):379-85. German.
PMID: 9629553 [PubMed - indexed for MEDLINE]

- ☐ **231:** Jelic V, Blomberg M, Dierks T, Basun H, Shigeta M, Julin P, Jensen M, Lannfelt L, Winblad B, Wahlund LO. Related Articles, Li
EEG slowing and cerebrospinal fluid tau levels in patients with cognitive decline.
Neuroreport. 1998 Jan 5;9(1):157-60.
PMID: 9592068 [PubMed - indexed for MEDLINE]
- ☐ **232:** Hock C, Drasch G, Golombowski S, Muller-Spahn F, Willershausen-Zonnchen B, Schwarz P, Hock U, Growdon JH, Nitsch RM. Related Articles, Li
Increased blood mercury levels in patients with Alzheimer's disease.
J Neural Transm. 1998;105(1):59-68.
PMID: 9588761 [PubMed - indexed for MEDLINE]
- ☐ **233:** Launes J, Siren J, Viinikka L, Hokkanen L, Lindsberg PJ. Related Articles, Li
Does glutamate mediate brain damage in acute encephalitis?
Neuroreport. 1998 Mar 9;9(4):577-81.
PMID: 9559919 [PubMed - indexed for MEDLINE]
- ☐ **234:** Galasko D. Related Articles, Li
CSF tau and Abeta42: logical biomarkers for Alzheimer's disease?
Neurobiol Aging. 1998 Mar-Apr;19(2):117-9. No abstract available.
PMID: 9558144 [PubMed - indexed for MEDLINE]
- ☐ **235:** Andreasen N, Vanmechelen E, Van de Voorde A, Davidsson P, Hesse C, Tarvonen S, Raiha I, Sourander L, Winblad B, Blennow K. Related Articles, Li
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study.
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):298-305.
PMID: 9527138 [PubMed - indexed for MEDLINE]
- ☐ **236:** Kennedy AM. Related Articles, Li
CSF tests for dementia: a potential headache?
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):288. No abstract available.
PMID: 9527136 [PubMed - indexed for MEDLINE]
- ☐ **237:** Molina JA, Benito-Leon J, Jimenez-Jimenez FJ, Orti-Pareja M, Berbel A, Tallon-Barranco A, de Bustos F, Hernanz A. Related Articles, Li
Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson disease patients.
Neurosci Lett. 1997 Dec 5;238(3):139-41.
PMID: 9464639 [PubMed - indexed for MEDLINE]
- ☐ **238:** Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P Sr, Soininen H. Related Articles, Li
The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease.
Neuroreport. 1997 Dec 22;8(18):3961-3.
PMID: 9462474 [PubMed - indexed for MEDLINE]
- ☐ **239:** Mitani K, Furiya Y, Uchihara T, Ishii K, Yamanouchi H, Mizusawa H, Mori H. Related Articles, Li
Increased CSF tau protein in corticobasal degeneration.
J Neurol. 1998 Jan;245(1):44-6.
PMID: 9457628 [PubMed - indexed for MEDLINE]
- ☐ **240:** Weber T, Otto M, Bodemer M, Zerr I. Related Articles, Li

Diagnosis of Creutzfeldt-Jakob disease and related human spongiform

-  **encephalopathies.**
Biomed Pharmacother. 1997;51(9):381-7. Review.
PMID: 9452787 [PubMed - indexed for MEDLINE]
- ☐ **241:** Iqbal K, Grundke-Iqbal I. Related Articles, Li
 **Elevated levels of tau and ubiquitin in brain and cerebrospinal fluid in Alzheimer's disease.**
Int Psychogeriatr. 1997;9 Suppl 1:289-96; discussion 317-21.
PMID: 9447449 [PubMed - indexed for MEDLINE]
- ☐ **242:** Tapiola T, Lehtovirta M, Ramberg J, Helisalmi S, Linnaranta K, Riekkinen P Sr, Soininen H. Related Articles, Li
 **CSF tau is related to apolipoprotein E genotype in early Alzheimer's disease**
Neurology. 1998 Jan;50(1):169-74.
PMID: 9443475 [PubMed - indexed for MEDLINE]
- ☐ **243:** Gasparini L, Racchi M, Binetti G, Trabucchi M, Solerte SB, Alkon D, Etcheberrigaray R, Gibson G, Blass J, Paoletti R, Govoni S. Related Articles, Li
 **Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease.**
FASEB J. 1998 Jan;12(1):17-34. Review.
PMID: 9438407 [PubMed - indexed for MEDLINE]
- ☐ **244:** Gifford DR. Related Articles, Li
 **Assessment of CSF levels of tau protein in patients with Alzheimer's disease and mild dementia.**
Neurology. 1997 Dec;49(6):1753. No abstract available.
PMID: 9409391 [PubMed - indexed for MEDLINE]
- ☐ **245:** Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Matsushita S, Machida N, Nakagawa T, Lee VM, Trojanowski JQ, Sasaki H. Related Articles, Li
 **Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease.**
J Am Geriatr Soc. 1997 Oct;45(10):1228-31.
PMID: 9329486 [PubMed - indexed for MEDLINE]
- ☐ **246:** Imakawa K, Carlson KD, McGuire WJ, Christenson RK, Taylor A. Related Articles, Li
 **Enhancement of ovine trophoblast interferon by granulocyte macrophage-colony stimulating factor: possible involvement of protein kinase C.**
J Mol Endocrinol. 1997 Oct;19(2):121-30.
PMID: 9343304 [PubMed - indexed for MEDLINE]
- ☐ **247:** Arai H, Morikawa Y, Higuchi M, Matsui T, Clark CM, Miura M, Machida N, Lee VM, Trojanowski JQ, Sasaki H. Related Articles, Li
 **Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct related pathology.**
Biochem Biophys Res Commun. 1997 Jul 18;236(2):262-4.
PMID: 9240421 [PubMed - indexed for MEDLINE]
- ☐ **248:** Okada H, Ito T, Ohtsuka H, Kirisawa R, Iwai H, Yamashita K, Yoshino T, Rosol TJ. Related Articles, Li
 **Detection of interleukin-1 and interleukin-6 on cryopreserved bovine mammary epithelial cells in vitro.**
J Vet Med Sci. 1997 Jul;59(7):503-7.
PMID: 9271442 [PubMed - indexed for MEDLINE]
- ☐ **249:** Lindh M, Blomberg M, Jensen M, Basun H, Lannfelt L, Engvall B, Scharnagel H, Marz W, Wahlund LO, Cowburn RF. Related Articles, Li
 **Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease**

patients are increased at follow up and show a correlation with levels of tau protein.

Neurosci Lett. 1997 Jun 27;229(2):85-8.

PMID: 9223597 [PubMed - indexed for MEDLINE]

- ☐ **250:** de Moraes AA, Davidson JA, Fleming JG, Bazer FW, Edwards JL, Betts JG, Hansen PJ. Related Articles, Li



Lack of effect of granulocyte-macrophage colony-stimulating factor on secretion of interferon-tau, other proteins, and prostaglandin E2 by the bovi and ovine conceptus.

Domest Anim Endocrinol. 1997 May;14(3):193-7.

PMID: 9171977 [PubMed - indexed for MEDLINE]

- ☐ **251:** Golombowski S, Muller-Spahn F, Romig H, Mendla K, Hock C. Related Articles, Li



Dependence of cerebrospinal fluid Tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease.

Neurosci Lett. 1997 Apr 11;225(3):213-5.

PMID: 9147408 [PubMed - indexed for MEDLINE]

- ☐ **252:** Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretschmar HA, Poser S. Related Articles, Li



Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease.

Neurosci Lett. 1997 Apr 11;225(3):210-2.

PMID: 9147407 [PubMed - indexed for MEDLINE]

- ☐ **253:** Aoki M, Abe K, Oda N, Ikeda M, Tsuda T, Kanai M, Shoji M, St George-Hyslop PH, Itoyama Y. Related Articles, Li



A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI.

Neurology. 1997 Apr;48(4):1118-20.

PMID: 9109915 [PubMed - indexed for MEDLINE]

- ☐ **254:** Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P. Related Articles, Li



Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease.

Neurology. 1997 Mar;48(3):632-5.

PMID: 9065538 [PubMed - indexed for MEDLINE]

- ☐ **255:** Martal J, Chene N, Camous S, Huynh L, Lantier F, Hermier P, L'Haridon R, Charpigny G, Charlier M, Chaouat G. Related Articles, Li



Recent developments and potentialities for reducing embryo mortality in ruminants: the role of IFN-tau and other cytokines in early pregnancy.

Reprod Fertil Dev. 1997;9(3):355-80. Review.

PMID: 9261883 [PubMed - indexed for MEDLINE]

- ☐ **256:** Arai H, Higuchi S, Sasaki H. Related Articles, Li



Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implicatic for the clinical diagnosis of Alzheimer's disease.

Gerontology. 1997;43 Suppl 1:2-10. Review.

PMID: 9187933 [PubMed - indexed for MEDLINE]











- ☐ **257:** Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D. Related Articles, Li





















The tau protein in human cerebrospinal fluid in Alzheimer's disease consist of proteolytically derived fragments.

J Neurochem. 1997 Jan;68(1):430-3.

PMID: 8978756 [PubMed - indexed for MEDLINE]

- ☐ **258:** Arai H, Satoh K, Terajima M, Nakagawa T, Higuchi M, Kosaka Y, Zhu C, Sasaki H. Related Articles, Li
 [Tau protein in cerebrospinal fluid--a potential marker of Alzheimer's disease
 Nippon Ronen Igakkai Zasshi. 1996 Sep;33(9):669-75. Japanese.
 PMID: 8940864 [PubMed - indexed for MEDLINE]
- ☐ **259:** Pierpaoli C, Alger JR, Righini A, Mattiello J, Dickerson R, Des Pres D, Barnett A, Di Chiro G. Related Articles, Li
 High temporal resolution diffusion MRI of global cerebral ischemia and reperfusion.
 J Cereb Blood Flow Metab. 1996 Sep;16(5):892-905.
 PMID: 8784233 [PubMed - indexed for MEDLINE]
- ☐ **260:** Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund LO. Related Articles, Li
 Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patient with apolipoprotein E allele epsilon 4 during 14 months follow-up.
 Neurosci Lett. 1996 Aug 23;214(2-3):163-6.
 PMID: 8878109 [PubMed - indexed for MEDLINE]
- ☐ **261:** Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Related Articles, Li
 Cerebrospinal protein tau is elevated in early Alzheimer's disease.
 Neurosci Lett. 1996 Jul 19;212(3):209-11.
 PMID: 8843109 [PubMed - indexed for MEDLINE]
- ☐ **262:** Arai H. Related Articles, Li
 Biological markers for the clinical diagnosis of Alzheimer's disease.
 Tohoku J Exp Med. 1996 Jun;179(2):65-79. Review.
 PMID: 8875763 [PubMed - indexed for MEDLINE]
- ☐ **263:** Frankenburg S, Axelrod O, Kutner S, Greenblatt CL, Klaus SN, Pirak EA, McMaster R, Lowell GH. Related Articles, Li
 Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine.
 Vaccine. 1996 Jun;14(9):923-9.
 PMID: 8843636 [PubMed - indexed for MEDLINE]
- ☐ **264:** Lovestone S, Anderton BH, Hartley C, Jensen TG, Jorgensen AL. Related Articles, Li
 The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific.
 Neuroreport. 1996 Apr 10;7(5):1005-8.
 PMID: 8804040 [PubMed - indexed for MEDLINE]
- ☐ **265:** Rosler N, Wichart I, Jellinger KA. Related Articles, Li
 Intra vitam lumbar cerebrospinal fluid and serum and postmortem ventricular immunoreactive apolipoprotein E in patients with Alzheimer's disease.
 J Neurol Neurosurg Psychiatry. 1996 Apr;60(4):452-4.
 PMID: 8774418 [PubMed - indexed for MEDLINE]
- ☐ **266:** Blennow K, Cowburn RF. Related Articles, Li
 The neurochemistry of Alzheimer's disease.
 Acta Neurol Scand Suppl. 1996;168:77-86. Review.
 PMID: 8997425 [PubMed - indexed for MEDLINE]
- ☐ **267:** Rosler N, Wichart I, Bancher C, Jellinger KA. Related Articles, Li
 Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease impact on non Alzheimer's dementia?
 J Neural Transm Suppl. 1996;47:259-66.
 PMID: 8841971 [PubMed - indexed for MEDLINE]

- ☐ **268:** Wu YL, Jiang XR, Allen PD, Jia L, Dronfield DM, Newland AC, Kelsey SM. Related Articles, Li
 Modulation of surface TNF expression by human leukaemic cells alters the sensitivity to exogenous TNF.
 Leuk Res. 1996 Jan;20(1):47-55.
 PMID: 8632677 [PubMed - indexed for MEDLINE]
- ☐ **269:** Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K. Related Articles, Li
 A population-based study of tau protein and ubiquitin in cerebrospinal fluid 85-year-olds: relation to severity of dementia and cerebral atrophy, but not the apolipoprotein E4 allele.
 Neurodegeneration. 1995 Dec;4(4):433-42.
 PMID: 8846237 [PubMed - indexed for MEDLINE]
- ☐ **270:** Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E. Related Articles, Li
 Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
 Mol Chem Neuropathol. 1995 Dec;26(3):231-45.
 PMID: 8748926 [PubMed - indexed for MEDLINE]
- ☐ **271:** Malmberg AB, Hamberger A, Hedner T. Related Articles, Li
 Effects of prostaglandin E2 and capsaicin on behavior and cerebrospinal fluid amino acid concentrations of unanesthetized rats: a microdialysis study.
 J Neurochem. 1995 Nov;65(5):2185-93.
 PMID: 7595506 [PubMed - indexed for MEDLINE]
- ☐ **272:** Roeske LC, Auchus AP. Related Articles, Li
 Neuropeptide changes in cortical and deep gray structures in Alzheimer's disease.
 Rev Neurosci. 1995 Oct-Dec;6(4):317-28. Review.
 PMID: 8845972 [PubMed - indexed for MEDLINE]
- ☐ **273:** Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al. Related Articles, Li
 Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
 Ann Neurol. 1995 Oct;38(4):643-8.
 PMID: 7574461 [PubMed - indexed for MEDLINE]
- ☐ **274:** Carretero MT, Harrington CR, Wischik CM. Related Articles, Li
 Changes in a CSF antigen associated with dementia.
 Dementia. 1995 Sep-Oct;6(5):281-5.
 PMID: 8528375 [PubMed - indexed for MEDLINE]
- ☐ **275:** Tato RE, Frank A, Hernanz A. Related Articles, Li
 Tau protein concentrations in cerebrospinal fluid of patients with dementia the Alzheimer type.
 J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):280-3.
 PMID: 7545739 [PubMed - indexed for MEDLINE]
- ☐ **276:** Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CL Jr, Fu PC, Whaley JM, Wolfert RL. Related Articles, Li
 Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.
 Ann Clin Lab Sci. 1995 May-Jun;25(3):207-17.
 PMID: 7605102 [PubMed - indexed for MEDLINE]

- ☐ **277:** Meliconi R, Uguccioni M, Chieco-Bianchi F, Pitzalis C, Bowman S, Facchini A, Gasbarrini G, Panayi GS, Kingsley GH. Related Articles, Li
-  The role of interleukin-8 and other cytokines in the pathogenesis of Felty's syndrome.
Clin Exp Rheumatol. 1995 May-Jun;13(3):285-91.
PMID: 7554553 [PubMed - indexed for MEDLINE]
- ☐ **278:** Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, Coria F, Chang L, Miller B, Lieberburg I, et al. Related Articles, Li
-  Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease.
Neurology. 1995 Apr;45(4):788-93.
PMID: 7723971 [PubMed - indexed for MEDLINE]
- ☐ **279:** Nitsch RM, Rebeck GW, Deng M, Richardson UI, Tennis M, Schenk DB, Vigo-Pelfrey C, Lieberburg I, Wurtman RJ, Hyman BT, et al. Related Articles, Li
-  Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.
Ann Neurol. 1995 Apr;37(4):512-8.
PMID: 7717688 [PubMed - indexed for MEDLINE]
- ☐ **280:** Calvo B, Pedraz JL, Gascon AR, Hernandez RM, Garcia-Ortega E, Vara F, Muriel C, Dominguez-Gil A. Related Articles, Li
-  The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia.
J Clin Pharmacol. 1995 Apr;35(4):426-31.
PMID: 7650234 [PubMed - indexed for MEDLINE]
- ☐ **281:** van Kamp GJ, Mulder K, Kuiper M, Wolters EC. Related Articles, Li
-  Changed transferrin sialylation in Parkinson's disease.
Clin Chim Acta. 1995 Mar 31;235(2):159-67.
PMID: 7554270 [PubMed - indexed for MEDLINE]
- ☐ **282:** Jensen M, Basun H, Lannfelt L. Related Articles, Li
-  Increased cerebrospinal fluid tau in patients with Alzheimer's disease.
Neurosci Lett. 1995 Feb 17;186(2-3):189-91.
PMID: 7777193 [PubMed - indexed for MEDLINE]
- ☐ **283:** Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, Usami M, Shoji M, Maruyama S, Hirai S. Related Articles, Li
-  Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau.
Neurosci Lett. 1995 Feb 17;186(2-3):181-3.
PMID: 7777192 [PubMed - indexed for MEDLINE]
- ☐ **284:** Blennow K, Fredman P. Related Articles, Li
-  Detection of cerebrospinal fluid leakage by isoelectric focusing on polyacrylamide gels with silver staining using the PhastSystem.
Acta Neurochir (Wien). 1995;136(3-4):135-9.
PMID: 8748843 [PubMed - indexed for MEDLINE]
- ☐ **285:** Tuck DP, Cerretti DP, Hand A, Guha A, Sorba S, Dainiak N. Related Articles, Li
-  Human macrophage colony-stimulating factor is expressed at and shed from the cell surface.
Blood. 1994 Oct 1;84(7):2182-8.
PMID: 7919334 [PubMed - indexed for MEDLINE]
- ☐ **286:** Mathialagan N, Roberts RM. Related Articles, Li



A role for cytokines in early pregnancy.

Indian J Physiol Pharmacol. 1994 Jul;38(3):153-62. Review.
PMID: 7814074 [PubMed - indexed for MEDLINE]

- ☐ **287:** Hahn T, Shulman LM, Ben-Hur H, Karov Y, Barak V, Handgretinger R, Barak Y. Related Articles, Li



Differential responses of fetal, neonatal, and adult myelopoietic progenitors to interferon and tumor necrosis factor.

Exp Hematol. 1994 Feb;22(2):114-21.
PMID: 8299733 [PubMed - indexed for MEDLINE]

- ☐ **288:** Delacourte A.

Related Articles, Li



Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration.

Biomed Pharmacother. 1994;48(7):287-95. Review.
PMID: 7858159 [PubMed - indexed for MEDLINE]

- ☐ **289:** Vandermeeren M, Mercken M, Vanmechelen E, Six J, van de Voorde A, Martin JJ, Cras P. Related Articles, Li



Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

J Neurochem. 1993 Nov;61(5):1828-34.
PMID: 8228996 [PubMed - indexed for MEDLINE]

- ☐ **290:** Goroll D, Arias P, Wuttke W.

Related Articles, Li



Preoptic release of amino acid neurotransmitters evaluated in peripubertal and young adult female rats by push-pull perfusion.

Neuroendocrinology. 1993 Jul;58(1):11-5.
PMID: 7903429 [PubMed - indexed for MEDLINE]

- ☐ **291:** Keynes RD, Greeff NG, Forster IC.

Related Articles, Li



Activation, inactivation and recovery in the sodium channels of the squid giant axon dialysed with different solutions.

Philos Trans R Soc Lond B Biol Sci. 1992 Sep 29;337(1282):471-84.
PMID: 1359591 [PubMed - indexed for MEDLINE]

- ☐ **292:** Haas J, Lipkow T, Mohamadzadeh M, Kolde G, Knop J.

Related Articles, Li



Induction of inflammatory cytokines in murine keratinocytes upon in vivo stimulation with contact sensitizers and tolerizing analogues.

Exp Dermatol. 1992 Aug;1(2):76-83.
PMID: 1365308 [PubMed - indexed for MEDLINE]

- ☐ **293:** Porter MJ, Brookes GB, Zeman AZ, Keir G.

Related Articles, Li



Use of protein electrophoresis in the diagnosis of cerebrospinal fluid rhinorrhoea.

J Laryngol Otol. 1992 Jun;106(6):504-6.
PMID: 1624884 [PubMed - indexed for MEDLINE]

- ☐ **294:** Xu FD, Spellman MJ Jr, Sato M, Baumgartner JE, Ciricillo SF, Severinghaus JW.

Related Articles, Li



Anomalous hypoxic acidification of medullary ventral surface.










J Appl Physiol. 1991 Dec;71(6):2211-7.
PMID: 1778915 [PubMed - indexed for MEDLINE]










- ☐ **295:** Roussel E, Greenberg AH.











Related Articles, Li



Granules of human CD3+ large granular lymphocytes contain a macrophage regulating factor(s) that induces macrophage H2O2 production and tumoricidal activity but decreases cell surface Ia antigen expression.

- ☐ **296:** Huether G, Lajtha A. Related Articles, Li
 **Changes in free amino acid concentrations in serum, brain, and CSF throughout embryogenesis.**
Neurochem Res. 1991 Feb;16(2):145-50.
PMID: 1679206 [PubMed - indexed for MEDLINE]
- ☐ **297:** Krutmann J, Kock A, Schauer E, Parlow F, Moller A, Kapp A, Forster E, Schopf E, Luger TA. Related Articles, Li
 **Tumor necrosis factor beta and ultraviolet radiation are potent regulators of human keratinocyte ICAM-1 expression.**
J Invest Dermatol. 1990 Aug;95(2):127-31.
PMID: 1974275 [PubMed - indexed for MEDLINE]
- ☐ **298:** Tripathi RC, Millard CB, Tripathi BJ, Noronha A. Related Articles, Li
 **Tau fraction of transferrin is present in human aqueous humor and is not unique to cerebrospinal fluid.**
Exp Eye Res. 1990 May;50(5):541-7.
PMID: 2373156 [PubMed - indexed for MEDLINE]
- ☐ **299:** Hamberger A, Nystrom B, Silvenius H, Wikkelsö C. Related Articles, Li
 **The contribution from the choroid plexus and the periventricular CNS to amino acids and proteins in the human CSF.**
Neurochem Res. 1990 Mar;15(3):307-12.
PMID: 1694975 [PubMed - indexed for MEDLINE]
- ☐ **300:** Pawelec G, Balko I, Rehbein A. Related Articles, Li
 **Cyclosporin A blocks the generation of alloindifferent but not of allospecific suppressive cells.**
Immunol Lett. 1988 Aug;18(4):293-6.
PMID: 2972611 [PubMed - indexed for MEDLINE]
- ☐ **301:** Peinado JM, Myers RD. Related Articles, Li
 **Cortical amino acid neurotransmitter release is altered by CCK perfused in frontal region of unrestrained aged rats.**
Peptides. 1988 May-Jun;9(3):631-6.
PMID: 2901740 [PubMed - indexed for MEDLINE]
- ☐ **302:** Yokoyama K, Hasegawa M, Shiba KS, Tomita S, Sugiyama K, Kin H, Yuzurihara M, Watanabe I. Related Articles, Li
 **Diagnosis of CSF rhinorrhea: detection of tau-transferrin in nasal discharge**
Otolaryngol Head Neck Surg. 1988 Apr;98(4):328-32. No abstract available.
PMID: 3132688 [PubMed - indexed for MEDLINE]
- ☐ **303:** Oberascher G. Related Articles, Li
 **Cerebrospinal fluid otorrhea--new trends in diagnosis.**
Am J Otol. 1988 Mar;9(2):102-8.
PMID: 2457322 [PubMed - indexed for MEDLINE]
- ☐ **304:** Elliott JR, Haydon DA, Hendry BM. Related Articles, Li
 **The mechanisms of sodium current inhibition by benzocaine in the squid giant axon.**
Pflugers Arch. 1987 Aug;409(6):596-600.
PMID: 2442718 [PubMed - indexed for MEDLINE]
- ☐ **305:** Peinado JM, Collins DM, Myers RD. Related Articles, Li

-  Ethanol challenge alters amino acid neurotransmitter release from frontal cortex of the aged rat.
Neurobiol Aging. 1987 May-Jun;8(3):241-7.
PMID: 2885769 [PubMed - indexed for MEDLINE]
- ☐ **306:** Pitkanen A, Riekkinen PJ, Halonen T, Ylinen A, Ruutinen T, Lehtinen M. Related Articles, Li
Amino acid levels in human CSF after generalized seizure.
J Neural Transm. 1987;70(3-4):313-9.
PMID: 3681287 [PubMed - indexed for MEDLINE]
-  Amino acid levels in human CSF after generalized seizure.
J Neural Transm. 1987;70(3-4):313-9.
PMID: 3681287 [PubMed - indexed for MEDLINE]
- ☐ **307:** Bracco F, Gallo P, Tavolato B, Battistin L. Related Articles, Li
Two-dimensional electrophoresis of cerebrospinal fluid proteins in normal and pathological conditions.
Neurochem Res. 1985 Sep;10(9):1203-19.
PMID: 3932893 [PubMed - indexed for MEDLINE]
-  Two-dimensional electrophoresis of cerebrospinal fluid proteins in normal and pathological conditions.
Neurochem Res. 1985 Sep;10(9):1203-19.
PMID: 3932893 [PubMed - indexed for MEDLINE]
- ☐ **308:** Gallo P, Bracco F, Morara S, Battistin L, Tavolato B. Related Articles, Li
The cerebrospinal fluid transferrin/tau proteins. A study by two-dimensional polyacrylamide gel electrophoresis (2D) and agarose isoelectrofocusing (IE) followed by double-antibody peroxidase labeling and avidin-biotin amplification.
J Neurol Sci. 1985 Aug;70(1):81-92.
PMID: 3930665 [PubMed - indexed for MEDLINE]
-  The cerebrospinal fluid transferrin/tau proteins. A study by two-dimensional polyacrylamide gel electrophoresis (2D) and agarose isoelectrofocusing (IE) followed by double-antibody peroxidase labeling and avidin-biotin amplification.
J Neurol Sci. 1985 Aug;70(1):81-92.
PMID: 3930665 [PubMed - indexed for MEDLINE]
- ☐ **309:** Kaneko K. Related Articles, Li
The effect of perinatal anoxia on amino acid metabolism in the developing brain. Part II: The effect of perinatal anoxia on the free amino acid patterns CSF of infants and children.
Brain Dev. 1985;7(4):400-7.
PMID: 4061776 [PubMed - indexed for MEDLINE]
-  The effect of perinatal anoxia on amino acid metabolism in the developing brain. Part II: The effect of perinatal anoxia on the free amino acid patterns CSF of infants and children.
Brain Dev. 1985;7(4):400-7.
PMID: 4061776 [PubMed - indexed for MEDLINE]
- ☐ **310:** Chapel HM, Esiri MM, Wilcock GK. Related Articles, Li
Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease.
J Clin Pathol. 1984 Jun;37(6):697-9.
PMID: 6427297 [PubMed - indexed for MEDLINE]
-  Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease.
J Clin Pathol. 1984 Jun;37(6):697-9.
PMID: 6427297 [PubMed - indexed for MEDLINE]
- ☐ **311:** Elliott JR, Haydon DA, Hendry BM. Related Articles, Li
The asymmetrical effects of some ionized n-octyl derivatives on the sodium current of the giant axon of *Loligo forbesi*.
J Physiol. 1984 May;350:429-45.
PMID: 6747855 [PubMed - indexed for MEDLINE]
-  The asymmetrical effects of some ionized n-octyl derivatives on the sodium current of the giant axon of *Loligo forbesi*.
J Physiol. 1984 May;350:429-45.
PMID: 6747855 [PubMed - indexed for MEDLINE]
- ☐ **312:** Poloni M, Cosi V, Scelsi R, Marchetti C, Moglia A, Rognone F, Piccolo G. Related Articles, Li
Ophthalmoplegia plus: CSF and CT features of seven cases.
Schweiz Arch Neurol Neurochir Psychiatr. 1984;134(1):41-52.
PMID: 6710088 [PubMed - indexed for MEDLINE]
-  Ophthalmoplegia plus: CSF and CT features of seven cases.
Schweiz Arch Neurol Neurochir Psychiatr. 1984;134(1):41-52.
PMID: 6710088 [PubMed - indexed for MEDLINE]
- ☐ **313:** Wikkelso C, Andersson M, Andersson R, Blomstrand C. Related Articles, Li
Isoelectric focusing followed by silver staining. A suitable method for routine investigation of cerebrospinal fluid proteins.
Eur Neurol. 1984;23(4):306-12.
PMID: 6208031 [PubMed - indexed for MEDLINE]
-  Isoelectric focusing followed by silver staining. A suitable method for routine investigation of cerebrospinal fluid proteins.
Eur Neurol. 1984;23(4):306-12.
PMID: 6208031 [PubMed - indexed for MEDLINE]
- ☐ **314:** Strand T, Alling C, Karlsson B, Karlsson I, Winblad B. Related Articles, Li

-  Brain and plasma proteins in spinal fluid as markers for brain damage and severity of stroke.
Stroke. 1984 Jan-Feb;15(1):138-44.
PMID: 6198785 [PubMed - indexed for MEDLINE]
- ☐ **315:** Takeoka T, Shinohara Y, Furumi K, Mori K. Related Articles, Li
-  Impairment of blood-cerebrospinal fluid barrier in multiple sclerosis.
J Neurochem. 1983 Oct;41(4):1102-8.
PMID: 6619849 [PubMed - indexed for MEDLINE]
- ☐ **316:** Vermes LM. Related Articles, Li
-  [Cerebrospinal fluid proteins: II. Normal values of protein fractions obtained by electrophoresis (variations related to race, sex and age)]
Arq Neuropsiquiatr. 1983 Mar;41(1):9-24. Portuguese.
PMID: 6870591 [PubMed - indexed for MEDLINE]
- ☐ **317:** Keynes RD, Kimura JE. Related Articles, Li
-  Kinetics of activation of the sodium conductance in the squid giant axon.
J Physiol. 1983 Mar;336:621-34.
PMID: 6308231 [PubMed - indexed for MEDLINE]
- ☐ **318:** Merelli E, Sola P, Faglioni P, Pavarotti V. Related Articles, Li
-  CFS transferrin in various neurological diseases.
Riv Patol Nerv Ment. 1982 Nov-Dec;103(6):253-61.
PMID: 7188234 [PubMed - indexed for MEDLINE]
- ☐ **319:** Thomsen J, Saxtrup O, Tos M. Related Articles, Li
-  Quantitated determination of proteins in perilymph in patients with acoustic neuromas.
ORL J Otorhinolaryngol Relat Spec. 1982;44(2):61-5.
PMID: 6175937 [PubMed - indexed for MEDLINE]
- ☐ **320:** Wikkelsö C, Blomstrand C, Nordquist P. Related Articles, Li
-  Cerebrospinal fluid investigations in multi-infarct dementia and senile dementia.
Acta Neurol Scand. 1981 Jul;64(1):1-11.
PMID: 7324870 [PubMed - indexed for MEDLINE]
- ☐ **321:** Takeoka T, Shinohara Y, Furumi K, Mori K. Related Articles, Li
-  Characteristic protein fractions of cerebrospinal fluid disc electrophoretic analysis.
Brain Res. 1980 Sep 29;198(1):147-56.
PMID: 7407581 [PubMed - indexed for MEDLINE]
- ☐ **322:** Kerenyi L, Koltai M, Szirmai I. Related Articles, Li
-  CSF transferrins characterized by the transferrin/albumin index.
Clin Chim Acta. 1980 Aug 4;105(2):195-9.
PMID: 6772353 [PubMed - indexed for MEDLINE]
- ☐ **323:** Weitbrecht WU, Henzi M. Related Articles, Li
-  [On the origin and diagnostic value of the CSF-beta-globulins (author's transl)]
Fortschr Neurol Psychiatr Grenzgeb. 1980 May;48(5):294-300. German.
PMID: 6156110 [PubMed - indexed for MEDLINE]
- ☐ **324:** Porvaznik M, MacVittie TJ. Related Articles, Li

Detection of gap junctions between the progeny of a canine macrophage



colony-forming cell in vitro.
J Cell Biol. 1979 Aug;82(2):555-64.
PMID: 314451 [PubMed - indexed for MEDLINE]

☐ **325:** [Siden A, Kjellin KG.](#)

[Related Articles](#), [Li](#)



Isoelectric focusing of CSF proteins in known or probable infectious neurological diseases and the Guillain-Barre syndrome.
J Neurol Sci. 1979 Jun;42(1):139-53.
PMID: 87493 [PubMed - indexed for MEDLINE]

☐ **326:** [Maurer J, Rieder HP.](#)

[Related Articles](#), [Li](#)



[Total proteins and electrophoretic protein fractions in the juvenile cerebrospinal fluid]
Schweiz Med Wochenschr. 1978 Nov 25;108(47):1854-60. German.
PMID: 715425 [PubMed - indexed for MEDLINE]

☐ **327:** [Stibler H.](#)

[Related Articles](#), [Li](#)



The normal cerebrospinal fluid proteins identified by means of thin-layer isoelectric focusing and crossed immunoelectrofocusing.
J Neurol Sci. 1978 Apr;36(2):273-88.
PMID: 77312 [PubMed - indexed for MEDLINE]

☐ **328:** [Siemes H, Siegert M, Rating D.](#)

[Related Articles](#), [Li](#)



[The relationship between age and the cerebrospinal fluid protein profile profile of normal children. Cellulose acetate and agarose gel electrophoretic studies]
Neuropadiatrie. 1975 Nov;6(4):383-97. German.
PMID: 1242522 [PubMed - indexed for MEDLINE]

Display

Summary

Show:

500

Sort

Send to

Text

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for tau AND CNS damage Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts


ClinicalTrials.gov

PubMed Central

Items 1 - 130 of 130

One p:

☐ 1: [Schneider A, Wright Araujo G, Trajkovic K, Herrmann MM, Merkler D, Mandelkow EM, Weissert R, Simons M.](#) Related Articles, Li

 Hyperphosphorylation and aggregation of tau in experimental autoimmune encephalomyelitis.

J Biol Chem. 2004 Oct 19 [Epub ahead of print]

PMID: 15494405 [PubMed - as supplied by publisher]

☐ 2: [Virmani A, Binienda Z.](#)

Related Articles, Li


 Role of carnitine esters in brain neuropathology.

Mol Aspects Med. 2004 Oct-Dec;25(5-6):533-49.

PMID: 15363640 [PubMed - in process]

☐ 3: [Hattori N, Mizuno Y.](#)

Related Articles, Li

 Pathogenetic mechanisms of parkin in Parkinson's disease.

Lancet. 2004 Aug 21;364(9435):722-4. Review.

PMID: 15325839 [PubMed - indexed for MEDLINE]

☐ 4: [Rogawski MA.](#)

Related Articles, Li


 What is the rationale for new treatment strategies in Alzheimer's disease?

CNS Spectr. 2004 Jul;9(7 Suppl 5):6-12.

PMID: 15241294 [PubMed - indexed for MEDLINE]

☐ 5: [Rose M, Dudas B, Cornelli U, Hanin I.](#)

Related Articles, Li


 Glycosaminoglycan C3 protects against AF64A-induced cholinotoxicity in a dose-dependent and time-dependent manner.

Brain Res. 2004 Jul 23;1015(1-2):96-102.

PMID: 15223371 [PubMed - indexed for MEDLINE]

☐ 6: [Nakashima H, Ishihara T, Yokota O, Terada S, Trojanowski JQ, Lee VM, Kuroda S.](#)

Related Articles, Li


 Effects of alpha-tocopherol on an animal model of tauopathies.

Free Radic Biol Med. 2004 Jul 15;37(2):176-86.

PMID: 15203189 [PubMed - in process]

☐ 7: [Kavec M, Grohn OH, Kettunen MI, Silvennoinen MJ, Garwood M, Kauppinen RA.](#)

Related Articles, Li


 Acute cerebral ischemia in rats studied by Carr-Purcell spin-echo magnetic resonance imaging: assessment of blood oxygenation level-dependent and tiss effects on the transverse relaxation.

Magn Reson Med. 2004 Jun;51(6):1138-46.

PMID: 15170833 [PubMed - indexed for MEDLINE]

☐ 8: [Dudas B, Hanin I, Rose M, Wulfert E.](#)


Related Articles, Li

 Protection against inflammatory neurodegeneration and glial cell death by 7beta-hydroxy epiandrosterone, a novel neurosteroid.


Neurobiol Dis. 2004 Mar;15(2):262-8.

PMID: 15006696 [PubMed - indexed for MEDLINE]


☐ **9:** Wen Y, Yang S, Liu R, Brun-Zinkernagel AM, Koulen P, Simpkins JW. Related Articles, Li

 **Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats.**
J Biol Chem. 2004 May 21;279(21):22684-92. Epub 2004 Feb 24.
PMID: 14982935 [PubMed - indexed for MEDLINE]


☐ **10:** Hoyer S. Related Articles, Li

 **Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications.**
Adv Exp Med Biol. 2004;541:135-52. Review.
PMID: 14977212 [PubMed - indexed for MEDLINE]


☐ **11:** Probst-Cousin S, Acker T, Epplen JT, Bergmann M, Plate KH, Neundorfer B, Heuss D. Related Articles, Li

 **Spinocerebellar ataxia type 2 with glial cell cytoplasmic inclusions.**
J Neurol Neurosurg Psychiatry. 2004 Mar;75(3):503-5.
PMID: 14966177 [PubMed - indexed for MEDLINE]


☐ **12:** Zou K, Kim D, Kakio A, Byun K, Gong JS, Kim J, Kim M, Sawamura N, Nishimoto S, Matsuzaki K, Lee B, Yanagisawa K, Michikawa M. Related Articles, Li

 **Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain.**
J Neurochem. 2003 Nov;87(3):609-19.
PMID: 14535944 [PubMed - indexed for MEDLINE]


☐ **13:** Zemlan FP, Mulchahey JJ, Gudelsky GA. Related Articles, Li

 **Quantification and localization of kainic acid-induced neurotoxicity employ a new biomarker of cell death: cleaved microtubule-associated protein-tau (C tau).**
Neuroscience. 2003;121(2):399-409.
PMID: 14521998 [PubMed - indexed for MEDLINE]


☐ **14:** Kalaria RN. Related Articles, Li

 **Comparison between Alzheimer's disease and vascular dementia: implication for treatment.**
Neurol Res. 2003 Sep;25(6):661-4. Review.
PMID: 14503021 [PubMed - indexed for MEDLINE]


☐ **15:** Peel AL, Bredesen DE. Related Articles, Li

 **Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice.**
Neurobiol Dis. 2003 Oct;14(1):52-62.
PMID: 13678666 [PubMed - indexed for MEDLINE]

☐ **16:** Hoyer S. Related Articles, Li

 **Memory function and brain glucose metabolism.**
Pharmacopsychiatry. 2003 Jun;36 Suppl 1:S62-7. Review.
PMID: 13130391 [PubMed - indexed for MEDLINE]

☐ **17:** Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM. Related Articles, Li

 **Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection.**
J Alzheimers Dis. 2003 Jun;5(3):209-28.
PMID: 12897406 [PubMed - indexed for MEDLINE]

☐ **18:** Virmani A, Gaetani F, Imam S, Binienda Z, Ali S. Related Articles, Li

Possible mechanism for the neuroprotective effects of L-carnitine on



methamphetamine-evoked neurotoxicity.

Ann N Y Acad Sci. 2003 May;993:197-207; discussion 287-8. Review.
PMID: 12853314 [PubMed - indexed for MEDLINE]

- ☐ **19:** Suo Z, Wu M, Citron BA, Palazzo RE, Festoff BW.

Related Articles, Li



Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling.

J Biol Chem. 2003 Sep 26;278(39):37681-9. Epub 2003 Jun 23.
PMID: 12821672 [PubMed - indexed for MEDLINE]

- ☐ **20:** Keck S, Nitsch R, Grune T, Ullrich O.

Related Articles, Li



Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease.

J Neurochem. 2003 Apr;85(1):115-22.
PMID: 12641733 [PubMed - indexed for MEDLINE]

- ☐ **21:** Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G, Carey PR.

Related Articles, Li



Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence.

Biochemistry. 2003 Mar 18;42(10):2768-73.
PMID: 12627941 [PubMed - indexed for MEDLINE]

- ☐ **22:** Wallace TL, Vorhees CV, Zemlan FP, Gudelsky GA.

Related Articles, Li



Methamphetamine enhances the cleavage of the cytoskeletal protein tau in the rat brain.

Neuroscience. 2003;116(4):1063-8.
PMID: 12617947 [PubMed - indexed for MEDLINE]

- ☐ **23:** Ghribi O, Herman MM, Savory J.

Related Articles, Li



Lithium inhibits Abeta-induced stress in endoplasmic reticulum of rabbit hippocampus but does not prevent oxidative damage and tau phosphorylation

J Neurosci Res. 2003 Mar 15;71(6):853-62.
PMID: 12605412 [PubMed - indexed for MEDLINE]

- ☐ **24:** Weiner I.

Related Articles, Li



The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment.

Psychopharmacology (Berl). 2003 Sep;169(3-4):257-97. Epub 2003 Feb 25. Review.
PMID: 12601500 [PubMed - indexed for MEDLINE]

- ☐ **25:** Rose M, Dudas B, Cornelli U, Hanin I.

Related Articles, Li



Protective effect of the heparin-derived oligosaccharide C3, on AF64A-induced cholinergic lesion in rats.

Neurobiol Aging. 2003 May-Jun;24(3):481-90.
PMID: 12600723 [PubMed - indexed for MEDLINE]

- ☐ **26:** Chetelat G, Baron JC.

Related Articles, Li



Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging.

Neuroimage. 2003 Feb;18(2):525-41.
PMID: 12595205 [PubMed - indexed for MEDLINE]

- ☐ **27:** Egana JT, Zambrano C, Nunez MT, Gonzalez-Billault C, Maccioni RB. Related Articles, Li



Iron-induced oxidative stress modifies tau phosphorylation patterns in hippocampal cell cultures.

Biometals. 2003 Mar;16(1):215-23.

- ☐ **28:** Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA. Related Articles, Li



Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease.

Biometals. 2003 Mar;16(1):77-81. Review.

PMID: 12572666 [PubMed - indexed for MEDLINE]

- ☐ **29:** Gudelsky GA, Yamamoto BK.

Related Articles, Li



Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine.

Methods Mol Med. 2003;79:55-73. Review.

PMID: 12506690 [PubMed - indexed for MEDLINE]

- ☐ **30:** Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E.

Related Articles, Li



Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain.

Neurobiol Dis. 2002 Nov;11(2):341-54.

PMID: 12505426 [PubMed - indexed for MEDLINE]

- ☐ **31:** Prasad KN, Cole WC, Prasad KC.

Related Articles, Li



Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment.

J Am Coll Nutr. 2002 Dec;21(6):506-22. Review.

PMID: 12480796 [PubMed - indexed for MEDLINE]

- ☐ **32:** Picklo MJ, Montine TJ, Amarnath V, Neely MD.

Related Articles, Li



Carbonyl toxicology and Alzheimer's disease.

Toxicol Appl Pharmacol. 2002 Nov 1;184(3):187-97. Review.

PMID: 12460747 [PubMed - indexed for MEDLINE]

- ☐ **33:** Oth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonzalez-Billault C, Maccioni RB. Related Articles, Li



AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mi Tg2576.

J Alzheimers Dis. 2002 Oct;4(5):417-30.

PMID: 12446973 [PubMed - indexed for MEDLINE]

- ☐ **34:** Ho PI, Ortiz D, Rogers E, Shea TB.

Related Articles, Li



Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage.

J Neurosci Res. 2002 Dec 1;70(5):694-702.

PMID: 12424737 [PubMed - indexed for MEDLINE]

- ☐ **35:** Hayes A, Thaker U, Iwatsubo T, Pickering-Brown SM, Mann DM.

Related Articles, Li



Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease.

Neurosci Lett. 2002 Oct 18;331(3):171-4.

PMID: 12383924 [PubMed - indexed for MEDLINE]

- ☐ **36:** de la Monte SM, Ganju N, Feroz N, Luong T, Banerjee K, Cannon J, Wands JR.










Related Articles, Li












Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells.

J Alzheimers Dis. 2000 Nov;2(3-4):261-81.









PMID: 12214088 [PubMed]


- ☐ **37:** Yamazaki S, Alones V, Menaker M. Related Articles, Li
 **Interaction of the retina with suprachiasmatic pacemakers in the control of circadian behavior.**
 J Biol Rhythms. 2002 Aug;17(4):315-29.
 PMID: 12164248 [PubMed - indexed for MEDLINE]
- ☐ **38:** Virmani A, Gaetani F, Imam S, Binienda Z, Ali S. Related Articles, Li
 **The protective role of L-carnitine against neurotoxicity evoked by drug of abuse, methamphetamine, could be related to mitochondrial dysfunction.**
 Ann N Y Acad Sci. 2002 Jun;965:225-32.
 PMID: 12105098 [PubMed - indexed for MEDLINE]
- ☐ **39:** Bartosik-Psujek H, Stelmasiak Z. Related Articles, Li
 **Biochemical markers of damage of the central nervous system in multiple sclerosis.**
 Ann Univ Mariae Curie Sklodowska [Med]. 2001;56:389-92. Review.
 PMID: 11977345 [PubMed - indexed for MEDLINE]
- ☐ **40:** Torreilles F, Touchon J. Related Articles, Li
 **Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer's disease.**
 Prog Neurobiol. 2002 Feb;66(3):191-203. Review.
 PMID: 11943451 [PubMed - indexed for MEDLINE]
- ☐ **41:** Galasko D. Related Articles, Li
 **Biological markers and the treatment of Alzheimer's disease.**
 J Mol Neurosci. 2001 Oct;17(2):119-25. Review.
 PMID: 11816785 [PubMed - indexed for MEDLINE]
- ☐ **42:** Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Ciesielczyk B, Cepek L, Bahn E, Ratzka P, Prange H, Otto M. Related Articles, Li
 **Serum tau protein level as a marker of axonal damage in acute ischemic stroke.**
 Eur Neurol. 2002;47(1):45-51.
 PMID: 11803192 [PubMed - indexed for MEDLINE]
- ☐ **43:** Irving EA, Bentley DL, Parsons AA. Related Articles, Li
 **Assessment of white matter injury following prolonged focal cerebral ischaemia in the rat.**
 Acta Neuropathol (Berl). 2001 Dec;102(6):627-35.
 PMID: 11761724 [PubMed - indexed for MEDLINE]
- ☐ **44:** Ren H, Ji Q, Liu Y, Ru B. Related Articles, Li
 **Different protective roles in vitro of alpha- and beta-domains of growth inhibitory factor (GIF) on neuron injuries caused by oxygen free radicals.**
 Biochim Biophys Acta. 2001 Dec 5;1568(2):129-34.
 PMID: 11750760 [PubMed - indexed for MEDLINE]
- ☐ **45:** Rovaris M, Bozzali M, Santuccio G, Ghezzi A, Caputo D, Montanari E, Bertolotto A, Bergamaschi R, Capra R, Mancardi G, Martinelli V, Comi G, Filippi M. Related Articles, Li
 **In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis.**
 Brain. 2001 Dec;124(Pt 12):2540-9.
 PMID: 11701606 [PubMed - indexed for MEDLINE]
- ☐ **46:** Kristjansdottir R, Uvebrant P, Lekman A, Mansson JE. Related Articles, Li

Cerebrospinal fluid markers in children with cerebral white matter

-  abnormalities.
Neuropediatrics. 2001 Aug;32(4):176-82.
PMID: 11571697 [PubMed - indexed for MEDLINE]
- ☐ 47: Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Related Articles, Li
 Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia.
Stroke. 2001 Sep;32(9):2149-54.
PMID: 11546910 [PubMed - indexed for MEDLINE]
- ☐ 48: Irazuzta JE, de Courten-Myers G, Zemlan FP, Bekkedal MY, Rossi J 3rd. Related Articles, Li
 Serum cleaved Tau protein and neurobehavioral battery of tests as markers of brain injury in experimental bacterial meningitis.
Brain Res. 2001 Sep 14;913(1):95-105.
PMID: 11532253 [PubMed - indexed for MEDLINE]
- ☐ 49: Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. Related Articles, Li
 The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer's disease-related cytoskeletal pathology.
Acta Neuropathol (Berl). 2001 Jun;101(6):555-64.
PMID: 11515783 [PubMed - indexed for MEDLINE]
- ☐ 50: Rub U, Schultz C, Del Tredici K, Braak H. Related Articles, Li
 Early involvement of the tegmentopontine reticular nucleus during the evolution of Alzheimer's disease-related cytoskeletal pathology.
Brain Res. 2001 Jul 27;908(2):107-12.
PMID: 11454320 [PubMed - indexed for MEDLINE]
- ☐ 51: Blennow K, Lind B, Andersson E, Andreassen N. Related Articles, Li
 [CSF-analyses in clinical diagnosis of Creutzfeldt-Jakob disease. A literature review and three cases from routine clinical practice]
Lakartidningen. 2001 May 16;98(20):2446-51. Swedish.
PMID: 11433975 [PubMed - indexed for MEDLINE]
- ☐ 52: Joel D. Related Articles, Li
 Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease.
Mov Disord. 2001 May;16(3):407-23. Review.
PMID: 11391734 [PubMed - indexed for MEDLINE]
- ☐ 53: Albers DS, Augood SJ. Related Articles, Li
 New insights into progressive supranuclear palsy.
Trends Neurosci. 2001 Jun;24(6):347-53. Review.
PMID: 11356507 [PubMed - indexed for MEDLINE]
- ☐ 54: Papaioannou N, Tooten PC, van Ederen AM, Bohl JR, Rofina J, Tsangaris T, Gruys E. Related Articles, Li
 Immunohistochemical investigation of the brain of aged dogs. I. Detection of neurofibrillary tangles and of 4-hydroxynonenal protein, an oxidative damage product, in senile plaques.
Amyloid. 2001 Mar;8(1):11-21.
PMID: 11293821 [PubMed - indexed for MEDLINE]
- ☐ 55: Kalaria RN, Ballard CG, Ince PG, Kenny RA, McKeith IG, Morris CM, O'Brien JT, Perry EK, Perry RH, Edwardson JA. Related Articles, Li

Multiple substrates of late-onset dementia: implications for brain protection.

-  Novartis Found Symp. 2001;235:49-60; discussion 60-5. Review.
PMID: 11280033 [PubMed - indexed for MEDLINE]
- ☐ **56:** Inglese M, Rovaris M, Bianchi S, La Mantia L, Mancardi GL, Ghezzi A, Montagna P, Salvi F, Filippi M. Related Articles, Li
Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage
Leber's hereditary optic neuropathy.
J Neurol Neurosurg Psychiatry. 2001 Apr;70(4):444-9.
PMID: 11254765 [PubMed - indexed for MEDLINE]
-  ☐ **57:** Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A. Related Articles, Li
Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia.
Acta Neurol Scand. 2001 Mar;103(3):166-74.
PMID: 11240564 [PubMed - indexed for MEDLINE]
- ☐ **58:** Pokela M, Anttila V, Rimpilainen J, Hirvonen J, Vainionpää V, Kiviluoma K, Ronsi P, Mennander A, Juvonen T. Related Articles, Li
Serum S-100beta protein predicts brain injury after hypothermic circulatory arrest in pigs.
Scand Cardiovasc J. 2000 Dec;34(6):570-4.
PMID: 11214009 [PubMed - indexed for MEDLINE]
-  ☐ **59:** Anderson AJ, Ruehl WW, Fleischmann LK, Stenstrom K, Entiken TL, Cummings BJ. Related Articles, Li
DNA damage and apoptosis in the aged canine brain: relationship to Abeta deposition in the absence of neuritic pathology.
Prog Neuropsychopharmacol Biol Psychiatry. 2000 Jul;24(5):787-99.
PMID: 11191713 [PubMed - indexed for MEDLINE]
- ☐ **60:** Sussmuth SD, Reiber H, Tumani H. Related Articles, Li
 Tau protein in cerebrospinal fluid (CSF): a blood-CSF barrier related evaluation in patients with various neurological diseases.
Neurosci Lett. 2001 Mar 9;300(2):95-8.
PMID: 11207383 [PubMed - indexed for MEDLINE]
- ☐ **61:** Kerokoski P, Suuronen T, Salminen A, Soininen H, Pirttilä T. Related Articles, Li
 The levels of cdk5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis.
Biochem Biophys Res Commun. 2001 Feb 2;280(4):998-1002.
PMID: 11162625 [PubMed - indexed for MEDLINE]
- ☐ **62:** Rub U, Del Tredici K, Schultz C, Thal DR, Braak E, Braak H. Related Articles, Li
 The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei.
Neuropathol Appl Neurobiol. 2000 Dec;26(6):553-67.
PMID: 11123722 [PubMed - indexed for MEDLINE]
- ☐ **63:** Kim D, Koh WK, Kim JU, Lee JH, Hong HN. Related Articles, Li
 Okadaic acid-induced upregulation of nitrotyrosine and heme oxygenase-1 in rat cortical neuron cultures.
Neurosci Lett. 2001 Jan 5;297(1):33-6.
PMID: 11114478 [PubMed - indexed for MEDLINE]
- ☐ **64:** Rovaris M, Bozzali M, Santuccio G, Iannucci G, Sormani MP, Colombo B, Comi G, Filippi M. Related Articles, Li
 Relative contributions of brain and cervical cord pathology to multiple



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for tau AND anoxia Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 39 of 39

One page

☐ 1: Uy R, Tede N, Ross-Ascuitto N, Ascuitto R.

Related Articles, Li

Performance of the neonatal pig heart subjected to oxygen insufficiency.
Biol Neonate. 2004;85(1):42-50. Epub 2003 Nov 19.
PMID: 14631166 [PubMed - indexed for MEDLINE]

☐ 2: Moons A.

Related Articles, Li

Osgstu3 and osgtu4, encoding tau class glutathione S-transferases, are heavy metal- and hypoxic stress-induced and differentially salt stress-responsive in roots.
FEBS Lett. 2003 Oct 23;553(3):427-32.
PMID: 14572664 [PubMed - indexed for MEDLINE]

☐ 3: Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM.

Related Articles, Li

Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection.
J Alzheimers Dis. 2003 Jun;5(3):209-28.
PMID: 12897406 [PubMed - indexed for MEDLINE]

☐ 4: Gu XQ, Haddad GG.

Related Articles, Li

Maturation of neuronal excitability in hippocampal neurons of mice chronically exposed to cyclic hypoxia.
Am J Physiol Cell Physiol. 2003 May;284(5):C1156-63.
PMID: 12676654 [PubMed - indexed for MEDLINE]

☐ 5: Kohelet D.

Related Articles, Li

Nitric oxide inhalation and high frequency oscillatory ventilation for hypoxemic respiratory failure in infants.
Isr Med Assoc J. 2003 Jan;5(1):19-23.
PMID: 12592952 [PubMed - indexed for MEDLINE]

☐ 6: Luo Y, Cheng S, Lai W, Luo L.

Related Articles, Li

[Effect of ipratropium bromide on calcium activated potassium channel in tracheal smooth muscle cells from chronically hypoxic rats]
Zhonghua Jie He He Hu Xi Za Zhi. 2002 May;25(5):287-91. Chinese.
PMID: 12133322 [PubMed - indexed for MEDLINE]

☐ 7: Akseirod S, Barak Y, Ben-Dov Y, Keselbrener L, Baharav A.

Related Articles, Li

Estimation of autonomic response based on individually determined time axis
Auton Neurosci. 2001 Jul 20;90(1-2):13-23. Review.
PMID: 11485280 [PubMed - indexed for MEDLINE]




















☐ 8: Pelletier MR, Pahapill PA, Pennefather PS, Carlen PL.










Related Articles, Li

Analysis of single K(ATP) channels in mammalian dentate gyrus granule cells.
J Neurophysiol. 2000 Nov;84(5):2291-301.
PMID: 11067973 [PubMed - indexed for MEDLINE]


☐ 9: Dollberg S, Marom R, Mimouni FB, Yeruchimovich M.


Related Articles, Li

-  **Normoblasts in large for gestational age infants.**
Arch Dis Child Fetal Neonatal Ed. 2000 Sep;83(2):F148-9.
PMID: 10952712 [PubMed - indexed for MEDLINE]
-  **10:** Nagashima M, Nollert G, Stock U, Sperling J, Hatsuoka S, Shum-Tim D, Takeuchi K, Nedder A, Mayer JE Jr. Related Articles, LI
D. Takeuchi K, Nedder A, Mayer JE Jr.
-  **Cardiac performance after deep hypothermic circulatory arrest in chronically cyanotic neonatal lambs.**
J Thorac Cardiovasc Surg. 2000 Aug;120(2):238-46.
PMID: 10917937 [PubMed - indexed for MEDLINE]
-  **11:** Wang ZF, Xue CS, Zhou QX, Wan ZB, Luo QS. Related Articles, LI
-  **Effects of tetrandrine on changes of NMDA receptor channel in cortical neurons of rat induced by anoxia.**
Zhongguo Yao Li Xue Bao. 1999 Aug;20(8):729-32.
PMID: 10678107 [PubMed - indexed for MEDLINE]
-  **12:** Henderson JL, Reynolds JD, Dexter F, Atkins B, Hrdy J, Poduska D, Penning DH. Related Articles, LI
-  **Chronic hypoxemia causes extracellular glutamate concentration to increase the cerebral cortex of the near-term fetal sheep.**
Brain Res Dev Brain Res. 1998 Feb 10;105(2):287-93.
PMID: 9541746 [PubMed - indexed for MEDLINE]
-  **13:** Gozes I, Bachar M, Bardea A, Davidson A, Rubinstein S, Fridkin M. Related Articles, LI
-  **Protection against developmental deficiencies by a lipophilic VIP analogue.**
Neurochem Res. 1998 May;23(5):689-93.
PMID: 9566607 [PubMed - indexed for MEDLINE]
-  **14:** Mayer-Lev H, Ar A. Related Articles, LI
-  **Changes in enzymatic antioxidant activity in pregnant rats exposed to hyperoxia or hypoxia.**
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1997 Nov;118(3):353-9.
PMID: 9467886 [PubMed - indexed for MEDLINE]
-  **15:** Shaw RM, Rudy Y. Related Articles, LI
-  **Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration.**
Cardiovasc Res. 1997 Aug;35(2):256-72.
PMID: 9349389 [PubMed - indexed for MEDLINE]
-  **16:** Goldman AP, Tasker RC, Hosiasson S, Henriksen T, Macrae DJ. Related Articles, LI
-  **Early response to inhaled nitric oxide and its relationship to outcome in children with severe hypoxemic respiratory failure.**
Chest. 1997 Sep;112(3):752-8.
PMID: 9315811 [PubMed - indexed for MEDLINE]
-  **17:** Coles SK, Dick TE. Related Articles, LI
-  **Neurons in the ventrolateral pons are required for post-hypoxic frequency decline in rats.**
J Physiol. 1996 Nov 15;497 (Pt 1):79-94.
PMID: 8951713 [PubMed - indexed for MEDLINE]
-  **18:** Do E, Ellis D, Noireaud J. Related Articles, LI
-  **Intracellular pH and intrinsic H⁺ buffering capacity in normal and hypertrophied right ventricle of ferret heart.**
Cardiovasc Res. 1996 May;31(5):729-38.
PMID: 8763402 [PubMed - indexed for MEDLINE]


- ☐ **19:** [Gleitz J, Tosch C, Beile A, Peters T.](#) Related Articles, Li
 **The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis ATP content and intracellular Na⁺ and Ca²⁺ of anoxic brain vesicles.**
 Neuropharmacology. 1996;35(12):1743-52.
 PMID: 9076753 [PubMed - indexed for MEDLINE]
- ☐ **20:** [Palmisano BW, Mehner RW, Baker JE, Stowe DF, Bosnjak ZJ, Kampine JP.](#) Related Articles, Li
 **Direct effects of halothane and isoflurane in infant rabbit hearts with right ventricular hypertrophy secondary to chronic hypoxemia.**
 Anesth Analg. 1995 Jun;80(6):1122-8.
 PMID: 7762838 [PubMed - indexed for MEDLINE]
- ☐ **21:** [Lorenzo PS, Otero-Losada ME, Adler-Graschinsky E.](#) Related Articles, Li
 **Effects of the in vitro treatment with gangliosides on the release of endogenous amino acids from rat hypoxic atria.**
 J Auton Pharmacol. 1995 Feb;15(1):9-17.
 PMID: 7744889 [PubMed - indexed for MEDLINE]
- ☐ **22:** [Paterson DH, Clement ID, Howard LS, Nagyova B, Robbins PA.](#) Related Articles, Li
 **The human ventilatory response to step changes in end-tidal PO₂ of differing amplitude.**
 Respir Physiol. 1993 Dec;94(3):309-21.
 PMID: 8108609 [PubMed - indexed for MEDLINE]
- ☐ **23:** [Benndorf K, Bollmann G, Friedrich M, Hirche H.](#) Related Articles, Li
 **Anoxia induces time-independent K⁺ current through KATP channels in isolated heart cells of the guinea-pig.**
 J Physiol. 1992 Aug;454:339-57.
 PMID: 1474494 [PubMed - indexed for MEDLINE]
- ☐ **24:** [Benndorf K, Friedrich M, Hirche H.](#) Related Articles, Li
 **Anoxia opens ATP regulated K channels in isolated heart cells of the guinea pig.**
 Pflugers Arch. 1991 Aug;419(1):108-10.
 PMID: 1945756 [PubMed - indexed for MEDLINE]
- ☐ **25:** [Benndorf K, Friedrich M, Hirche H.](#) Related Articles, Li
 **Reoxygenation-induced arrhythmogenic transient inward currents in isolated cells of the guinea-pig heart.**
 Pflugers Arch. 1991 Apr;418(3):248-60.
 PMID: 1857634 [PubMed - indexed for MEDLINE]
- ☐ **26:** [Brooks SP, Storey KB.](#) Related Articles, Li
 **The role of protein kinases in anoxia tolerance in facultative anaerobes: purification and characterization of a protein kinase that phosphorylates pyruvate kinase.**
 Biochim Biophys Acta. 1991 Mar 4;1073(2):253-9.
 PMID: 2009278 [PubMed - indexed for MEDLINE]
- ☐ **27:** [Nilsson GE, Alfaro AA, Lutz PL.](#) Related Articles, Li
 **Changes in turtle brain neurotransmitters and related substances during anoxia.**
 Am J Physiol. 1990 Aug;259(2 Pt 2):R376-84.
 PMID: 1696793 [PubMed - indexed for MEDLINE]
- ☐ **28:** [Gronow G, Klaus N, Malyusz M.](#) Related Articles, Li


Support of hypoxic renal cell volume regulation by glycine.

 Adv Exp Med Biol. 1990;277:705-12.
PMID: 2096671 [PubMed - indexed for MEDLINE]


 **29:** [Esau SA.](#)


[Related Articles](#), [Li](#)

 Hypoxic, hypercapnic acidosis decreases tension and increases fatigue in hamster diaphragm muscle in vitro.
Am Rev Respir Dis. 1989 Jun;139(6):1410-7.
PMID: 2658701 [PubMed - indexed for MEDLINE]


 **30:** [Springer C, Barstow TJ, Cooper DM.](#)


[Related Articles](#), [Li](#)

 Effect of hypoxia on ventilatory control during exercise in children and adult
Pediatr Res. 1989 Mar;25(3):285-90.
PMID: 2704597 [PubMed - indexed for MEDLINE]


 **31:** [Ameredes BT, Clanton TL.](#)


[Related Articles](#), [Li](#)

 Hyperoxia and moderate hypoxia fail to affect inspiratory muscle fatigue in humans.
J Appl Physiol. 1989 Feb;66(2):894-900.
PMID: 2708219 [PubMed - indexed for MEDLINE]


 **32:** [Nakamura Y, Wiegner AW, Bing OH.](#)


[Related Articles](#), [Li](#)

 Measurement of relaxation in isolated rat ventricular myocardium during hypoxia and reoxygenation.
Cardiovasc Res. 1986 Sep;20(9):690-7.
PMID: 3791360 [PubMed - indexed for MEDLINE]


 **33:** [Kaneko K.](#)


[Related Articles](#), [Li](#)

 The effect of perinatal anoxia on amino acid metabolism in the developing brain. Part II: The effect of perinatal anoxia on the free amino acid patterns in CSF of infants and children.
Brain Dev. 1985;7(4):400-7.
PMID: 4061776 [PubMed - indexed for MEDLINE]


 **34:** [Kaneko K.](#)


[Related Articles](#), [Li](#)

 The effect of perinatal anoxia on amino acid metabolism in the developing brain. Part I: The effect of experimental anoxia on the free amino acid pattern in the brain of neonatal rats.
Brain Dev. 1985;7(4):392-9.
PMID: 4061775 [PubMed - indexed for MEDLINE]


 **35:** [Stupfel M, Busnel MC, Molin D, Thierry H, Gourlet V.](#)


[Related Articles](#), [Li](#)

 Respiratory behavior in groups of deaf and non-deaf GFF male mice.
Physiol Behav. 1984 May;32(5):823-30.
PMID: 6494287 [PubMed - indexed for MEDLINE]


 **36:** [Snow TR, Caspar T.](#)


[Related Articles](#), [Li](#)

 Substrate dependence of myocardial response to hypoxia in the presence of theophylline.
Am J Physiol. 1983 Aug;245(2):H363-7.
PMID: 6881369 [PubMed - indexed for MEDLINE]

 **37:** [Ikeda K, Hiraoka M.](#)

[Related Articles](#), [Li](#)

 Effects of hypoxia on passive electrical properties of canine ventricular muscle
Pflugers Arch. 1982 Mar;393(1):45-50.
PMID: 7088684 [PubMed - indexed for MEDLINE]

 **38:** [Metcalfe J, Bissonnette JM, Bowles RE, Matsumoto JA, Dunham SJ.](#)

[Related Articles](#), [Li](#)



Hen's eggs with retarded gas exchange. I. Chorioallantoic capillary growth.

Respir Physiol. 1979 Feb;36(2):97-101.

PMID: 441579 [PubMed - indexed for MEDLINE]



39: Lantz RC, Wong F, Mauro A.

[Related Articles, LI](#)



Lability of the prolonged depolarizing afterpotential in Balanus photoreceptc

J Gen Physiol. 1977 Oct;70(4):441-52.

PMID: 915471 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** Sort **Send to** **Text**

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56

Search PubMed for tau AND ischemia

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts


ClinicalTrials.gov

PubMed Central


Items 1 - 291 of 291

One p:


☐ 1: Yip G, Khandheria B, Belohlavek M, Pislaru C, Seward J, Bailey K, Tajik AJ, Pellikka P, Abraham T. Related Articles, Li

 Strain echocardiography tracks dobutamine-induced decrease in regional myocardial perfusion in nonocclusive coronary stenosis.
J Am Coll Cardiol. 2004 Oct 19;44(8):1664-71.
PMID: 15489101 [PubMed - in process]


☐ 2: Wen Y, Yang S, Liu R, Simpkins JW. Related Articles, Li

 Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein.
Brain Res. 2004 Oct 1;1022(1-2):30-8.
PMID: 15353210 [PubMed - in process]


☐ 3: Cox Jr CS, Fischer UM, Allen SJ, Laine GA. Related Articles, Li

 Lymphatic Diversion Prevents Myocardial Edema Following Mesenteric Ischemia/Reperfusion.
Microcirculation. 2004;11(1):1-8.
PMID: 15280094 [PubMed - as supplied by publisher]


☐ 4: Wada-Isoe K, Wakutani Y, Urakami K, Nakashima K. Related Articles, Li

 Elevated interleukin-6 levels in cerebrospinal fluid of vascular dementia patients.
Acta Neurol Scand. 2004 Aug;110(2):124-7.
PMID: 15242421 [PubMed - indexed for MEDLINE]


☐ 5: Ayata C, Dunn AK, Gursoy-OZdemir Y, Huang Z, Boas DA, Moskowitz MA. Related Articles, Li

 Laser speckle flowmetry for the study of cerebrovascular physiology in normal and ischemic mouse cortex.
J Cereb Blood Flow Metab. 2004 Jul;24(7):744-55.
PMID: 15241182 [PubMed - indexed for MEDLINE]

☐ 6: Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL. Related Articles, Li










 Proteins released from degenerating neurons are surrogate markers for acute brain damage.
Neurobiol Dis. 2004 Jul;16(2):311-20.
PMID: 15193288 [PubMed - indexed for MEDLINE]

☐ 7: George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A, Herz I, Miller H, Keren G. Related Articles, Li










 Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation.
Eur Heart J. 2004 Jun;25(12):1003-8.
PMID: 15191769 [PubMed - indexed for MEDLINE]

☐ 8: Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, Sherer Y, Adler Y, Behar S. Related Articles, Li

Is hypoglycaemia a marker for increased long-term mortality risk in patients

-  with coronary artery disease? An 8-year follow-up.
Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):135-43.
PMID: 15187817 [PubMed - indexed for MEDLINE]
- ☐ **9:** Sadowski M, Pankiewicz J, Scholtzova H, Li YS, Quartermain D, Duff K, Wisniewski T. Related Articles, Li
Links between the pathology of Alzheimer's disease and vascular dementia.
Neurochem Res. 2004 Jun;29(6):1257-66.
PMID: 15176482 [PubMed - indexed for MEDLINE]
- ☐ **10:** Shiia N, Kuniyara T, Miyatake T, Matsuzaki K, Yasuda K. Related Articles, Li
 Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery.
Ann Thorac Surg. 2004 Jun;77(6):2034-8.
PMID: 15172260 [PubMed - indexed for MEDLINE]
- ☐ **11:** Kavec M, Grohn OH, Kettunen MI, Silvennoinen MJ, Garwood M, Kauppinen RA. Related Articles, Li
 Acute cerebral ischemia in rats studied by Carr-Purcell spin-echo magnetic resonance imaging: assessment of blood oxygenation level-dependent and tissue effects on the transverse relaxation.
Magn Reson Med. 2004 Jun;51(6):1138-46.
PMID: 15170833 [PubMed - indexed for MEDLINE]
- ☐ **12:** George J, Shmuel SB, Roth A, Herz I, Izraelov S, Deutsch V, Keren G, Miller H. Related Articles, Li
 L-arginine attenuates lymphocyte activation and anti-oxidized LDL antibody levels in patients undergoing angioplasty.
Atherosclerosis. 2004 Jun;174(2):323-7.
PMID: 15136062 [PubMed - indexed for MEDLINE]
- ☐ **13:** Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Related Articles, Li
 Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Circulation. 2004 May 11;109(18):2197-202. Epub 2004 May 03.
PMID: 15123532 [PubMed - indexed for MEDLINE]
- ☐ **14:** Silverberg GD. Related Articles, Li
 Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both.
Brain. 2004 May;127(Pt 5):947-8. No abstract available.
PMID: 15111447 [PubMed - indexed for MEDLINE]
- ☐ **15:** Hasdai D, Behar S, Boyko V, Battler A. Related Articles, Li
 Treatment modalities of diabetes mellitus and outcomes of acute coronary syndromes.
Coron Artery Dis. 2004 May;15(3):129-35.
PMID: 15096993 [PubMed - indexed for MEDLINE]
- ☐ **16:** Takeuchi K, Minakawa M, Otaki M, Odagiri S, Itoh K, Murakami A, Yaku H, Kitamura N. Related Articles, Li
 Hyperthyroidism causes mechanical insufficiency of myocardium with possibly increased SR Ca²⁺-ATPase activity.
Jpn J Physiol. 2003 Dec;53(6):411-6.
PMID: 15038839 [PubMed - indexed for MEDLINE]
- ☐ **17:** Hochhauser E, Kaminski O, Shalom H, Leshem D, Shneyvays V, Shainberg A, Vidne BA. Related Articles, Li
 Role of adenosine receptor activation in antioxidant enzyme regulation during









ischemia-reperfusion in the isolated rat heart.
Antioxid Redox Signal. 2004 Apr;6(2):335-44.
PMID: 15025935 [PubMed - in process]










- ☐ **18:** Tal R, Lask DM, Keslin J, Livne PM. Related Articles, Li
 **Abdominal compartment syndrome: urological aspects.**
BJU Int. 2004 Mar;93(4):474-7. Review.
PMID: 15008712 [PubMed - indexed for MEDLINE]
- ☐ **19:** Wen Y, Yang S, Liu R, Brun-Zinkernagel AM, Koulen P, Simpkins JW. Related Articles, Li
 **Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats.**
J Biol Chem. 2004 May 21;279(21):22684-92. Epub 2004 Feb 24.
PMID: 14982935 [PubMed - indexed for MEDLINE]
- ☐ **20:** Klass O, Fischer UM, Perez E, Easo J, Bosse M, Fischer JH, Tossios P, Mehlhorn U. Related Articles, Li
 **Effect of the Na⁺/H⁺ exchange inhibitor eniporide on cardiac performance a myocardial high energy phosphates in pigs subjected to cardioplegic arrest.**
Ann Thorac Surg. 2004 Feb;77(2):658-63.
PMID: 14759455 [PubMed - indexed for MEDLINE]
- ☐ **21:** Carmeli E, Moas M, Reznick AZ, Coleman R. Related Articles, Li
 **Matrix metalloproteinases and skeletal muscle: a brief review.**
Muscle Nerve. 2004 Feb;29(2):191-7. Review.
PMID: 14755482 [PubMed - indexed for MEDLINE]
- ☐ **22:** Uchiyama T, Nakamura A, Arai T, Ikeda K, Tsuchiya K. Related Articles, Li
 **Microglial tau undergoes phosphorylation-independent modification after ischemia.**
Glia. 2004 Jan 15;45(2):180-7.
PMID: 14730711 [PubMed - indexed for MEDLINE]
- ☐ **23:** Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L, Behar S. Related Articles, Li
 **Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis.**
Cardiology. 2003;100(4):207-15.
PMID: 14713732 [PubMed - indexed for MEDLINE]
- ☐ **24:** Hughes PM, Anthony DC, Ruddin M, Botham MS, Rankine EL, Sablone M, Baumann D, Mir AK, Perry VH. Related Articles, Li
 **Focal lesions in the rat central nervous system induced by endothelin-1.**
J Neuropathol Exp Neurol. 2003 Dec;62(12):1276-86.
PMID: 14692703 [PubMed - indexed for MEDLINE]
- ☐ **25:** Funahashi M. Related Articles, Li
 **Effects of ischemic preconditioning on myocardial protective on cardiac surgery: possibility of ischemic preconditioning and adenosine administratio**
Ann Thorac Cardiovasc Surg. 2003 Oct;9(5):307-13.
PMID: 14672527 [PubMed - indexed for MEDLINE]
- ☐ **26:** Chouraqui P, Asman A, Guetta V, Daka F, Baron J, Rozen E, Sternberg M, Shechter M. Related Articles, Li
 **Noninvasive detection of collateral flow to the infarct-related coronary artery in patients after myocardial infarction by Tl-201 tomographic imaging.**
J Nucl Cardiol. 2003 Nov-Dec;10(6):669-75.
PMID: 14668780 [PubMed - indexed for MEDLINE]











- ☐ **27:** Sharshar T, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E, Dorandeu A, Orlikowski D, Raphael JC, Gajdos P, Annane D. Related Articles, Li
Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock.
 Lancet. 2003 Nov 29;362(9398):1799-805.
 PMID: 14654318 [PubMed - indexed for MEDLINE]
- ☐ **28:** Yanada A, Ohte N, Narita H, Akita S, Miyabe H, Takada N, Goto T, Mukai S, Hayano J, Kimura G. Related Articles, Li
The role of apically directed intraventricular isovolumic relaxation flow in speeding early diastolic left ventricular filling.
 J Am Soc Echocardiogr. 2003 Dec;16(12):1226-30.
 PMID: 14652600 [PubMed - indexed for MEDLINE]
- ☐ **29:** George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G. Related Articles, Li
Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis.
 Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):e57-60. Epub 2003 Nov 13.
 PMID: 14615392 [PubMed - indexed for MEDLINE]
- ☐ **30:** Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Related Articles, Li
Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
 J Am Coll Cardiol. 2003 Nov 5;42(9):1666-73.
 PMID: 14607457 [PubMed - indexed for MEDLINE]
- ☐ **31:** Schwammenthal E, Adler Y, Amichai K, Sagie A, Behar S, Hod H, Feinberg MS. Related Articles, Li
Prognostic value of global myocardial performance indices in acute myocardial infarction: comparison to measures of systolic and diastolic left ventricular function.
 Chest. 2003 Nov;124(5):1645-51.
 PMID: 14605029 [PubMed - indexed for MEDLINE]
- ☐ **32:** Hasdai D, Haim M, Behar S, Boyko V, Battler A. Related Articles, Li
Acute coronary syndromes in patients with prior cerebrovascular events: lessons from the Euro-Heart Survey of Acute Coronary Syndromes.
 Am Heart J. 2003 Nov;146(5):832-8.
 PMID: 14597932 [PubMed - indexed for MEDLINE]
- ☐ **33:** Tanne D, Levine SR, Brey RL, Lin H, Tilley BC, NINDS rt-PA Stroke Study Group. Related Articles, Li
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.
 Neurology. 2003 Oct 28;61(8):1158-9. No abstract available.
 PMID: 14581697 [PubMed - indexed for MEDLINE]
- ☐ **34:** Wallin A, Sjogren M, Blennow K, Davidsson P. Related Articles, Li
Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia.
 Dement Geriatr Cogn Disord. 2003;16(4):200-7.
 PMID: 14512714 [PubMed - indexed for MEDLINE]
- ☐ **35:** Nagueh SF, Rao L, Soto J, Middleton KJ, Khoury DS. Related Articles, Li
Haemodynamic insights into the effects of ischaemia and cycle length on tissue Doppler-derived mitral annulus diastolic velocities.

- ☐ **36:** Arranz J, Soriano A, Garcia I, Garcia I, Concepcion MT, Navarro J, Arteaga A, Filella X, Gonzalez F, Fernandez C, Barrera M, Munoz L, Perera AJ, Pozo JL, Jimenez A, Macia M, Arteaga I. Related Articles, Li
Association between anatomopathologic graft disorders during reperfusion a vena cava sIL-2r in orthotopic liver transplantation.
Transplant Proc. 2003 Aug;35(5):1880-3.
PMID: 12962833 [PubMed - indexed for MEDLINE]
- ☐ **37:** Shilo L, Feldman J, Gendelman V, Shenkman L, Berner YN. Related Articles, Li
Is the treatment of hyperlipidemia as secondary prevention adequate in different age groups in Israel?
Isr Med Assoc J. 2003 Jul;5(7):479-81.
PMID: 12901241 [PubMed - indexed for MEDLINE]
- ☐ **38:** Hasdai D, Behar S, Boyko V, Danchin N, Bassand JP, Battler A. Related Articles, Li
Cardiac biomarkers and acute coronary syndromes--the Euro Heart Survey o Acute Coronary Syndromes Experience.
Eur Heart J. 2003 Jul;24(13):1189-94.
PMID: 12831812 [PubMed - indexed for MEDLINE]
- ☐ **39:** Hasdai D, Porter A, Rosengren A, Behar S, Boyko V, Battler A. Related Articles, Li
Effect of gender on outcomes of acute coronary syndromes.
Am J Cardiol. 2003 Jun 15;91(12):1466-9, A6. No abstract available.
PMID: 12804736 [PubMed - indexed for MEDLINE]
- ☐ **40:** Tanne D, Haim M, Boyko V, Goldbourt U, Reshef T, Adler Y, Brunner D, Mekori YA, Behar S. Related Articles, Li
Prospective study of Chlamydia pneumoniae IgG and IgA seropositivity and risk of incident ischemic stroke.
Cerebrovasc Dis. 2003;16(2):166-70.
PMID: 12792175 [PubMed - indexed for MEDLINE]
- ☐ **41:** George J, Biner S, Keren P, Barshack I, Goldberg I, Sherez J, Levitzki A, Keren G, Roth A. Related Articles, Li
Tyrphostin AG-556 reduces myocardial infarct size and improves cardiac performance in the rat.
Exp Mol Pathol. 2003 Jun;74(3):314-8.
PMID: 12782020 [PubMed - indexed for MEDLINE]
- ☐ **42:** Hochhauser E, Kivity S, Offen D, Maulik N, Otani H, Barhum Y, Pannet H, Shneyvays V, Shainberg A, Goldshtaub V, Tobar A, Vidne BA. Related Articles, Li
Bax ablation protects against myocardial ischemia-reperfusion injury in transgenic mice.
Am J Physiol Heart Circ Physiol. 2003 Jun;284(6):H2351-9.
PMID: 12742833 [PubMed - indexed for MEDLINE]
- ☐ **43:** Jaroudi WA, Jurjus AR, El-Sabban ME, Kamal MT, Bitar KM, Bikhazi AB. Related Articles, Li
Endothelium and myocyte cellular insulin receptor alterations in a rat model myocardial infarction.
Can J Physiol Pharmacol. 2003 Mar;81(3):267-73.
PMID: 12733825 [PubMed - indexed for MEDLINE]
- ☐ **44:** Shiner Z, Baharav A, Akselrod S. Related Articles, Li

Detection of different recumbent body positions from the electrocardiogram.

-  Med Biol Eng Comput. 2003 Mar;41(2):206-10.
PMID: 12691442 [PubMed - indexed for MEDLINE]
- ☐ 45: Schafer FK, Schafer PJ, Jahnke T, Walluscheck K, Priebe M, Hentsch A, Heller M, Brossmann J. Related Articles, Li
[First clinical results in a study of contrast enhanced magnetic resonance angiography with the 1.0 molar gadobutrol in peripheral arterial occlusive disease--comparison to intraarterial DSA]
Rofo. 2003 Apr;175(4):556-64. German.
PMID: 12677513 [PubMed - indexed for MEDLINE]
-  [Effects of isometric exercise on the diastolic function in patients with severe aortic stenosis]
Medicina (B Aires). 2003;63(1):33-6. Spanish.
PMID: 12673958 [PubMed - indexed for MEDLINE]
- ☐ 46: Donato M, Gabay J, Pascua A, Saban M, Sabarros J, Gelpi RJ, Grinfeld L. Related Articles, Li
[Effects of isometric exercise on the diastolic function in patients with severe aortic stenosis]
Medicina (B Aires). 2003;63(1):33-6. Spanish.
PMID: 12673958 [PubMed - indexed for MEDLINE]
- ☐ 47: Scheinowitz M, Heled Y, Chouraqui P, Vered Z, Hayardeni Y, Kotlyar A, Castel D, Livschitz S, Barak V, Savion N, Eldar M. Related Articles, Li
Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.
Cardiovasc Drugs Ther. 2002 Jul;16(4):303-9.
PMID: 12652099 [PubMed - indexed for MEDLINE]
-  Dalteparin sodium (fragmin) administration following acute infarction does not affect myocardial perfusion and function in swine.
Cardiovasc Drugs Ther. 2002 Jul;16(4):303-9.
PMID: 12652099 [PubMed - indexed for MEDLINE]
- ☐ 48: Leather HA, De Wolff MH, Wouters PF. Related Articles, Li
Effects of propofol on the systolic and diastolic performance of the postischaemic, reperfused myocardium in rabbits.
Eur J Anaesthesiol. 2003 Mar;20(3):191-8.
PMID: 12650489 [PubMed - indexed for MEDLINE]
-  Effects of propofol on the systolic and diastolic performance of the postischaemic, reperfused myocardium in rabbits.
Eur J Anaesthesiol. 2003 Mar;20(3):191-8.
PMID: 12650489 [PubMed - indexed for MEDLINE]
- ☐ 49: Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, Brunner D, Behar S, Sela BA. Related Articles, Li
Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease.
Stroke. 2003 Mar;34(3):632-6. Epub 2003 Feb 20.
PMID: 12624283 [PubMed - indexed for MEDLINE]
-  Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease.
Stroke. 2003 Mar;34(3):632-6. Epub 2003 Feb 20.
PMID: 12624283 [PubMed - indexed for MEDLINE]
- ☐ 50: Chouraqui P, Schnall RP, Dvir I, Rozanski A, Qureshi E, Arditti A, Saef J, Feigin PD, Sheffy J. Related Articles, Li
Assessment of peripheral artery tonometry in the detection of treadmill exercise-induced myocardial ischemia.
J Am Coll Cardiol. 2002 Dec 18;40(12):2195-200.
PMID: 12505234 [PubMed - indexed for MEDLINE]
-  Assessment of peripheral artery tonometry in the detection of treadmill exercise-induced myocardial ischemia.
J Am Coll Cardiol. 2002 Dec 18;40(12):2195-200.
PMID: 12505234 [PubMed - indexed for MEDLINE]
- ☐ 51: Diederich ER, Behnke BJ, McDonough P, Kindig CA, Barstow TJ, Poole DC, Musch TI. Related Articles, Li
Dynamics of microvascular oxygen partial pressure in contracting skeletal muscle of rats with chronic heart failure.
Cardiovasc Res. 2002 Dec;56(3):479-86.
PMID: 12445889 [PubMed - indexed for MEDLINE]
-  Dynamics of microvascular oxygen partial pressure in contracting skeletal muscle of rats with chronic heart failure.
Cardiovasc Res. 2002 Dec;56(3):479-86.
PMID: 12445889 [PubMed - indexed for MEDLINE]
- ☐ 52: Mohri M, Suehiro K, Yamamoto S, Yamaguchi H, Ishino K, Sano S. Related Articles, Li
Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors.
Jpn J Thorac Cardiovasc Surg. 2002 Oct;50(10):430-4.
PMID: 12428383 [PubMed - indexed for MEDLINE]
-  Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors.
Jpn J Thorac Cardiovasc Surg. 2002 Oct;50(10):430-4.
PMID: 12428383 [PubMed - indexed for MEDLINE]
- ☐ 53: Fisman EZ, Tenenbaum A, Pines A. Related Articles, Li

-  **Systemic hypertension in postmenopausal women: a clinical approach.**
Curr Hypertens Rep. 2002 Dec;4(6):464-70. Review.
PMID: 12419176 [PubMed - indexed for MEDLINE]
- ☐ **54:** Pasipoularides AD, Shu M, Shah A, Glower DD. Related Articles, Li
-  **Right ventricular diastolic relaxation in conscious dog models of pressure overload, volume overload, and ischemia.**
J Thorac Cardiovasc Surg. 2002 Nov;124(5):964-72.
PMID: 12407380 [PubMed - indexed for MEDLINE]
- ☐ **55:** Micheletti R, Mattera GG, Rocchetti M, Schiavone A, Loi MF, Zaza A, Gagnol RJ, De Munari S, Melloni P, Carminati P, Bianchi G, Ferrari P. Related Articles, Li
-  **Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoximino)androstane-6,17-dione hydrochloride (PST2744).**
J Pharmacol Exp Ther. 2002 Nov;303(2):592-600.
PMID: 12388640 [PubMed - indexed for MEDLINE]
- ☐ **56:** Ginzburg K, Solomon Z, Bleich A. Related Articles, Li
-  **Repressive coping style, acute stress disorder, and posttraumatic stress disorder after myocardial infarction.**
Psychosom Med. 2002 Sep-Oct;64(5):748-57.
PMID: 12271105 [PubMed - indexed for MEDLINE]
- ☐ **57:** d'Entremont MI, Paulson AT, Marble AE. Related Articles, Li
-  **Impedance spectroscopy: an accurate method of differentiating between viable and ischaemic or infarcted muscle tissue.**
Med Biol Eng Comput. 2002 Jul;40(4):380-7.
PMID: 12227623 [PubMed - indexed for MEDLINE]
- ☐ **58:** Steine K, Stugaard M, Smiseth O. Related Articles, Li
-  **Mechanisms of diastolic intraventricular regional pressure differences and flow in the inflow and outflow tracts.**
J Am Coll Cardiol. 2002 Sep 4;40(5):983-90.
PMID: 12225727 [PubMed - indexed for MEDLINE]
- ☐ **59:** Tanne D, Haim M, Boyko V, Goldbourt U, Reshef T, Matetzky S, Adler Y, Mekori YA, Behar S. Related Articles, Li
-  **Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort.**
Stroke. 2002 Sep;33(9):2182-6.
PMID: 12215584 [PubMed - indexed for MEDLINE]
- ☐ **60:** Pitsavos C, Panagiotakos DB, Chrysohooou C, Skoumas J, Tzioumis K, Stefanadis C, Toutouzas P. Related Articles, Li
-  **Association between exposure to environmental tobacco smoke and the development of acute coronary syndromes: the CARDIO2000 case-control study.**
Tob Control. 2002 Sep;11(3):220-5.
PMID: 12198272 [PubMed - indexed for MEDLINE]
- ☐ **61:** De Hert SG, ten Broecke PW, Mertens E, Van Sommeren EW, De Blier IG, Stockman BA, Rodrigus IE. Related Articles, Li
-  **Sevoflurane but not propofol preserves myocardial function in coronary surgery patients.**
Anesthesiology. 2002 Jul;97(1):42-9.
PMID: 12131102 [PubMed - indexed for MEDLINE]
- ☐ **62:** Schwammenthal E, Popescu AC, Popescu BA, Freimark D, Hod H. Related Articles, Li

-  Mechanism of mitral regurgitation in inferior wall acute myocardial infarction.
Am J Cardiol. 2002 Aug 1;90(3):306-9. No abstract available.
PMID: 12127618 [PubMed - indexed for MEDLINE]
-  **63:** Calza G, Lerzo F, Perfumo F, Borini I, Panizzon G, Moretti R, Grasso P, Virgone A, Zannini L. Related Articles, Li
Clinical evaluation of oxidative stress and myocardial reperfusion injury in pediatric cardiac surgery.
J Cardiovasc Surg (Torino). 2002 Aug;43(4):441-7.
PMID: 12124549 [PubMed - indexed for MEDLINE]
-  **64:** Nordhaug D, Steensrud T, Korvald C, Aghajani E, Myrnes T. Related Articles, Li
Preserved myocardial energetics in acute ischemic left ventricular failure -- studies in an experimental pig model.
Eur J Cardiothorac Surg. 2002 Jul;22(1):135-42.
PMID: 12103387 [PubMed - indexed for MEDLINE]
-  **65:** Kushnir T, Luria O. Related Articles, Li
Supervisors' attitudes toward return to work after myocardial infarction or coronary artery bypass graft.
J Occup Environ Med. 2002 Apr;44(4):331-7.
PMID: 11977419 [PubMed - indexed for MEDLINE]
-  **66:** Nagaya N, Goto Y, Satoh T, Sumida H, Kojima S, Miyatake K, Kangawa K. Related Articles, Li
Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial infarction.
J Cardiovasc Pharmacol. 2002 May;39(5):754-60.
PMID: 11973420 [PubMed - indexed for MEDLINE]
-  **67:** Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grund M, Levine SR. Related Articles, Li
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
Circulation. 2002 Apr 9;105(14):1679-85.
PMID: 11940547 [PubMed - indexed for MEDLINE]
-  **68:** Sinagra-Gallego R, Cavalheiro EA, Coimbra CG. Related Articles, Li
Postischemic hyperthermia induces Alzheimer-like pathology in the rat brain.
Acta Neuropathol (Berl). 2002 May;103(5):444-52. Epub 2002 Feb 06.
PMID: 11935259 [PubMed - indexed for MEDLINE]
-  **69:** Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Related Articles, Li
Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study.
Neuroepidemiology. 2002 Mar-Apr;21(2):93-9.
PMID: 11901279 [PubMed - indexed for MEDLINE]
-  **70:** Wakiyama H, Cowan DB, Toyoda Y, Federman M, Levitsky S, McCully JD. Related Articles, Li
Selective opening of mitochondrial ATP-sensitive potassium channels during surgically induced myocardial ischemia decreases necrosis and apoptosis.
Eur J Cardiothorac Surg. 2002 Mar;21(3):424-33.
PMID: 11888758 [PubMed - indexed for MEDLINE]
-  **71:** Scheinowitz M, Kotlyar AA, Zimand S, Leibovitz I, Varda-Bloom N. Related Articles, Li



Effect of basic fibroblast growth factor on left ventricular geometry in rats subjected to coronary occlusion and reperfusion.

Isr Med Assoc J. 2002 Feb;4(2):109-13.

PMID: 11875982 [PubMed - indexed for MEDLINE]

☐ 72: Goldbourt U, Tanne D.

Related Articles, Li



Body height is associated with decreased long-term stroke but not coronary heart disease mortality?

Stroke. 2002 Mar;33(3):743-8.

PMID: 11872898 [PubMed - indexed for MEDLINE]

☐ 73: Church TS, Lavie CJ, Milani RV, Kirby GS.

Related Articles, Li



Improvements in blood rheology after cardiac rehabilitation and exercise training in patients with coronary heart disease.

Am Heart J. 2002 Feb;143(2):349-55.

PMID: 11835042 [PubMed - indexed for MEDLINE]

☐ 74: Kanauchi M, Motomiya K, Hashimoto T.

Related Articles, Li



Insulin secretion and sensitivity in non-obese and obese Japanese patients with coronary artery disease.

Metabolism. 2002 Feb;51(2):184-8.

PMID: 11833046 [PubMed - indexed for MEDLINE]

☐ 75: Pape A, Kemming G, Meisner F, Kleen M, Habler O.

Related Articles, Li



Diaspirin cross-linked hemoglobin fails to improve left ventricular diastolic function after fluid resuscitation from hemorrhagic shock.

Eur Surg Res. 2001 Sep-Dec;33(5-6):318-26.

PMID: 11805391 [PubMed - indexed for MEDLINE]

☐ 76: Bitsch A, Horn C, Kemmling Y, Seipelt M, Hellenbrand U, Stiefel M, Ciesielczyk B, Cepek L, Bahn E, Ratzka P, Prange H, Otto M.

Related Articles, Li



Serum tau protein level as a marker of axonal damage in acute ischemic stroke.

Eur Neurol. 2002;47(1):45-51.

PMID: 11803192 [PubMed - indexed for MEDLINE]

☐ 77: Sherer Y, Shoenfeld Y.

Related Articles, Li



Atherosclerosis.

Ann Rheum Dis. 2002 Feb;61(2):97-9.

PMID: 11796391 [PubMed - indexed for MEDLINE]

☐ 78: Lin CS, Grosskreutz J, Burke D.

Related Articles, Li



Sodium channel function and the excitability of human cutaneous afferents during ischaemia.

J Physiol. 2002 Jan 15;538(Pt 2):435-46.

PMID: 11790811 [PubMed - indexed for MEDLINE]

☐ 79: Tanne D, Shotan A, Goldbourt U, Haim M, Boyko V, Adler Y, Mandelzweig L, Behar S, Bezafibrate Infarction Prevention Study Group.

Related Articles, Li



Severity of angina pectoris and risk of ischemic stroke.

Stroke. 2002 Jan;33(1):245-50.

PMID: 11779917 [PubMed - indexed for MEDLINE]

☐ 80: Irving EA, Bentley DL, Parsons AA.

Related Articles, Li



Assessment of white matter injury following prolonged focal cerebral ischaemia in the rat.

Acta Neuropathol (Berl). 2001 Dec;102(6):627-35.

☐ **81:** Singer P, Cohen J, Cynober L. Related Articles, Li



Effect of nutritional state of brain-dead organ donor on transplantation.
Nutrition. 2001 Nov-Dec;17(11-12):948-52. Review.
PMID: 11744347 [PubMed - indexed for MEDLINE]

☐ **82:** Tanne D, Koren-Morag N, Graff E, Goldbourt U. Related Articles, Li



Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor.
Circulation. 2001 Dec 11;104(24):2892-7.
PMID: 11739302 [PubMed - indexed for MEDLINE]

☐ **83:** Shilo L, Hadari R, Kovatz S, Qasim M, Shenkman L. Related Articles, Li



Appropriateness of nitrate use in a general medicine population.
Ann Pharmacother. 2001 Nov;35(11):1339-42.
PMID: 11724079 [PubMed - indexed for MEDLINE]

☐ **84:** Hongo M, Hironaka E, Yokoseki O, Watanabe N, Shibamoto T, Owa M, Ryoike T. Related Articles, Li



Effects of growth hormone following chronic angiotensin-converting enzyme inhibition in chronic heart failure: their relation to infarct size.
Cardiovasc Drugs Ther. 2001;15(3):241-9.
PMID: 11713892 [PubMed - indexed for MEDLINE]

☐ **85:** Motro M, Shemesh J, Grossman E. Related Articles, Li



Coronary benefits of calcium antagonist therapy for patients with hypertension.
Curr Opin Cardiol. 2001 Nov;16(6):349-55. Review.
PMID: 11704704 [PubMed - indexed for MEDLINE]

☐ **86:** Ohte N, Narita H, Akita S, Kurokawa K, Hayano J, Kimura G. Related Articles, Li



Striking effect of left ventricular systolic performance on propagation velocity of left ventricular early diastolic filling flow.
J Am Soc Echocardiogr. 2001 Nov;14(11):1070-4.
PMID: 11696830 [PubMed - indexed for MEDLINE]

☐ **87:** Firstenberg MS, Smedira NG, Greenberg NL, Prior DL, McCarthy PM, Garcia MJ, Thomas JD. Related Articles, Li



Relationship between early diastolic intraventricular pressure gradients, an index of elastic recoil, and improvements in systolic and diastolic function.
Circulation. 2001 Sep 18;104(12 Suppl 1):I330-5.
PMID: 11568078 [PubMed - indexed for MEDLINE]

☐ **88:** Tanne D, Turgeman D, Adler Y. Related Articles, Li












Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics.
Drugs. 2001;61(10):1439-53. Review.
PMID: 11558833 [PubMed - indexed for MEDLINE]










☐ **89:** Scherrer-Crosbie M, Ullrich R, Bloch KD, Nakajima H, Nasser B, Aretz HT, Lindsey ML, Vancon AC, Huang PL, Lee RT, Zapol WM, Picard MH. Related Articles, Li





















Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice.
Circulation. 2001 Sep 11;104(11):1286-91.
PMID: 11551881 [PubMed - indexed for MEDLINE]

☐ **90:** Khnychenko LK, Bul'on VV, Sapronov NS. Related Articles, Li

-  [Effect of the novel taurine derivative on various parameters of metabolism c
experimental myocardial infarction]
Eksp Klin Farmakol. 2001 Mar-Apr;64(2):38-40. Russian.
PMID: 11548446 [PubMed - indexed for MEDLINE]
- ☐ **91:** Sasaki C, Hayashi T, Zhang WR, Warita H, Manabe Y, Sakai K, Abe K. Related Articles, Li
Different expression of glycogen synthase kinase-3beta between young and c
rat brains after transient middle cerebral artery occlusion.
Neurol Res. 2001 Sep;23(6):588-92.
PMID: 11547926 [PubMed - indexed for MEDLINE]
-  Different expression of glycogen synthase kinase-3beta between young and c
rat brains after transient middle cerebral artery occlusion.
Neurol Res. 2001 Sep;23(6):588-92.
PMID: 11547926 [PubMed - indexed for MEDLINE]
- ☐ **92:** Imai H, Masayasu H, Dewar D, Graham DI, Macrae IM. Related Articles, Li
 Ebselen protects both gray and white matter in a rodent model of focal cereb
ischemia.
Stroke. 2001 Sep;32(9):2149-54.
PMID: 11546910 [PubMed - indexed for MEDLINE]
- ☐ **93:** Bolognesi R, Tsialtas D, Barilli AL, Manca C, Zeppellini R, Javernaro A, Cucchini F. Related Articles, Li
 Detection of early abnormalities of left ventricular function by hemodynamic
echo-tissue Doppler imaging, and mitral Doppler flow techniques in patients
with coronary artery disease and normal ejection fraction.
J Am Soc Echocardiogr. 2001 Aug;14(8):764-72.
PMID: 11490324 [PubMed - indexed for MEDLINE]
- ☐ **94:** Ruppin E, Reggia JA. Related Articles, Li
 Cortical spreading depression and the pathogenesis of brain disorders: a
computational and neural network-based investigation.
Neurol Res. 2001 Jul;23(5):447-56.
PMID: 11474800 [PubMed - indexed for MEDLINE]
- ☐ **95:** Tanne D, Hassin-Baer S. Related Articles, Li
 Neurologic manifestations of the antiphospholipid syndrome.
Curr Rheumatol Rep. 2001 Aug;3(4):286-92. Review.
PMID: 11470046 [PubMed - indexed for MEDLINE]
- ☐ **96:** Marcu L, Fishbein MC, Maarek JM, Grundfest WS. Related Articles, Li
 Discrimination of human coronary artery atherosclerotic lipid-rich lesions by
time-resolved laser-induced fluorescence spectroscopy.
Arterioscler Thromb Vasc Biol. 2001 Jul;21(7):1244-50.
PMID: 11451759 [PubMed - indexed for MEDLINE]
- ☐ **97:** Danton MH, Byrne JG, Flores KQ, Hsin M, Martin JS, Laurence RG, Cohn LH, Aklog L. Related Articles, Li
 Modified Glenn connection for acutely ischemic right ventricular failure
reverses secondary left ventricular dysfunction.
J Thorac Cardiovasc Surg. 2001 Jul;122(1):80-91.
PMID: 11436040 [PubMed - indexed for MEDLINE]
- ☐ **98:** Gilad R, Lampl Y, Eschel Y, Sadeh M. Related Articles, Li
 Antiepileptic treatment in patients with early postischemic stroke seizures: a
retrospective study.
Cerebrovasc Dis. 2001;12(1):39-43.
PMID: 11435678 [PubMed - indexed for MEDLINE]
- ☐ **99:** Aschoff AJ, Sulman A, Martinez M, Duerk JL, Resnick MI, MacLennan GT, Lewin JS. Related Articles, Li

-  **Perfusion-modulated MR imaging-guided radiofrequency ablation of the kidney in a porcine model.**
AJR Am J Roentgenol. 2001 Jul;177(1):151-8.
PMID: 11418417 [PubMed - indexed for MEDLINE]
- ☐ **100:** Motro M, Shemesh J. Related Articles, Li
-  **Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics.**
Hypertension. 2001 Jun;37(6):1410-3.
PMID: 11408386 [PubMed - indexed for MEDLINE]
- ☐ **101:** Birnbaum Y, Criger DA, Wagner GS, Strasberg B, Mager A, Gates K, Granger CB, Ross AM, Barbash GI. Related Articles, Li
-  **Prediction of the extent and severity of left ventricular dysfunction in anterior acute myocardial infarction by the admission electrocardiogram.**
Am Heart J. 2001 Jun;141(6):915-24.
PMID: 11376304 [PubMed - indexed for MEDLINE]
- ☐ **102:** Miyashita T, Okano Y, Takaki H, Satoh T, Kobayashi Y, Goto Y. Related Articles, Li
-  **Relation between exercise capacity and left ventricular systolic versus diastolic function during exercise in patients after myocardial infarction.**
Coron Artery Dis. 2001 May;12(3):217-25.
PMID: 11352078 [PubMed - indexed for MEDLINE]
- ☐ **103:** Viel JJ, McManus DQ, Cady C, Evans MS, Brewer GJ. Related Articles, Li
-  **Temperature and time interval for culture of postmortem neurons from adult rat cortex.**
J Neurosci Res. 2001 May 15;64(4):311-21.
PMID: 11340637 [PubMed - indexed for MEDLINE]
- ☐ **104:** Rimpilainen J, Pokela M, Kiviluoma K, Vainionpaa V, Hirvonen J, Ohtonen P, Jantti V, Anttila V, Heinonen H, Juvonen T. Related Articles, Li
-  **The N-methyl-D-aspartate antagonist memantine has no neuroprotective effect during hypothermic circulatory arrest: a study in the chronic porcine model.**
J Thorac Cardiovasc Surg. 2001 May;121(5):957-68; discussion 968-70.
PMID: 11326240 [PubMed - indexed for MEDLINE]
- ☐ **105:** Birnbaum Y. Related Articles, Li
-  **Augmentation of ultrasound-induced clot disruption by nongas-filled microparticles.**
Echocardiography. 2001 Apr;18(3):265-8. Review.
PMID: 11322910 [PubMed - indexed for MEDLINE]
- ☐ **106:** Oron U, Yaakobi T, Oron A, Hayam G, Gepstein L, Rubin O, Wolf T, Ben Haim S. Related Articles, Li
-  **Attenuation of infarct size in rats and dogs after myocardial infarction by low energy laser irradiation.**
Lasers Surg Med. 2001;28(3):204-11.
PMID: 11295753 [PubMed - indexed for MEDLINE]
- ☐ **107:** Birnbaum Y, Strasberg B. Related Articles, Li
-  **The predischARGE electrocardiographic pattern in anterior acute myocardial infarction: relation between evolutionary ST segment and T-wave configuration and prediction of myocardial infarct size and left ventricular systolic function by the QRS Selvester score.**
J Electrocardiol. 2000;33 Suppl:73-80.
PMID: 11265740 [PubMed - indexed for MEDLINE]

- ☐ **108:** Yano M, Kohno M, Kobayashi S, Obayashi M, Seki K, Ohkusa T, Miura T, Fujii T, Matsuzaki M. Related Articles, Li
 **Influence of timing and magnitude of arterial wave reflection on left ventricular relaxation.**
 Am J Physiol Heart Circ Physiol. 2001 Apr;280(4):H1846-52.
 PMID: 11247800 [PubMed - indexed for MEDLINE]
- ☐ **109:** Fisman EZ, Motro M, Tenenbaum A, Boyko V, Mandelzweig L, Behar S. Related Articles, Li
 **Impaired fasting glucose concentrations in nondiabetic patients with ischemic heart disease: a marker for a worse prognosis.**
 Am Heart J. 2001 Mar;141(3):485-90.
 PMID: 11231448 [PubMed - indexed for MEDLINE]
- ☐ **110:** Houplon P, Selton-Suty C, Grentzinger A, Preiss JP, Juilliere Y. Related Articles, Li
 **[Changes in velocity of left ventricular filling measured by color M-mode during dobutamine stress echocardiography]**
 Arch Mal Coeur Vaiss. 2000 Jan;93(1):63-9. French.
 PMID: 11227720 [PubMed - indexed for MEDLINE]
- ☐ **111:** Oron U, Yaakobi T, Oron A, Mordechovitz D, Shofti R, Hayam G, Dror U, Gepstein L, Wolf T, Haudenschield C, Haim SB. Related Articles, Li
 **Low-energy laser irradiation reduces formation of scar tissue after myocardial infarction in rats and dogs.**
 Circulation. 2001 Jan 16;103(2):296-301.
 PMID: 11208692 [PubMed - indexed for MEDLINE]
- ☐ **112:** Kuke D, Donghua L, Xiaoyan S, Yanjun Z. Related Articles, Li
 **Alteration of blood hemorheologic properties during cerebral ischemia and reperfusion in rats.**
 J Biomech. 2001 Feb;34(2):171-5.
 PMID: 11165280 [PubMed - indexed for MEDLINE]
- ☐ **113:** Donato M, Morales C, Bagnarelli A, Scapin O, Gelpi RJ. Related Articles, Li
 **[Exogenous adenosine and postischemic dysfunction in the isolated rabbit heart]**
 Medicina (B Aires). 1999;59(4):339-47. Spanish.
 PMID: 10752197 [PubMed - indexed for MEDLINE]
- ☐ **114:** Habler O, Kleen M, Podtschaske A, Hutter J, Tiede M, Kemming G, Messmer K. Related Articles, Li
 **[Acute normovolemic hemodilution (ANH). Effects of ANH on the diastolic function of the left ventricle]**
 Anaesthesist. 2000 Nov;49(11):939-48. German.
 PMID: 11151814 [PubMed - indexed for MEDLINE]
- ☐ **115:** Korolevich AN, Meglinsky IV. Related Articles, Li
 **Experimental study of the potential use of diffusing wave spectroscopy to investigate the structural characteristics of blood under multiple scattering.**
 Bioelectrochemistry. 2000 Dec;52(2):223-7.
 PMID: 11129246 [PubMed - indexed for MEDLINE]
- ☐ **116:** Tenenbaum A, Motro M, Fisman EZ, Boyko V, Mandelzweig L, Reicher-Reiss H, Graff E, Brunner D, Behar S. Related Articles, Li
 **Clinical impact of borderline and undiagnosed diabetes mellitus in patients with coronary artery disease.**
 Am J Cardiol. 2000 Dec 15;86(12):1363-6, A4-5.
 PMID: 11113414 [PubMed - indexed for MEDLINE]

- ☐ **117:** Kiernan MC, Bostock H. Related Articles, Li
 Effects of membrane polarization and ischaemia on the excitability properties of human motor axons.
 Brain. 2000 Dec;123 Pt 12:2542-51.
 PMID: 11099455 [PubMed - indexed for MEDLINE]
- ☐ **118:** Pelletier MR, Pahapill PA, Pennefather PS, Carlen PL. Related Articles, Li
 Analysis of single K(ATP) channels in mammalian dentate gyrus granule cells.
 J Neurophysiol. 2000 Nov;84(5):2291-301.
 PMID: 11067973 [PubMed - indexed for MEDLINE]
- ☐ **119:** Heininger K. Related Articles, Li
 A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events.
 Rev Neurosci. 2000;11 Spec No:213-328. Review.
 PMID: 11065271 [PubMed - indexed for MEDLINE]
- ☐ **120:** Firstenberg MS, Greenberg NL, Smedira NG, Castro P, Thomas JD, Garcia MJ. Related Articles, Li
 The effects of acute coronary occlusion on noninvasive echocardiographically derived systolic and diastolic myocardial strain rates.
 Curr Surg. 2000 Sep 1;57(5):466-472.
 PMID: 11064071 [PubMed - as supplied by publisher]
- ☐ **121:** Lukiw WJ, Bazan NG. Related Articles, Li
 Neuroinflammatory signaling upregulation in Alzheimer's disease.
 Neurochem Res. 2000 Oct;25(9-10):1173-84. Review.
 PMID: 11059791 [PubMed - indexed for MEDLINE]
- ☐ **122:** Davis GK, Millner RW, Roberts DH. Related Articles, Li
 Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function.
 Eur J Heart Fail. 2000 Sep;2(3):253-6.
 PMID: 10938484 [PubMed - indexed for MEDLINE]
- ☐ **123:** Nagashima M, Nollert G, Stock U, Sperling J, Hatsuoka S, Shum-Tim D, Takeuchi K, Nedder A, Mayer JE Jr. Related Articles, Li
 Cardiac performance after deep hypothermic circulatory arrest in chronically cyanotic neonatal lambs.
 J Thorac Cardiovasc Surg. 2000 Aug;120(2):238-46.
 PMID: 10917937 [PubMed - indexed for MEDLINE]
- ☐ **124:** Huang Y, Han L, Guo J. Related Articles, Li
 [Protective effect of selenium on human erythrocyte rheology]
 Zhonghua Yi Xue Za Zhi. 1998 Feb;78(2):101-4. Chinese.
 PMID: 10923417 [PubMed - indexed for MEDLINE]
- ☐ **125:** Nath R, Davis M, Probert AW, Kupina NC, Ren X, Schielke GP, Wang KK. Related Articles, Li
 Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells.
 Biochem Biophys Res Commun. 2000 Jul 21;274(1):16-21. Erratum in: Biochem Biophys Res Commun 2000 Sep 16;276(1):390.
 PMID: 10903889 [PubMed - indexed for MEDLINE]
- ☐ **126:** [No authors listed] Related Articles, Li



Secondary prevention by raising HDL cholesterol and reducing triglyceride in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.

Circulation. 2000 Jul 4;102(1):21-7.

PMID: 10880410 [PubMed - indexed for MEDLINE]

☐ **127:** Barbier P, Solomon S, Schiller NB, Glantz SA.

Related Articles, Li



Determinants of forward pulmonary vein flow: an open pericardium pig model.

J Am Coll Cardiol. 2000 Jun;35(7):1947-59.

PMID: 10841248 [PubMed - indexed for MEDLINE]

☐ **128:** Valeriani V, Dewar D, McCulloch J.

Related Articles, Li



Quantitative assessment of ischemic pathology in axons, oligodendrocytes, and neurons: attenuation of damage after transient ischemia.

J Cereb Blood Flow Metab. 2000 May;20(5):765-71.

PMID: 10826526 [PubMed - indexed for MEDLINE]

☐ **129:** Calvani M, Reda E, Arrigoni-Martelli E.

Related Articles, Li



Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions.

Basic Res Cardiol. 2000 Apr;95(2):75-83. Review.

PMID: 10826498 [PubMed - indexed for MEDLINE]

☐ **130:** Ikeda K, Akiyama H, Arai T, Kondo H, Haga C, Tsuchiya K, Yamada S, Murayama S, Hori A. Related Articles, Li



Neurons containing Alz-50-immunoreactive granules around the cerebral infarction: evidence for the lysosomal degradation of altered tau in human brain?

Neurosci Lett. 2000 Apr 28;284(3):187-9.

PMID: 10773430 [PubMed - indexed for MEDLINE]

☐ **131:** Weingarten MA, Katzir I, Sprecher E, Kobzantsev S, Zelzer C, Kahan E. Related Articles, Li



Diabetes and ischemic heart disease among Yemenite immigrants in Israel.

Isr Med Assoc J. 2000 Mar;2(3):207-10.

PMID: 10774268 [PubMed - indexed for MEDLINE]

☐ **132:** de Zeeuw S, Trines SA, Krams R, Verdouw PD, Duncker DJ.

Related Articles, Li



Cardiovascular profile of the calcium sensitizer EMD 57033 in open-chest anaesthetized pigs with regionally stunned myocardium.

Br J Pharmacol. 2000 Apr;129(7):1413-22.

PMID: 10742297 [PubMed - indexed for MEDLINE]

☐ **133:** Mailliot C, Podevin-Dimster V, Rosenthal RE, Sergeant N, Delacourte A, Fiskum G, Buee L. Related Articles, Li



Rapid tau protein dephosphorylation and differential rephosphorylation during cardiac arrest-induced cerebral ischemia and reperfusion.

J Cereb Blood Flow Metab. 2000 Mar;20(3):543-9.

PMID: 10724119 [PubMed - indexed for MEDLINE]

☐ **134:** Pincombe B, Mazumdar J, Hamilton-Craig I.

Related Articles, Li












Effects of multiple stenoses and post-stenotic dilatation on non-Newtonian blood flow in small arteries.










Med Biol Eng Comput. 1999 Sep;37(5):595-9.










PMID: 10723896 [PubMed - indexed for MEDLINE]










☐ **135:** Kun S, Peura RA.










Related Articles, Li










-  **Selection of measurement frequencies for optimal extraction of tissue impedance model parameters.**
Med Biol Eng Comput. 1999 Nov;37(6):699-703.
PMID: 10723875 [PubMed - indexed for MEDLINE]
- ☐ **136:** Tenenbaum A, Shemesh J, Fisman EZ, Motro M. Related Articles, Li
-  **Advanced mitral annular calcification is associated with severe coronary calcification on fast dual spiral computed tomography.**
Invest Radiol. 2000 Mar;35(3):193-8.
PMID: 10719829 [PubMed - indexed for MEDLINE]
- ☐ **137:** Kun S, Ristic B, Peura RA, Dunn RM. Related Articles, Li
-  **Real-time extraction of tissue impedance model parameters for electrical impedance spectrometer.**
Med Biol Eng Comput. 1999 Jul;37(4):428-32.
PMID: 10696697 [PubMed - indexed for MEDLINE]
- ☐ **138:** Garcia MJ, Smedira NG, Greenberg NL, Main M, Firstenberg MS, Odabashian J, Thomas JD. Related Articles, Li
-  **Color M-mode Doppler flow propagation velocity is a preload insensitive index of left ventricular relaxation: animal and human validation.**
J Am Coll Cardiol. 2000 Jan;35(1):201-8.
PMID: 10636281 [PubMed - indexed for MEDLINE]
- ☐ **139:** Sapronov NS, Torkunov PA, Eliseev VV, Krylova IB, Evdokimova NR. Related Articles, Li
-  **[The effect of a new phenylalkyl taurine derivative on the size of the necrot area in experimental myocardial infarct in rats]**
Patol Fiziol Eksp Ter. 1999 Oct-Dec(4):19-20. Russian.
PMID: 10598458 [PubMed - indexed for MEDLINE]
- ☐ **140:** Maor Y, Cohen Y, Olmer L, Mozes B. Related Articles, Li
-  **Factors associated with health indicators in patients undergoing coronary artery bypass surgery.**
Chest. 1999 Dec;116(6):1570-4.
PMID: 10593778 [PubMed - indexed for MEDLINE]
- ☐ **141:** Natale E, Tubaro M, Di Marcotullio G, Celli P, Carelli M, Malinconico U, Polizzi CA, Milazzotto F, Vajola SF. Related Articles, Li
-  **The effect of verapamil on left ventricular remodelling and diastolic function after acute myocardial infarction (the Verapamil Infarction Study on Remodelling and Relaxation--VISOR).**
Cardiovasc Drugs Ther. 1999 Jul;13(4):315-24.
PMID: 10516867 [PubMed - indexed for MEDLINE]
- ☐ **142:** Tenenbaum A, Fisman EZ, Boyko V, Goldbourt U, Auerbach I, Shemesh J, Shotan A, Reicher-Reiss H, Behar S, Motro M. Related Articles, Li
-  **Prevalence and prognostic significance of unrecognized systemic hypertension in patients with diabetes mellitus and healed myocardial infarction and/or stable angina pectoris.**
Am J Cardiol. 1999 Aug 1;84(3):294-8.
PMID: 10496438 [PubMed - indexed for MEDLINE]
- ☐ **143:** Halow JM, Figueredo VM, Shames DM, Camacho SA, Baker AJ. Related Articles, Li
-  **Role of slowed Ca(2+) transient decline in slowed relaxation during myocardial ischemia.**
J Mol Cell Cardiol. 1999 Sep;31(9):1739-48.
PMID: 10471357 [PubMed - indexed for MEDLINE]







- ☐ **144:** Calvani M, Arrigoni-Martelli E. Related Articles, Li
 **Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion.**
 Int J Tissue React. 1999;21(1):1-6. Review.
 PMID: 10463134 [PubMed - indexed for MEDLINE]
- ☐ **145:** Ohte N, Narita H, Hashimoto T, Hayano J, Akita S, Kurokawa K. Related Articles, Li
 **Differentiation of abnormal relaxation pattern with aging from abnormal relaxation pattern with coronary artery disease in transmitral flow with the use of tissue Doppler imaging of the mitral annulus.**
 J Am Soc Echocardiogr. 1999 Aug;12(8):629-35.
 PMID: 10441218 [PubMed - indexed for MEDLINE]
- ☐ **146:** Barbier P, Solomon SB, Schiller NB, Glantz SA. Related Articles, Li
 **Left atrial relaxation and left ventricular systolic function determine left atrial reservoir function.**
 Circulation. 1999 Jul 27;100(4):427-36.
 PMID: 10421605 [PubMed - indexed for MEDLINE]
- ☐ **147:** Imahashi K, Kusuoka H, Hashimoto K, Yoshioka J, Yamaguchi H, Nishimura T. Related Articles, Li
 **Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury.**
 Circ Res. 1999 Jun 25;84(12):1401-6.
 PMID: 10381892 [PubMed - indexed for MEDLINE]
- ☐ **148:** Shackelford DA, Yeh RY. Related Articles, Li
 **Dephosphorylation of tau during transient forebrain ischemia in the rat.**
 Mol Chem Neuropathol. 1998 Jun-Aug;34(2-3):103-20.
 PMID: 10327411 [PubMed - indexed for MEDLINE]
- ☐ **149:** McCully JD, Uematsu M, Levitsky S. Related Articles, Li
 **Adenosine-enhanced ischemic preconditioning provides myocardial protection equal to that of cold blood cardioplegia.**
 Ann Thorac Surg. 1999 Mar;67(3):699-704.
 PMID: 10215213 [PubMed - indexed for MEDLINE]
- ☐ **150:** Steine K, Stugaard M, Smiseth OA. Related Articles, Li
 **Mechanisms of retarded apical filling in acute ischemic left ventricular failure.**
 Circulation. 1999 Apr 20;99(15):2048-54.
 PMID: 10209011 [PubMed - indexed for MEDLINE]
- ☐ **151:** Ruppin E, Ofer E, Reggia JA, Revett K, Goodall S. Related Articles, Li
 **Pathogenic mechanisms in ischemic damage: a computational study.**
 Comput Biol Med. 1999 Jan;29(1):39-59.
 PMID: 10207654 [PubMed - indexed for MEDLINE]
- ☐ **152:** Inbal A, Freimark D, Modan B, Chetrit A, Matetzky S, Rosenberg N, Dardik R, Baron Z, Seligsohn U. Related Articles, Li
 **Synergistic effects of prothrombotic polymorphisms and atherogenic factor on the risk of myocardial infarction in young males.**
 Blood. 1999 Apr 1;93(7):2186-90.
 PMID: 10090925 [PubMed - indexed for MEDLINE]
- ☐ **153:** Birnbaum Y, Wagner GS, Barbash GI, Gates K, Criger DA, Sclarovsky S, Siegel RJ, Granger CB, Reiner JS, Ross AM. Related Articles, Li











-  Correlation of angiographic findings and right (V1 to V3) versus left (V4 to V6) precordial ST-segment depression in inferior wall acute myocardial infarction.
Am J Cardiol. 1999 Jan 15;83(2):143-8.
PMID: 10073811 [PubMed - indexed for MEDLINE]
- ☐ 154: Ambrose J, Pribnow DG, Giraud GD, Perkins KD, Muldoon L, Greenberg BH. Related Articles, Li
 Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
J Cardiovasc Pharmacol. 1999 Mar;33(3):433-9.
PMID: 10069680 [PubMed - indexed for MEDLINE]
- ☐ 155: Miyamoto MI, Rose GA, Weissman NJ, Guerrero JL, Semigran MJ, Picard MH. Related Articles, Li
 Abnormal global left ventricular relaxation occurs early during the development of pharmacologically induced ischemia.
J Am Soc Echocardiogr. 1999 Feb;12(2):113-20.
PMID: 9950970 [PubMed - indexed for MEDLINE]
- ☐ 156: Burkhart KK, Beard DC, Lehman RA, Billingsley ML. Related Articles, Li
 Alterations in tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation.
Exp Neurol. 1998 Dec;154(2):464-72.
PMID: 9878182 [PubMed - indexed for MEDLINE]
- ☐ 157: Yamamoto Y, Yamano S, Minami S, Nomura K, Fukui R, Takaoka M, Uemura S, Kawamoto A, Hashimoto T, Dohi K. Related Articles, Li
 [Carotid artery atherosclerosis in patients with myocardial infarction]
J Cardiol. 1998 Nov;32(5):307-13. Japanese.
PMID: 9864687 [PubMed - indexed for MEDLINE]
- ☐ 158: Ohte N, Narita H, Hashimoto T, Akita S, Kurokawa K, Fujinami T. Related Articles, Li
 Evaluation of left ventricular early diastolic performance by color tissue Doppler imaging of the mitral annulus.
Am J Cardiol. 1998 Dec 1;82(11):1414-7.
PMID: 9856929 [PubMed - indexed for MEDLINE]
- ☐ 159: Minger SL, Geddes JW, Holtz ML, Craddock SD, Whiteheart SW, Siman RG, Pettigrew LC. Related Articles, Li
 Glutamate receptor antagonists inhibit calpain-mediated cytoskeletal proteolysis in focal cerebral ischemia.
Brain Res. 1998 Nov 9;810(1-2):181-99.
PMID: 9813316 [PubMed - indexed for MEDLINE]
- ☐ 160: Scheinowitz M, Kotlyar A, Zimand S, Ohad D, Leibovitz I, Bloom N, Goldberg I, Nass D, Engelberg S, Savion N, Eldar M. Related Articles, Li
 Basic fibroblast growth factor induces myocardial hypertrophy following acute infarction in rats.
Exp Physiol. 1998 Sep;83(5):585-93.
PMID: 9793779 [PubMed - indexed for MEDLINE]
- ☐ 161: Morales C, Rodriguez M, Scapin O, Gelpi RJ. Related Articles, Li
 Comparison of the effects of ACE inhibition with those of angiotensin II receptor antagonism on systolic and diastolic myocardial stunning in isolate rabbit heart.
Mol Cell Biochem. 1998 Sep;186(1-2):117-21.
PMID: 9774192 [PubMed - indexed for MEDLINE]

- ☐ **162:** Li P, Kang Y, Wang GX. Related Articles, Li
 Prophylactic effects of taurine and diltiazem, alone or combined, on reperfusion arrhythmias in rats.
 Zhongguo Yao Li Xue Bao. 1996 Mar;17(2):122-4.
 PMID: 9772659 [PubMed - indexed for MEDLINE]
- ☐ **163:** Hongo M, Sentianin EM, Tanaka N, Mao L, McKirnan MD, Clark RG, Won W, Chien KR, Ross J Jr. Related Articles, Li
 Angiotensin II blockade followed by growth hormone as adjunctive therapy after experimental myocardial infarction.
 J Card Fail. 1998 Sep;4(3):213-24.
 PMID: 9754592 [PubMed - indexed for MEDLINE]
- ☐ **164:** Cain BS, Meldrum DR, Joo KS, Wang JF, Meng X, Cleveland JC Jr, Banerjee A, Harken AH. Related Articles, Li
 Human SERCA2a levels correlate inversely with age in senescent human myocardium.
 J Am Coll Cardiol. 1998 Aug;32(2):458-67.
 PMID: 9708476 [PubMed - indexed for MEDLINE]
- ☐ **165:** Chouraqui P, Livschitz S, Sharir T, Wainer N, Wilk M, Moalem I, Baron J. Related Articles, Li
 Evaluation of an attenuation correction method for thallium-201 myocardia perfusion tomographic imaging of patients with low likelihood of coronary artery disease.
 J Nucl Cardiol. 1998 Jul-Aug;5(4):369-77.
 PMID: 9715981 [PubMed - indexed for MEDLINE]
- ☐ **166:** Semb SO, Lunde PK, Holt E, Tonnessen T, Christensen G, Sejersted OM. Related Articles, Li
 Reduced myocardial Na⁺, K(+) -pump capacity in congestive heart failure following myocardial infarction in rats.
 J Mol Cell Cardiol. 1998 Jul;30(7):1311-28.
 PMID: 9710800 [PubMed - indexed for MEDLINE]
- ☐ **167:** Gelpi RJ, Morales C, Rodriguez M, Bagnarelli A, Hita A, Scapin O. Related Articles, Li
 [Effect of enalaprilat on postischemic systolic and diastolic dysfunction (stunned myocardium) on the isolated rabbit heart]
 Medicina (B Aires). 1998;58(1):22-8. Spanish.
 PMID: 9674204 [PubMed - indexed for MEDLINE]
- ☐ **168:** Maglaveras N, Van Capelle FJ, De Bakker JM. Related Articles, Li
 Wave propagation simulation in normal and infarcted myocardium: computational and modelling issues.
 Med Inform (Lond). 1998 Apr-Jun;23(2):105-18.
 PMID: 9667044 [PubMed - indexed for MEDLINE]
- ☐ **169:** Yamaguchi K, Tatsuno M, Kiuchi Y. Related Articles, Li
 Maturational change of KCl-induced Ca²⁺ increase in the rat brain synaptosomes.
 Brain Dev. 1998 Jun;20(4):234-8.
 PMID: 9661968 [PubMed - indexed for MEDLINE]
- ☐ **170:** Pai RG, Stoletniy L. Related Articles, Li
 Hemodynamic basis of mitral E transmission in the left ventricular cavity at its relation to the left ventricular relaxation process.
 Am J Cardiol. 1998 Jun 1;81(11):1385-8.
 PMID: 9631985 [PubMed - indexed for MEDLINE]

- ☐ **171:** Arstall MA, Zhao YZ, Hornberger L, Kennedy SP, Buchholz RA, Osathanondh R, Kelly RA. Related Articles, Li
 Human ventricular myocytes in vitro exhibit both early and delayed preconditioning responses to simulated ischemia.
 J Mol Cell Cardiol. 1998 May;30(5):1019-25.
 PMID: 9618242 [PubMed - indexed for MEDLINE]
- ☐ **172:** Singh Rao SK, Thomas P, Wood JD, MacMillan JC, Neal JW, Harper PS, Jones AL. Related Articles, Li
 Huntingtin protein colocalizes with lesions of neurodegenerative diseases: investigation in Huntington's, Alzheimer's, and Pick's diseases.
 Exp Neurol. 1998 Apr;150(2):213-22.
 PMID: 9527890 [PubMed - indexed for MEDLINE]
- ☐ **173:** Scheinowitz M, Abramov D, Kotlyar A, Savion N, Eldar M. Related Articles, Li
 Continuous administration of insulin-like growth factor-I and basic fibroblast growth factor does not affect left ventricular geometry after acute myocardial infarction in rats.
 Int J Cardiol. 1998 Feb 28;63(3):217-21.
 PMID: 9578347 [PubMed - indexed for MEDLINE]
- ☐ **174:** Eldar M, Canetti M, Rotstein Z, Boyko V, Gottlieb S, Kaplinsky E, Behar S. Related Articles, Li
 Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Group
 Circulation. 1998 Mar 17;97(10):965-70.
 PMID: 9529264 [PubMed - indexed for MEDLINE]
- ☐ **175:** Alegre M, Noe E, Luquin MR. Related Articles, Li
 [Pathogenesis of Alzheimer's disease]
 Rev Med Univ Navarra. 1997 Jan-Mar;41(1):46-57. Review. Spanish.
 PMID: 9527714 [PubMed - indexed for MEDLINE]
- ☐ **176:** Lo EH, Pierce AR, Matsumoto K, Kano T, Evans CJ, Newcomb R. Related Articles, Li
 Alterations in K⁺ evoked profiles of neurotransmitter and neuromodulator amino acids after focal ischemia-reperfusion.
 Neuroscience. 1998 Mar;83(2):449-58.
 PMID: 9460753 [PubMed - indexed for MEDLINE]
- ☐ **177:** Shaw RM, Rudy Y. Related Articles, Li
 Electrophysiologic effects of acute myocardial ischemia: a theoretical study altered cell excitability and action potential duration.
 Cardiovasc Res. 1997 Aug;35(2):256-72.
 PMID: 9349389 [PubMed - indexed for MEDLINE]
- ☐ **178:** de Oliveira NC, Boeve TJ, Torchiana DF, Kantor HL, Titus JS, Schmidt CJ, Lu CZ, Kim J, Daggett WM, Geffin GA. Related Articles, Li
 Ischemic intervals during warm blood cardioplegia in the canine heart evaluated by phosphorus 31-magnetic resonance spectroscopy.
 J Thorac Cardiovasc Surg. 1997 Dec;114(6):1070-9; discussion 1079-80.
 PMID: 9434702 [PubMed - indexed for MEDLINE]
- ☐ **179:** Roses AD, Saunders AM. Related Articles, Li
 ApoE, Alzheimer's disease, and recovery from brain stress.
 Ann N Y Acad Sci. 1997 Sep 26;826:200-12. Review.
 PMID: 9329691 [PubMed - indexed for MEDLINE]
- ☐ **180:** Portman MA, Panos AL, Xiao Y, Anderson DL, Alfieri GM, Ning XH, Lupinetti FM. Related Articles, Li

-  Influence of the pH of cardioplegic solutions on cellular energy metabolism and hydrogen ion flux during neonatal hypothermic circulatory arrest and reperfusion: a dynamic ³¹P nuclear magnetic resonance study in a pig model. *J Thorac Cardiovasc Surg.* 1997 Oct;114(4):601-8.
PMID: 9338646 [PubMed - indexed for MEDLINE]
- ☐ **181:** Reasoner DK, Hindman BJ, Dexter F, Subieta A, Cutkomp J, Smith T. Related Articles, Li
-  Doxycycline reduces early neurologic impairment after cerebral arterial air embolism in the rabbit.
Anesthesiology. 1997 Sep;87(3):569-76.
PMID: 9316962 [PubMed - indexed for MEDLINE]
- ☐ **182:** Green SL, Kulp KS, Vulliet R. Related Articles, Li
-  Cyclin-dependent protein kinase 5 activity increases in rat brain following ischemia.
Neurochem Int. 1997 Oct;31(4):617-23.
PMID: 9308012 [PubMed - indexed for MEDLINE]
- ☐ **183:** Vanden Hoek TL, Li C, Shao Z, Schumacker PT, Becker LB. Related Articles, Li
-  Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion.
J Mol Cell Cardiol. 1997 Sep;29(9):2571-83.
PMID: 9299379 [PubMed - indexed for MEDLINE]
- ☐ **184:** Vanden Hoek TL, Shao Z, Li C, Schumacker PT, Becker LB. Related Articles, Li
-  Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes.
J Mol Cell Cardiol. 1997 Sep;29(9):2441-50.
PMID: 9299367 [PubMed - indexed for MEDLINE]
- ☐ **185:** Irving EA, Yatsushiro K, McCulloch J, Dewar D. Related Articles, Li
-  Rapid alteration of tau in oligodendrocytes after focal ischemic injury in the rat: involvement of free radicals.
J Cereb Blood Flow Metab. 1997 Jun;17(6):612-22.
PMID: 9236718 [PubMed - indexed for MEDLINE]
- ☐ **186:** Kline JA, Raymond RM, Leonova ED, Williams TC, Watts JA. Related Articles, Li
-  Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines.
Cardiovasc Res. 1997 May;34(2):289-98.
PMID: 9205542 [PubMed - indexed for MEDLINE]
- ☐ **187:** Duval-Moulin AM, Dupouy P, Brun P, Zhuang F, Pelle G, Perez Y, Teiger E, Castaigne A, Gueret P, Dubois-Rande JL. Related Articles, Li
-  Alteration of left ventricular diastolic function during coronary angioplasty-induced ischemia: a color M-mode Doppler study.
J Am Coll Cardiol. 1997 May;29(6):1246-55.
PMID: 9137220 [PubMed - indexed for MEDLINE]
- ☐ **188:** Irving EA, McCulloch J, Dewar D. Related Articles, Li
-  The effect of postmortem delay on the distribution of microtubule-associated proteins tau, MAP2, and MAP5 in the rat.
Mol Chem Neuropathol. 1997 Apr;30(3):253-71.
PMID: 9165490 [PubMed - indexed for MEDLINE]
- ☐ **189:** Moon MR, DeAnda A, Castro LJ, Daughters GT 2nd, Ingels NB Jr, Miller DC. Related Articles, Li

-  Effects of mechanical left ventricular support on right ventricular diastolic function.
J Heart Lung Transplant. 1997 Apr;16(4):398-407.
PMID: 9154950 [PubMed - indexed for MEDLINE]
- ☐ 190: Davis CP, Schopke WD, Seifert B, Schneider E, Pfammatter T, Debatin JF. Related Articles, Li
MR angiography of patients with peripheral arterial disease before and after transluminal angioplasty.
AJR Am J Roentgenol. 1997 Apr;168(4):1027-34.
PMID: 9124109 [PubMed - indexed for MEDLINE]
-  ☐ 191: Tei C, Nishimura RA, Seward JB, Tajik AJ. Related Articles, Li
Noninvasive Doppler-derived myocardial performance index: correlation with simultaneous measurements of cardiac catheterization measurements.
J Am Soc Echocardiogr. 1997 Mar;10(2):169-78.
PMID: 9083973 [PubMed - indexed for MEDLINE]
- ☐ 192: Piasecka A, Koter M, Buczynski A, Leyko W, Kedziora J, Tkaczewski W, Bryszewska M. Related Articles, Li
Effect of perindopril therapy on fluidity and potential of erythrocyte membrane from individuals with coronary heart disease.
Scand J Clin Lab Invest. 1997 Feb;57(1):65-71.
PMID: 9127459 [PubMed - indexed for MEDLINE]
-  ☐ 193: Mogyoros I, Kiernan MC, Burke D, Bostock H. Related Articles, Li
Excitability changes in human sensory and motor axons during hyperventilation and ischaemia.
Brain. 1997 Feb;120 (Pt 2):317-25.
PMID: 9117378 [PubMed - indexed for MEDLINE]
-  ☐ 194: Sugawara M, Uchida K, Kondoh Y, Magosaki N, Niki K, Jones CJ, Sugimachi M, Sunagawa K. Related Articles, Li
Aortic blood momentum--the more the better for the ejecting heart in vivo?
Cardiovasc Res. 1997 Feb;33(2):433-46.
PMID: 9074709 [PubMed - indexed for MEDLINE]
- ☐ 195: Green HJ, McKee NH, Carvalho AJ, Phillips SM. Related Articles, Li
Reductions in sarcoplasmic reticulum Ca²⁺ ATPase activity in rat skeletal muscles of different fibre composition with ischemia and reperfusion.
Can J Physiol Pharmacol. 1997 Jan;75(1):78-82.
PMID: 9101069 [PubMed - indexed for MEDLINE]
-  ☐ 196: Goldbourt U, Yaari S, Medalie JH. Related Articles, Li
Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.
Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):107-13.
PMID: 9012644 [PubMed - indexed for MEDLINE]
- ☐ 197: Moreyra AE, Conway RS, Wilson AC, Chen WH, Schmidling MJ, Kostis JB. Related Articles, Li
Attenuation of myocardial stunning in isolated rat hearts by a 21-aminosteroid (U74389G).
J Cardiovasc Pharmacol. 1996 Nov;28(5):659-64.
PMID: 8945679 [PubMed - indexed for MEDLINE]
-  ☐ 198: Pettigrew LC, Holtz ML, Craddock SD, Minger SL, Hall N, Geddes JW. Related Articles, Li
Microtubular proteolysis in focal cerebral ischemia.

-  J Cereb Blood Flow Metab. 1996 Nov;16(6):1189-202.
PMID: 8898691 [PubMed - indexed for MEDLINE]
- ☐ **199:** Gatewood LB, Larson DF, Bowers MC, Bond S, Cardy A, Sethi GK, Copeland JG. Related Articles, Li
A novel mechanism for cyclosporine: inhibition of myocardial ischemia and reperfusion injury in a heterotopic rabbit heart transplant model.
J Heart Lung Transplant. 1996 Sep;15(9):936-47.
PMID: 8889990 [PubMed - indexed for MEDLINE]
-  A novel mechanism for cyclosporine: inhibition of myocardial ischemia and reperfusion injury in a heterotopic rabbit heart transplant model.
J Heart Lung Transplant. 1996 Sep;15(9):936-47.
PMID: 8889990 [PubMed - indexed for MEDLINE]
- ☐ **200:** Pierpaoli C, Alger JR, Righini A, Mattiello J, Dickerson R, Des Pres D, Barnett A, Di Chiro G. Related Articles, Li
High temporal resolution diffusion MRI of global cerebral ischemia and reperfusion.
J Cereb Blood Flow Metab. 1996 Sep;16(5):892-905.
PMID: 8784233 [PubMed - indexed for MEDLINE]
-  High temporal resolution diffusion MRI of global cerebral ischemia and reperfusion.
J Cereb Blood Flow Metab. 1996 Sep;16(5):892-905.
PMID: 8784233 [PubMed - indexed for MEDLINE]
- ☐ **201:** Irving EA, Nicoll J, Graham DI, Dewar D. Related Articles, Li
Increased tau immunoreactivity in oligodendrocytes following human stroke and head injury.
Neurosci Lett. 1996 Aug 9;213(3):189-92.
PMID: 8873146 [PubMed - indexed for MEDLINE]
-  Increased tau immunoreactivity in oligodendrocytes following human stroke and head injury.
Neurosci Lett. 1996 Aug 9;213(3):189-92.
PMID: 8873146 [PubMed - indexed for MEDLINE]
- ☐ **202:** Irving EA, McCulloch J, Dewar D. Related Articles, Li
Intracortical perfusion of glutamate in vivo induces alterations of tau and microtubule-associated protein 2 immunoreactivity in the rat.
Acta Neuropathol (Berl). 1996 Aug;92(2):186-96.
PMID: 8841665 [PubMed - indexed for MEDLINE]
-  Intracortical perfusion of glutamate in vivo induces alterations of tau and microtubule-associated protein 2 immunoreactivity in the rat.
Acta Neuropathol (Berl). 1996 Aug;92(2):186-96.
PMID: 8841665 [PubMed - indexed for MEDLINE]
- ☐ **203:** Kern KB, Hilwig RW, Rhee KH, Berg RA. Related Articles, Li
Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning.
J Am Coll Cardiol. 1996 Jul;28(1):232-40.
PMID: 8752819 [PubMed - indexed for MEDLINE]
-  Myocardial dysfunction after resuscitation from cardiac arrest: an example of global myocardial stunning.
J Am Coll Cardiol. 1996 Jul;28(1):232-40.
PMID: 8752819 [PubMed - indexed for MEDLINE]
- ☐ **204:** Kersten JR, Lowe D, Hettrick DA, Pagel PS, Gross GJ, Wartier DC. Related Articles, Li
Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium.
Anesth Analg. 1996 Jul;83(1):27-33.
PMID: 8659760 [PubMed - indexed for MEDLINE]
-  Glyburide, a KATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium.
Anesth Analg. 1996 Jul;83(1):27-33.
PMID: 8659760 [PubMed - indexed for MEDLINE]
- ☐ **205:** Vinet A, Cardinal R, LeFranc P, Helie F, Rocque P, Kus T, Page P. Related Articles, Li
Cycle length dynamics and spatial stability at the onset of postinfarction monomorphic ventricular tachycardias induced in patients and canine preparations.
Circulation. 1996 May 15;93(10):1845-59.
PMID: 8635264 [PubMed - indexed for MEDLINE]
-  Cycle length dynamics and spatial stability at the onset of postinfarction monomorphic ventricular tachycardias induced in patients and canine preparations.
Circulation. 1996 May 15;93(10):1845-59.
PMID: 8635264 [PubMed - indexed for MEDLINE]
- ☐ **206:** Dupouy P, Geschwind H, Pelle G, Aptekar E, Hittinger L, El Ghalid A, Dubois-Rande JL. Related Articles, Li
Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans.
J Am Coll Cardiol. 1996 May;27(6):1374-80.
PMID: 8626946 [PubMed - indexed for MEDLINE]
-  Repeated coronary artery occlusions during routine balloon angioplasty do not induce myocardial preconditioning in humans.
J Am Coll Cardiol. 1996 May;27(6):1374-80.
PMID: 8626946 [PubMed - indexed for MEDLINE]
- ☐ **207:** Sladek T, Sladkova J, Kolar F, Papousek F, Cicutti N, Korecky B, Rakusan K. Related Articles, Li
The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery occlusion in the rat.
-  The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery occlusion in the rat.

artery ligation in rats.

Cardiovasc Res. 1996 Apr;31(4):568-76.

PMID: 8689648 [PubMed - indexed for MEDLINE]

- ☐ **208:** Dalmas S, Marsch SC, Philbin DM, Gavaghan DJ, Ryder WA, Foex P. Related Articles, Li



Effects and interactions of myocardial ischaemia and alterations in circulatory blood volume on canine left ventricular diastolic function.

Br J Anaesth. 1996 Mar;76(3):419-27.

PMID: 8785145 [PubMed - indexed for MEDLINE]

- ☐ **209:** Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Related Articles, Li



Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group.

Arterioscler Thromb Vasc Biol. 1996 Mar;16(3):351-6.

PMID: 8630658 [PubMed - indexed for MEDLINE]

- ☐ **210:** Pessotto P, Liberati R, Petrella O, Hulsmann WC. Related Articles, Li



Quaternary nitrogen compounds affect carnitine distribution in rats. Particular emphasis on edrophonium.

Biochim Biophys Acta. 1996 Jan 19;1299(2):245-51.

PMID: 8555270 [PubMed - indexed for MEDLINE]

- ☐ **211:** Gleitz J, Tosch C, Beile A, Peters T. Related Articles, Li



The protective action of tetrodotoxin and (+/-)-kavain on anaerobic glycolysis, ATP content and intracellular Na⁺ and Ca²⁺ of anoxic brain vesicles.

Neuropharmacology. 1996;35(12):1743-52.

PMID: 9076753 [PubMed - indexed for MEDLINE]

- ☐ **212:** Moreyra AE, Carriquiriborde M, Mosca SM. Related Articles, Li



Protective effect of nifedipine on myocardial stunning in isolated rabbit hearts: role of high energy phosphates stores.

Arch Physiol Biochem. 1996;104(3):265-71.

PMID: 8793016 [PubMed - indexed for MEDLINE]

- ☐ **213:** Wang YL, He RR. Related Articles, Li



Effects of dipfluzine on cortical somatosensory evoked potentials and amino acid contents in ischemic rat brain.

Zhongguo Yao Li Xue Bao. 1996 Jan;17(1):41-4.

PMID: 8737451 [PubMed - indexed for MEDLINE]

- ☐ **214:** Schipke JD, Korbmacher B, Dorszewski A, Selcan G, Sunderdiek U, Arnold G. Related Articles, Li



Haemodynamic and energetic properties of stunned myocardium in rabbit hearts.

Heart. 1996 Jan;75(1):55-61.

PMID: 8624873 [PubMed - indexed for MEDLINE]

- ☐ **215:** Shackelford DA, Nelson KE. Related Articles, Li













Changes in phosphorylation of tau during ischemia and reperfusion in the rabbit spinal cord.










J Neurochem. 1996 Jan;66(1):286-95.










PMID: 8522966 [PubMed - indexed for MEDLINE]










- ☐ **216:** Candinas R, Mayer IV, Heywood JT, Hu Z, Hess OM. Related Articles, Li

Influence of exercise induced myocardial ischemia on right ventricular dP/c

-  potential implications for rate responsive pacing.
Pacing Clin Electrophysiol. 1995 Dec;18(12 Pt 1):2121-7.
PMID: 8771122 [PubMed - indexed for MEDLINE]
- ☐ **217:** Chang Q, Natelson BH, Ottenweller JE, Conway RS. Related Articles, Li
 Stress triggers different pathophysiological mechanisms in younger and old cardiomyopathic hamsters.
Cardiovasc Res. 1995 Dec;30(6):985-91.
PMID: 8746215 [PubMed - indexed for MEDLINE]
- ☐ **218:** Aggarwal R, Boyden PA. Related Articles, Li
 Diminished Ca²⁺ and Ba²⁺ currents in myocytes surviving in the epicardia border zone of the 5-day infarcted canine heart.
Circ Res. 1995 Dec;77(6):1180-91.
PMID: 7586231 [PubMed - indexed for MEDLINE]
- ☐ **219:** Santos PE, Barcellos LC, Mill JG, Masuda MO. Related Articles, Li
 Ventricular action potential and L-type calcium channel in infarct-induced hypertrophy in rats.
J Cardiovasc Electrophysiol. 1995 Nov;6(11):1004-14.
PMID: 8589869 [PubMed - indexed for MEDLINE]
- ☐ **220:** Pagel PS, Hettrick DA, Lowe D, Tessmer JP, Warltier DC. Related Articles, Li
 Desflurane and isoflurane exert modest beneficial actions on left ventricular diastolic function during myocardial ischemia in dogs.
Anesthesiology. 1995 Nov;83(5):1021-35.
PMID: 7486153 [PubMed - indexed for MEDLINE]
- ☐ **221:** Uchihara T, Tsuchiya K, Kondo H, Hayama T, Ikeda K. Related Articles, Li
 Widespread appearance of Alz-50 immunoreactive neurons in the human brain with cerebral infarction.
Stroke. 1995 Nov;26(11):2145-8.
PMID: 7482663 [PubMed - indexed for MEDLINE]
- ☐ **222:** Shander GS, Fan Z, Makielski JC. Related Articles, Li
 Slowly recovering cardiac sodium current in rat ventricular myocytes: effect of conditioning duration and recovery potential.
J Cardiovasc Electrophysiol. 1995 Oct;6(10 Pt 1):786-95.
PMID: 8542075 [PubMed - indexed for MEDLINE]
- ☐ **223:** Tamiya K, Beppu T, Ishihara K. Related Articles, Li
 Double-exponential curve fitting of isometric relaxation: a new measure for myocardial lusitropism.
Am J Physiol. 1995 Aug;269(2 Pt 2):H393-406.
PMID: 7653603 [PubMed - indexed for MEDLINE]
- ☐ **224:** Dewar D, Dawson D. Related Articles, Li
 Tau protein is altered by focal cerebral ischaemia in the rat: an immunohistochemical and immunoblotting study.
Brain Res. 1995 Jun 26;684(1):70-8.
PMID: 7583206 [PubMed - indexed for MEDLINE]
- ☐ **225:** Caldarone CA, Krukenkamp IB, Burns PG, Gaudette GR, Schulman J, Levitsky S. Related Articles, Li
 Blood cardioplegia in the senescent heart.
J Thorac Cardiovasc Surg. 1995 Feb;109(2):269-74.
PMID: 7853880 [PubMed - indexed for MEDLINE]

- ☐ **226:** Mahaffey KW, Raya TE, Pennock GD, Morkin E, Goldman S. Related Articles, Li
 Left ventricular performance and remodeling in rabbits after myocardial infarction. Effects of a thyroid hormone analogue.
 Circulation. 1995 Feb 1;91(3):794-801.
 PMID: 7828308 [PubMed - indexed for MEDLINE]
- ☐ **227:** Peschechera A, Ferrari LE, Arrigoni-Martelli E, Hulsmann WC. Related Articles, Li
 Uptake and release of carnitine by vascular endothelium in culture; effects of protons and oxygen free radicals.
 Mol Cell Biochem. 1995 Jan 26;142(2):99-106.
 PMID: 7770071 [PubMed - indexed for MEDLINE]
- ☐ **228:** Moran MA, Probst A, Navarro C, Gomez-Ramos P. Related Articles, Li
 Alzheimer's disease-type neurofibrillary degeneration in verrucose dysplasia of the cerebral cortex.
 Acta Neuropathol (Berl). 1995;90(4):356-65.
 PMID: 8546026 [PubMed - indexed for MEDLINE]
- ☐ **229:** Masuyama T, Uematsu M, Doi Y, Yamamoto K, Mano T, Naito J, Kondo H, Nagano R, Hori M, Kamada T. Related Articles, Li
 Abnormal coronary flow dynamics at rest and during tachycardia associated with impaired left ventricular relaxation in humans: implication for tachycardia-induced myocardial ischemia.
 J Am Coll Cardiol. 1994 Dec;24(7):1625-32.
 PMID: 7963107 [PubMed - indexed for MEDLINE]
- ☐ **230:** Marsch SC, Dalmas S, Philbin DM, Wanigasekera VA, Ryder WA, Wong LS, Foex P. Related Articles, Li
 Post-ischemic diastolic dysfunction.
 J Cardiothorac Vasc Anesth. 1994 Dec;8(6):611-7.
 PMID: 7880987 [PubMed - indexed for MEDLINE]
- ☐ **231:** Zhang J, Niu X. Related Articles, Li
 Changes of monoamines, purines and amino acids in rat striatum as measured by intercerebral microdialysis during ischemia/reperfusion.
 Chin Med Sci J. 1994 Dec;9(4):225-9.
 PMID: 7718861 [PubMed - indexed for MEDLINE]
- ☐ **232:** Cannon MB, Vine AJ, Kantor HL, Lahorra JA, Nickell SA, Hahn C, Allyn JW, Teplick RS, Titus JS, Torchiana DF, et al. Related Articles, Li
 Warm and cold blood cardioplegia. Comparison of myocardial function and metabolism using 31p magnetic resonance spectroscopy.
 Circulation. 1994 Nov;90(5 Pt 2):II328-38.
 PMID: 7955275 [PubMed - indexed for MEDLINE]
- ☐ **233:** Navon G, Werrmann JG, Maron R, Cohen SM. Related Articles, Li
 31P NMR and triple quantum filtered 23Na NMR studies of the effects of inhibition of Na⁺/H⁺ exchange on intracellular sodium and pH in working and ischemic hearts.
 Magn Reson Med. 1994 Nov;32(5):556-64.
 PMID: 7808256 [PubMed - indexed for MEDLINE]
- ☐ **234:** Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R. Related Articles, Li
 Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus.
 J Neurosci. 1994 Sep;14(9):5373-80.
 PMID: 8083742 [PubMed - indexed for MEDLINE]

- ☐ **235:** Moreyra AE, Gelpi RJ, Mosca SM, Cingolani HE. Related Articles, Li
 Chronic administration of nicardipine attenuates myocardial stunning in isolated rabbit hearts.
 J Mol Cell Cardiol. 1994 Aug;26(8):979-84.
 PMID: 7799452 [PubMed - indexed for MEDLINE]
- ☐ **236:** Geddes JW, Schwab C, Craddock S, Wilson JL, Pettigrew LC. Related Articles, Li
 Alterations in tau immunostaining in the rat hippocampus following transie cerebral ischemia.
 J Cereb Blood Flow Metab. 1994 Jul;14(4):554-64.
 PMID: 7516935 [PubMed - indexed for MEDLINE]
- ☐ **237:** Zmudka K, Dubiel J, Vanhaecke J, Flameng W, De Geest H. Related Articles, Li
 Effects of oral pretreatment with metoprolol on left ventricular wall motion infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion.
 Cardiovasc Drugs Ther. 1994 Jun;8(3):479-87.
 PMID: 7947365 [PubMed - indexed for MEDLINE]
- ☐ **238:** Dewar D, Graham DI, Teasdale GM, McCulloch J. Related Articles, Li
 Cerebral ischemia induces alterations in tau and ubiquitin proteins.
 Dementia. 1994 May-Aug;5(3-4):168-73.
 PMID: 8087173 [PubMed - indexed for MEDLINE]
- ☐ **239:** Aureli T, Miccheli A, Di Cocco ME, Ghirardi O, Giuliani A, Ramacci MT, Conti F. Related Articles, Li
 Effect of acetyl-L-carnitine on recovery of brain phosphorus metabolites an lactic acid level during reperfusion after cerebral ischemia in the rat--study 13P- and 1H-NMR spectroscopy.
 Brain Res. 1994 Apr 18;643(1-2):92-9.
 PMID: 8032936 [PubMed - indexed for MEDLINE]
- ☐ **240:** Caldarone CA, Krukenkamp IB, Burns PG, Misare BD, Gaudette GR, Levitsky S. Related Articles, Li
 Ischemia-dependent efficacy of phosphodiesterase inhibition.
 Ann Thorac Surg. 1994 Mar;57(3):540-5.
 PMID: 8147619 [PubMed - indexed for MEDLINE]
- ☐ **241:** Camacho SA, Brandes R, Figueredo VM, Weiner MW. Related Articles, Li
 Ca²⁺ transient decline and myocardial relaxation are slowed during low flo ischemia in rat hearts.
 J Clin Invest. 1994 Mar;93(3):951-7.
 PMID: 8132781 [PubMed - indexed for MEDLINE]
- ☐ **242:** Sparks DL, Danner FW, Davis DG, Hackney C, Landers T, Coyne CM. Related Articles, Li
 Neurochemical and histopathologic alterations characteristic of Pick's disea in a non-demented individual.
 J Neuropathol Exp Neurol. 1994 Jan;53(1):37-42.
 PMID: 8301318 [PubMed - indexed for MEDLINE]
- ☐ **243:** Fehske W, Niedeggen A, Omran H, Pizzulli L, Manz M, Luderitz B. Related Articles, Li
 [Effect of nisoldipine and diltiazem on systolic and diastolic function of the left ventricle in patients with coronary heart disease]
 Z Kardiol. 1994 Jan;83(1):50-9. German.
 PMID: 8147070 [PubMed - indexed for MEDLINE]

- ☐ **244:** Perlini S, Meyer TE, Bernardi L, Solda P, Calciati A, Finardi G, Foex P. Related Articles, Li
 [During experimental coronary occlusion dobutamine further slows down the time constant of isovolumetric relaxation]
 Cardiologia. 1994 Jan;39(1):33-9. Italian.
 PMID: 8020054 [PubMed - indexed for MEDLINE]
- ☐ **245:** Vesci L, Mattera GG, Botarelli M, Tobia P, Corsico N, Martelli EA. Related Articles, Li
 Decreased density of endothelin binding sites in adrenal glands but not in aorta, of long term infarcted rats.
 Life Sci. 1994;55(22):PL421-4.
 PMID: 7968244 [PubMed - indexed for MEDLINE]
- ☐ **246:** Haciyakupoglu S, Ildan F, Polat S, Cetinalp E, Boyar B, Kaya M. Related Articles, Li
 Effect of GSH on cerebral vasospasm in dogs.
 Neurosurg Rev. 1994;17(4):283-9.
 PMID: 7753417 [PubMed - indexed for MEDLINE]
- ☐ **247:** Ardissino D, Merlini PA, Kubica J, Bramucci E, Barberis P, Eleuteri E, Colombi E, Angoli L, Specchia G, Montemartini C. Related Articles, Li
 Assessment of left ventricular function by isometric handgrip exercise after thrombolysis in patients with refractory unstable angina.
 Am J Cardiol. 1993 Dec 16;72(19):140G-144G.
 PMID: 8279351 [PubMed - indexed for MEDLINE]
- ☐ **248:** Stugaard M, Smiseth OA, Risoe C, Ihlen H. Related Articles, Li
 Intraventricular early diastolic filling during acute myocardial ischemia, assessment by multigated color m-mode Doppler echocardiography.
 Circulation. 1993 Dec;88(6):2705-13.
 PMID: 8252682 [PubMed - indexed for MEDLINE]
- ☐ **249:** Ten Cate FJ, Widimsky P, Cornel JH, Waldstein DJ, Serruys PW, Waaler A. Related Articles, Li
 Intracoronary albumin. Its effects on left ventricular hemodynamics, function and coronary sinus flow in humans.
 Circulation. 1993 Nov;88(5 Pt 1):2123-7.
 PMID: 8222106 [PubMed - indexed for MEDLINE]
- ☐ **250:** Rice T, Sprecher DL, Borecki IB, Mitchell LE, Laskarzewski PM, Rao DC. Related Articles, Li
 The Cincinnati Myocardial Infarction and Hormone Family Study: family resemblance for dehydroepiandrosterone sulfate in control and myocardial infarction families.
 Metabolism. 1993 Oct;42(10):1284-90.
 PMID: 8412740 [PubMed - indexed for MEDLINE]
- ☐ **251:** Pennock GD, Raya TE, Bahl JJ, Goldman S, Morkin E. Related Articles, Li
 Combination treatment with captopril and the thyroid hormone analogue 3,3'-diiodothyropropionic acid. A new approach to improving left ventricular performance in heart failure.
 Circulation. 1993 Sep;88(3):1289-98.
 PMID: 8353891 [PubMed - indexed for MEDLINE]
- ☐ **252:** Barletta G, Di Donato M, Fantini F, Baroni M. Related Articles, Li
 Effects of positive inotropic stimulation (post-extrasystolic potentiation) on non-uniformity of left ventricular contraction in patients with coronary artery disease.
 Eur Heart J. 1993 Aug;14(8):1056-64.

- ☐ **253:** Elliott EM, Mattson MP, Vanderklish P, Lynch G, Chang I, Sapolsky RM. Related Articles, Li
Corticosterone exacerbates kainate-induced alterations in hippocampal tau immunoreactivity and spectrin proteolysis in vivo.
J Neurochem. 1993 Jul;61(1):57-67.
PMID: 8515288 [PubMed - indexed for MEDLINE]
- ☐ **254:** Hein HO, Suadicani P, Gyntelberg F. Related Articles, Li
[Social inequalities as a risk of ischemic heart disease--a matter of smoking habits? 17 years' follow-up in the Copenhagen Male Study]
Ugeskr Laeger. 1993 Jun 21;155(25):1935-9. Danish.
PMID: 8317056 [PubMed - indexed for MEDLINE]
- ☐ **255:** Byrne JG, Murphy MP, Smith WJ, Couper GS, Appleyard RF, Cohn LH. Related Articles, Li
Prevention of CD18-mediated reperfusion injury enhances the efficacy of U solution for 15-hr heart preservation.
J Surg Res. 1993 Jun;54(6):625-30.
PMID: 8105148 [PubMed - indexed for MEDLINE]
- ☐ **256:** Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH. Related Articles, Li
Stability of time-tradeoff utilities in survivors of myocardial infarction.
Med Decis Making. 1993 Apr-Jun;13(2):161-5.
PMID: 8483401 [PubMed - indexed for MEDLINE]
- ☐ **257:** Micheletti R, Di Paola ED, Schiavone A, English E, Benatti P, Capasso JM, Anversa P, Bianchi G. Related Articles, Li
Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats.
Am J Physiol. 1993 Apr;264(4 Pt 2):H1111-7.
PMID: 8476087 [PubMed - indexed for MEDLINE]
- ☐ **258:** Dewar D, Graham DI, Teasdale GM, McCulloch J. Related Articles, Li
Alz-50 and ubiquitin immunoreactivity is induced by permanent focal cerebral ischaemia in the cat.
Acta Neuropathol (Berl). 1993;86(6):623-9.
PMID: 8310818 [PubMed - indexed for MEDLINE]
- ☐ **259:** Baur LH, Schipperheyn JJ, Cats VM, van der Wall EE, Baan J, van Dijk AD, Bruschke AV. Related Articles, Li
Left ventricular filling after long-term angiotensin converting enzyme inhibition in congestive heart failure.
Eur Heart J. 1992 Nov;13 Suppl E:52-6.
PMID: 1478210 [PubMed - indexed for MEDLINE]
- ☐ **260:** Wiesfeld AC, Remme WJ, Look MP, Kruijssen DA, van Hoogenhuyze DC. Related Articles, Li
Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol.
Am J Cardiol. 1992 Oct 15;70(11):997-1003.
PMID: 1414918 [PubMed - indexed for MEDLINE]
- ☐ **261:** Jiang D. Related Articles, Li
[Mechanism of neuronal damage caused by cerebral ischemia]
Zhonghua Yi Xue Za Zhi. 1992 Aug;72(8):487-90, 510-1. Chinese.
PMID: 1337725 [PubMed - indexed for MEDLINE]

- ☐ **262:** Kikuchi J, Koiwa Y, Takagi T, Honda H, Hoshi N, Butler JP, Takishima T. Related Articles, Li
Effects of mechanical vibration on left ventricular diastolic properties during global ischemia.
Am J Physiol. 1992 Jul;263(1 Pt 2):H88-95.
PMID: 1636776 [PubMed - indexed for MEDLINE]
- ☐ **263:** Hein HO, Suadicani P, Gyntelberg F. Related Articles, Li
Ischaemic heart disease incidence by social class and form of smoking: the Copenhagen Male Study--17 years' follow-up.
J Intern Med. 1992 May;231(5):477-83.
PMID: 1602285 [PubMed - indexed for MEDLINE]
- ☐ **264:** Simari RD, Bell MR, Schwartz RS, Nishimura RA, Holmes DR Jr. Related Articles, Li
Ventricular relaxation and myocardial ischemia: a comparison of different models of tau during coronary angioplasty.
Cathet Cardiovasc Diagn. 1992 Apr;25(4):278-84.
PMID: 1571988 [PubMed - indexed for MEDLINE]
- ☐ **265:** Bohm M. Related Articles, Li
Improved isovolumetric relaxation in canine reperfused myocardium after beta 1 adrenergic stimulation.
Cardiovasc Res. 1992 Mar;26(3):273-8.
PMID: 1358444 [PubMed - indexed for MEDLINE]
- ☐ **266:** Naruse H, Itano M, Kondo T, Kogame T, Yamamoto J, Morita M, Kawamoto H, Fukutake N, Ohyanagi M, Iwasaki T, et al. Related Articles, Li
[Myocardial imaging in acute myocardial infarction using beta-methyl-p-(123I)-iodophenylpentadecanoic acid: comparison with 201Tl imaging and wall motion]
Kaku Igaku. 1992 Jan;29(1):77-84. Japanese.
PMID: 1578823 [PubMed - indexed for MEDLINE]
- ☐ **267:** Calvin JE. Related Articles, Li
Right ventricular diastolic function after experimental right ventricular infarction: effects independent of the pericardium.
Clin Invest Med. 1991 Aug;14(4):346-54.
PMID: 1782733 [PubMed - indexed for MEDLINE]
- ☐ **268:** Aureli T, Miccheli A, Ramacci MT, Conti F. Related Articles, Li
Transient cerebral ischemia in the rat: a study by nuclear magnetic resonance spectroscopy.
Ital J Neurol Sci. 1991 Jun;12(3 Suppl 11):39-43.
PMID: 1757221 [PubMed - indexed for MEDLINE]
- ☐ **269:** Benndorf K, Friedrich M, Hirche H. Related Articles, Li
Reoxygenation-induced arrhythmogenic transient inward currents in isolate cells of the guinea-pig heart.
Pflugers Arch. 1991 Apr;418(3):248-60.
PMID: 1857634 [PubMed - indexed for MEDLINE]
- ☐ **270:** Vandeplassche G, Hermans C, Wouters L, Borgers M. Related Articles, Li
Effects of R 56,865, a preventer of cellular calcium overload, on left ventricular diastolic properties during pacing-induced ischemia in dogs.
J Cardiovasc Pharmacol. 1991 Apr;17(4):621-6.
PMID: 1711630 [PubMed - indexed for MEDLINE]

☐ 271: Leasure JE, Kordenat K. Related Articles, Li



Effect of propionyl-L-carnitine on experimental myocardial infarction in dogs.

Cardiovasc Drugs Ther. 1991 Feb;5 Suppl 1:85-95.

PMID: 2031876 [PubMed - indexed for MEDLINE]

☐ 272: Bell MR, Nishimura RA, Holmes DR Jr, Bailey KR, Schwartz RS, Vlietstra RE. Related Articles, Li



Does intracoronary infusion of Fluosol-DA 20% prevent left ventricular diastolic dysfunction during coronary balloon angioplasty?

J Am Coll Cardiol. 1990 Oct;16(4):959-66.

PMID: 2212378 [PubMed - indexed for MEDLINE]

☐ 273: Kushner M, Nencini P, Reivich M, Rango M, Jamieson D, Fazekas F, Zimmerman R, Chawluk J, Alavi A, Alves W. Related Articles, Li



Relation of hyperglycemia early in ischemic brain infarction to cerebral anatomy, metabolism, and clinical outcome.

Ann Neurol. 1990 Aug;28(2):129-35.

PMID: 2221843 [PubMed - indexed for MEDLINE]

☐ 274: Bunzel B, Grundbock A, Laczkovics A, Holzinger C. Related Articles, Li



[Surgical success following heart transplantation in relation to preoperative status]

Wien Klin Wochenschr. 1990 Jun 22;102(13):375-8. German.

PMID: 2382445 [PubMed - indexed for MEDLINE]

☐ 275: Boyden PA, Dresdner KP Jr. Related Articles, Li



Electrogenic Na(+)-K+ pump in Purkinje myocytes isolated from control noninfarcted and infarcted hearts.

Am J Physiol. 1990 Mar;258(3 Pt 2):H766-72.

PMID: 2156455 [PubMed - indexed for MEDLINE]

☐ 276: Miyazaki S, Guth BD, Miura T, Indolfi C, Schulz R, Ross J Jr. Related Articles, Li



Changes of left ventricular diastolic function in exercising dogs without and with ischemia.

Circulation. 1990 Mar;81(3):1058-70.

PMID: 2407371 [PubMed - indexed for MEDLINE]

☐ 277: Farhi ER, Canty JM Jr, Klocke FJ. Related Articles, Li



Effects of graded reductions in coronary perfusion pressure on the diastolic pressure-segment length relation and the rate of isovolumic relaxation in the resting conscious dog.

Circulation. 1989 Nov;80(5):1458-68.

PMID: 2805277 [PubMed - indexed for MEDLINE]

☐ 278: Dawson JR, Gibson DG. Related Articles, Li



Left ventricular filling and early diastolic function at rest and during angina patients with coronary artery disease.

Br Heart J. 1989 Mar;61(3):248-57.

PMID: 2930663 [PubMed - indexed for MEDLINE]

☐ 279: Stoddard MF, Pearson AC, Kern MJ, Ratcliff J, Mrosek DG, Labovitz AJ. Related Articles, Li



Left ventricular diastolic function: comparison of pulsed Doppler echocardiographic and hemodynamic indexes in subjects with and without coronary artery disease.

J Am Coll Cardiol. 1989 Feb;13(2):327-36.

- ☐ **280:** Uwatoko M, Miyagi Y, Nomura M, Shiga Y, Koike A, Tateishi R, Mitsuguchi F, Mano K, Hishida H, Mizuno Y. Related Articles, Li



[Evaluation of coronary blood flow using digital subtraction technique and cine coronary angiography: a preliminary report]

J Cardiol. 1988 Jun;18(2):279-90. Japanese.

PMID: 2977791 [PubMed - indexed for MEDLINE]

- ☐ **281:** Courtois MR, Kurnik PB, Ludbrook PA. Related Articles, Li



Sensitivity of isovolumic relaxation to hypothermia during myocardial infarction.

J Am Coll Cardiol. 1988 Jan;11(1):201-6.

PMID: 3335699 [PubMed - indexed for MEDLINE]

- ☐ **282:** Naumov VG, Grigor'iants RA, Al-Shaer AM, Firsov NN, Khodzhakuliev BG. Related Articles, Li



[Blood rheologic properties in patients with dilated cardiomyopathy]

Biull Vsesoiuznogo Kardiolog Nauchn Tsentra AMN SSSR. 1988;11(2):9-12. Russian.

PMID: 3233159 [PubMed - indexed for MEDLINE]

- ☐ **283:** Katritsis D, Lythall DA, Cooper IC, Crowther A, Webb-Peploe MM. Related Articles, Li



Assessment of coronary angioplasty: comparison of visual assessment, hand held caliper measurement and automated digital quantitation.

Cathet Cardiovasc Diagn. 1988;15(4):237-42.

PMID: 2976306 [PubMed - indexed for MEDLINE]

- ☐ **284:** Fukuyama H, Kameyama M. Related Articles, Li



[Internal neurology--a. Trends in the study of dementia and cerebrovascular disorders]

Nippon Rinsho. 1987 Sep;45(9):2125-32. Japanese. No abstract available.

PMID: 2892955 [PubMed - indexed for MEDLINE]

- ☐ **285:** Doyle RL, Foex P, Ryder WA, Jones LA. Related Articles, Li



Differences in ischaemic dysfunction after gradual and abrupt coronary occlusion: effects on isovolumic relaxation.

Cardiovasc Res. 1987 Jul;21(7):507-14.

PMID: 3677140 [PubMed - indexed for MEDLINE]

- ☐ **286:** Voelker W, Mauser M, Kimmig A, Hoffmeister HM, Overkamp D, Karsch KR. Related Articles, Li



[Effect of rapid atrial pacing on left ventricular ejection fraction in patients without organic heart disease]

Z Kardiolog. 1987 Apr;76(4):223-30. German.

PMID: 3604375 [PubMed - indexed for MEDLINE]

- ☐ **287:** Snow TR. Related Articles, Li



A study of the effects of substrates on intracellular pH in toad ventricular strips.

J Mol Cell Cardiol. 1986 Jul;18(7):723-32.

PMID: 3091840 [PubMed - indexed for MEDLINE]

- ☐ **288:** Paschen W, Sato M, Pawlik G, Umbach C, Heiss WD. Related Articles, Li



Neurologic deficit, blood flow and biochemical sequelae of reversible focal cerebral ischemia in cats.

J Neurol Sci. 1985 May;68(2-3):119-34.

PMID: 4009201 [PubMed - indexed for MEDLINE]

Parker JA, Markis JE, Royal HD.

☐ 289:

[Related Articles](#), [Li](#)



Assessment of regional wall motion and perfusion by multigated myocardial scintigraphy after intracoronary Tl-201.

Radiology. 1985 Mar;154(3):783-6.

PMID: 3969484 [PubMed - indexed for MEDLINE]

☐ 290: [Chaturani P](#), [Samy RP](#).

[Related Articles](#), [Li](#)



A study of non-Newtonian aspects of blood flow through stenosed arteries and its applications in arterial diseases.

Biorheology. 1985;22(6):521-31.

PMID: 3834958 [PubMed - indexed for MEDLINE]

☐ 291: [Sato M](#), [Paschen W](#), [Pawlik G](#), [Heiss WD](#).

[Related Articles](#), [Li](#)



Neurologic deficit and cerebral ATP depletion after temporary focal ischemia in cats.

J Cereb Blood Flow Metab. 1984 Jun;4(2):173-7.

PMID: 6725429 [PubMed - indexed for MEDLINE]

Display Show:

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56

Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:24:37 ON 16 NOV 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'ANABSTR' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:24:46 ON 16 NOV 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 17:24:46 ON 16 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'CAPLUS' ENTERED AT 17:24:46 ON 16 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 17:24:46 ON 16 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'FOMAD' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'HEALSAFE' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetic Chemists

FILE 'LIFESCI' ENTERED AT 17:24:46 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'MEDLINE' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 17:24:46 ON 16 NOV 2004

Compiled and distributed by the NTIS, U.S. Department of Commerce.

It contains copyrighted material.

All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 17:24:46 ON 16 NOV 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 17:24:46 ON 16 NOV 2004

Any reproduction or dissemination in part or in full,

by means of any process and on any support whatsoever

is prohibited without the prior written agreement of INIST-CNRS.

COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 17:24:46 ON 16 NOV 2004

Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 17:24:46 ON 16 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 17:24:46 ON 16 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:24:46 ON 16 NOV 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 17:24:46 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 17:24:46 ON 16 NOV 2004

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s tau
30 FILES SEARCHED...
65 FILES SEARCHED...
L1 270352 TAU

=> S anoxia OR ischemia
33 FILES SEARCHED...
66 FILES SEARCHED...
L2 898483 ANOXIA OR ISCHEMIA

=> S CSF OR cerebrospinal fluid
15 FILES SEARCHED...
32 FILES SEARCHED...
65 FILES SEARCHED...
L3 640103 CSF OR CEREBROSPINAL FLUID

=> S L1 AND L2 AND L3
44 FILES SEARCHED...
L4 366 L1 AND L2 AND L3

=> DUP REM L4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5 312 DUP REM L4 (54 DUPLICATES REMOVED)

=> D L5 1-312

L5 ANSWER 1 OF 312 MEDLINE on STN
AN 2004212496 MEDLINE
DN PubMed ID: 15111447
TI Normal pressure hydrocephalus (NPH): ischaemia, ***CSF*** stagnation
or both.
CM Comment on: Brain. 2004 May;127(Pt 5):965-72. PubMed ID: 15033897
AU Silverberg Gerald D
SO Brain; a journal of neurology, (2004 May) 127 (Pt 5) 947-8.
Journal code: 0372537. ISSN: 0006-8950.
CY England: United Kingdom
DT Commentary
Editorial
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200406
ED Entered STN: 20040428
Last Updated on STN: 20040624
Entered Medline: 20040621

L5 ANSWER 2 OF 312 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 1
AN 2004-14350 BIOTECHDS
TI Diagnosing or monitoring disease/condition e.g., multiple sclerosis by
measuring target marker such as truncated disease-associated protein in
sample and determining if quantity of target marker is indicative of
presence/absence of disease;
monoclonal antibody for specific protein detection for use in disease
diagnosis
AU BAR-OR D; BAR-OR R
PA DMI BIOSCIENCES INC
PI WO 2004030522 15 Apr 2004
AI WO 2003-US31226 2 Oct 2003
PRAI US 2003-503185 15 Sep 2003; US 2002-415908 2 Oct 2002
DT Patent
LA English
OS WPI: 2004-356992 [33]

L5 ANSWER 3 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2
AN 2004:513138 CAPLUS

TI Markers and test devices for symptom-based differential diagnosis and
 methods of use thereof
 IN Buechler, Kenneth F.; Maisel, Alan
 PA Biosite Inc., USA
 SO U.S. Pat. Appl. Publ., 42 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004121343	A1	20040624	US 2002-330696	20021227
	US 2004203083	A1	20041014	US 2003-728067	20031203
	WO 2004059293	A2	20040715	WO 2003-US41453	20031223
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-436301P	P	20021224		
	US 2001-835298	A2	20010413		
	US 2001-288871P	P	20010504		
	US 2001-313775P	P	20010820		
	US 2001-315642P	P	20010828		
	US 2001-334964P	P	20011130		
	US 2002-346485P	P	20020102		
	US 2002-139086	A2	20020504		
	US 2002-225082	A2	20020820		
	US 2002-330696	A2	20021227		
	US 2003-371149	A	20030220		
	US 2003-603891	A2	20030624		
	US 2003-673077	A	20030926		
	US 2003-714078	A	20031114		

L5 ANSWER 4 OF 312 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3

AN 10702137 IFIPAT;IFIUDB;IFICDB
 TI DIAGNOSIS AND MONITORING OF DISEASES
 IN Bar-Or David; Bar-Or Raphael
 PA Unassigned Or Assigned To Individual (68000)
 PI US 2004209379 A1 20041021
 AI US 2003-679699 20031002
 PRAI US 2002-415908P 20021002 (Provisional)
 US 2003-489039P 20030721 (Provisional)
 US 2003-503185P 20030915 (Provisional)
 FI US 2004209379 20041021
 DT Utility; Patent Application - First Publication
 FS CHEMICAL APPLICATION

CLMN 46

GI 5 Figure(s).

FIG. 1: Printout from a mass spectrometer. The sample was recombinant beta-human chorionic gonadotropin processed by liquid chromatography followed by mass spectrometry.
 FIG. 2: Printout from a mass spectrometer. The sample was a plasma sample from a pregnant woman (patient 4) processed by liquid chromatography followed by mass spectrometry.
 FIG. 3: Printout from a mass spectrometer. The sample was recombinant erythropoietin processed by liquid chromatography followed by mass spectrometry.
 FIG. 4: Printout from a mass spectrometer. The sample was a plasma sample from a pregnant woman (patient 4) processed by liquid chromatography followed by mass spectrometry.
 FIG. 5: A clustering dendrogram.

L5 ANSWER 5 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:570130 CAPLUS

DN 141:119811

TI Markers for differential diagnosis and methods of use thereof
 IN Buechler, Kenneth F.; Maisel, Alan; Anderberg, Joseph Michael; Mcpherson,

PA Biosite Incorporated, USA
SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004059293	A2	20040715	WO 2003-US41453	20031223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004121343	A1	20040624	US 2002-330696	20021227
	US 2003199000	A1	20031023	US 2003-371149	20030220
	US 2004209307	A1	20041021	US 2003-673077	20030926
	US 2004219509	A1	20041104	US 2003-714078	20031114
PRAI	US 2002-436301P	P	20021224		
	US 2002-330696	A	20021227		
	US 2003-371149	A	20030220		
	US 2003-603891	A	20030624		
	US 2003-673077	A	20030926		
	US 2003-714078	A	20031114		
	US 2001-313775P	P	20010820		
	US 2001-334964P	P	20011130		
	US 2002-346485P	P	20020102		
	US 2002-225082	A2	20020820		
	WO 2002-US26604	A2	20020820		

L5 ANSWER 6 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:565091 CAPLUS
DN 141:99726
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
IN Gervais, Francine; Bellini, Francesco
PA Neurochem International Limited, Switz.
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058258	A1	20040715	WO 2003-CA2011	20031224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-436379P	P	20021224		
	US 2003-482214P	P	20030623		
OS	MARPAT 141:99726				

L5 ANSWER 7 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:565074 CAPLUS
DN 141:99725
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing 3 different types of agents
IN Gervais, Francine; Bellini, Francesco
PA Neurochem International Limited, Switz.
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2

LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004058239	A1	20040715	WO 2003-CA2021	20031224
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2002-436379P	P	20021224		
	US 2003-482214P	P	20030623		
OS	MARPAT 141:99725				

L5 ANSWER 8 OF 312 USPATFULL on STN
AN 2004:287884 USPATFULL
TI Compositions and methods for treating neurological disorders and diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul, Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2004226056 A1 20041111
AI US 2004-776013 A1 20040209 (10)
RLI Continuation-in-part of Ser. No. US 2001-948904, filed on 10 Sep 2001, ABANDONED Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2001-975072, filed on 12 Oct 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-194967, filed on 15 Jul 2002, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 12774
INCL INCLM: 800/012.000
NCL NCLM: 800/012.000
IC [7]
ICM: A01K067-00

L5 ANSWER 9 OF 312 USPATFULL on STN
AN 2004:286945 USPATFULL
TI Keratinocyte derived interferon
IN LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PI US 2004225113 A1 20041111
AI US 2002-197816 A1 20020912 (10)
RLI Continuation-in-part of Ser. No. US 2001-908594, filed on 20 Jul 2001, GRANTED, Pat. No. US 6472512 Continuation-in-part of Ser. No. US 2000-487792, filed on 20 Jan 2000, GRANTED, Pat. No. US 6433145 Continuation-in-part of Ser. No. WO 2000-US1239, filed on 20 Jan 2000, PENDING Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US16424, filed on 21 Jul 1999, PENDING Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999, ABANDONED
PRAI US 2001-336165P 20011206 (60)
US 2001-292934P 20010524 (60)
US 2000-219621P 20000721 (60)
US 1998-93643P 19980721 (60)
US 1998-93643P 19980721 (60)
DT Utility
FS APPLICATION
LN.CNT 16223
INCL INCLM: 530/351.000
NCL NCLM: 530/351.000

L5 ANSWER 10 OF 312 USPATFULL on STN
 AN 2004:286784 USPATFULL
 TI Fused bicyclic-substituted amines as histamine-3 receptor ligands
 IN Cowart, Marlon D., Round Lake Beach, IL, UNITED STATES
 Ku, Yi-Yin, Buffalo Grove, IL, UNITED STATES
 Chang, Sou-Jen, Prairie View, IL, UNITED STATES
 Fernando, Dilinie P., Gurnee, IL, UNITED STATES
 Grieme, Timothy A., Chicago, IL, UNITED STATES
 Altenbach, Robert J., Chicago, IL, UNITED STATES
 PI US 2004224952 A1 20041111
 AI US 2003-431152 A1 20030507 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 3694
 INCL INCLM: 514/249.000
 INCLS: 514/301.000; 514/302.000; 544/350.000; 546/114.000; 546/115.000
 NCL NCLM: 514/249.000
 NCLS: 514/301.000; 514/302.000; 544/350.000; 546/114.000; 546/115.000
 IC [7]
 ICM: C07D491-02
 ICS: C07D498-02; A61K031-498; A61K031-4745

L5 ANSWER 11 OF 312 USPATFULL on STN
 AN 2004:286776 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors
 IN Bebbington, David, Newbury Berkshire, UNITED KINGDOM
 Binch, Hayley, Harwell, UNITED KINGDOM
 Knegetel, Ronald, Abingdom, UNITED KINGDOM
 Golec, Julian, Swinden Wilts, UNITED KINGDOM
 Patel, Sanjay, Abingdom, UNITED KINGDOM
 Charrier, Jean-Damien, Southam, UNITED KINGDOM
 Kay, David, Church Path, UNITED KINGDOM
 Davies, Robert, Arlington, MA, UNITED STATES
 Li, Pan, Arlington, MA, UNITED STATES
 Wannamaker, Marion, Stow, MA, UNITED STATES
 Forster, Cornelia, Pelham, NH, UNITED STATES
 Pierce, Albert, Somerville, MA, UNITED STATES
 PI US 2004224944 A1 20041111
 AI US 2003-624800 A1 20030722 (10)
 RLI Division of Ser. No. US 2001-952671, filed on 14 Sep 2001, GRANTED, Pat.
 No. US 6660731
 PRAI US 2000-232795P 20000915 (60)
 US 2000-257887P 20001221 (60)
 US 2001-286949P 20010427 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8533
 INCL INCLM: 514/227.500
 INCLS: 514/235.500; 514/252.190; 514/275.000; 544/060.000; 544/122.000;
 544/295.000; 544/331.000
 NCL NCLM: 514/227.500
 NCLS: 514/235.500; 514/252.190; 514/275.000; 544/060.000; 544/122.000;
 544/295.000; 544/331.000
 IC [7]
 ICM: A61K031-541
 ICS: A61K031-5377; A61K031-506; C07D043-14; C07D413-14; C07D417-14

L5 ANSWER 12 OF 312 USPATFULL on STN
 AN 2004:285862 USPATFULL
 TI Compositions and methods for treating or preventing diseases of body
 IN Hunter, William L., Vancouver, CANADA
 Machan, Lindsay S., Vancouver, CANADA
 PA ANGIOTECH PHARMACEUTICALS, INC., Vancouver, CANADA, V6A 1B6 (non-U.S.
 corporation)
 THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver, CANADA, V6T 1Z3 (non-U.S.
 corporation)
 PI US 2004224023 A1 20041111
 AI US 2003-671327 A1 20030925 (10)
 RLI Continuation of Ser. No. US 2001-933652, filed on 20 Aug 2001, GRANTED,
 Pat. No. US 6759431 Continuation of Ser. No. US 1996-653207, filed on 24
 May 1996, ABANDONED
 DT Utility

LN.CNT 4774
INCL INCLM: 424/486.000
NCL NCLM: 424/486.000
IC [7]
ICM: A61K009-14

L5 ANSWER 13 OF 312 USPATFULL on STN
AN 2004:280899 USPATFULL
TI Compositions useful as protein kinase inhibitors
IN Maltais, Francois, Tewksbury, MA, UNITED STATES
Aronov, Alex, Watertown, MA, UNITED STATES
Hale, Michael R., Bedford, MA, UNITED STATES
Moon, Young-Choon, Belle Meade, NJ, UNITED STATES
PI US 2004220200 A1 20041104
AI US 2004-798766 A1 20040311 (10)
PRAI US 2003-454405P 20030313 (60)
DT Utility
FS APPLICATION

LN.CNT 2447
INCL INCLM: 514/269.000
INCLS: 514/275.000; 514/343.000; 544/331.000; 546/276.400
NCL NCLM: 514/269.000
NCLS: 514/275.000; 514/343.000; 544/331.000; 546/276.400
IC [7]
ICM: C07D043-02
ICS: A61K031-513; A61K031-506

L5 ANSWER 14 OF 312 USPATFULL on STN
AN 2004:280209 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use thereof
IN Valkirs, Gunars E., Escondido, CA, UNITED STATES
Dahlen, Jeffrey R., San Diego, CA, UNITED STATES
Kirchick, Howard J., San Diego, CA, UNITED STATES
Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PA Biosite, Inc. (U.S. corporation)
PI US 2004219509 A1 20041104
AI US 2003-714078 A1 20031114 (10)
RLI Continuation-in-part of Ser. No. US 2003-673077, filed on 26 Sep 2003,
PENDING Continuation-in-part of Ser. No. US 2003-371149, filed on 20 Feb
2003, PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on
20 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225082,
filed on 20 Aug 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
DT Utility
FS APPLICATION
LN.CNT 5344
INCL INCLM: 435/004.000
INCLS: 435/007.210
NCL NCLM: 435/004.000
NCLS: 435/007.210
IC [7]
ICM: C12Q001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 312 USPATFULL on STN
AN 2004:274315 USPATFULL
TI Diaminotriazoles useful as inhibitors of protein kinases
IN Pierce, Albert C., Cambridge, MA, UNITED STATES
Amost, Michael, North Andover, MA, UNITED STATES
Davies, Robert J., Arlington, MA, UNITED STATES
Forster, Cornelia J., Pelham, NH, UNITED STATES
Galullo, Vincent, South Grafton, MA, UNITED STATES
Grey, Ronald, JR., Cambridge, MA, UNITED STATES
Ledeboer, Mark, Acton, MA, UNITED STATES
Tian, Shi-Kai, Waltham, MA, UNITED STATES
Xu, Jinwang, Framingham, MA, UNITED STATES
Binch, Hayley, Harwell, UNITED KINGDOM
Ledford, Brian, Attleboro, MA, UNITED STATES
Messersmith, David, Somerville, MA, UNITED STATES

Jayaraj, Andrew, Needham, MA, UNITED STATES
Henkel, Greg, Carlsbad, CA, UNITED STATES
Salituro, Francesco G., Marlboro, MA, UNITED STATES
Wang, Jian, Newton, MA, UNITED STATES

PI US 2004214817 A1 20041028
AI US 2003-715111 A1 20031117 (10)
PRAI US 2002-426681P 20021115 (60)
US 2003-447705P 20030211 (60)

DT Utility
FS APPLICATION
LN.CNT 11848
INCL INCLM: 514/217.090
INCLS: 514/227.500; 514/235.800; 514/254.050; 514/326.000; 514/383.000;
544/060.000; 544/132.000; 544/366.000; 546/208.000; 548/264.800

NCL NCLM: 514/217.090
NCLS: 514/227.500; 514/235.800; 514/254.050; 514/326.000; 514/383.000;
544/060.000; 544/132.000; 544/366.000; 546/208.000; 548/264.800

IC [7]
ICM: C07D417-02
ICS: C07D413-02; C07D043-02; A61K031-55; A61K031-541; A61K031-5377;
A61K031-4196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 312 USPATFULL on STN
AN 2004:274312 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Golec, Julian, Swindon, UNITED KINGDOM
Miller, Andrew, Didcot, UNITED KINGDOM
Knegtel, Ronald, Abingdon, UNITED KINGDOM

PI US 2004214814 A1 20041028
AI US 2001-26992 A1 20011219 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)

DT Utility
FS APPLICATION
LN.CNT 8610
INCL INCLM: 514/217.060
INCLS: 514/227.800; 514/235.800; 514/252.190; 514/275.000; 540/601.000;
544/060.000; 544/295.000; 544/328.000

NCL NCLM: 514/217.060
NCLS: 514/227.800; 514/235.800; 514/252.190; 514/275.000; 540/601.000;
544/060.000; 544/295.000; 544/328.000

IC [7]
ICM: A61K031-55
ICS: A61K031-541; A61K031-5377; A61K031-506; C07D417-14; C07D413-14;
C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 312 USPATFULL on STN
AN 2004:267766 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use
thereof
IN Valkirs, Gunars, Escondido, CA, UNITED STATES
Dahlen, Jeffrey, San Diego, CA, UNITED STATES
Kirchick, Howard, San Diego, CA, UNITED STATES
Buechler, Kenneth F., San Diego, CA, UNITED STATES

PA Biosite Incorporated (U.S. corporation)
PI US 2004209307 A1 20041021
AI US 2003-673077 A1 20030926 (10)

RLI Continuation-in-part of Ser. No. US 2003-371149, filed on 20 Feb 2003,
PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20
Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-225082, filed
on 20 Aug 2002, PENDING

PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)

DT Utility
FS APPLICATION
LN.CNT 5149
INCL INCLM: 435/007.100

IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 312 USPATFULL on STN
AN 2004:267337 USPATFULL
TI Combination therapy with co-stimulatory factors
IN Khare, Sanjay D., Newbury Park, CA, UNITED STATES
PI US 2004208874 A1 20041021
AI US 2003-748112 A1 20031229 (10)
PRAI US 2002-437405P 20021230 (60)
DT Utility
FS APPLICATION
LN.CNT 5149
INCL INCLM: 424/145.100
INCLS: 514/012.000
NCL NCLM: 424/145.100
NCLS: 514/012.000

IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 312 USPATFULL on STN
AN 2004:260600 USPATFULL
TI Kinases and phosphatases
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Lee, Ernestine A, Kensington, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Becha, Shanya D, San Francisco, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Gururajan, Rajagopal, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Arvizu, Chandra S, San Diego, CA, UNITED STATES
Luo, Wen, San Diego, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Gandhi, Ameena E, San Francisco, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Borowsky, Mark L, Needham, MA, UNITED STATES
Zebardjian, Yeganeh, San Francisco, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Marquis, Joseph P, San Jose, CA, UNITED STATES
Chien, David, Davis, CA, UNITED STATES
Jin, Pei, Palo Alto, CA, UNITED STATES
PI US 2004203097 A1 20041014
AI US 2003-478146 A1 20031118 (10)
WO 2002-US16634 20020523
PRAI US 2001-293665P 20010524 (60)
US 2001-298712P 20010615 (60)
US 2001-303418P 20010706 (60)
US 2001-306967P 20010719 (60)
US 2001-308183P 20010727 (60)
US 2001-343007P 20011219 (60)
US 2002-357675P 20020215 (60)
US 2002-376988P 20020430 (60)
DT Utility
FS APPLICATION
LN.CNT 8063
INCL INCLM: 435/069.100
INCLS: 435/194.000; 435/196.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/194.000; 435/196.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 312 USPATFULL on STN
AN 2004:260586 USPATFULL
TI Use of thrombus precursor protein and monocyte chemoattractant protein
as diagnostic and prognostic indicators in vascular diseases
IN Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
Maisel, Alan, Solana Beach, CA, UNITED STATES
PA Biosite, Inc. (U.S. corporation)
PI US 2004203083 A1 20041014
AI US 2003-728067 A1 20031203 (10)
RLI Continuation-in-part of Ser. No. US 2003-603891, filed on 24 Jun 2003,
PENDING Continuation-in-part of Ser. No. US 2002-330696, filed on 27 Dec
2002, PENDING Continuation-in-part of Ser. No. US 2002-139086, filed on
4 May 2002, PENDING Continuation-in-part of Ser. No. US 2001-835298,
filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US
2002-225082, filed on 20 Aug 2002, PENDING
PRAI US 2002-436301P 20021224 (60)
US 2001-288871P 20010504 (60)
US 2001-315642P 20010828 (60)
US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
DT Utility
FS APPLICATION
LN.CNT 3527
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 312 USPATFULL on STN
AN 2004:260517 USPATFULL
TI Neurotransmission-associated proteins
IN Honchell, Cynthia D., San Francisco, CA, UNITED STATES
Warren, Bridget A., San Marcos, CA, UNITED STATES
Borowsky, Mark L., Needham, MA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Li, Joana X., Millbrae, CA, UNITED STATES
Lee, Soo Yeun, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Forsythe, Ian J., Edmonton, CANADA
Marquis, Joseph P., San Jose, CA, UNITED STATES
Gietzen, Kimberly J., San Jose, CA, UNITED STATES
Baughn, Mariah R., Los Angeles, CA, UNITED STATES
Tran, Uyen K., San Jose, CA, UNITED STATES
Lehr-Mason, Patricia M., Morgan Hill, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Emerling, Brooke M., Chicago, IL, UNITED STATES
Lee, Ernestine A., Kensington, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Hafalia, April J.A., Daly City, CA, UNITED STATES
Duggan, Brendan M., Sunnyvale, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Kable, Amy E., Silver Spring, MD, UNITED STATES
Chang, Hsin-Ru, Belmont, CA, UNITED STATES
Khare, Reena, Saratoga, CA, UNITED STATES
Becha, Shanya D., San Francisco, CA, UNITED STATES
Jin, Pei, Palo Alto, CA, UNITED STATES
Lee, Sally, San Jose, CA, UNITED STATES
PI US 2004203014 A1 20041014
AI US 2004-489372 A1 20040312 (10)
WO 2002-US29219 20020912
PRAI US 2001-60322180 20010914
US 2001-60326096 20010928
US 2001-60327446 20011004
US 2001-60345837 20011026
US 2001-60343903 20011102
US 2001-60334020 20011127
US 2001-60340226 20011207
US 2002-60345008 20020104
US 2002-60365645 20020318

DT Utility
FS APPLICATION
LN.CNT 10849
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N015-00; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 312 USPATFULL on STN
AN 2004:255220 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Green, Jeremy, Burlington, MA, UNITED STATES
Aronov, Alex, Watertown, MA, UNITED STATES
Pierce, Albert C., Cambridge, MA, UNITED STATES
PI US 2004198750 A1 20041007
AI US 2004-808678 A1 20040325 (10)
PRAI US 2003-460042P 20030403 (60)
DT Utility
FS APPLICATION
LN.CNT 3285
INCL INCLM: 514/260.100
INCLS: 514/302.000; 514/456.000; 544/279.000; 546/114.000; 549/403.000
NCL NCLM: 514/260.100
NCLS: 514/302.000; 514/456.000; 544/279.000; 546/114.000; 549/403.000
IC [7]
ICM: C07D491-02
ICS: A61K031-519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 312 USPATFULL on STN
AN 2004:255120 USPATFULL
TI Means for inhibiting proteolytical processing of parkin
IN Jensen, Poul, Højbjerg, DENMARK
PI US 2004198650 A1 20041007
AI US 2004-473226 A1 20040412 (10)
WO 2002-DK221 20020402
PRAI DK 2001-525 20010329
US 2001-281286P 20010403 (60)
DT Utility
FS APPLICATION
LN.CNT 2714
INCL INCLM: 514/012.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.500
NCL NCLM: 514/012.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
536/023.500
IC [7]
ICM: A61K038-17
ICS: C12Q001-68; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 312 USPATFULL on STN
AN 2004:254344 USPATFULL
TI Human tumor necrosis factor receptor TR9
IN Ni, Jian, Germantown, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Fan, Ping, Rockville, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte-Mg, BRAZIL
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.
corporation)
PI US 2004197870 A1 20041007
AI US 2004-834966 A1 20040430 (10)
RLI Division of Ser. No. US 2002-41574, filed on 10 Jan 2002, PENDING
Division of Ser. No. US 2000-527236, filed on 16 Mar 2000, GRANTED, Pat.
No. US 6358508 Continuation-in-part of Ser. No. US 1998-95094, filed on
10 Jun 1998, PENDING
PRAI US 1999-134220P 19990514 (60)
US 1999-126019P 19990324 (60)
US 1997-52991P 19970611 (60)
DT Utility

LN.CNT 9555
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-715
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 312 USPATFULL on STN
AN 2004:254292 USPATFULL
TI MinK-related genes, formation of potassium channels and association with
cardiac arrhythmia
IN Splawski, Igor, Alston, MA, UNITED STATES
Keating, Mark T., Brookline, MA, UNITED STATES
Abbott, Geoffrey W., New Haven, CT, UNITED STATES
Sesti, Federico, New Haven, CT, UNITED STATES
Goldstein, Steve A. N., Guilford, CT, UNITED STATES
PA The University of Utah Research Foundation, Salt Lake City, UT (U.S.
corporation)
Yale University, New Haven, CT (U.S. corporation)
PI US 2004197818 A1 20041007
AI US 2004-842558 A1 20040511 (10)
RLI Division of Ser. No. US 2000-550163, filed on 14 Apr 2000, PENDING
PRAI US 1999-129404P 19990415 (60)
DT Utility
FS APPLICATION
LN.CNT 4323
INCL INCLM: 435/006.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000; 530/350.000
NCL NCLM: 435/006.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000; 530/350.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 312 USPATFULL on STN
AN 2004:248096 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Green, Jeremy, Burlington, MA, UNITED STATES
Grey, Ronald, JR., Cambridge, MA, UNITED STATES
Pierce, Albert C., Cambridge, MA, UNITED STATES
PI US 2004192696 A1 20040930
AI US 2003-738956 A1 20031217 (10)
PRAI WO 2003-US39990 20031217
US 2002-435124P 20021218 (60)
DT Utility
FS APPLICATION
LN.CNT 2397
INCL INCLM: 514/248.000
INCLS: 514/227.800; 514/234.500; 544/060.000; 544/236.000; 544/117.000
NCL NCLM: 514/248.000
NCLS: 514/227.800; 514/234.500; 544/060.000; 544/236.000; 544/117.000
IC [7]
ICM: C07D417-02
ICS: C07D487-04; A61K031-541; A61K031-5377; A61K031-503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 312 USPATFULL on STN
AN 2004:248091 USPATFULL
TI Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the
use thereof
IN Hogenkamp, Derk J., Carlsbad, CA, UNITED STATES
Nguyen, Phong, Placentia, CA, UNITED STATES
Shao, Bin, Richboro, PA, UNITED STATES
PA Euro-Celtique S.A. (U.S. corporation)
PI US 2004192691 A1 20040930
AI US 2003-738989 A1 20031219 (10)
RLI Division of Ser. No. US 2001-803659, filed on 12 Mar 2001, PENDING
PRAI US 2000-188188P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 2431

INCLS: 514/252.100; 514/256.000; 544/182.000; 544/333.000; 544/405.000;
514/255.050
NCL NCLM: 514/242.000
NCLS: 514/252.100; 514/256.000; 544/182.000; 544/333.000; 544/405.000;
514/255.050
IC [7]
ICM: A61K031-53
ICS: A61K031-497; A61K031-505
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 312 USPATFULL on STN
AN 2004:248082 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Green, Jeremy, Burlington, MA, UNITED STATES
Grey, Ronald, Cambridge, MA, UNITED STATES
Pierce, Albert C., Cambridge, MA, UNITED STATES
PI US 2004192682 A1 20040930
AI US 2004-772219 A1 20040204 (10)
PRAI WO 2004-US3061 20040204
US 2003-445529P 20030206 (60)
DT Utility
FS APPLICATION
LN.CNT 1928
INCL INCLM: 514/227.800
INCLS: 514/234.500; 514/248.000; 544/060.000; 544/117.000; 544/236.000
NCL NCLM: 514/227.800
NCLS: 514/234.500; 514/248.000; 544/060.000; 544/117.000; 544/236.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-503; C07D487-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 312 USPATFULL on STN
AN 2004:240304 USPATFULL
TI 4-Substituted-5-cyano-1H-pyrimidin-6-(thi) ones as GSK-3 inhibitors
IN Moon, Young-Choon, Belle Meade, NJ, UNITED STATES
PI US 2004186119 A1 20040923
AI US 2004-799507 A1 20040312 (10)
PRAI US 2003-454878P 20030312 (60)
DT Utility
FS APPLICATION
LN.CNT 1732
INCL INCLM: 514/269.000
INCLS: 544/314.000
NCL NCLM: 514/269.000
NCLS: 544/314.000
IC [7]
ICM: A61K031-513
ICS: C07D239-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 312 USPATFULL on STN
AN 2004:240300 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Ledebor, Mark, Action, MA, UNITED STATES
Davies, Robert J., Arlington, MA, UNITED STATES
Messersmith, David, Somerville, MA, UNITED STATES
Moon, Young-Choon, Belle Mead, NJ, UNITED STATES
Mullican, Michael D., Needham, MA, UNITED STATES
PI US 2004186115 A1 20040923
AI US 2003-738965 A1 20031217 (10)
PRAI WO 2003-US39989 20031217
US 2002-434880P 20021218 (60)
DT Utility
FS APPLICATION
LN.CNT 2181
INCL INCLM: 514/260.100
INCLS: 514/275.000; 514/302.000; 544/279.000; 544/331.000
NCL NCLM: 514/260.100
NCLS: 514/275.000; 514/302.000; 544/279.000; 544/331.000
IC [7]
ICM: A61K031-519
ICS: A61K031-506; A61K031-4745; C07D491-02; C07D413-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2004:239705 USPATFULL
TI HSC70 directed diagnostics and therapeutics for multidrug resistant
neoplastic disease
IN Georges, Elias, Laval, CANADA
Serfass, Lucile, Montreal, CANADA
Bonneau, Anne-Marie, Laval, CANADA
Dallaire, Frederic, Montreal, CANADA
PA Aurelium BioPharma, Inc. (non-U.S. corporation)
PI US 2004185511 A1 20040923
AI US 2003-737350 A1 20031215 (10)
PRAI US 2003-438012P 20030103 (60)
DT Utility
FS APPLICATION
LN.CNT 5612
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 312 USPATFULL on STN
AN 2004:233832 USPATFULL
TI Anti-inflammatory medicaments
IN Flynn, Daniel L., Lawrence, KS, UNITED STATES
Petillo, Peter A., Arlington, MA, UNITED STATES
PI US 2004180906 A1 20040916
AI US 2003-746460 A1 20031224 (10)
PRAI US 2002-437487P 20021231 (60)
US 2002-437403P 20021231 (60)
US 2002-437415P 20021231 (60)
US 2002-437304P 20021231 (60)
DT Utility
FS APPLICATION
LN.CNT 2786
INCL INCLM: 514/256.000
INCLS: 514/340.000; 514/365.000; 514/374.000; 514/396.000; 514/406.000;
514/422.000
NCL NCLM: 514/256.000
NCLS: 514/340.000; 514/365.000; 514/374.000; 514/396.000; 514/406.000;
514/422.000
IC [7]
ICM: A61K031-505
ICS: A61K031-444; A61K031-4439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 312 USPATFULL on STN
AN 2004:229002 USPATFULL
TI Methods and compositions for the identification and treatment of
neurodegenerative disorders
IN Botas, Juan, Houston, TX, UNITED STATES
Zoghbi, Huda, Houston, TX, UNITED STATES
Fernandez-Funez, Pedro, Houston, TX, UNITED STATES
PA Baylor College of Medicine (U.S. corporation)
PI US 2004177388 A1 20040909
AI US 2002-291871 A1 20021108 (10)
RLI Continuation of Ser. No. US 2001-17761, filed on 29 Oct 2001, ABANDONED
PRAI US 2000-244101P 20001027 (60)
DT Utility
FS APPLICATION
LN.CNT 5191
INCL INCLM: 800/008.000
NCL NCLM: 800/008.000
IC [7]
ICM: A01K067-033

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 34 OF 312 USPATFULL on STN
AN 2004:228528 USPATFULL
TI Methods and compositions for measuring biologically active natriuretic
peptides and for improving their therapeutic potential
IN Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
Whittaker, Michael, San Diego, CA, UNITED STATES
PA Biosite Incorporated (U.S. corporation)
PI US 2004176914 A1 20040909
AI US 2003-645874 A1 20030820 (10)

PENDING Continuation-in-part of Ser. No. US 2001-835298, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2002-139086, filed on 4 May 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20 Aug 2002, PENDING

PRAI US 2001-288871P 20010504 (60)
US 2001-315642P 20010828 (60)
US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)

DT Utility
FS APPLICATION

LN.CNT 2809

INCL INCLM: 702/019.000
INCLS: 435/007.100

NCL NCLM: 702/019.000
NCLS: 435/007.100

IC [7]

ICM: G01N033-53

ICS: G06F019-00; G01N033-48; G01N033-50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 312 USPATFULL on STN

AN 2004:227906 USPATFULL

TI Methods and compositions for enhancing cognitive function using morphogenic proteins

IN Charette, Marc F., Needham, MA, UNITED STATES

PI US 2004176292 A1 20040909

AI US 2003-734472 A1 20031212 (10)

RLI Division of Ser. No. US 1998-12846, filed on 23 Jan 1998, PENDING

DT Utility

FS APPLICATION

LN.CNT 2698

INCL INCLM: 514/012.000

INCLS: 514/044.000

NCL NCLM: 514/012.000

NCLS: 514/044.000

IC [7]

ICM: A61K048-00

ICS: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 312 USPATFULL on STN

AN 2004:227885 USPATFULL

TI Compositions useful as inhibitors of JAK and other protein kinases

IN Bethiel, Randy S., Lexington, MA, UNITED STATES

Moon, Young-Choon, Belle Mead, NJ, UNITED STATES

PI US 2004176271 A1 20040909

AI US 2003-702113 A1 20031105 (10)

PRAI WO 2003-US35188 20031105

US 2002-424043P 20021105 (60)

DT Utility

FS APPLICATION

LN.CNT 1993

INCL INCLM: 514/002.000

NCL NCLM: 514/002.000

IC [7]

ICM: A61K038-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 312 USPATFULL on STN

AN 2004:227368 USPATFULL

TI Diagnosis and monitoring of inflammation, ***ischemia*** and appendicitis

IN Bar-Or, David, Englewood, CO, UNITED STATES

Bar-Or, Raphael, Denver, CO, UNITED STATES

Winkler, James V., Denver, CO, UNITED STATES

Yukl, Richard L., Denver, CO, UNITED STATES

PI US 2004175754 A1 20040909

AI US 2003-680935 A1 20031002 (10)

PRAI US 2002-417741P 20021009 (60)

US 2002-434692P 20021218 (60)

US 2003-464471P 20030421 (60)

US 2003-489169P 20030721 (60)

US 2003-496360P 20030818 (60)

DT Utility

LN.CNT 3585
INCL INCLM: 435/007.100
NCL NCLM: 435/007.100
IC [7]
ICM: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 312 USPATFULL on STN
AN 2004:221853 USPATFULL
TI Compositions and methods for targeting cerebral circulation and
treatment of headache
IN Frome, Bruce, P O Box 15157, Beverly Hills, CA, UNITED STATES 90209
PI US 2004171625 A1 20040902
AI US 2004-483509 A1 20040112 (10)
WO 2002-US26613 20020820
PRAI WO 2001-US26459 20010823
DT Utility
FS APPLICATION

LN.CNT 972
INCL INCLM: 514/263.310
INCLS: 424/449.000
NCL NCLM: 514/263.310
NCLS: 424/449.000
IC [7]
ICM: A61K031-522
ICS: A61K009-70

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 312 USPATFULL on STN
AN 2004:216032 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Golec, Julian, Swindon, UNITED KINGDOM
Pierard, Francoise, Drayton, UNITED KINGDOM
PI US 2004167141 A1 20040826
AI US 2004-775699 A1 20040210 (10)
RLI Division of Ser. No. US 2001-34019, filed on 20 Dec 2001, GRANTED, Pat.
No. US 6727251
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION

LN.CNT 2292
INCL INCLM: 514/269.000
INCLS: 544/310.000
NCL NCLM: 514/269.000
NCLS: 544/310.000
IC [7]
ICM: A61K031-513
ICS: C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 312 USPATFULL on STN
AN 2004:216012 USPATFULL
TI Indazolinone compositions useful as kinase inhibitors
IN Aronov, Alex, Watertown, MA, UNITED STATES
Lauffer, David J., Stow, MA, UNITED STATES
Li, Huan Qui, Cambridge, MA, UNITED STATES
Tomlinson, Ronald Charles, Marlborough, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
PI US 2004167121 A1 20040826
AI US 2003-694534 A1 20031027 (10)
PRAI US 2002-421398P 20021025 (60)
DT Utility
FS APPLICATION

LN.CNT 6438
INCL INCLM: 514/217.070
INCLS: 514/303.000; 514/407.000; 514/322.000; 540/603.000; 546/119.000;
546/199.000; 548/361.500
NCL NCLM: 514/217.070
NCLS: 514/303.000; 514/407.000; 514/322.000; 540/603.000; 546/119.000;
546/199.000; 548/361.500
IC [7]
ICM: C07D471-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 312 USPATFULL on STN
AN 2004:204001 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
PI US 2004157893 A1 20040812
AI US 2003-722374 A1 20031125 (10)
RLI Continuation of Ser. No. US 2001-34683, filed on 20 Dec 2001, GRANTED,
Pat. No. US 6656939
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 2148
INCL INCLM: 514/341.000
INCLS: 546/275.400
NCL NCLM: 514/341.000
NCLS: 546/275.400
IC [7]
ICM: A61K031-4439
ICS: C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 312 USPATFULL on STN
AN 2004:184159 USPATFULL
TI Method for modulating glutamate and/or aspartate release in a central
nervous system locus
IN Kubek, Michael J., Indianapolis, IN, UNITED STATES
PA Advanced Research and Technology Institute, Inc., Indianapolis, IN,
UNITED STATES, 46202 (U.S. corporation)
PI US 2004142042 A1 20040722
AI US 2004-753116 A1 20040108 (10)
RLI Division of Ser. No. US 2002-256691, filed on 27 Sep 2002, GRANTED, Pat.
No. US 6699491 Division of Ser. No. US 2001-897179, filed on 2 Jul 2001,
GRANTED, Pat. No. US 6491939 Division of Ser. No. US 1999-242776, filed
on 22 Feb 1999, GRANTED, Pat. No. US 6303134 A 371 of International Ser.
No. WO 1997-US15184, filed on 28 Aug 1997, PENDING
PRAI US 1996-25171P 19960829 (60)
DT Utility
FS APPLICATION
LN.CNT 758
INCL INCLM: 424/489.000
INCLS: 514/012.000
NCL NCLM: 424/489.000
NCLS: 514/012.000
IC [7]
ICM: A61K009-14
ICS: A61K038-23

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 312 USPATFULL on STN
AN 2004:184069 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Rockville, MD, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PI US 2004141952 A1 20040722
AI US 2004-774622 A1 20040210 (10)
RLI Continuation of Ser. No. US 2001-874138, filed on 6 Jun 2001, GRANTED,
Pat. No. US 6743625 Continuation of Ser. No. US 2000-565009, filed on 4
May 2000, PENDING Continuation-in-part of Ser. No. US 1998-42583, filed
on 17 Mar 1998, PENDING
PRAI US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)
DT Utility
FS APPLICATION
LN.CNT 8875
INCL INCLM: 424/085.100

NCL NCLM: 424/085.100
IC NCLS: 424/131.100; 514/012.000; 514/192.000; 514/210.090; 514/200.000
[7]
ICM: A61K038-19
ICS: A61K038-17; A61K039-395; A61K031-496; A61K031-704; A61K031-545;
A61K031-397; A61K031-407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 312 USPATFULL on STN
AN 2004:177787 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2004136951 A1 20040715
AI US 2003-648825 A1 20030827 (10)
RLI Continuation-in-part of Ser. No. US 2000-565009, filed on 4 May 2000,
PENDING Continuation-in-part of Ser. No. US 1998-42583, filed on 17 Mar
1998, PENDING
PRAI US 2002-413747P 20020927 (60)
US 2002-406307P 20020828 (60)
US 1999-148939P 19990813 (60)
US 1999-133238P 19990507 (60)
US 1999-132498P 19990504 (60)
US 1997-54021P 19970729 (60)
US 1997-40846P 19970317 (60)
DT Utility
FS APPLICATION
LN.CNT 12832
INCL INCLM: 424/085.100
INCLS: 424/131.100
NCL NCLM: 424/085.100
NCLS: 424/131.100
IC [7]
ICM: A61K038-19
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 45 OF 312 USPATFULL on STN
AN 2004:177786 USPATFULL
TI Death domain containing receptor 4
IN Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Gentz, Reiner L., Belo-Horizonte, BRAZIL
PA Human Genome Sciences, Inc. (U.S. corporation)
The Regents of the University of Michigan (U.S. corporation)
PI US 2004136950 A1 20040715
AI US 2003-648786 A1 20030827 (10)
RLI Continuation-in-part of Ser. No. US 2000-565918, filed on 5 May 2000,
GRANTED, Pat. No. US 6433147 Continuation-in-part of Ser. No. US
1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
PRAI US 2002-413861P 20020927 (60)
US 2002-406922P 20020830 (60)
US 1999-132922P 19990506 (60)
US 1997-37829P 19970205 (60)
US 1997-35722P 19970128 (60)
DT Utility
FS APPLICATION
LN.CNT 13407
INCL INCLM: 424/085.100
INCLS: 424/144.100
NCL NCLM: 424/085.100
NCLS: 424/144.100
IC [7]
ICM: A61K038-19
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 46 OF 312 USPATFULL on STN
AN 2004:172813 USPATFULL
TI Rational evolution of cytokines for higher stability, the cytokines and
encoding nucleic acid molecules
IN Gantier, Rene, Elancourt, FRANCE

Drittanti, Lila, Vigneux-sur-Seine, FRANCE
Guyon, Thierry, Palaiseau, FRANCE
PI US 2004132977 A1 20040708
AI US 2003-658834 A1 20030908 (10)
PRAI US 2003-457135P 20030321 (60)
US 2002-409898P 20020909 (60)
DT Utility
FS APPLICATION
LN.CNT 7935
INCL INCLM: 530/351.000
NCL NCLM: 530/351.000
IC [7]
ICM: C07K014-52
ICS: C07K014-54

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 47 OF 312 USPATFULL on STN
AN 2004:172617 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
PI US 2004132781 A1 20040708
AI US 2003-736426 A1 20031215 (10)
RLI Continuation of Ser. No. US 2001-26966, filed on 19 Dec 2001, ABANDONED
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8905
INCL INCLM: 514/341.000
INCLS: 546/275.400
NCL NCLM: 514/341.000
NCLS: 546/275.400
IC [7]
ICM: A61K031-4439
ICS: C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 48 OF 312 USPATFULL on STN
AN 2004:165981 USPATFULL
TI Methods of treating age associated memory impairment (AAMI), mild
cognitive impairment (MCI), and dementias with cell cycle inhibitors
IN Reisberg, Barry, New York, NY, UNITED STATES
PI US 2004127471 A1 20040701
AI US 2003-664817 A1 20030917 (10)
PRAI US 2002-411282P 20020917 (60)
DT Utility
FS APPLICATION
LN.CNT 1448
INCL INCLM: 514/165.000
INCLS: 514/456.000; 514/414.000; 514/557.000; 514/152.000
NCL NCLM: 514/165.000
NCLS: 514/456.000; 514/414.000; 514/557.000; 514/152.000
IC [7]
ICM: A61K031-65
ICS: A61K031-60; A61K031-404; A61K031-353; A61K031-19

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 49 OF 312 USPATFULL on STN
AN 2004:158608 USPATFULL
TI Regulation of the growth hormone/IGF-1 axis
IN Distefano, Peter, Southboro, MA, UNITED STATES
Bayley, Cynthia A., Norwell, MA, UNITED STATES
Cannon, L. Edward, Cambridge, MA, UNITED STATES
PA ELIXIR PHARMACEUTICALS, INC. (U.S. corporation)
PI US 2004121407 A1 20040624
AI US 2003-656530 A1 20030905 (10)
PRAI US 2003-487308P 20030714 (60)
US 2003-487344P 20030714 (60)
US 2002-408560P 20020906 (60)
DT Utility
FS APPLICATION
LN.CNT 4491
INCL INCLM: 435/007.100
INCLS: 436/518.000; 800/003.000

NCLS: 436/518.000; 800/003.000
[7]
ICM: G01N033-00
ICS: G01N033-53; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 312 USPATFULL on STN
AN 2004:158550 USPATFULL
TI Novel 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566,
65552 and 65577 molecules and uses therefor
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Carroll, Joseph M., Cambridge, MA, UNITED STATES
Cook, William James, Hanover, NH, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Weich, Nadine S., Brookline, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004121349 A1 20040624
AI US 2003-391364 A1 20030318 (10)
RLI Continuation-in-part of Ser. No. US 2001-950370, filed on 10 Sep 2001,
ABANDONED Continuation-in-part of Ser. No. US 2002-294039, filed on 13
Nov 2002, PENDING Continuation-in-part of Ser. No. US 2002-266035, filed
on 7 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2000-717926,
filed on 21 Nov 2000, GRANTED, Pat. No. US 6569657 Continuation-in-part
of Ser. No. US 2002-268036, filed on 9 Oct 2002, PENDING
Continuation-in-part of Ser. No. US 2001-922138, filed on 3 Aug 2001,
PENDING Continuation-in-part of Ser. No. US 2001-945327, filed on 31 Aug
2001, PENDING Continuation-in-part of Ser. No. US 2002-163316, filed on
5 Jun 2002, PENDING Continuation-in-part of Ser. No. US 2002-103377,
filed on 21 Mar 2002, PENDING
PRAI US 2000-231084P 20000908 (60)
US 2001-338587P 20011113 (60)
US 2001-328198P 20011009 (60)
US 2000-214707P 20000627 (60)
US 2001-327820P 20011009 (60)
US 2000-229299P 20000901 (60)
US 2000-229425P 20000831 (60)
US 2001-297863P 20010613 (60)
US 2001-278347P 20010323 (60)
DT Utility
FS APPLICATION
LN.CNT 15849
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C07K014-47; C12P021-02;
C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 51 OF 312 USPATFULL on STN
AN 2004:152232 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Davies, Robert, Arlington, MA, UNITED STATES
Bebbington, David, Berkshire, UNITED KINGDOM
Knegt, Ronald, Abingdom, UNITED KINGDOM
Wannamaker, Marion, Stow, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
Forster, Cornelia, Pelham, NH, UNITED STATES
Pierce, Albert, Somerville, MA, UNITED STATES
PI US 2004116454 A1 20040617
AI US 2003-692355 A1 20031023 (10)
RLI Division of Ser. No. US 2001-955601, filed on 14 Sep 2001, GRANTED, Pat.
No. US 6696452
PRAI US 2000-232795P 20000915 (60)
US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8549
INCL INCLM: 514/275.000

NCL NCLM: 514/275.000
NCLS: 544/328.000
IC [7]
ICM: A61K031-506
ICS: C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 312 USPATFULL on STN
AN 2004:150954 USPATFULL
TI Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
IN Blau, Helen M., Menlo Park, CA, UNITED STATES
Brazelton, Timothy, Cupertino, CA, UNITED STATES
Weimann, James M., Palo Alto, CA, UNITED STATES
PA The Board of Trustees of the Leland, Palo Alto, CA (U.S. corporation)
PI US 2004115175 A1 20040617
AI US 2003-688747 A1 20031016 (10)
RLI Continuation-in-part of Ser. No. US 2001-993045, filed on 13 Nov 2001, PENDING
PRAI US 2000-247128P 20001110 (60)
DT Utility
FS APPLICATION
LN.CNT 2455
INCL INCLM: 424/093.700
NCL NCLM: 424/093.700
IC [7]
ICM: A61K045-00

L5 ANSWER 53 OF 312 USPATFULL on STN
AN 2004:139439 USPATFULL
TI Protein kinase inhibitors and uses thereof
IN Cochran, John, Marshfield, MA, UNITED STATES
Green, Jeremy, Burlington, MA, UNITED STATES
Hale, Michael R., Bedford, MA, UNITED STATES
Ledford, Brian, Attleboro, MA, UNITED STATES
Maltais, Francois, Tewksbury, MA, UNITED STATES
Nanthakumar, Suganthini, Newton, MA, UNITED STATES
PI US 2004106615 A1 20040603
AI US 2003-639784 A1 20030812 (10)
PRAI US 2002-403256P 20020814 (60)
US 2002-416802P 20021008 (60)
DT Utility
FS APPLICATION
LN.CNT 5486
INCL INCLM: 514/242.000
INCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000;
544/331.000
NCL NCLM: 514/242.000
NCLS: 514/247.000; 514/252.030; 514/275.000; 544/238.000; 544/183.000;
544/331.000
IC [7]
ICM: A61K031-53
ICS: A61K031-501; A61K031-506; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 312 USPATFULL on STN
AN 2004:138675 USPATFULL
TI Promoting Recovery from Damage to the Central Nervous System
IN Finklestein, Seth P., 308A Hunnewell St, Needham, MA, UNITED STATES
02494
Snyder, Evan Y., 22 Hillcroft Rd, Jamaica Plain, MA, UNITED STATES
02130
PI US 2004105847 A1 20040603
AI US 2003-605456 A1 20030930 (10)
RLI Continuation of Ser. No. US 2000-642277, filed on 18 Aug 2000, PENDING
PRAI US 1999-149561P 19990818 (60)
DT Utility
FS APPLICATION
LN.CNT 1943
INCL INCLM: 424/093.700
INCLS: 514/012.000
NCL NCLM: 424/093.700
NCLS: 514/012.000
IC [7]
ICM: A61K045-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 55 OF 312 USPATFULL on STN
AN 2004:134075 USPATFULL
TI Alzheimer's disease-associated proteins
IN Xu, Yuming, Mountain View, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
PA Incyte Corporation, Palo Alto, CA, UNITED STATES, 94304 (U.S.
corporation)
PI US 2004102612 A1 20040527
AI US 2003-398694 A1 20030403 (10)
WO 2001-US31076 20011003
DT Utility
FS APPLICATION
LN.CNT 4410
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/368.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/368.000; 536/023.500
IC [7]
ICM: C07K014-47
ICS: C07H021-04; C12N005-08; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 312 USPATFULL on STN
AN 2004:133988 USPATFULL
TI Compositions and methods of treating neurological disease and providing
neuroprotection
IN Kozachuk, Walter E., Kensington, MD, UNITED STATES
PI US 2004102525 A1 20040527
AI US 2003-442985 A1 20030522 (10)
PRAI US 2002-382072P 20020522 (60)
DT Utility
FS APPLICATION
LN.CNT 3666
INCL INCLM: 514/662.000
NCL NCLM: 514/662.000
IC [7]
ICM: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 57 OF 312 USPATFULL on STN
AN 2004:133348 USPATFULL
TI Molecules for disease detection and treatment
IN Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Arvizu, Chandra S., San Diego, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Tran, Bao, Santa Clara, CA, UNITED STATES
Lee, Soo Yeun, Mountain View, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Baughn, Mariah R., Los Angeles, CA, UNITED STATES
Emerling, Brooke M, Chicago, IL, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Becha, Shanya D, San Francisco, CA, UNITED STATES
Marquis, Joseph P, San Jose, CA, UNITED STATES
Kable, Amy E, Silver Spring, MD, UNITED STATES
PI US 2004101884 A1 20040527
AI US 2003-473576 A1 20030929 (10)
WO 2002-US9809 20020329

FS APPLICATION
LN.CNT 11182
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 58 OF 312 USPATFULL on STN
AN 2004:127550 USPATFULL
TI Composition for the protection and regeneration of nerve cells
containing berberine derivatives
IN Choi, Byung-Kil, Seo-gu, KOREA, REPUBLIC OF
Kim, Yun-Hee, Seoul, KOREA, REPUBLIC OF
Kim, Soo-Kyung, Jung-gu, KOREA, REPUBLIC OF
Lim, Jung-Su, Seoul, KOREA, REPUBLIC OF
Kim, Hyo-Sup, Namdong-gu, KOREA, REPUBLIC OF
Park, Dae-Sung, Seoul, KOREA, REPUBLIC OF
Chang, Chi-Young, Bucheon-si, KOREA, REPUBLIC OF
PA EUGENBIO INC., Chungcheongnam-do, KOREA, REPUBLIC OF (non-U.S.
corporation)
PI US 2004097534 A1 20040520
AI US 2003-389693 A1 20030314 (10)
RLI Continuation of Ser. No. WO 2002-KR1307, filed on 10 Jul 2002, UNKNOWN
PRAI KR 2001-41248 20010710
KR 2002-40015 20020710
DT Utility
FS APPLICATION
LN.CNT 1579
INCL INCLM: 514/283.000
NCL NCLM: 514/283.000
IC [7]
ICM: A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 59 OF 312 USPATFULL on STN
AN 2004:127517 USPATFULL
TI Triazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury Berkshire, UNITED KINGDOM
Knegtel, Ronald, Abingdon, UNITED KINGDOM
Binch, Hayley, Harwell Oxon, UNITED KINGDOM
Golec, Julian, Asbury Swinden, UNITED KINGDOM
Li, Pan, Arlington, MA, UNITED STATES
Charier, Jean-Damien, Bishop's Itchington, UNITED KINGDOM
PI US 2004097501 A1 20040520
AI US 2001-953471 A1 20010914 (9)
PRAI US 2000-232795P 20000915 (60)
US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 9118
INCL INCLM: 514/241.000
INCLS: 514/252.020; 514/255.050; 514/256.000; 544/212.000; 544/238.000;
544/328.000
NCL NCLM: 514/241.000
NCLS: 514/252.020; 514/255.050; 514/256.000; 544/212.000; 544/238.000;
544/328.000
IC [7]
ICM: A61K031-53
ICS: A61K031-506; C07D043-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 60 OF 312 USPATFULL on STN
AN 2004:121119 USPATFULL
TI Benzimidazole quinolinones and uses thereof
IN Barsanti, Paul A., Walnut Creek, CA, UNITED STATES
Bussiere, Dirksen, San Leandro, CA, UNITED STATES
Harrison, Stephen D., Albany, CA, UNITED STATES
Heise, Carla C., Benicia, CA, UNITED STATES
Jansen, Johanna M., San Francisco, CA, UNITED STATES
Jazan, Elisa, Richmond, CA, UNITED STATES

McBride, Christopher, Oakland, CA, UNITED STATES
McCrea, William R., JR., Berkeley, CA, UNITED STATES
Ng, Simon, Walnut Creek, CA, UNITED STATES
Ni, Zhi-Jie, Fremont, CA, UNITED STATES
Pecchi, Sabina, Oakland, CA, UNITED STATES
Pfister, Keith B., San Ramon, CA, UNITED STATES
Ramurthy, Savithri, Walnut Creek, CA, UNITED STATES
Renhowe, Paul A., Danville, CA, UNITED STATES
Shafer, Cynthia M., El Sobrante, CA, UNITED STATES
Silver, Joel B., Concord, NH, UNITED STATES
Wagman, Allan S., Belmont, CA, UNITED STATES
Wiesmann, Marion, Brisbane, CA, UNITED STATES

PA Chiron Corporation (U.S. corporation)
PI US 2004092535 A1 20040513
AI US 2003-644055 A1 20030819 (10)
PRAI US 2002-405729P 20020823 (60)
US 2002-426107P 20021113 (60)
US 2002-426226P 20021113 (60)
US 2002-426282P 20021113 (60)
US 2002-428210P 20021121 (60)
US 2003-460328P 20030403 (60)
US 2003-460493P 20030403 (60)
US 2003-460327P 20030403 (60)
US 2003-478916P 20030616 (60)
US 2003-484048P 20030701 (60)

DT Utility
FS APPLICATION

LN.CNT 18050

INCL INCLM: 514/263.220
INCLS: 514/303.000; 514/312.000

NCL NCLM: 514/263.220
NCLS: 514/303.000; 514/312.000

IC [7]
ICM: A61K031-52
ICS: A61K031-4709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 61 OF 312 USPATFULL on STN

AN 2004:121032 USPATFULL

TI Uses of kappa-conotoxin PVIIA

IN Cornell-Bell, Ann H., Westbrook, CT, UNITED STATES

Pemberton, Karen E., Guilford, CT, UNITED STATES

Temple, Davis L., JR., Clinton, CT, UNITED STATES

Layer, Richard T., Sandy, UT, UNITED STATES

McCabe, R. Tyler, Salt Lake City, UT, UNITED STATES

Jones, Robert M., San Diego, CA, UNITED STATES

PA Cognetix, Inc., Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)

PI US 2004092447 A1 20040513

AI US 2003-627685 A1 20030728 (10)

RLI Continuation of Ser. No. US 2000-666837, filed on 21 Sep 2000, ABANDONED

PRAI US 2000-219438P 20000720 (60)

US 1999-155135P 19990922 (60)

DT Utility

FS APPLICATION

LN.CNT 1528

INCL INCLM: 514/012.000

INCLS: 514/013.000

NCL NCLM: 514/012.000

NCLS: 514/013.000

IC [7]

ICM: A61K038-17

ICS: A61K038-10

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 62 OF 312 USPATFULL on STN

AN 2004:107249 USPATFULL

TI Adzymes and uses thereof

IN Afeyan, Noubar B., Lexington, MA, UNITED STATES

Lee, Frank D., Chestnut Hill, MA, UNITED STATES

Wong, Gordon G., Brookline, MA, UNITED STATES

Das Gupta, Ruchira, Auburndale, MA, UNITED STATES

Baynes, Brian, Somerville, MA, UNITED STATES

PI US 2004081648 A1 20040429

AI US 2003-650592 A1 20030827 (10)

US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 8325
INCL INCLM: 424/094.630
INCLS: 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 63 OF 312 USPATFULL on STN
AN 2004:107248 USPATFULL
TI Adzymes and uses thereof
IN Afeyan, Noubar B., Lexington, MA, UNITED STATES
Lee, Frank D., Chestnut Hill, MA, UNITED STATES
Wong, Gordon G., Brookline, MA, UNITED STATES
DasGupta, Ruchira, Auburndale, MA, UNITED STATES
Baynes, Brian, Somerville, MA, UNITED STATES
PI US 2004081647 A1 20040429
AI US 2003-650591 A1 20030827 (10)
PRAI US 2002-406517P 20020827 (60)
US 2002-423754P 20021105 (60)
US 2002-430001P 20021127 (60)
DT Utility
FS APPLICATION
LN.CNT 7919
INCL INCLM: 424/094.630
INCLS: 435/069.700; 435/226.000
NCL NCLM: 424/094.630
NCLS: 435/069.700; 435/226.000
IC [7]
ICM: A61K038-48
ICS: C12N009-64; C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 64 OF 312 USPATFULL on STN
AN 2004:95351 USPATFULL
TI Neuroprotective spirostenol pharmaceutical compositions
IN Yao, Zhi-Xing, Arlington, VA, UNITED STATES
Lecanu, Laurent, McLean, VA, UNITED STATES
Teper, Gary L., Potomac, MD, UNITED STATES
Greeson, Janet, Las Vegas, NV, UNITED STATES
Papadopoulos, Vassilios, North Potomac, MD, UNITED STATES
PI US 2004072806 A1 20040415
AI US 2003-389189 A1 20030314 (10)
PRAI US 2002-364140P 20020315 (60)
US 2003-319846P 20030109 (60)
DT Utility
FS APPLICATION
LN.CNT 2193
INCL INCLM: 514/169.000
INCLS: 514/177.000; 514/178.000
NCL NCLM: 514/169.000
NCLS: 514/177.000; 514/178.000
IC [7]
ICM: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 312 USPATFULL on STN
AN 2004:94809 USPATFULL
TI Method for the diagnosis and differential diagnosis of neurological diseases
IN Kostanjevecki, Vesna, Sint-Denijs-Westrem, BELGIUM
Vanmechelen, Eugeen, Nazareth-Eke, BELGIUM
De Brabandere, Veronique, Gent, BELGIUM
PI US 2004072261 A1 20040415
AI US 2003-601100 A1 20030620 (10)
PRAI EP 2002-447121 20020621
US 2002-396438P 20020717 (60)
DT Utility
FS APPLICATION

INCL INCLM: 435/007.200
NCL NCLM: 435/007.200
IC [7]
ICM: G01N033-53
ICS: G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 312 USPATFULL on STN
AN 2004:77440 USPATFULL
TI Systems and methods for making noninvasive assessments of cardiac tissue
and parameters
IN Mourad, Pierre D., Seattle, WA, UNITED STATES
Kliot, Michel, Bellevue, WA, UNITED STATES
Patterson, Rex, Kirkland, WA, UNITED STATES
Rooke, George Alec, Shoreline, WA, UNITED STATES
PA ALLEZ PHYSIONIX LIMITED, Victoria, CANADA, V8S 3V3 (U.S. corporation)
UNIVERSITY OF WASHINGTON, Seattle, WA, UNITED STATES, 98105-4608 (U.S.
corporation)
PI US 2004059220 A1 20040325
AI US 2003-612483 A1 20030701 (10)
RLI Continuation-in-part of Ser. No. US 2001-995897, filed on 28 Nov 2001,
PENDING
PRAI US 2003-475803P 20030603 (60)
US 2002-393293P 20020701 (60)
US 2000-253959P 20001128 (60)
DT Utility
FS APPLICATION
LN.CNT 2248
INCL INCLM: 600/442.000
NCL NCLM: 600/442.000
IC [7]
ICM: A61B008-00

L5 ANSWER 67 OF 312 USPATFULL on STN
AN 2004:76577 USPATFULL
TI Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700,
21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or
593 molecules and uses therefor
IN Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Curtis, Rory A. J., Framingham, MA, UNITED STATES
Olandt, Peter J., Newton, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004058355 A1 20040325
AI US 2003-423543 A1 20030425 (10)
RLI Continuation-in-part of Ser. No. US 2002-278036, filed on 22 Oct 2002,
PENDING Continuation of Ser. No. US 2000-711216, filed on 9 Nov 2000,
ABANDONED Continuation-in-part of Ser. No. US 2001-12055, filed on 13
Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-3690, filed
on 15 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-797039,
filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US
2002-217168, filed on 12 Aug 2002, PENDING Continuation-in-part of Ser.
No. US 2001-929218, filed on 14 Aug 2001, ABANDONED Continuation-in-part
of Ser. No. US 2001-963159, filed on 25 Sep 2001, ABANDONED
Continuation-in-part of Ser. No. US 2002-121911, filed on 12 Apr 2002,
GRANTED, Pat. No. US 6607892 Division of Ser. No. US 1999-412210, filed
on 5 Oct 1999, GRANTED, Pat. No. US 6403358 Continuation-in-part of Ser.
No. US 2002-105989, filed on 25 Mar 2002, PENDING Continuation of Ser.
No. US 1999-392189, filed on 9 Sep 1999, ABANDONED Continuation-in-part
of Ser. No. US 2003-336153, filed on 3 Jan 2003, PENDING Continuation of
Ser. No. US 2001-845044, filed on 27 Apr 2001, ABANDONED
Continuation-in-part of Ser. No. US 2001-928531, filed on 13 Aug 2001,
ABANDONED Continuation-in-part of Ser. No. US 2001-920346, filed on 31
Jul 2001, PENDING Continuation-in-part of Ser. No. US 2001-8016, filed
on 8 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2001-909743,
filed on 20 Jul 2001, PENDING Division of Ser. No. US 1999-448076, filed
on 23 Nov 1999, GRANTED, Pat. No. US 6300092 Continuation-in-part of

6140056 Continuation-in-part of Ser. No. US 2003-336489, filed on 2 Jan 2003, PENDING Continuation of Ser. No. US 2000-608921, filed on 30 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1998-163821, filed on 30 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-60763, filed on 30 Jan 2002, ABANDONED Continuation of Ser. No. US 1999-365162, filed on 30 Jul 1999, ABANDONED

PRAI US 2000-205447P 20000519 (60)
US 2000-248325P 20001114 (60)
US 2000-248893P 20001115 (60)
US 2000-186061P 20000229 (60)
US 2001-312539P 20010815 (60)
US 2000-257511P 20001222 (60)
US 2000-234922P 20000925 (60)
US 2000-200688P 20000428 (60)
US 2000-235035P 20000925 (60)
US 2000-221925P 20000731 (60)
US 2001-260166P 20010105 (60)
US 2000-246669P 20001108 (60)
US 1999-117580P 19990127 (60)

DT Utility
FS APPLICATION
LN.CNT 14751
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
530/388.220

NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
530/388.220

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705; C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 68 OF 312 USPATFULL on STN
AN 2004:70777 USPATFULL
TI Sodium channel blocker compositions and the use thereof
IN Lan, Nancy C., Altadena, CA, UNITED STATES
PI US 2004054005 A1 20040318
AI US 2003-644783 A1 20030821 (10)
RLI Division of Ser. No. US 2001-971007, filed on 5 Oct 2001, PENDING
Continuation of Ser. No. WO 2000-US9387, filed on 10 Apr 2000, PENDING

PRAI US 1999-128543P 19990409 (60)
DT Utility
FS APPLICATION
LN.CNT 1215
INCL INCLM: 514/561.000
INCLS: 514/217.000; 514/590.000

NCL NCLM: 514/561.000
NCLS: 514/217.000; 514/590.000

IC [7]
ICM: A61K031-55
ICS: A61K031-195; A61K031-175

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 69 OF 312 USPATFULL on STN
AN 2004:70167 USPATFULL
TI Human kinases
IN Gururajan, Rajagopal, SAN JOSE, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Yao, Monique G, Carmel, INDIA
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Hafalia, April J A, Daly City, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES

Recipon, Shirley A, San Francisco, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Borowsky, Mark L, Northampton, MA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES

PI US 2004053394 A1 20040318
AI US 2003-415011 A1 20030418 (10)
WO 2001-US47728 20011020

DT Utility
FS APPLICATION

LN.CNT 9902

INCL INCLM: 435/252.300

NCL NCLM: 435/252.300

IC [7]

ICM: C12N001-20

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 70 OF 312 USPATFULL on STN

AN 2004:64615 USPATFULL

TI System and methods for treatment of alzheimer's and other
deposition-related disorders of the brain

IN Tosaya, Carol A., Los Altos, CA, UNITED STATES

Sliwa, John W., JR., Los Altos, CA, UNITED STATES

PI US 2004049134 A1 20040311

AI US 2003-612171 A1 20030701 (10)

PRAI US 2002-394089P 20020702 (60)

DT Utility

FS APPLICATION

LN.CNT 2910

INCL INCLM: 601/002.000

NCL NCLM: 601/002.000

IC [7]

ICM: A61H001-00

L5 ANSWER 71 OF 312 USPATFULL on STN

AN 2004:63778 USPATFULL

TI Human tumor necrosis factor TR20 and methods based thereon

IN Ruben, Steven M., Brookeville, MD, UNITED STATES

Baker, Kevin P., Darnestown, MD, UNITED STATES

Ni, Jian, Germantown, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

PI US 2004048296 A1 20040311

AI US 2003-618797 A1 20030715 (10)

RLI Division of Ser. No. US 2001-848295, filed on 4 May 2001, GRANTED, Pat.
No. US 6623941

PRAI US 2000-202193P 20000505 (60)

DT Utility

FS APPLICATION

LN.CNT 11643

INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 72 OF 312 USPATFULL on STN

AN 2004:58396 USPATFULL

TI Tissue-engineered vascular structures

IN Bischoff, Joyce, Weston, MA, UNITED STATES

Kaushal, Sunjay, Baltimore, MD, UNITED STATES

Mayer Jr, John E., Wellesley, MA, UNITED STATES

Perry, Tjorvi Ellert, Dedham, MA, UNITED STATES

PI US 2004044403 A1 20040304

AI US 2003-399092 A1 20030919 (10)

WO 2001-US48946 20011030

DT Utility

FS APPLICATION

LN.CNT 990

INCL INCLM: 623/001.410

NCL NCLM: 623/001.410
 NCLS: 623/002.150; 623/916.000
 IC [7]
 ICM: A61F002-06
 ICS: A61F002-24

L5 ANSWER 73 OF 312 USPATFULL on STN
 AN 2004:58011 USPATFULL
 TI Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor
 IN Fisher, Abraham, Holon, ISRAEL
 Bar-Ner, Nira, Rishon Le-Zion, ISRAEL
 Karton, Yishai, Ness Ziona, ISRAEL
 PA ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (non-U.S. corporation)
 PI US 2004044018 A1 20040304
 AI US 2003-429277 A1 20030502 (10)
 PRAI US 2002-377433P 20020503 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 4580
 INCL INCLM: 514/278.000
 INCLS: 514/365.000; 514/374.000; 514/409.000; 514/406.000; 514/362.000;
 546/015.000; 546/017.000; 548/126.000; 548/181.000; 548/147.000;
 548/216.000; 548/357.500; 548/408.000; 514/263.200; 544/230.000

NCL NCLM: 514/278.000
 NCLS: 514/365.000; 514/374.000; 514/409.000; 514/406.000; 514/362.000;
 546/015.000; 546/017.000; 548/126.000; 548/181.000; 548/147.000;
 548/216.000; 548/357.500; 548/408.000; 514/263.200; 544/230.000

IC [7]
 ICM: A61K031-4747
 ICS: A61K031-52; A61K031-407; C07D473-00; C07D471-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 74 OF 312 USPATFULL on STN
 AN 2004:51576 USPATFULL
 TI Compositions useful as inhibitors of GSK-3
 IN Forster, Cornelia J., Pelham, NH, UNITED STATES
 Park, Larry C., Waltham, MA, UNITED STATES
 Wannamaker, Marion W., Stow, MA, UNITED STATES
 Yao, Yung-Mae M., Newton, MA, UNITED STATES
 PI US 2004039007 A1 20040226
 AI US 2003-632340 A1 20030801 (10)
 PRAI US 2002-400967P 20020802 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2000
 INCL INCLM: 514/275.000
 INCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;
 544/295.000; 544/328.000

NCL NCLM: 514/275.000
 NCLS: 514/228.500; 514/234.500; 514/252.180; 544/060.000; 544/122.000;
 544/295.000; 544/328.000

IC [7]
 ICM: A61K031-541
 ICS: A61K031-5377; A61K031-506; C07D417-14; C07D413-14; C07D043-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 75 OF 312 USPATFULL on STN
 AN 2004:50919 USPATFULL
 TI Heteromultimeric TNF ligand family members
 IN Hilbert, David M., Bethesda, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 PI US 2004038349 A1 20040226
 AI US 2002-202062 A1 20020725 (10)
 PRAI US 2001-307838P 20010727 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 14327
 INCL INCLM: 435/069.500
 INCLS: 435/320.100; 435/325.000; 530/351.000

NCL NCLM: 435/069.500
 NCLS: 435/320.100; 435/325.000; 530/351.000

IC [7]
 ICM: C12P021-02
 ICS: C07K014-52

L5 ANSWER 76 OF 312 USPATFULL on STN
 AN 2004:45044 USPATFULL
 TI Heteroaryl compounds useful as inhibitors of GSK-3
 IN Harbeson, Scott L., Cambridge, MA, UNITED STATES
 Arnost, Michael, Andover, MA, UNITED STATES
 Green, Jeremy, Burlington, MA, UNITED STATES
 Savic, Vladimir, Saffron Walden, UNITED KINGDOM
 PI US 2004034037 A1 20040219
 AI US 2003-360535 A1 20030206 (10)
 PRAI US 2002-354843P 20020206 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2253
 INCL INCLM: 514/255.050
 INCLS: 514/364.000; 514/394.000; 544/405.000; 548/125.000; 548/304.400
 NCL NCLM: 514/255.050
 NCLS: 514/364.000; 514/394.000; 544/405.000; 548/125.000; 548/304.400
 IC [7]
 ICM: A61K031-497
 ICS: A61K031-4245; A61K031-4184; C07D413-04; C07D043-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 77 OF 312 USPATFULL on STN
 AN 2004:31898 USPATFULL
 TI Inhibitors of GSK-3 and uses thereof
 IN Green, Jeremy, Burlington, MA, UNITED STATES
 Arnost, Michael J., North Andover, MA, UNITED STATES
 Pierce, Albert, Cambridge, MA, UNITED STATES
 PI US 2004024040 A1 20040205
 AI US 2002-212471 A1 20020802 (10)
 PRAI US 2001-309838P 20010803 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3014
 INCL INCLM: 514/404.000
 INCLS: 514/341.000
 NCL NCLM: 514/404.000
 NCLS: 514/341.000
 IC [7]
 ICM: A61K031-416
 ICS: A61K031-4439
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 78 OF 312 USPATFULL on STN
 AN 2004:30644 USPATFULL
 TI Proteins and nucleic acids encoding same
 IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Wolenc, Adam R., New Haven, CT, UNITED STATES
 Vernet, Corine, North Branford, CT, UNITED STATES
 Eisen, Andrew J., Rockville, MD, UNITED STATES
 Liu, Xiaohong, Lexington, MA, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Tchernev, Velizar, Branford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES
 Gorman, Linda, Branford, CT, UNITED STATES
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Gusev, Vladimir Y., Madison, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Rastelli, Luca, Guilford, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Burgess, Catherine E., Wethersfield, CT, UNITED STATES
 Edinger, Shlomit R., New Haven, CT, UNITED STATES
 Ellerman, Karen, Branford, CT, UNITED STATES
 Gunther, Erik, Branford, CT, UNITED STATES
 Smithson, Glennnda, Guilford, CT, UNITED STATES
 Millet, Isabelle, Milford, CT, UNITED STATES
 MacDougall, John R., Hamden, CT, UNITED STATES
 PI US 2004022781 A1 20040205

PRAI US 2000-258928P 20001229 (60)
 US 2001-259415P 20010102 (60)
 US 2001-259785P 20010104 (60)
 US 2001-269814P 20010220 (60)
 US 2001-279832P 20010329 (60)
 US 2001-279833P 20010329 (60)
 US 2001-279863P 20010329 (60)
 US 2001-283889P 20010413 (60)
 US 2001-284447P 20010418 (60)
 US 2001-286683P 20010425 (60)
 US 2001-294080P 20010529 (60)
 US 2001-312915P 20010816 (60)
 US 2001-313325P 20010817 (60)
 US 2001-322699P 20010917 (60)
 US 2001-333350P 20011126 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 19237
 INCL INCLM: 424/130.100
 INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;
 530/350.000; 536/023.100; 530/388.250
 NCL NCLM: 424/130.100
 NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 435/007.200;
 530/350.000; 536/023.100; 530/388.250
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-53; G01N033-567; C07H021-04; A61K039-395; C12P021-02;
 C12N005-06; C07K014-47; C07K016-22
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 79 OF 312 USPATFULL on STN
 AN 2004:26075 USPATFULL
 TI Calcium binding proteins
 IN Sonderegger, Peter, UNITED STATES
 Hintsch, Gustav, Z?uuml;rich, SWITZERLAND
 Kinter, Jochen, Z?uuml;rich, SWITZERLAND
 Meskenait, Virginija, Z?uuml;rich, SWITZERLAND
 Schrimpf, Sabine, Z?uuml;rich, SWITZERLAND
 Vogt, Lorenz, Wetzikon, SWITZERLAND
 Zurlinden, Andreas, Zuuml;rich, SWITZERLAND
 PI US 2004019919 A1 20040129
 AI US 2003-380705 A1 20030630 (10)
 WO 2001-IB1662 20010913
 PRAI EP 2000-810830 20000914
 DT Utility
 FS APPLICATION
 LN.CNT 4366
 INCL INCLM: 800/014.000
 INCLS: 514/044.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.200; 514/012.000
 NCL NCLM: 800/014.000
 NCLS: 514/044.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.200; 514/012.000
 IC [7]
 ICM: A01K067-027
 ICS: C07H021-04; A61K038-17; C07K014-47
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 80 OF 312 USPATFULL on STN
 AN 2004:25276 USPATFULL
 TI NMDA receptor antagonists and their use in inhibiting abnormal
 hyperphosphorylation of microtubule associated protein ***tau***
 IN Iqbal, Khalid, Staten Island, NY, UNITED STATES
 Grundke-Iqbal, Inge, Staten Island, NY, UNITED STATES
 PI US 2004019118 A1 20040129
 AI US 2003-622163 A1 20030717 (10)
 PRAI US 2002-397434P 20020719 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1948
 INCL INCLM: 514/659.000
 NCL NCLM: 514/659.000
 IC [7]
 ICM: A61K031-13
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 81 OF 312 USPATFULL on STN
 AN 2004:24650 USPATFULL
 TI Detection of RNA
 IN Ma, WuPo, Madison, WI, UNITED STATES
 Lyamichev, Victor, Madison, WI, UNITED STATES
 Kaiser, Michael, Madison, WI, UNITED STATES
 Lyamichieva, Natalie E., Madison, WI, UNITED STATES
 Allawi, Hatim Taysir, Madison, WI, UNITED STATES
 Lukowiak, Andrew A., Madison, WI, UNITED STATES
 Schaefer, James J., Madison, WI, UNITED STATES
 Lukowiak, Andrew A., Madison, WI, UNITED STATES
 PI US 2004018489 A1 20040129
 AI US 2001-864426 A1 20010524 (9)
 RLI Continuation-in-part of Ser. No. US 2000-577304, filed on 24 May 2000,
 PENDING Continuation-in-part of Ser. No. US 1999-350309, filed on 9 Jul
 1999, GRANTED, Pat. No. US 6348314 Continuation-in-part of Ser. No. US
 1991-756386, filed on 9 Sep 1991, GRANTED, Pat. No. US 337472
 Continuation-in-part of Ser. No. US 1995-381212, filed on 31 Jan 1995,
 GRANTED, Pat. No. US 5608651 Continuation-in-part of Ser. No. US
 1997-823516, filed on 24 Mar 1997, GRANTED, Pat. No. US 5994069
 Continuation-in-part of Ser. No. US 1996-759038, filed on 2 Dec 1996,
 GRANTED, Pat. No. US 6090543 Continuation-in-part of Ser. No. US
 1996-682853, filed on 12 Jul 1996, GRANTED, Pat. No. US 6001567
 Continuation-in-part of Ser. No. US 1996-599491, filed on 24 Jan 1996,
 GRANTED, Pat. No. US 5846717 Continuation-in-part of Ser. No. US
 2000-381212, filed on 8 Feb 2000, PENDING Continuation-in-part of Ser.
 No. US 2001-758282, filed on 11 Jan 2001, GRANTED, Pat. No. US 6635463
 PRAI WO 1997-US1072 19970121
 DT Utility
 FS APPLICATION
 LN.CNT 10762
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/091.200; 435/199.000; 435/320.100; 435/325.000;
 536/023.200
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/091.200; 435/199.000; 435/320.100; 435/325.000;
 536/023.200
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12P019-34; C12N009-22; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 82 OF 312 USPATFULL on STN
 AN 2004:19356 USPATFULL
 TI Insulin-associated peptides with effects on cerebral health
 IN During, Matthew J., Philadelphia, PA, UNITED STATES
 Haile, Colin N., Katy, TX, UNITED STATES
 PI US 2004014660 A1 20040122
 AI US 2003-430545 A1 20030506 (10)
 PRAI US 2002-378318P 20020506 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2477
 INCL INCLM: 514/012.000
 INCLS: 530/350.000
 NCL NCLM: 514/012.000
 NCLS: 530/350.000
 IC [7]
 ICM: A61K038-17
 ICS: C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 83 OF 312 USPATFULL on STN
 AN 2004:18791 USPATFULL
 TI Polynucleotide encoding a novel cysteine protease of the calpain
 superfamily, Protease-42
 IN Duclos, Franck, Washington Crossing, PA, UNITED STATES
 Chen, Jian, Princeton, NJ, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Nayeem, Akbar, Newtown, PA, UNITED STATES
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 PI US 2004014093 A1 20040122
 AI US 2003-390585 A1 20030314 (10)
 PRAI US 2002-364941P 20020314 (60)
 DT Utility

LN.CNT 19269
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200;
702/019.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200;
702/019.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C07H021-04; C12N009-64;
C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 84 OF 312 USPATFULL on STN
AN 2004:13473 USPATFULL
TI Protein kinase inhibitors and uses thereof
IN Moon, Young-Choon, Belle Mead, NJ, UNITED STATES
Green, Jeremy, Burlington, MA, UNITED STATES
Davies, Robert, Arlington, MA, UNITED STATES
Choquette, Deborah, Medford, MA, UNITED STATES
Pierce, Albert, Cambridge, MA, UNITED STATES
Ledeboer, Mark, Acton, MA, UNITED STATES
PI US 2004009996 A1 20040115
AI US 2002-172888 A1 20020614 (10)
PRAI US 2001-298646P 20010615 (60)
DT Utility
FS APPLICATION
LN.CNT 1465
INCL INCLM: 514/275.000
INCLS: 544/331.000
NCL NCLM: 514/275.000
NCLS: 544/331.000
IC [7]
ICM: A61K031-506
ICS: C07D413-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 85 OF 312 USPATFULL on STN
AN 2004:13459 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Bebbington, David, Newbury, UNITED KINGDOM
Binch, Hayley, Harwell, UNITED KINGDOM
Charrier, Jean-Damien, Grove Wantage, UNITED KINGDOM
Everitt, Simon, Beaconsfield, UNITED KINGDOM
Golec, Julian M.C., Ashbury, UNITED KINGDOM
Kay, David, Purton, UNITED KINGDOM
Knegt, Ronald, Abingdon, UNITED KINGDOM
Miller, Andrew, Upton, UNITED KINGDOM
Pierard, Francoise, Drayton, UNITED KINGDOM
PI US 2004009981 A1 20040115
AI US 2003-389259 A1 20030314 (10)
PRAI US 2002-364864P 20020315 (60)
DT Utility
FS APPLICATION
LN.CNT 1804
INCL INCLM: 514/242.000
INCLS: 514/260.100; 514/265.100; 514/269.000; 514/263.200; 514/266.230;
544/182.000; 544/262.000; 544/277.000; 544/280.000; 544/284.000;
544/317.000
NCL NCLM: 514/242.000
NCLS: 514/260.100; 514/265.100; 514/269.000; 514/263.200; 514/266.230;
544/182.000; 544/262.000; 544/277.000; 544/280.000; 544/284.000;
544/317.000
IC [7]
ICM: A61K031-53
ICS: A61K031-519; A61K031-517; A61K031-52; C07D487-02; C07D473-02;
C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 86 OF 312 USPATFULL on STN
AN 2004:13452 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Bebbington, David, Newbury, UNITED KINGDOM
Binch, Hayley, Harwell, UNITED KINGDOM
Charrier, Jean-Damien, Grove Wantage, FRANCE

Golec, Julian M.C., Ashbury, UNITED KINGDOM
 Kay, David, Purton, UNITED KINGDOM
 Knegtel, Ronald, Abingdon, DENMARK
 Miller, Andrew, Upton, UNITED KINGDOM
 Pierard, Francoise, Drayton, BELGIUM
 PI US 2004009974 A1 20040115
 AI US 2003-389296 A1 20030314 (10)
 PRAI US 2002-365003P 20020315 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1872
 INCL INCLM: 514/227.800
 INCLS: 514/235.800; 514/252.190; 514/269.000; 514/242.000; 544/060.000;
 544/123.000; 544/182.000; 544/295.000; 544/317.000
 NCL NCLM: 514/227.800
 NCLS: 514/235.800; 514/252.190; 514/269.000; 514/242.000; 544/060.000;
 544/123.000; 544/182.000; 544/295.000; 544/317.000
 IC [7]
 ICM: A61K031-541
 ICS: A61K031-5377; A61K031-53; A61K031-513; C07D417-14; C07D413-14;
 C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 87 OF 312 USPATFULL on STN
 AN 2004:12629 USPATFULL
 TI Apoptosis inducing molecule II and methods of use
 IN Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Zhai, Yifan, Rockville, MD, UNITED STATES
 Ullrich, Stephen, Rockville, MD, UNITED STATES
 PA Human Genome Sciences, Inc. (U.S. corporation)
 PI US 2004009147 A1 20040115
 AI US 2003-375680 A1 20030228 (10)
 RLI Continuation-in-part of Ser. No. US 2000-523323, filed on 10 Mar 2000,
 GRANTED, Pat. No. US 6635743 Continuation-in-part of Ser. No. US
 1999-252656, filed on 19 Feb 1999, GRANTED, Pat. No. US 6495520
 Continuation-in-part of Ser. No. US 1998-27287, filed on 20 Feb 1998,
 GRANTED, Pat. No. US 6479254 Continuation-in-part of Ser. No. US
 1998-3886, filed on 7 Jan 1998, ABANDONED Continuation-in-part of Ser.
 No. US 1997-822953, filed on 21 Mar 1997, ABANDONED
 PRAI US 2002-360234P 20020301 (60)
 US 1999-168380P 19991202 (60)
 US 1999-148326P 19990811 (60)
 US 1999-142657P 19990706 (60)
 US 1999-137457P 19990604 (60)
 US 1999-124041P 19990311 (60)
 US 1998-75409P 19980220 (60)
 US 1996-13923P 19960322 (60)
 US 1996-30157P 19961031 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 13322
 INCL INCLM: 424/085.100
 INCLS: 424/144.100; 514/012.000; 514/011.000; 514/109.000; 514/171.000
 NCL NCLM: 424/085.100
 NCLS: 424/144.100; 514/012.000; 514/011.000; 514/109.000; 514/171.000
 IC [7]
 ICM: A61K038-19
 ICS: A61K038-18; A61K038-13; A61K039-395; A61K031-66; A61K031-573

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 88 OF 312 USPATFULL on STN
 AN 2004:2500 USPATFULL
 TI Aryl substituted pyrazoles, triazoles and tetrazoles, and the use
 thereof
 IN Hogenkamp, Derk J., Carlsbad, CA, UNITED STATES
 Nguyen, Phong, Placentia, CA, UNITED STATES
 Yang, Ji, Plainsboro, NJ, UNITED STATES
 PA Euro-Celtique S.A. (U.S. corporation)
 PI US 2004002523 A1 20040101
 AI US 2003-456735 A1 20030609 (10)
 RLI Division of Ser. No. US 2001-814123, filed on 22 Mar 2001, PENDING
 PRAI US 2000-191757P 20000324 (60)
 DT Utility

LN.CNT 1226
INCL INCLM: 514/359.000
INCLS: 514/381.000; 514/383.000; 514/406.000; 548/252.000; 548/255.000;
548/263.200; 548/266.800; 548/366.100; 548/374.100
NCL NCLM: 514/359.000
NCLS: 514/381.000; 514/383.000; 514/406.000; 548/252.000; 548/255.000;
548/263.200; 548/266.800; 548/366.100; 548/374.100
IC [7]
ICM: A61K031-4196
ICS: A61K031-4192; A61K031-4152; C07D249-12; C07D231-04; C07D231-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 89 OF 312 USPATFULL on STN
AN 2004:2473 USPATFULL
TI Compositions useful as inhibitors of protein kinases
IN Bebbington, David, Newbury, UNITED KINGDOM
Binch, Hayley, Harwell, UNITED KINGDOM
Charrier, Jean-Damien, Grove Wantage, UNITED KINGDOM
Everitt, Simon, Beaconsfield, UNITED KINGDOM
Golec, Julian M. C., Ashbury, UNITED KINGDOM
Kay, David, Wiltshire, UNITED KINGDOM
Knegtel, Ronald, Abingdon, UNITED KINGDOM
Miller, Andrew, Upton, UNITED KINGDOM
Pierard, Francoise, Drayton, UNITED KINGDOM
PI US 2004002496 A1 20040101
AI US 2003-389709 A1 20030314 (10)
PRAI WO 2003-US7904 20030314
US 2002-364840P 20020315 (60)

DT Utility
FS APPLICATION

LN.CNT 1760
INCL INCLM: 514/245.000
INCLS: 514/227.800; 514/238.800; 514/252.190; 514/275.000; 544/060.000;
544/198.000; 544/209.000; 544/113.000; 544/122.000; 544/295.000;
544/324.000
NCL NCLM: 514/245.000
NCLS: 514/227.800; 514/238.800; 514/252.190; 514/275.000; 544/060.000;
544/198.000; 544/209.000; 544/113.000; 544/122.000; 544/295.000;
544/324.000
IC [7]
ICM: C07D417-14
ICS: C07D413-14; C07D043-14; A61K031-541; A61K031-5377; A61K031-53;
A61K031-506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 90 OF 312 USPATFULL on STN
AN 2004:2147 USPATFULL
TI Apparatus and methods for detecting ***cerebrospinal***
fluid
IN Remington, Benjamin J., Modesto, CA, UNITED STATES
Bearss, David J., Modesto, CA, UNITED STATES
Shahi, Kavian, Granite Bay, CA, UNITED STATES
PA NeuroPro Technologies, Inc., Salida, CA, UNITED STATES (U.S.
corporation)
PI US 2004002168 A1 20040101
AI US 2003-460742 A1 20030611 (10)
PRAI US 2002-388537P 20020613 (60)
US 2002-394806P 20020710 (60)

DT Utility
FS APPLICATION

LN.CNT 1535
INCL INCLM: 436/518.000
INCLS: 435/287.200; 530/388.250
NCL NCLM: 436/518.000
NCLS: 435/287.200; 530/388.250

IC [7]
ICM: G01N033-543
ICS: C12M001-34; C07K016-18; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 91 OF 312 USPATFULL on STN
AN 2004:276474 USPATFULL
TI Neutrokin-alpha polypeptides
IN Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States

PA Rosen, Craig A., Laytonsville, MD, United States
 Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
 corporation)
 PI US 6812327 B1 20041102
 AI US 2000-507968 20000222 (9)
 RLI Continuation-in-part of Ser. No. US 1999-225794, filed on 23 Feb 1999,
 now patented, Pat. No. US 6716576 Continuation-in-part of Ser. No. US
 1998-5874, filed on 12 Jan 1998, now patented, Pat. No. US 6689579
 Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996
 PRAI US 2000-176015P 20000114 (60)
 US 1999-171626P 19991223 (60)
 US 1999-171108P 19991216 (60)
 US 1999-168624P 19991203 (60)
 US 1999-167239P 19991124 (60)
 US 1999-145824P 19990727 (60)
 US 1999-142659P 19990706 (60)
 US 1999-136784P 19990528 (60)
 US 1999-131673P 19990429 (60)
 US 1999-131278P 19990427 (60)
 US 1999-130696P 19990423 (60)
 US 1999-130412P 19990416 (60)
 US 1999-127598P 19990402 (60)
 US 1999-126599P 19990326 (60)
 US 1999-124097P 19990312 (60)
 US 1999-122388P 19990302 (60)
 US 1997-36100P 19970114 (60)
 DT Utility
 FS GRANTED
 LN.CNT 15944
 INCL INCLM: 530/351.000
 INCLS: 435/069.500; 424/085.100; 424/198.100; 514/002.000; 514/012.000;
 530/300.000; 530/350.000; 530/399.000
 NCL NCLM: 530/351.000
 NCLS: 435/069.500; 424/085.100; 424/198.100; 514/002.000; 514/012.000;
 530/300.000; 530/350.000; 530/399.000
 IC [7]
 ICM: A61K038-16
 ICS: C07K002-00; C07K014-00; C07K014-52
 EXF 536/300; 536/399; 536/350; 536/23.1; 536/23.5; 424/85.1; 424/198.1;
 435/4; 435/6; 435/69.5; 435/70.1; 514/2; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 92 OF 312 USPATFULL on STN
 AN 2004:242000 USPATFULL
 TI Method of detecting axonal damage, from associated disease states using
 ****tau*** monoclonal antibodies
 IN Zemlan, Frank P., Cincinnati, OH, United States
 Campbell, Thomas A., Massillon, OH, United States
 PA University of Cincinnati, Cincinnati, OH, United States (U.S.
 corporation)
 PI US 6797478 B1 20040928
 AI US 1998-35708 19980305 (9)
 DT Utility
 FS GRANTED
 LN.CNT 915
 INCL INCLM: 435/007.100
 INCLS: 435/007.920; 435/007.940
 NCL NCLM: 435/007.100
 NCLS: 435/007.920; 435/007.940
 IC [7]
 ICM: G08N033-53
 ICS: G08N033-577; G08N033-68
 EXF 435/7.1; 435/7.92; 435/7.94
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 93 OF 312 USPATFULL on STN
 AN 2004:146863 USPATFULL
 TI Methods, compositions and kits for promoting recovery from damage to the
 central nervous system
 IN Finkelstein, Seth P., Needham, MA, United States
 Snyder, Evan Y., Jamaica Plain, MA, United States
 PA The General Hospital Corporation, Boston, MA, United States (U.S.
 corporation)
 Children's Medical Center Corporation, Boston, MA, United States (U.S.
 corporation)

AI US 2000-642277 20000818 (9)
PRAI US 1999-149561P 19990818 (60)
DT Utility
FS GRANTED
LN.CNT 2033
INCL INCLM: 424/093.700
INCLS: 424/093.100; 514/012.000
NCL NCLM: 424/093.700
NCLS: 424/093.100; 514/012.000
IC [7]
ICM: A61K035-14
ICS: A61K038-08
EXF 424/93.7; 424/198.1; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 94 OF 312 USPATFULL on STN
AN 2004:78840 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Berkeley, CA, United States
Ni, Jian, Rockville, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
Gentz, Reiner L., Rockville, MD, United States
Dillon, Patrick J., Carlsbad, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6713061 B1 20040330
AI US 2000-557908 20000421 (9)
RLI Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar 1997, now patented, Pat. No. US 6153402
PRAI US 1999-136741P 19990528 (60)
US 1999-130488P 19990422 (60)
US 1997-37341P 19970206 (60)
US 1996-28711P 19961017 (60)
US 1996-13285P 19960312 (60)
DT Utility
FS GRANTED
LN.CNT 8849
INCL INCLM: 424/185.100
INCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 424/185.100
NCLS: 424/192.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: A61K039-00
ICS: C07K014-705
EXF 530/350; 536/23.5; 435/69.1; 424/185.1; 424/192.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 95 OF 312 USPATFULL on STN
AN 2004:72577 USPATFULL
TI Hyperthermic inducible expression vectors for gene therapy and methods of use thereof
IN Tsang, Tom, Tucson, AZ, United States
Gerner, Eugene W., Tucson, AZ, United States
Harris, David T., Tucson, AZ, United States
Hersh, Evan, Tucson, AZ, United States
PA The Arizona Board of Regents on behalf of The University of Arizona, Tucson, AZ, United States (U.S. corporation)
PI US 6709858 B1 20040323
AI US 1998-185243 19981103 (9)
PRAI US 1997-64088P 19971103 (60)
DT Utility
FS GRANTED
LN.CNT 2122
INCL INCLM: 435/320.100
INCLS: 435/069.100; 435/455.000; 435/456.000; 435/458.000; 424/093.200; 514/044.000
NCL NCLM: 435/320.100
NCLS: 424/093.200; 435/069.100; 435/455.000; 435/456.000; 435/458.000; 514/044.000
IC [7]
ICM: C12N015-85
ICS: C12N015-86; A61K048-00
EXF 435/69.1; 435/70; 435/320; 435/325; 435/375; 435/446; 435/455; 435/456;

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 96 OF 312 USPATFULL on STN
 AN 2004:14935 USPATFULL
 TI Methods of inhibiting tumor growth using adenosine receptor activated cells
 IN Neely, Constance, Raleigh, NC, United States
 PA Endacea, Inc., Research Triangle Park, NC, United States (U.S. corporation)
 PI US 6680052 B1 20040120
 AI US 1999-465478 19991216 (9)
 RLI Division of Ser. No. US 1999-748559, filed on 8 Nov 1999, now patented, Pat. No. US 6159701
 DT Utility
 FS GRANTED
 LN.CNT 866
 INCL INCLM: 424/093.700
 INCLS: 424/130.100; 424/143.100; 514/046.000; 530/387.100; 536/027.600
 NCL NCLM: 424/093.700
 NCLS: 424/130.100; 424/143.100; 514/046.000; 530/387.100; 536/027.600
 IC [7]
 ICM: A01N063-00
 EXF 424/130.1; 424/143.1; 424/93.7; 514/46; 530/387.1; 536/27.6
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 97 OF 312 MEDLINE on STN DUPLICATE 4
 AN 2004272993 MEDLINE
 DN PubMed ID: 15172260
 TI ***Tau*** protein in the ***cerebrospinal*** ***fluid*** is a marker of brain injury after aortic surgery.
 AU Shiya Norihiko; Kuniyara Takashi; Miyatake Tsukasa; Matsuzaki Kenji; Yasuda Keishu
 CS Department of Cardiovascular Surgery, Hokkaido University Hospital, Sapporo, Japan.. shiyanor@med.hokudai.ac.jp
 SO Annals of thoracic surgery, (2004 Jun) 77 (6) 2034-8.
 Journal code: 15030100R. ISSN: 0003-4975.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 200406
 ED Entered STN: 20040603
 Last Updated on STN: 20040630
 Entered Medline: 20040629

L5 ANSWER 98 OF 312 EMBAL COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
 AN 2004464114 EMBASE Alert (EMBAL)
 TI A novel marker for traumatic brain injury: ***CSF*** .alpha.II-spectrin breakdown product levels.
 AU Ringger N.C.; O'Steen B.E.; Brabham J.G.; Silver X.; Pineda J.; Wang K.K.W.; Hayes R.L.; Papa L.
 CS Dr. N.C. Ringger, Department of Neuroscience, McKnight Brain Institute, University of Florida, 100 S. Newell Dr., Gainesville, FL 32610, United States. ringger@ufbi.ufl.edu
 SO Journal of Neurotrauma, (2004) 21/10 (1443-1456): Refs: 68.
 CODEN: JNEUE ISSN: 0897-7151
 CY United States
 DT Article
 LA English
 SL English

L5 ANSWER 99 OF 312 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 5
 AN 2004:336426 BIOSIS
 DN PREV200400335150
 TI Proteins released from degenerating neurons are surrogate markers for acute brain damage.
 AU Siman, Robert [Reprint Author]; McIntosh, Tracy K.; Soltesz, Kristie M.; Chen, Zhaoming; Neumar, Robert W.; Roberts, Victoria L.
 CS Sch MedDept Pharmacol, Univ Penn, 3620 Hamilton Walk, Philadelphia, PA, 19104, USA
 siman@pharm.med.upenn.edu
 SO Neurobiology of Disease, (July 2004) Vol. 16, No. 2, pp. 311-320. print.

DT Article
 LA English
 ED Entered STN: 4 Aug 2004
 Last Updated on STN: 4 Aug 2004

L5 ANSWER 100 OF 312 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 1040261268 JICST-EPlus
 TI Diagnose in the Mild Cognitive Impairment Stage of Alzheimer's Disease
 AU MARUYAMA MASAHIRO; MATSUI TOSHIFUMI; TANJI HARUKO; OTSUKI MARI
 OKAMURA NOBUYUKI
 MATSUSHITA SACHIO; HIGUCHI SUSUMU
 KODAMA MANABU
 ARAI HIROYUKI
 CS Tohoku Univ., Hospital, JPN
 Tohokudai Byoin Saiboubyotaiyakurigaku
 Tohokudai Byoin Senshinkampochiryoigaku
 Kurihama National Hospital, JPN
 Kodamahosupitaru Chihoseishikkanse
 SO Seishin Shinkeigaku Zasshi (Psychiatria et Neurology Japonica), (2004)
 vol. 106, no. 3, pp. 269-280. Journal Code: Z0692A (Fig. 7, Ref. 30)
 ISSN: 0033-2658
 CY Japan
 DT Journal; General Review
 LA Japanese
 STA New

L5 ANSWER 101 OF 312 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 2004:469271 SCISEARCH
 GA The Genuine Article (R) Number: 820SZ
 TI Biomarkers of proteolytic damage following traumatic brain injury
 AU Pineda J A (Reprint); Wang K K W; Hayes R L
 CS POB 100296, Gainesville, FL 32610 USA (Reprint); Univ Florida, Ctr Traumat
 Brain Injury Studies, Evelyn F & William L McKnight Brain Inst,
 Gainesville, FL USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610
 USA; Univ Florida, Dept Pediat, Gainesville, FL USA; Univ Florida, Dept
 Psychiat, Gainesville, FL 32611 USA
 CYA USA
 SO BRAIN PATHOLOGY, (APR 2004) Vol. 14, No. 2, pp. 202-209.
 Publisher: INT SOC NEUROPATHOLOGY, UCLA MEDICAL CENTER, SECTION
 NEUROPATHOLGY, C H S 18-126, LOS ANGELES, CA 90095-1732 USA.
 ISSN: 1015-6305.
 DT General Review; Journal
 LA English
 REC Reference Count: 135
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 102 OF 312 JICST-EPlus COPYRIGHT 2004 JST on STN
 AN 1040663415 JICST-EPlus
 TI Comprehensive study on pathology and treatment of alcohol- and
 drug-related disorders. Ischemic brain disorders and death of nerve cells
 in alcoholism.
 AU ARAI HIROYUKI; MATSUI TOSHIFUMI
 MATSUSHITA YUKIO; HIGUCHI SUSUMU
 SUZUKI GO
 YOSHIDA YOICHI
 CS Tohokudai Ronennaikasenshinkampochiryoigaku
 Kurihama National Hospital, JPN
 National Defense Medical Coll., JPN
 Miyagiken'onagawachobyoin
 SO Arukoru, Yakubutsu Kanren Shogai no Byotai to Chiryo ni kansuru Sogoteki
 Kenkyu Heisei 13-15 Nendo Sokatsu Kenkyu Hokokusho, (2004) pp. 175-182.
 Journal Code: N20041588 (Fig. 2, Ref. 6)
 CY Japan
 DT Journal; Short Communication
 LA Japanese
 STA New

L5 ANSWER 103 OF 312 MEDLINE on STN
 AN 2004339965 MEDLINE
 DN PubMed ID: 15242421
 TI Elevated interleukin-6 levels in ***cerebrospinal*** ***fluid***
 of vascular dementia patients.
 AU Wada-Isoe K; Wakutani Y; Urakami K; Nakashima K
 CS Department of Neurology, Institute of Neurological Sciences, Faculty of

u.ac.jp
SO Acta neurologica Scandinavica, (2004 Aug) 110 (2) 124-7.
Journal code: 0370336. ISSN: 0001-6314.
CY Denmark
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200410
ED Entered STN: 20040710
Last Updated on STN: 20041020
Entered Medline: 20041019

L5 ANSWER 104 OF 312 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 6
AN 10394913 IFIPAT;IFIUDB;IFICDB
TI METHODS AND COMPOSITIONS FOR PROMOTING ANGIOGENESIS; IN SITU SUPPLYING
ANTIISCHEMIC AGENTS
IN Cao Renhai (SE); Cao Yihai (SE); LeBoulch Phillipe; Pawliuk Robert
PA Genetix Pharmaceuticals Inc (60500)
PI US 2003139333 A1 20030724
AI US 2002-198917 20020719
PRAI WO 2002-US1666 20020118
FI US 2003139333 20030724
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION

CLMN 46

GI 22 Figure(s).

FIG. 1 is a graph comparing levels of angiogenesis in the Matrigel model using a low dose of transduced cells encoding GFP alone (control), VEGF-A, VEGF-C, VEGF-D, bFGF or PDGF-BB. C57Bl/10 mice were each injected subcutaneously into the abdominal with a low dose of 3×10^5 retrovirally transduced autologous myoblast cells, suspended in 0.4 ml of Matrigel. Mice were sacrificed 13 days later and the Matrigel pellet and a section of the abdominal muscle adjacent to the pellet was removed. Samples were sectioned and the number of microvessels in the abdominal muscle was quantified by visual inspection of sections under the microscope. Shown is the number of microvessels per 10 high power fields counted. The most potent angiogenic effect was observed with VEGF-A, PDGF-BB and bFGF. Analysis of the dose response curve for PDGF-BB and VEGF-A transduced cells showed that PDGF-BB was more potent than VEGFA at lower doses.

FIG. 2 is a graph comparing levels of angiogenesis in the Matrigel model using a high dose of cells transduced to express bFGF, VEGF-A and PDGF-BB. C57Bl/10 mice were each injected with a high cell dose of 2×10^6 retrovirally transduced autologous myoblast cells suspended in 0.4 ml of Matrigel. Mice were sacrificed 13 days later, the pellets were recovered, sectioned and the number of microvessels counted by visual inspection. Shown are the number of microvessels per 10 high power fields. At this cell dose, PDGF-BB was as potent as either bFGF or VEGFA at stimulating angiogenesis.

FIG. 3 shows photographs of mouse corneas 6 days following the implantation of pellets coated with control saline (A), PDGF-BB (B), VEGF-A (C) or bFGF (D) alone. Bottom panels: Quantification of the angiogenic effect elicited by each factor. Vessel length (E), clock hours (F) and area (G) are shown.

FIG. 4(A) shows photographs of mouse corneas 6 days following the implantation of pellets coated with VEGF-A alone (left panel), bFGF (middle panel) or both factors combined (right panel). (B) shows the quantification of the angiogenic effect elicited by each growth factor in terms of clock hours (left panel), vessel length (middle panel) and area (right panel).

FIG. 5 (top panels) shows photographs of mouse corneas 6 days post-transplantation of pellets coated with bFGF alone (left panel) or bFGF combined with PDGF-BB (middle and right panels). Bottom panels show photographs of mouse corneas 6 days posttransplantation of pellets coated with either VEGF-A alone (left panel) or VEGF-A combined with PDGF-BB (right panel).

FIG. 6 is a graph comparing the quantification of angiogenesis in the mouse cornea model using PDGF-BB, VEGF-A or bFGF either alone or in combination. Corneal micropockets were created with a cataract knife in the eyes of 8-week old C57Bl/6 mice. Into this pocket, aluminum sulfate pellets coated with between 80 and 160 ng of recombinant human PDGF-BB, VEGF-A, bFGF or combinations thereof were implanted and mice were monitored daily. A total of 5 mice were transplanted per group. The area of newly grown vessels was assessed 5 days post implantation. Mice implanted with control pellets showed no evidence of angiogenesis. When

by VEGF-A and PDGF-BB. The level of angiogenesis stimulated by VEGF-A in combination with PDGFBB was equivalent to that observed for bFGF alone. Unexpectedly, the most potent combination was PDGF-BB and bFGF. Of all combinations tested, PDGF-BB and bFGF together stimulated the greatest level of angiogenesis, significantly greater than that observed for VEGF-A and bFGF.

FIG. 7 is a schematic illustration of the experimental strategy to make heparin sepharose/alginate microcapsules. Heparin sepharose beads (Pharmacia: 50-150 μ m in size) are mixed with a solution of sodium alginate to a final concentration of 200 mg/ml. The heparin sepharose/alginate solution is then loaded into a 5 ml syringe and slowly injected into a coaxial airflow system constructed at Genetix. The coaxial air flow creates a mist of the heparin sepharose/alginate solution which drops into a 1.5% calcium chloride bath. Once the alginate hits the calcium solution the alginate becomes cross-linked, forming a solid gel capsule roughly in the shape of a sphere. The size of the microcapsules can vary greatly from 50-400 μ m. Large microcapsules (greater than 200 μ m in size) are removed from the capsule mixture using a 200 μ m sieve. Once formed the capsules are washed twice in sterile water and stored in buffer composed of 0.9% sodium chloride and 1 mM calcium chloride. Capsules are loaded with recombinant human PDGF-BB by incubation in binding buffer (0.9% NaCl, 1 mM CaCl₂ and 0.05% gelatin) at 4 degrees C. overnight (*16 hours) with gentle shaking. The next day the capsules are removed, washed twice in binding buffer and either cultured in vitro to determine the kinetics of PDGF-BB release or injected in vivo to assess angiogenesis. The efficiency of PDGF-BB uptake is quantified by ELISA of the binding buffer following removal of the capsules.

FIG. 8 is a graph showing that heparin sepharose/alginate capsules bind large amounts of recombinant human PDGF-BB. Shown is the amount of PDGF-BB absorbed by 3000 capsules following incubation with various quantities of growth factor. The amount of PDGF-BB remaining in the binding buffer following incubation with capsules was quantified by ELISA. Three thousand capsules were able to absorb at least 35 μ g of PDGF-BB representing 13 ng of PDGF-BB per capsule.

FIG. 9 is a graph showing that heparin sepharose/alginate microcapsules provide sustained and long term release of bound PDGF-BB at high levels in vitro. Ten μ g of recombinant human PDGF-BB was incubated with three different types of test samples. The first test sample was composed of non-encapsulated heparin sepharose beads while the second and third groups were composed of alginate encapsulated heparin sepharose beads made using either a 1.2% or a 1.6% alginate solution.

FIG. 10 is a graph showing that PDGF-BB microcapsules potentially stimulate angiogenesis in vivo in the stringent Matrigel model. Three thousand microcapsules loaded with 1 μ g or 10 μ g of PDGF-BB were mixed with 400 μ l of Matrigel and subcutaneously injected into the abdominal region of C57Bl/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope.

FIG. 11 is a graph showing that PDGF-BB microcapsules stimulate angiogenesis in infarcted rat hearts 3 weeks post-injection. Infarcted rat hearts were injected with 1600 microcapsules containing μ g (control) or 18 μ g of PDGF-BB in a volume of 20 μ l. Three weeks post injection rats were sacrificed, hearts were removed, fixed, sectioned and the number of microvessels within the infarct region quantified by visual inspection under a microscope. Shown is the number of microvessels per 5 high power fields for recipients of control and PDGF-BB microcapsules.

FIG. 12 shows an analysis of cardiac function in rats injected with control vs. PDGF-BB microcapsules following myocardial infarction. Left ventricular pressure (LVP), dp/dt , neg dp/dt and τ were measured prior to sacrifice at 3 weeks post injection. Left ventricular pressure (LVP) is the maximum pressure in the left ventricle during contraction. The dp/dt variable is the first derivative of the pressure wave and is separately viewed for the upstroke (dp/dt) and the downstroke (neg dp/dt). The upstroke (dp/dt) is a measure of contractility and reflects the condition of the muscle independent of the pressure. Neg dp/dt reflects the relaxation of the muscle, which together with the relaxation constant, τ , provides information on the stiffness of the ventricular wall following infarction. A significant improvement in all parameters was detected in rats injected with PDGF-BB microcapsules.

FIG. 13 is a graph showing that PDGF-BB and bFGF delivered by slow release microcapsules potentially synergize to stimulate angiogenesis in vivo in the stringent Matrigel model. Three thousand microcapsules loaded with 1 μ g

into the abdominal region of C57BL/10 mice. Thirteen days later mice were sacrificed, the pellets and a section of the adjacent abdominal muscle was removed, fixed, sectioned and the number of microvessels quantified by visual inspection of the sections under the microscope.

FIG. 14 is a schematic illustration of the structure of various angiogenic expression plasmids. All vectors were constructed using the pCI vector backbone from Promega. All vectors contained the Cytomegalovirus immediate-early enhancer/promoter region, a chimeric intron and the late poly adenylation signal from SV40. The cDNA encoding either human PDGF-BB, VEGF-A or bFGF was inserted into this vector downstream of the chimeric intron. A cDNA encoding for the mature PDGF-BB protein was cislinked to the secretory signal from the murine IgG kappa immunoglobulin light chain gene while the VEGF-A cDNA utilized its endogenous secretory signal. The bFGF cDNA was linked in cis to the secretory signal from the human Interleukin-2 cDNA. The level of angiogenic protein secreted from transiently transfected 293T cells, as assessed by ELISA, is shown to the right.

FIG. 15 is a comparison of angiogenic features of the PDGF family. Micropellets of PDGF-AA (a), PDGF-BB (b) or PDGF-AB (c) were implanted into corneal micropockets of C57BL/6 mice. Corneal neovascularization was measured on day 5 after growth factor implantation. Arrows point to the implanted pellets. Photographs represent 20 x amplification of the mouse eye. Quantification of corneal neovascularization is presented as maximal areas of neovascularization (e). Graphs represent mean values (+SEM) of 11-16 eyes (6-8 mice) in each group. Nylon meshes containing PDGF-BB (g) or BSA (t) were implanted on CAMs of 6-d-old chick embryos. After 6-day implantation, the formation of new blood vessels was examined under a stereoscope. A CAM with a methylcellulose mesh containing BSA alone served as a negative control (f). New blood vessels and sprouts are marked with arrows in g. M=mesh.

FIG. 16 shows synergistic angiogenesis induced by bFGF and PDGFBB. Micropellets containing no growth factor (a), 160 ng PDGFBB (b), 160 ng VEGF (c), 160 ng PDGF-BB plus 160 ng VEGF (d), 80 ng FGF-2 (e), or 160 ng PDGF-BB plus 80 ng FGF-2 (f) were implanted into corneal micropockets of C57BL/6 mice. Corneal neovascularization was examined on day 5 after growth factor implantation. Arrows point to the implanted pellets. Photographs represent 20 x amplification of the mouse eye. Quantification of corneal neovascularization is presented as maximal vessel areas of neovascularization (g and h). Graphs represent mean values (+SEM) of 12-16 eyes (6-8 mice) in each group. Slow release microcapsules containing PDGF-BB alone, FGF2 alone, or PDGF-BB plus FGF-2 was subcutaneously injected into the abdominal region of C57BL/6 mice. Neovascularization was quantified by counting microvessels in histological sections under a microscope (i). At least 10 different fields were randomly counted.

FIG. 17 shows stability of blood vessels induced by micropellets containing 160 ng PDGF-BB, 40 ng FGF-2, 160 ng PDGF-BB plus 40 ng FGF-2, 160 ng VEGF, or 160 ng PDGF-BB plus 160 ng VEGF. Micropellets were implanted into mouse corneal micropockets. The corneal neovascularization was examined and photographed at the indicated time points. Arrows indicate the implanted pellet. Asterisks indicate positions of pellets in those corneas that lost implanted pellets.

FIG. 18 shows corneal neovascularization after depletion of angiogenic factors. Angiogenic factors were implanted into corneal micropockets of C57BL/6 mice. Ten to twelve corneas were used in each group. At day 6 after implantation, the implanted angiogenic factors were removed. The corneal neovascularization was examined and photographed at the indicated time points. Arrows indicate the implanted pellet. Asterisks indicate former positions of removed pellets.

FIG. 19 shows graphs of vessel Maturation Index as percentages of mural positive vessels at day 5 (a), day 12 (b), and day 25 (c). Results are presented as mean determinants (+SEM) of 6-8 serial sections in each group (20 x).

FIG. 20 shows stimulation of collateralogenesis and improvement of blood perfusion by dual delivery of FGF-2/PDGF-BB. Panels a-d show day 23 after ligation of femoral artery (position marked with asterisks), angiograph analysis of ischemic hind limbs of PBS buffer-(a), FGF-2-(b), PDGF-BB-(c) and FGF-2/PDGF-BB-(d) treated groups. Arrows in panels b-d point to newly formed collaterals and arrowheads in b and d point to a direct comparison of vessel dilation of FGF-2- and FGF-2/PDGF-BB-induced collaterals. Panels f-n show anti-alpha-SMA staining of histological sections of PBS buffer-(f and g), FGF-2-(h and i), PDGF-BB-(and k) and FGF-2/PDGF-BB-(l-n) treated ischemic hind limb muscle tissues. Arrows in f-n point to newly formed arterial vessels. Panel o shows quantification of large vessel lumen areas (greater-than 700 μm^2) as % of total vessel

perfusion.
 FIG. 21 shows in situ detection of PDGFR-alpha and -beta on newly formed blood vessels. Mouse corneas implanted with FGF-2 (a, c and e) or PDGF-BB (b and d) were removed at day 5 after implantation. Bright-field photomicrographs of emulsion autoradiograms of corneal tissue sections hybridized with the oligonucleotide probes for mouse PDGFR-alpha (a and b) and beta (c and d) show labeled vascular endothelial cells and smooth muscle cells. A 50-mer random probe was used as a negative control in detection of FGF-2-induced corneal vessels (e). Panel f shows a schematic representation of the role of FGF-2/PDGF in blood vessel stability.
 FIG. 22 shows the effect of PDGF-BB on heart tissue remodeling by improvement in endocardial regional wall motion with no increase in normalized wall thickening. Panel (a) shows the change in the extent of target area with reduced endocardial motion at stress. Panel (b) shows a similar result when the ratio of AUCtarget/AUCnon-target was used as a measure of regional wall motion.!

L5 ANSWER 105 OF 312 USPATFULL on STN DUPLICATE 7
 AN 2003:251870 USPATFULL
 TI Adipocyte-specific protein homologs
 IN Sheppard, Paul O., Granite Falls, WA, UNITED STATES
 PA ZymoGenetics, Inc. (U.S. corporation)
 PI US 2003176659 A1 20030918
 US 6803450 B2 20041012
 AI US 2003-392706 A1 20030320 (10)
 RLI Continuation of Ser. No. US 2000-506852, filed on 17 Feb 2000, GRANTED, Pat. No. US 6566499 Continuation-in-part of Ser. No. US 1998-118408, filed on 17 Jul 1998, GRANTED, Pat. No. US 6265544
 PRAI US 1997-53154P 19970718 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3646
 INCL INCLM: 530/356.000
 INCLS: 530/388.250; 536/023.500; 435/006.000; 435/069.100; 435/320.100; 435/325.000
 NCL NCLM: 530/350.000
 NCLS: 536/023.100; 435/252.300; 435/325.000; 435/320.100; 435/069.100
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C07K014-78
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 106 OF 312 USPATFULL on STN DUPLICATE 8
 AN 2003:120843 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors
 IN Davies, Robert, Arlington, MA, UNITED STATES
 Li, Pan, Arlington, MA, UNITED STATES
 PI US 2003083327 A1 20030501
 US 6610677 B2 20030826
 AI US 2001-952833 A1 20010914 (9)
 PRAI US 2000-232795P 20000915 (60)
 US 2000-257887P 20001221 (60)
 US 2001-286949P 20010427 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8910
 INCL INCLM: 514/227.800
 INCLS: 514/235.800; 514/252.020; 514/252.030; 514/255.050; 514/256.000; 514/275.000; 544/060.000; 544/120.000; 544/122.000; 544/238.000; 544/295.000; 544/331.000; 514/241.000; 544/212.000
 NCL NCLM: 514/183.000
 NCLS: 514/217.050; 514/217.060; 514/233.500; 514/235.800; 514/236.200; 514/236.500; 514/242.000; 514/245.000; 514/252.010; 514/252.020; 514/252.030; 514/252.040; 514/252.050; 514/252.060; 514/252.110; 514/255.050; 540/598.000; 540/601.000; 544/111.000; 544/112.000; 544/113.000; 544/114.000; 544/120.000; 544/122.000; 544/179.000; 544/182.000; 544/238.000; 544/357.000; 544/405.000
 IC [7]
 ICM: A61K031-541
 ICS: A61K031-5377; A61K031-506; C07D417-14; C07D413-14; C07D043-14
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 107 OF 312 USPATFULL on STN DUPLICATE 9
 AN 2003:113534 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors

Charri r, Jean-Damien, Wantage, UNITED KINGDOM
 Davies, Robert, Arlington, MA, UNITED STATES
 Golec, Julian M.C., Swindon, UNITED KINGDOM
 Kay, David, Purton, UNITED KINGDOM
 Knegtel, Ronald, Abingdon, UNITED KINGDOM
 Patel, Sanjay, Abingdon, UNITED KINGDOM

PI US 2003078275 A1 20030424
 US 6653301 B2 20031125

AI US 2001-27001 A1 20011219 (10)

PRAI US 2000-257887P 20001221 (60)
 US 2001-286949P 20010427 (60)

DT Utility
 FS APPLICATION
 LN.CNT 9081

INCL INCLM: 514/260.100
 INCLS: 514/261.100; 514/262.100; 514/264.110; 514/265.100; 514/266.230;
 544/278.000; 544/284.000; 544/256.000; 544/254.000

NCL NCLM: 514/183.000
 NCLS: 514/231.200; 514/258.100; 514/262.100; 514/263.100; 514/266.300;
 514/266.400; 514/408.000; 544/106.000; 544/253.000; 544/264.000;
 544/279.000; 544/283.000; 544/286.000; 544/293.000; 544/309.000;
 544/326.000

IC [7]
 ICM: A61K031-519
 ICS: A61K031-517; C07D487-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 108 OF 312 USPATFULL on STN DUPLICATE 10
 AN 2003:113425 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors
 IN Davies, Robert, Arlington, MA, UNITED STATES
 Bebbington, David, Newbury, UNITED KINGDOM
 Knegtel, Ronald, Abingdom, UNITED KINGDOM
 Wannamaker, Marion, Stow, MA, UNITED STATES
 Li, Pan, Arlington, MA, UNITED STATES
 Forster, Cornelia, Pelham, NH, UNITED STATES
 Pierce, Albert, Somerville, MA, UNITED STATES

PI US 2003078166 A1 20030424
 US 6696452 B2 20040224

AI US 2001-955601 A1 20010914 (9)

PRAI US 2000-232795P 20000915 (60)
 US 2000-257887P 20001221 (60)
 US 2001-286949P 20010427 (60)

DT Utility
 FS APPLICATION
 LN.CNT 8804

INCL INCLM: 504/239.000
 INCLS: 544/060.000; 544/122.000; 544/328.000

NCL NCLM: 514/256.000
 NCLS: 514/266.230; 514/269.000; 544/284.000; 544/298.000; 544/319.000;
 544/327.000; 544/328.000

IC [7]
 ICM: A01N043-54
 ICS: C07D417-14; C07D413-14; C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 109 OF 312 USPATFULL on STN DUPLICATE 11
 AN 2003:106775 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors
 IN Bebbington, David, Newbury Berkshire, UNITED KINGDOM
 Binch, Hayley, Harwell Oxon, UNITED KINGDOM
 Knegtel, Ronald, Abingdom, UNITED KINGDOM
 Golec, Julian, Ashbury, UNITED KINGDOM
 Patel, Sanjay, Abingdom, UNITED KINGDOM
 Charrier, Jean-Damien, Bishop's Itchington, UNITED KINGDOM
 Kay, David, Church Path, UNITED KINGDOM
 Davies, Robert, Arlington, MA, UNITED STATES
 Li, Pan, Arlington, MA, UNITED STATES
 Wannamaker, Marion, Stow, MA, UNITED STATES
 Forster, Cornelia, Pelham, NH, UNITED STATES
 Pierce, Albert, Somerville, MA, UNITED STATES

PI US 2003073687 A1 20030417
 US 6660731 B2 20031209

AI US 2001-952671 A1 20010914 (9)

PRAI US 2000-232795P 20000915 (60)

DT US 2001-286949P 20010427 (60)
FS Utility
LN.CNT APPLICATION
INCL 8698
INCLM: 514/228.200
INCLS: 514/233.800; 514/252.170; 514/266.220; 514/266.230; 544/060.000;
544/116.000; 544/284.000
NCL NCLM: 514/217.060
NCLS: 514/235.800; 514/252.190; 514/275.000; 540/601.000; 544/122.000;
544/295.000; 544/298.000; 544/328.000
IC [7]
ICM: C07D417-14
ICS: C07D413-14; C07D043-14; A61K031-541; A61K031-5377; A61K031-517
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 110 OF 312 USPATFULL on STN DUPLICATE 12
AN 2003:100181 USPATFULL
TI Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and
pyrroles, and the use thereof
IN Hogenkamp, Derk, Carlsbad, CA, UNITED STATES
Upasani, Ravindra, Foothill Ranch, CA, UNITED STATES
Nguyen, Phong, Placentia, CA, UNITED STATES
PA EURO-CELTIQUE S.A. (U.S. corporation)
PI US 2003069292 A1 20030410
US 6737418 B2 20040518
AI US 2002-134697 A1 20020430 (10)
RLI Division of Ser. No. US 2000-533864, filed on 24 Mar 2000, GRANTED, Pat.
No. US 6414011
PRAI US 1999-126553P 19990326 (60)
DT Utility
FS APPLICATION
LN.CNT 2990
INCL INCLM: 514/365.000
INCLS: 514/374.000; 514/396.000; 514/406.000; 548/182.000; 548/204.000;
548/225.000; 548/235.000; 548/354.100; 548/377.100; 548/530.000;
514/408.000; 548/577.000
NCL NCLM: 514/183.000
NCLS: 514/365.000; 514/374.000; 514/396.000; 514/399.000; 548/202.000;
548/204.000; 548/205.000; 548/235.000; 548/300.100; 548/311.100;
548/333.100; 548/335.500; 548/341.500
IC [7]
ICM: A61K031-421
ICS: A61K031-426; A61K031-4164; A61K031-415; A61K031-40; C07D277-32
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 111 OF 312 USPATFULL on STN DUPLICATE 13
AN 2003:93620 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Knegetel, Ronald, Abingdom, UNITED KINGDOM
Bebbington, David, Newbury Berkshire, UNITED KINGDOM
Binch, Hayley, Oxon, UNITED KINGDOM
Golec, Julian, Swinden, UNITED KINGDOM
Patel, Sanjay, Oxon, UNITED KINGDOM
Charrier, Jean-Damien, Bishop's Itchington, UNITED KINGDOM
Kay, David, Purton Wiltshire, UNITED KINGDOM
Davies, Robert, Arlington, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
Wannamaker, Marion, Stow, MA, UNITED STATES
Forster, Cornelia, Pelham, NH, UNITED STATES
Pierce, Albert, Somerville, MA, UNITED STATES
PI US 2003064981 A1 20030403
US 6613776 B2 20030902
AI US 2001-952836 A1 20010914 (9)
PRAI US 2000-232795P 20000915 (60)
US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8962
INCL INCLM: 514/227.800
INCLS: 514/235.800; 514/241.000; 514/252.030; 514/255.050; 514/256.000;
514/333.000; 514/341.000; 514/252.020
NCL NCLM: 514/300.000
NCLS: 514/217.040; 514/217.050; 514/231.500; 514/252.130; 514/303.000;
514/310.000; 514/314.000; 514/320.000; 514/321.000; 514/333.000;

546/139.000; 546/159.000; 546/193.000; 546/275.400; 546/276.100

IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-506; A61K031-501; A61K031-498; A61K031-444;
A61K031-4439

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 112 OF 312 USPATFULL on STN DUPLICATE 14
AN 2003:79117 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Davies, Robert, Arlington, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
Golec, Julian, Ashbury, UNITED KINGDOM
PI US 2003055044 A1 20030320
US 6638926 B2 20031028
AI US 2001-953505 A1 20010914 (9)
PRAI US 2000-232795P 20000915 (60)
US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 9881
INCL INCLM: 514/217.050
INCLS: 514/245.000; 514/227.800; 514/235.800
NCL NCLM: 514/217.050
NCLS: 514/236.500; 514/245.000; 540/598.000; 544/113.000; 544/209.000;
544/212.000

IC [7]
ICM: A61K031-55
ICS: A61K031-541; A61K031-5377; A61K031-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 113 OF 312 USPATFULL on STN DUPLICATE 15
AN 2003:51585 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Golec, Julian, Swindon, UNITED KINGDOM
Miller, Andrew, Didcot, UNITED KINGDOM
Knegtel, Ronald, Abingdon, UNITED KINGDOM
PI US 2003036543 A1 20030220
US 6664247 B2 20031216
AI US 2001-25164 A1 20011219 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8794
INCL INCLM: 514/234.500
INCLS: 514/266.210; 514/269.000; 544/114.000; 544/116.000; 544/295.000;
544/284.000; 544/315.000; 514/252.170; 514/252.190
NCL NCLM: 514/183.000
NCLS: 514/247.000; 514/256.000; 514/269.000; 514/274.000; 514/406.000;
514/407.000; 544/315.000; 544/326.000; 544/333.000; 548/356.100;
548/371.400; 548/373.100

IC [7]
ICM: C07D413-14
ICS: C07D043-14; A61K031-5377; A61K031-517

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 114 OF 312 USPATFULL on STN DUPLICATE 16
AN 2003:30936 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Golec, Julian, Swindon, UNITED KINGDOM
Pierard, Francoise, Drayton, UNITED KINGDOM
PI US 2003022885 A1 20030130
US 6727251 B2 20040427
AI US 2001-34019 A1 20011220 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 2271

INCLS: 514/217.060; 514/227.800; 514/235.800; 514/245.000; 514/269.000;
514/275.000; 540/599.000; 540/601.000; 544/060.000; 544/112.000;
544/122.000; 544/206.000; 544/209.000; 544/324.000
NCL NCLM: 514/241.000
NCLS: 514/256.000; 544/194.000; 544/204.000; 544/212.000; 544/328.000
IC [7]
ICM: C07D417-14
ICS: C07D413-14; C07D043-14; A61K031-55; A61K031-5377; A61K031-506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 115 OF 312 USPATFULL on STN DUPLICATE 17
AN 2003:4125 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
PI US 2003004164 A1 20030102
US 6656939 B2 20031202
AI US 2001-34683 A1 20011220 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 2215
INCL INCLM: 514/242.000
INCLS: 514/252.050; 544/238.000; 544/182.000
NCL NCLM: 514/242.000
NCLS: 514/336.000; 514/365.000; 514/366.000; 514/438.000; 544/182.000;
546/275.400; 548/161.000; 548/182.000; 548/190.000; 549/083.000
IC [7]
ICM: C07D043-04
ICS: A61K031-53; A61K031-501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 116 OF 312 USPATFULL on STN DUPLICATE 18
AN 2003:4122 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Golec, Julian, Swindon, UNITED KINGDOM
Green, Jeremy, Burlington, MA, UNITED STATES
Kay, David, Wiltshire, UNITED KINGDOM
Knegt, Ronald, Abingdon, UNITED KINGDOM
Miller, Andrew, Upton Didcot, UNITED KINGDOM
Tomlison, Ronald, Marlborough, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
PI US 2003004161 A1 20030102
US 6653300 B2 20031125
AI US 2001-26975 A1 20011219 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 9244
INCL INCLM: 514/227.800
INCLS: 514/234.500; 514/235.800; 514/252.190; 514/252.170; 514/266.230;
514/269.000; 544/060.000; 544/123.000; 544/284.000; 544/317.000
NCL NCLM: 514/183.000
NCLS: 514/264.100; 514/266.100; 514/266.230; 514/266.400; 514/269.000;
514/274.000; 514/403.000; 544/253.000; 544/283.000; 544/286.000;
544/296.000; 544/298.000; 544/315.000; 544/322.000; 544/326.000;
544/333.000; 548/354.100; 548/356.100; 548/364.700; 548/371.400
IC [7]
ICM: C07D417-14
ICS: C07D413-14; C07D043-14; A61K031-541; A61K031-5377; A61K031-517;
A61K031-513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 117 OF 312 USPATFULL on STN
AN 2003:324335 USPATFULL
TI Antibodies that immunospecifically bind to TRAIL receptors
IN Salcedo, Theodora, East Syracuse, NY, UNITED STATES
Roschke, Viktor, Rockville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
PI US 2003228309 A1 20031211

RLI Continuation-in-part of Ser. No. US 2001-986149, filed on 7 Nov 2001,
 PENDING
 PRAI US 2001-331309P 20011114 (60)
 US 2002-377973P 20020507 (60)
 US 2002-403376P 20020815 (60)
 US 2000-246612P 20001108 (60)
 US 2000-248847P 20001116 (60)
 US 2000-252904P 20001127 (60)
 US 2001-295018P 20010604 (60)
 US 2001-327359P 20011009 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15635
 INCL INCLM: 424/144.100
 INCLS: 530/388.220
 NCL NCLM: 424/144.100
 NCLS: 530/388.220
 IC [7]
 ICM: A61K039-395
 ICS: C07K016-30
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 118 OF 312 USPATFULL on STN
 AN 2003:319331 USPATFULL
 TI Carbocyclic and heterocyclic substituted semicarbazones and
 thiosemicarbazones and the use thereof
 IN Wang, Yan, San Diego, CA, UNITED STATES
 Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Lan, Nancy C., Altadena, CA, UNITED STATES
 Keana, John FW, Eugene, OR, UNITED STATES
 Ilyin, Victor I, Irvine, CA, UNITED STATES
 Weber, Eckard, San Diego, CA, UNITED STATES
 PA Euro-Celtiques S.A. (U.S. corporation)
 PI US 2003225080 A1 20031204
 AI US 2003-463814 A1 20030618 (10)
 RLI Continuation of Ser. No. US 1999-421403, filed on 21 Oct 1999, GRANTED,
 Pat. No. US 6613803 Continuation of Ser. No. WO 1998-US8004, filed on 22
 Apr 1998, PENDING
 PRAI US 1997-44530P 19970422 (60)
 US 1997-62649P 19971022 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2463
 INCL INCLM: 514/235.200
 INCLS: 514/317.000; 514/252.130; 514/255.010; 544/111.000; 544/259.000;
 546/226.000
 NCL NCLM: 514/235.200
 NCLS: 514/317.000; 514/252.130; 514/255.010; 544/111.000; 544/259.000;
 546/226.000
 IC [7]
 ICM: C07D413-02
 ICS: C07D043-02; A61K031-5377; A61K031-496
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 119 OF 312 USPATFULL on STN
 AN 2003:319324 USPATFULL
 TI Compositions useful as inhibitors of protein kinases
 IN Bebbington, David, Newbury, UNITED KINGDOM
 Binch, Hayley, Harwell, UNITED KINGDOM
 Charrier, Jean-Damien, Grove Wantage, UNITED KINGDOM
 Everitt, Simon, Beaconsfield, UNITED KINGDOM
 Golec, Julian M.C., Ashbury, UNITED KINGDOM
 Kay, David, Purton, UNITED KINGDOM
 Knegtel, Ronald, Abingdon, UNITED KINGDOM
 Miller, Andrew, Upton, UNITED KINGDOM
 Pierard, Francoise, Drayton, UNITED KINGDOM
 Pierce, Albert C., Cambridge, MA, UNITED STATES
 PI US 2003225073 A1 20031204
 AI US 2003-389707 A1 20030314 (10)
 PRAI US 2002-364842P 20020315 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1902
 INCL INCLM: 514/227.800
 INCLS: 514/241.000; 514/242.000; 544/182.000; 514/235.800; 544/060.000;

NCL NCLM: 514/227.800
NCLS: 514/241.000; 514/242.000; 544/182.000; 514/235.800; 544/060.000;
544/112.000; 544/113.000; 544/209.000

IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-53; C07D417-14; C07D413-14; C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 120 OF 312 USPATFULL on STN

AN 2003:318636 USPATFULL

TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases

IN Becker, Kenneth David, San Diego, CA, UNITED STATES

Velicelebi, Gonul, San Diego, CA, UNITED STATES

Ellliott, Kathryn J., San Diego, CA, UNITED STATES

Wang, Xin, San Diego, CA, UNITED STATES

Tanzi, Rudolph E., Hull, MA, UNITED STATES

Bertram, Lars, Brighton, MA, UNITED STATES

Saunders, Aleister J., Philadelphia, PA, UNITED STATES

Mullin, Kristina M., south Boston, MA, UNITED STATES

Sampson, Andrew Joseph, Dayton, OH, UNITED STATES

PA The General Hospital Corporation (U.S. corporation)

PI US 2003224380 A1 20031204

AI US 2002-282174 A1 20021025 (10)

PRAI US 2001-339525P 20011025 (60)

US 2001-338010P 20011108 (60)

US 2001-336929P 20011108 (60)

US 2001-338363P 20011109 (60)

US 2001-337052P 20011204 (60)

US 2002-368919P 20020328 (60)

US 2001-348065P 20011025 (60)

US 2001-336983P 20011102 (60)

DT Utility

FS APPLICATION

LN.CNT 13662

INCL INCLM: 435/006.000

NCL NCLM: 435/006.000

IC [7]

ICM: C12Q001-68

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 121 OF 312 USPATFULL on STN

AN 2003:318635 USPATFULL

TI Novel nucleic acids and polypeptides

IN Tang, Y. Tom, San Jose, CA, UNITED STATES

Yang, Yonghong, San Jose, CA, UNITED STATES

Wang, Zhiwei, Sunnyvale, CA, UNITED STATES

Weng, Gezhi, Piedmont, CA, UNITED STATES

Ma, Yunging, Santa Clara, CA, UNITED STATES

PI US 2003224379 A1 20031204

AI US 2002-243552 A1 20020912 (10)

RLI Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed
on 21 Jan 2000, PENDING

PRAI WO 2001-US2623 20010125

WO 2001-US3800 20010205

WO 2001-US4927 20010226

WO 2001-US4941 20010305

WO 2001-US8631 20010330

WO 2001-US8656 20010416

WO 2001-US14827 20010516

US 2001-322511P 20010913 (60)

DT Utility

FS APPLICATION

LN.CNT 13810

INCL INCLM: 435/006.000

INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200

NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200

IC [7]

ICM: C12Q001-68

ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47; C12N009-00

L5 ANSWER 122 OF 312 USPATFULL on STN
AN 2003:318254 USPATFULL
TI Antibodies that immunospecifically bind to BLYS
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Choi, Gil H., Rockville, MD, UNITED STATES
Vaughan, Tristan, Cambridge, UNITED KINGDOM
Hilbert, David, Bethesda, MD, UNITED STATES
PI US 2003223996 A1 20031204
AI US 2002-293418 A1 20021114 (10)
RLI Continuation-in-part of Ser. No. US 2001-880748, filed on 15 Jun 2001,
PENDING
PRAI US 2001-331469P 20011116 (60)
US 2001-340817P 20011219 (60)
US 2000-212210P 20000616 (60)
US 2000-240816P 20001017 (60)
US 2001-276248P 20010316 (60)
US 2001-277379P 20010321 (60)
US 2001-293499P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 18910
INCL INCLM: 424/146.100
INCLS: 530/388.260
NCL NCLM: 424/146.100
NCLS: 530/388.260
IC [7]
ICM: A61K039-395
ICS: C07K016-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 123 OF 312 USPATFULL on STN
AN 2003:312278 USPATFULL
TI Albumin fusion proteins
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PI US 2003219875 A1 20031127
AI US 2001-833118 A1 20010412 (9)
PRAI US 2000-256931P 20001221 (60)
US 2000-199384P 20000425 (60)
US 2000-229358P 20000412 (60)
DT Utility
FS APPLICATION
LN.CNT 15415
INCL INCLM: 435/069.700
INCLS: 435/325.000; 435/320.100; 530/362.000; 514/012.000; 536/023.500
NCL NCLM: 435/069.700
NCLS: 435/325.000; 435/320.100; 530/362.000; 514/012.000; 536/023.500
IC [7]
ICM: A61K038-38
ICS: C07H021-04; C12P021-04; C07K014-76

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 124 OF 312 USPATFULL on STN
AN 2003:312137 USPATFULL
TI Polypeptides related to natriuretic peptides and methods of their
identification and use
IN Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PA Biosite Incorporated (U.S. corporation)
PI US 2003219734 A1 20031127
AI US 2003-419059 A1 20030417 (10)
RLI Continuation-in-part of Ser. No. US 2001-835298, filed on 13 Apr 2001,
PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20
Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-139086, filed
on 4 May 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
US 2001-288871P 20010504 (60)
US 2001-315642P 20010828 (60)
DT Utility
FS APPLICATION
LN.CNT 1949
INCL INCLM: 435/005.000

NCL NCLM: 435/005.000
 NCLS: 435/007.100; 436/518.000; 702/019.000
 IC [7]
 ICM: C12Q001-70
 ICS: G01N033-53; G06F019-00; G01N033-48; G01N033-50; G01N033-543
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 125 OF 312 USPATFULL on STN
 AN 2003:306455 USPATFULL
 TI Non-selective cation channel in neural cells and methods for treating brain swelling
 IN Simard, J. Marc, Baltimore, MD, UNITED STATES
 Chen, Mingkui, Baltimore, MD, UNITED STATES
 PI US 2003215889 A1 20031120
 AI US 2003-391561 A1 20030320 (10)
 PRAI US 2002-365933P 20020320 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2611
 INCL INCLM: 435/007.200
 INCLS: 514/342.000; 514/369.000; 514/592.000; 435/368.000; 435/317.100
 NCL NCLM: 435/007.200
 NCLS: 514/342.000; 514/369.000; 514/592.000; 435/368.000; 435/317.100
 IC [7]
 ICM: A61K031-4439
 ICS: A61K031-426; G01N033-53; G01N033-567; A61K031-175; C12N005-08
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 126 OF 312 USPATFULL on STN
 AN 2003:306440 USPATFULL
 TI Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same
 IN Gewirth, Daniel T., Durham, NC, UNITED STATES
 Nicchitta, Christopher V., Durham, NC, UNITED STATES
 PA Duke University (U.S. corporation)
 PI US 2003215874 A1 20031120
 AI US 2002-260104 A1 20020930 (10)
 PRAI US 2001-326291P 20011001 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 12401
 INCL INCLM: 435/007.100
 INCLS: 435/189.000; 702/019.000
 NCL NCLM: 435/007.100
 NCLS: 435/189.000; 702/019.000
 IC [7]
 ICM: G01N033-53
 ICS: G06F019-00; G01N033-48; G01N033-50; C12N009-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 127 OF 312 USPATFULL on STN
 AN 2003:300398 USPATFULL
 TI Methods and compositions to assess oxidative brain injury
 IN Roberts, L. Jackson, II, Gallatin, TN, UNITED STATES
 PI US 2003211622 A1 20031113
 AI US 2003-383704 A1 20030307 (10)
 RLI Continuation-in-part of Ser. No. US 1999-342813, filed on 29 Jun 1999, GRANTED, Pat. No. US 6620800
 PRAI US 1998-91136P 19980629 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1995
 INCL INCLM: 436/062.000
 NCL NCLM: 436/062.000
 IC [7]
 ICM: G01N033-18
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 128 OF 312 USPATFULL on STN
 AN 2003:294814 USPATFULL
 TI Inducible expression vectors and methods of use thereof
 IN Tsang, Thomas Chun-Chang, Tucson, AZ, UNITED STATES
 Gerner, Eugene W., Tucson, AZ, UNITED STATES
 Harris, David T., Tucson, AZ, UNITED STATES

PA Vasanwala, Farha, Tucson, AZ, UNITED STATES
The Arizona Board of Regents, Tucson, AZ, UNITED STATES, 85721 (U.S. corporation)
PI US 2003207832 A1 20031106
AI US 2002-152577 A1 20020523 (10)
RLI Continuation-in-part of Ser. No. US 2002-108486, filed on 29 Mar 2002, PENDING Continuation-in-part of Ser. No. US 1998-185243, filed on 3 Nov 1998, PENDING
PRAI US 2001-292943P 20010523 (60)
US 2001-279634P 20010329 (60)
US 1997-64088P 19971103 (60)
DT Utility
FS APPLICATION
LN.CNT 2578
INCL INCLM: 514/044.000
INCLS: 600/001.000
NCL NCLM: 514/044.000
NCLS: 600/001.000
IC [7]
ICM: A61K048-00
ICS: A61N005-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 129 OF 312 USPATFULL on STN
AN 2003:294294 USPATFULL
TI Diagnostics and therapeutics for macular degeneration-related disorders
IN Hageman, Gregory S., Coralville, IA, UNITED STATES
Mullins, Robert F., Coralville, IA, UNITED STATES
PA University of Iowa Research Foundation, Iowa City, IA, UNITED STATES (U.S. corporation)
PI US 2003207309 A1 20031106
AI US 2003-419305 A1 20030418 (10)
RLI Continuation of Ser. No. US 2001-845745, filed on 30 Apr 2001, ABANDONED Continuation-in-part of Ser. No. US 2000-510230, filed on 22 Feb 2000, ABANDONED
PRAI US 2000-200698P 20000429 (60)
DT Utility
FS APPLICATION
LN.CNT 3105
INCL INCLM: 435/006.000
INCLS: 435/007.100
NCL NCLM: 435/006.000
NCLS: 435/007.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 130 OF 312 USPATFULL on STN
AN 2003:283182 USPATFULL
TI Pyrimidine-based compounds useful as GSK-3 inhibitors
IN Choquette, Deborah, Medford, MA, UNITED STATES
Davies, Robert J., Arlington, MA, UNITED STATES
Wannamaker, Marion W., Stow, MA, UNITED STATES
PI US 2003199526 A1 20031023
AI US 2002-314905 A1 20021209 (10)
PRAI US 2001-338857P 20011207 (60)
DT Utility
FS APPLICATION
LN.CNT 2100
INCL INCLM: 514/260.100
INCLS: 514/263.210; 514/261.100; 514/265.100; 514/264.110; 544/254.000; 544/255.000; 544/277.000; 544/276.000; 544/278.000; 544/279.000; 544/280.000; 544/296.000; 514/256.000
NCL NCLM: 514/260.100
NCLS: 514/263.210; 514/261.100; 514/265.100; 514/264.110; 544/254.000; 544/255.000; 544/277.000; 544/276.000; 544/278.000; 544/279.000; 544/280.000; 544/296.000; 514/256.000
IC [7]
ICM: A61K031-52
ICS: A61K031-519; C07D473-34; C07D491-02; C07D487-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 131 OF 312 USPATFULL on STN
AN 2003:283125 USPATFULL

IN Schwartz, Gary K., Briarcliff Manor, NY, UNITED STATES
PA Albino, Anthony P., New York, NY, UNITED STATES
PI Sloan - Kettering Institute for Cancer Research (U.S. corporation)
AI US 2003199469 A1 20031023
RLI US 2002-215178 A1 20020807 (10)
Continuation of Ser. No. US 1998-137442, filed on 20 Aug 1998, GRANTED,
Pat. No. US 6444638 Continuation of Ser. No. WO 1997-US3341, filed on 20
Feb 1997, PENDING Continuation-in-part of Ser. No. US 1996-619304, filed
on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US
1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072
DT Utility
FS APPLICATION
LN.CNT 5326
INCL INCLM: 514/044.000
INCLS: 514/410.000; 514/078.000; 514/449.000; 514/450.000; 514/211.080;
435/007.230
NCL NCLM: 514/044.000
NCLS: 514/410.000; 514/078.000; 514/449.000; 514/450.000; 514/211.080;
435/007.230
IC [7]
ICM: A61K048-00
ICS: G01N033-574; A61K031-685; A61K031-551; A61K031-553; A61K031-407;
A61K031-337
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 132 OF 312 USPATFULL on STN
AN 2003:282657 USPATFULL
TI Diagnostic markers of stroke and cerebral injury and methods of use
thereof
IN Valkirs, Gunars E., Escondido, CA, UNITED STATES
Dahlen, Jeffery, San Diego, CA, UNITED STATES
Kirchick, Howard J., San Diego, CA, UNITED STATES
Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED STATES
PI US 2003199000 A1 20031023
AI US 2003-371149 A1 20030220 (10)
RLI Continuation-in-part of Ser. No. US 2002-225082, filed on 20 Aug 2002,
PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20
Aug 2002, PENDING
PRAI US 2001-313775P 20010820 (60)
US 2001-334964P 20011130 (60)
US 2002-346485P 20020102 (60)
DT Utility
FS APPLICATION
LN.CNT 4629
INCL INCLM: 435/007.100
INCLS: 435/287.200
NCL NCLM: 435/007.100
NCLS: 435/287.200
IC [7]
ICM: G01N033-53
ICS: C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 133 OF 312 USPATFULL on STN
AN 2003:276726 USPATFULL
TI Method for identifying modulators of ion channels
IN Dubin, Adrienne, San Diego, CA, UNITED STATES
Chaplan, Sandra, San Diego, CA, UNITED STATES
Brown, Sean, Encinitas, CA, UNITED STATES
Kaftan, Edward, Mount Prospect, IL, UNITED STATES
PI US 2003194751 A1 20031016
AI US 2002-121759 A1 20020412 (10)
DT Utility
FS APPLICATION
LN.CNT 1039
INCL INCLM: 435/007.200
INCLS: 514/012.000; 514/559.000; 435/069.100; 435/320.100; 435/325.000;
530/350.000
NCL NCLM: 435/007.200
NCLS: 514/012.000; 514/559.000; 435/069.100; 435/320.100; 435/325.000;
530/350.000
IC [7]
ICM: G01N033-53
ICS: G01N033-567; A61K038-18; C07K014-47; C12P021-02; C12N005-06;
A61K031-203

L5 ANSWER 134 OF 312 USPATFULL on STN
 AN 2003:276720 USPATFULL
 TI Cysteine mutants and methods for detecting ligand binding to biological molecules
 IN McDowell, Robert S., San Francisco, CA, UNITED STATES
 Flanagan, W. Michael, Menlo Park, CA, UNITED STATES
 PI US 2003194745 A1 20031016
 AI US 2002-214419 A1 20020805 (10)
 RLI Continuation-in-part of Ser. No. US 2001-981547, filed on 17 Oct 2001, PENDING Division of Ser. No. US 1998-105372, filed on 26 Jun 1998, GRANTED, Pat. No. US 6335155 Continuation-in-part of Ser. No. US 2001-990421, filed on 21 Nov 2001, PENDING Continuation-in-part of Ser. No. US 2002-121216, filed on 10 Apr 2002, PENDING
 PRAI US 2001-310725P 20010807 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3109
 INCL INCLM: 435/007.100
 INCLS: 702/019.000
 NCL NCLM: 435/007.100
 NCLS: 702/019.000
 IC [7]
 ICM: G01N033-53
 ICS: G06F019-00; G01N033-48; G01N033-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 135 OF 312 USPATFULL on STN
 AN 2003:271082 USPATFULL
 TI Antibodies that immunospecifically bind to trail receptors
 IN Salcedo, Theodora, Montgomery Village, MD, UNITED STATES
 Ruben, Steven M., Brookeville, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Albert, Vivian R., Rockville, MD, UNITED STATES
 Dobson, Claire, Cambridge, UNITED KINGDOM
 Vaughan, Tristan, Cambridge, UNITED KINGDOM
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
 PI US 2003190685 A1 20031009
 AI US 2002-139785 A1 20020507 (10)
 PRAI US 2001-293473P 20010525 (60)
 US 2001-294981P 20010604 (60)
 US 2001-309176P 20010802 (60)
 US 2001-323807P 20010921 (60)
 US 2001-327364P 20011009 (60)
 US 2001-331044P 20011107 (60)
 US 2001-331310P 20011114 (60)
 US 2001-341237P 20011220 (60)
 US 2002-369860P 20020405 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 11875
 INCL INCLM: 435/007.230
 INCLS: 530/388.220
 NCL NCLM: 435/007.230
 NCLS: 530/388.220
 IC [7]
 ICM: G01N033-574
 ICS: C07K016-30
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 136 OF 312 USPATFULL on STN
 AN 2003:265302 USPATFULL
 TI Protein-protein interactions in neurodegenerative diseases
 IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
 Bartel, Paul L., Salt Lake City, UT, UNITED STATES
 Heichman, Karen, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
 PI US 2003186317 A1 20031002
 AI US 2001-971782 A1 20011009 (9)
 PRAI US 2000-240790P 20001017 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3143
 INCL INCLM: 435/007.100

NCL NCLM: 435/007.100
NCLS: 435/007.900
IC [7]
ICM: G01N033-53
ICS: G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 137 OF 312 USPATFULL on STN
AN 2003:265223 USPATFULL
TI RNA detection assays
IN Allawi, Hatim, Madison, WI, UNITED STATES
Argue, Brad T., Sun Prairie, WI, UNITED STATES
Bartholomay, Christian Tor, Madison, WI, UNITED STATES
Chehak, LuAnne, Janesville, WI, UNITED STATES
Curtis, Michelle L., Cottage Grove, WI, UNITED STATES
Eis, Peggy S., Madison, WI, UNITED STATES
Hall, Jeff G., Madison, WI, UNITED STATES
Ip, Hon S., Madison, WI, UNITED STATES
Ji, Lin, Madison, WI, UNITED STATES
Kaiser, Michael, Madison, WI, UNITED STATES
Kwiatkowski, Robert W., JR., Verona, WI, UNITED STATES
Lukowiak, Andrew A., Stoughton, WI, UNITED STATES
Lyamichev, Victor, Madison, WI, UNITED STATES
Lymaicheva, Natalie E., Madison, WI, UNITED STATES
Ma, WuPo, Madison, WI, UNITED STATES
Neri, Bruce P., Madison, WI, UNITED STATES
Olson, Sarah M., Cross Plains, WI, UNITED STATES
Olson-Munoz, Marilyn C., Madison, WI, UNITED STATES
Schaefer, James J., Madison, WI, UNITED STATES
Skrzypczynski, Zbigniew, Verona, WI, UNITED STATES
Takova, Tsetska Y., Madison, WI, UNITED STATES
Thompson, Lisa C., Madison, WI, UNITED STATES
Vedvik, Kevin L., Madison, WI, UNITED STATES
PI US 2003186238 A1 20031002
AI US 2002-84839 A1 20020226 (10)
RLI Continuation-in-part of Ser. No. US 2001-864636, filed on 24 May 2001,
PENDING Continuation-in-part of Ser. No. US 2000-577304, filed on 24 May
2000, PENDING Continuation-in-part of Ser. No. US 1999-350309, filed on
9 Jul 1999, GRANTED, Pat. No. US 6348314 Continuation-in-part of Ser.
No. US 1991-756386, filed on 9 Sep 1991, GRANTED, Pat. No. US 337472
Continuation-in-part of Ser. No. US 1995-381212, filed on 31 Jan 1995,
GRANTED, Pat. No. US 5608651 Continuation-in-part of Ser. No. US
1997-823516, filed on 24 Mar 1997, GRANTED, Pat. No. US 5994069
Continuation-in-part of Ser. No. US 1996-759038, filed on 2 Dec 1996,
GRANTED, Pat. No. US 6090543 Continuation-in-part of Ser. No. US
1996-682853, filed on 12 Jul 1996, GRANTED, Pat. No. US 6001567
Continuation-in-part of Ser. No. US 1996-599491, filed on 24 Jan 1996,
GRANTED, Pat. No. US 5846717 Continuation-in-part of Ser. No. US
2001-758282, filed on 11 Jan 2001, PENDING
PRAI WO 1997-US1072 19970121
DT Utility
FS APPLICATION
LN.CNT 12043
INCL INCLM: 435/006.000
INCLS: 435/005.000; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/005.000; 435/091.200
IC [7]
ICM: C12Q001-68
ICS: C12Q001-70; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 138 OF 312 USPATFULL on STN
AN 2003:257689 USPATFULL
TI Differential expression screening method
IN Kingsman, Alan John, Oxford, UNITED KINGDOM
PI US 2003180740 A1 20030925
AI US 2003-204724 A1 20030102 (10)
WO 2001-GB758 20010222
PRAI GB 2000-4197 20000222
GB 2000-18679 20000728
DT Utility
FS APPLICATION
LN.CNT 3757
INCL INCLM: 435/006.000

IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 139 OF 312 USPATFULL on STN
AN 2003:257246 USPATFULL
TI Antibodies that immunospecifically bind to trail receptors
IN Salcedo, Theodora, East Syracuse, NY, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Albert, Vivian R., Rockville, MD, UNITED STATES
Humphreys, Robin, Frederick, MD, UNITED STATES
Vaughan, Tristan, Cambridge, UNITED KINGDOM

PI US 2003180296 A1 20030925
AI US 2002-322673 A1 20021219 (10)
PRAI US 2001-341237P 20011220 (60)
US 2002-369877P 20020405 (60)
US 2002-384828P 20020604 (60)
US 2002-396591P 20020718 (60)
US 2002-403370P 20020815 (60)
US 2002-425737P 20021113 (60)

DT Utility
FS APPLICATION

LN.CNT 12359
INCL INCLM: 424/143.100
INCLS: 530/388.220
NCL NCLM: 424/143.100
NCLS: 530/388.220

IC [7]
ICM: A61K039-395
ICS: C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 140 OF 312 USPATFULL on STN
AN 2003:251869 USPATFULL
TI Adipocyte-specific protein homologs
IN Sheppard, Paul O., Granite Falls, WA, UNITED STATES
PA ZymoGenetics, Inc. (U.S. corporation)
PI US 2003176658 A1 20030918
AI US 2003-392531 A1 20030320 (10)
RLI Continuation of Ser. No. US 2000-506852, filed on 17 Feb 2000, GRANTED,
Pat. No. US 6566499 Continuation-in-part of Ser. No. US 1998-118408,
filed on 17 Jul 1998, GRANTED, Pat. No. US 6265544

PRAI US 1997-53154P 19970718 (60)

DT Utility
FS APPLICATION

LN.CNT 3611
INCL INCLM: 530/356.000
INCLS: 530/388.250; 435/006.000; 435/069.100; 435/320.100; 435/325.000;
536/023.500
NCL NCLM: 530/356.000
NCLS: 530/388.250; 435/006.000; 435/069.100; 435/320.100; 435/325.000;
536/023.500

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-78; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 141 OF 312 USPATFULL on STN
AN 2003:251168 USPATFULL
TI Human embryoid body-derived cells
IN Shambloott, Michael J., Baltimore, MD, UNITED STATES
Gearhart, John D., Baltimore, MD, UNITED STATES

PI US 2003175954 A1 20030918
AI US 2001-767421 A1 20010122 (9)
PRAI US 2000-177287P 20000121 (60)

DT Utility
FS APPLICATION

LN.CNT 2867
INCL INCLM: 435/366.000
INCLS: 435/069.100
NCL NCLM: 435/366.000
NCLS: 435/069.100

IC [7]
ICM: C12N005-08
ICS: C12P021-02

L5 ANSWER 142 OF 312 USPATFULL on STN
 AN 2003:250423 USPATFULL
 TI Neutrokin- α and neutrokin- α splice variant
 IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Ullrich, Stephen, Rockville, MD, UNITED STATES
 Laird, Michael, Germantown, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.
 corporation)
 PI US 2003175208 A1 20030918
 AI US 2002-270487 A1 20021016 (10)
 RLI Continuation-in-part of Ser. No. US 2001-929493, filed on 15 Aug 2001,
 PENDING Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun
 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-589285, filed
 on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286,
 filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US
 2000-589287, filed on 8 Jun 2000, GRANTED, Pat. No. US 6403770
 Continuation-in-part of Ser. No. US 2000-589288, filed on 8 Jun 2000,
 PENDING Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb
 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on
 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 2000-588947,
 filed on 8 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US
 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser.
 No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of
 Ser. No. US 2000-589288, filed on 8 Jun 2000, PENDING
 Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000,
 PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb
 1999, PENDING Continuation-in-part of Ser. No. US 1998-5874, filed on 12
 Jan 1998, PENDING Continuation-in-part of Ser. No. WO 1996-US17957,
 filed on 25 Oct 1996, PENDING Continuation-in-part of Ser. No. US
 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser.
 No. US 1998-5874, filed on 12 Jan 1998, PENDING
 PRAI US 2001-329508P 20011017 (60)
 US 2001-329747P 20011018 (60)
 US 2001-330835P 20011031 (60)
 US 2001-331478P 20011116 (60)
 US 2001-336726P 20011207 (60)
 US 2002-368548P 20020401 (60)
 US 2000-225628P 20000815 (60)
 US 2000-227008P 20000823 (60)
 US 2000-234338P 20000922 (60)
 US 2000-240806P 20001017 (60)
 US 2000-250020P 20001130 (60)
 US 2001-276248P 20010316 (60)
 US 2001-293499P 20010525 (60)
 US 2001-296122P 20010607 (60)
 US 2001-304809P 20010713 (60)
 US 1999-122388P 19990302 (60)
 US 1999-124097P 19990312 (60)
 US 1999-126599P 19990326 (60)
 US 1999-127598P 19990402 (60)
 US 1999-130412P 19990416 (60)
 US 1999-130696P 19990423 (60)
 US 1999-131278P 19990427 (60)
 US 1999-131673P 19990429 (60)
 US 1999-136784P 19990528 (60)
 US 1999-142659P 19990706 (60)
 US 1999-145824P 19990727 (60)
 US 1999-167239P 19991124 (60)
 US 1999-168624P 19991203 (60)
 US 1999-171108P 19991216 (60)
 US 1999-171626P 19991223 (60)
 US 2000-176015P 20000114 (60)
 US 1999-122388P 19990302 (60)
 US 1999-124097P 19990312 (60)
 US 1999-126599P 19990326 (60)
 US 1999-127598P 19990402 (60)
 US 1999-130412P 19990416 (60)
 US 1999-130696P 19990423 (60)
 US 1999-131278P 19990427 (60)
 US 1999-131673P 19990429 (60)
 US 1999-136784P 19990528 (60)

US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
US 1997-36100P 19970114 (60)

DT Utility
FS APPLICATION

LN.CNT 18884

INCL INCLM: 424/001.490
INCLS: 424/001.690

NCL NCLM: 424/001.490
NCLS: 424/001.690

IC [7]

ICM: A61K051-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 143 OF 312 USPATFULL on STN

AN 2003:245133 USPATFULL

TI Adipocyte-specific protein homologs

IN Sheppard, Paul O., Redmond, WA, UNITED STATES

Humes, Jacqueline M., Seattle, WA, UNITED STATES

PA ZymoGenetics, Inc. (U.S. corporation)

PI US 2003171547 A1 20030911

AI US 2002-197293 A1 20020716 (10)

RLI Continuation of Ser. No. US 2000-686838, filed on 10 Oct 2000, GRANTED,
Pat. No. US 6482612 Division of Ser. No. US 1998-140804, filed on 26 Aug
1998, GRANTED, Pat. No. US 6197930

PRAI US 1997-56983P 19970826 (60)

DT Utility

FS APPLICATION

LN.CNT 3818

INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000

NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000

IC [7]

ICM: C12P021-02

ICS: C07K014-705; C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 144 OF 312 USPATFULL on STN

AN 2003:244942 USPATFULL

TI Methods for alzheimer's disease treatment and cognitive enhancement

IN Etcheberrigaray, Rene, Bethesda, MD, UNITED STATES

Alkon, Daniel L., Bethesda, MD, UNITED STATES

PA Neurologic, Inc. (U.S. corporation)

PI US 2003171356 A1 20030911

AI US 2002-167491 A1 20020613 (10)

PRAI US 2002-362080P 20020307 (60)

DT Utility

FS APPLICATION

LN.CNT 1098

INCL INCLM: 514/212.030
INCLS: 514/424.000; 514/450.000

NCL NCLM: 514/212.030
NCLS: 514/424.000; 514/450.000

IC [7]

ICM: A61K031-55

ICS: A61K031-4015; A61K031-353

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 145 OF 312 USPATFULL on STN

AN 2003:243804 USPATFULL

TI METHODS AND COMPOSITIONS FOR ENHANCING COGNITIVE FUNCTION USING
MORPHOGENIC PROTEINS

IN CHARETTE, MARC F., NEEDHAM, MA, UNITED STATES

PI US 2003170213 A1 20030911

AI US 1998-12846 A1 19980123 (9)

DT Utility

FS APPLICATION

LN.CNT 2687

INCL INCLM: 424/093.210
INCLS: 514/012.000; 514/044.000

IC NCLS: 514/012.000; 514/044.000
[7]
ICM: A61K048-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 146 OF 312 USPATFULL on STN
AN 2003:243794 USPATFULL
TI Death domain containing receptors
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner L., Belo Horizonte, BRAZIL
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 2003170203 A1 20030911
AI US 2002-189189 A1 20020705 (10)
RLI Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000,
PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar
1997, GRANTED, Pat. No. US 6153402
PRAI US 2001-314314P 20010824 (60)
US 2001-303155P 20010706 (60)
US 1999-136741P 19990528 (60)
US 1999-130488P 19990422 (60)
US 1997-37341P 19970206 (60)
US 1996-28711P 19961017 (60)
US 1996-13285P 19960312 (60)
DT Utility
FS APPLICATION
LN.CNT 9858
INCL INCLM: 424/085.100
INCLS: 424/145.100; 514/210.090; 514/011.000
NCL NCLM: 424/085.100
NCLS: 424/145.100; 514/210.090; 514/011.000
IC [7]
ICM: A61K039-395
ICS: A61K031-407; A61K038-19; A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 147 OF 312 USPATFULL on STN
AN 2003:238706 USPATFULL
TI Human tumor necrosis factor delta and epsilon
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Gentz, Reiner, Belo Horizonte-Mg, BRAZIL
PI US 2003166864 A1 20030904
AI US 2002-268951 A1 20021011 (10)
RLI Continuation-in-part of Ser. No. US 2001-879919, filed on 14 Jun 2001,
PENDING Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar
1997, GRANTED, Pat. No. US 6509170 Continuation-in-part of Ser. No. US
1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170
Continuation-in-part of Ser. No. US 2002-82260, filed on 26 Feb 2002,
GRANTED, Pat. No. US 6506882 Division of Ser. No. US 1997-815783, filed
on 12 Mar 1997, GRANTED, Pat. No. US 6509170
PRAI US 2001-328401P 20011012 (60)
US 2000-211537P 20000615 (60)
US 2000-241952P 20001023 (60)
US 2000-254875P 20001213 (60)
US 2001-277978P 20010323 (60)
US 2001-276248P 20010316 (60)
US 2001-293499P 20010525 (60)
US 1996-16812P 19960314 (60)
US 1996-16812P 19960314 (60)
US 1996-16812P 19960314 (60)
DT Utility
FS APPLICATION
LN.CNT 14873
INCL INCLM: 530/351.000
INCLS: 435/069.500; 435/320.100; 435/325.000; 536/023.500; 424/085.100;
424/450.000
NCL NCLM: 530/351.000
NCLS: 435/069.500; 435/320.100; 435/325.000; 536/023.500; 424/085.100;
424/450.000
IC [7]
ICM: C07K014-525
ICS: C07H021-04; C12P021-02; A61K038-19; A61K009-127

L5 ANSWER 148 OF 312 USPATFULL on STN
AN 2003:237862 USPATFULL
TI Monoclonal antibody
IN Wiltfang, Jens, Eddigehausen, GERMANY, FEDERAL REPUBLIC OF
Dyrks, Thomas, Berlin, GERMANY, FEDERAL REPUBLIC OF
Monning, Ursula, Berlin, GERMANY, FEDERAL REPUBLIC OF
PI US 2003166019 A1 20030904
AI US 2002-170272 A1 20020611 (10)
PRAI EP 2001-114192 20010612
DT Utility
FS APPLICATION
LN.CNT 3683
INCL INCLM: 435/007.210
INCLS: 530/388.260
NCL NCLM: 435/007.210
NCLS: 530/388.260
IC [7]
ICM: G01N033-567
ICS: C07K016-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 149 OF 312 USPATFULL on STN
AN 2003:237678 USPATFULL
TI Cell stress regulated human MHC class I gene
IN Spies, Thomas, Seattle, WA, UNITED STATES
Spies, Veronika, Seattle, WA, UNITED STATES
PA Fred Hutchinson Cancer Research Center Inc. (U.S. corporation)
PI US 2003165835 A1 20030904
AI US 2001-855612 A1 20010514 (9)
RLI Continuation of Ser. No. US 1999-303161, filed on 29 Apr 1999, ABANDONED
PRAI WO 1997-US20170 19971029
US 1996-29044P 19961029 (60)
DT Utility
FS APPLICATION
LN.CNT 5079
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/366.000; 800/008.000; 800/018.000; 424/093.210;
424/155.100
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/366.000; 800/008.000; 800/018.000; 424/093.210;
424/155.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; A01K067-027; A61K048-00; A61K039-395; C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 150 OF 312 USPATFULL on STN
AN 2003:237373 USPATFULL
TI Adipocyte complement related protein homolog zacrp3
IN Piddington, Christopher S., Thousand Oaks, CA, UNITED STATES
Bishop, Paul D., Fall City, WA, UNITED STATES
PI US 2003165530 A1 20030904
AI US 2002-321164 A1 20021217 (10)
RLI Division of Ser. No. US 2000-552225, filed on 19 Apr 2000, GRANTED, Pat.
No. US 6521233
PRAI US 1999-130199P 19990420 (60)
DT Utility
FS APPLICATION
LN.CNT 3481
INCL INCLM: 424/192.100
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 424/192.100
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: A61K039-00
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 151 OF 312 USPATFULL on STN
AN 2003:231619 USPATFULL
TI Pluripotent embryonic-like stem cells, compositions, methods and uses
thereof
IN Young, Henry E., Macon, GA, UNITED STATES
Lucas, Paul A., Poughkeepsie, NY, UNITED STATES

AI US 2001-820320 A1 20010328 (9)

DT Utility
FS APPLICATION

LN.CNT 10419

INCL INCLM: 424/093.210

INCLS: 435/366.000

NCL NCLM: 424/093.210

NCLS: 435/366.000

IC [7]

ICM: A61K048-00

ICS: C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 152 OF 312 USPATFULL on STN

AN 2003:220208 USPATFULL

TI Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

IN Ni, Jian, Germantown, MD, UNITED STATES

Ruben, Steven M., Brookeville, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)

PI US 2003153499 A1 20030814

AI US 2002-277966 A1 20021023 (10)

RLI Division of Ser. No. US 2000-512363, filed on 23 Feb 2000, GRANTED, Pat. No. US 6503184 Division of Ser. No. US 1998-176200, filed on 21 Oct 1998, PENDING

PRAI US 1999-121648P 19990224 (60)

US 1999-134172P 19990513 (60)

US 1999-144076P 19990716 (60)

US 1997-63212P 19971021 (60)

DT Utility

FS APPLICATION

LN.CNT 11222

INCL INCLM: 514/012.000

INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000

NCL NCLM: 514/012.000

NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000

IC [7]

ICM: A61K038-17

ICS: C07K014-715; C12P021-02; C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 153 OF 312 USPATFULL on STN

AN 2003:215352 USPATFULL

TI Diagnostics and therapeutics for arterial wall disruptive disorders

IN Hageman, Gregory S., Coralville, IA, UNITED STATES

PI US 2003149997 A1 20030807

AI US 2000-511008 A1 20000222 (9)

PRAI US 1999-120822P 19990219 (60)

US 1999-120668P 19990219 (60)

US 1999-123052P 19990305 (60)

DT Utility

FS APPLICATION

LN.CNT 6580

INCL INCLM: 800/008.000

INCLS: 435/006.000; 800/009.000; 435/007.100

NCL NCLM: 800/008.000

NCLS: 435/006.000; 800/009.000; 435/007.100

IC [7]

ICM: A01K067-00

ICS: C12Q001-68; G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 154 OF 312 USPATFULL on STN

AN 2003:200443 USPATFULL

TI Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2

IN Ni, Jian, Germantown, MD, UNITED STATES

Ruben, Steven M., Brookville, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

PI US 2003138426 A1 20030724

AI US 2002-283105 A1 20021030 (10)

RLI Continuation-in-part of Ser. No. US 2001-915593, filed on 27 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-512363, filed on 23 Feb 2000, GRANTED, Pat. No. US 6503184 Continuation-in-part of Ser. No. US

PRAI US 2001-330757P 20011030 (60)
US 2000-221577P 20000728 (60)
US 1999-144076P 19990716 (60)
US 1999-134172P 19990513 (60)
US 1999-121648P 19990224 (60)
US 1997-63212P 19971021 (60)
DT Utility
FS APPLICATION
LN.CNT 12581
INCL INCLM: 424/146.100
INCLS: 435/007.200; 530/388.260
NCL NCLM: 424/146.100
NCLS: 435/007.200; 530/388.260
IC [7]
ICM: A61K039-395
ICS: G01N033-53; G01N033-567; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 155 OF 312 USPATFULL on STN
AN 2003:188372 USPATFULL
TI Method for treating neurodegenerative disorders
IN Reitz, Allen B., Lansdale, PA, UNITED STATES
Demeter, David A., Fishers, IN, UNITED STATES
Lee, Daniel H.S., Northhampton, PA, UNITED STATES
Wang, Hoau-Yan, Philadelphia, PA, UNITED STATES
Chen, Robert H., Belle Mead, NJ, UNITED STATES
Ross, Tina Morgan, Audubon, PA, UNITED STATES
Scott, Malcolm K., Lansdale, PA, UNITED STATES
Plata-Salaman, Carlos R., Ambler, PA, UNITED STATES
PI US 2003130165 A1 20030710
AI US 2002-162821 A1 20020605 (10)
RLI Division of Ser. No. US 1999-320885, filed on 27 May 1999, GRANTED, Pat.
No. US 6441049
PRAI US 1998-87577P 19980601 (60)
DT Utility
FS APPLICATION
LN.CNT 1505
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 156 OF 312 USPATFULL on STN
AN 2003:187888 USPATFULL
TI Methods, pharmaceutical formulations and kits for identification of
subjects at risk for cancer
IN Neely, Constance, Raleigh, NC, UNITED STATES
PI US 2003129678 A1 20030710
AI US 2002-316423 A1 20021211 (10)
RLI Continuation of Ser. No. US 2000-569394, filed on 12 May 2000, ABANDONED
PRAI US 1999-134276P 19990514 (60)
DT Utility
FS APPLICATION
LN.CNT 1261
INCL INCLM: 435/007.230
INCLS: 424/085.500; 514/054.000
NCL NCLM: 435/007.230
NCLS: 424/085.500; 514/054.000
IC [7]
ICM: G01N033-574
ICS: A61K038-21; A61K031-739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 157 OF 312 USPATFULL on STN
AN 2003:187403 USPATFULL
TI Tumor necrosis factor-gamma
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Zhang, Jun, San Diego, CA, UNITED STATES
PI US 2003129189 A1 20030710
AI US 2002-226294 A1 20020823 (10)
RLI Continuation-in-part of Ser. No. US 2001-899059, filed on 6 Jul 2001,
PENDING Continuation-in-part of Ser. No. US 2000-559290, filed on 27 Apr

on 8 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1998-131237,
filed on 7 Aug 1998, PENDING Continuation-in-part of Ser. No. US
1998-5020, filed on 9 Jan 1998, ABANDONED Continuation-in-part of Ser.
No. US 1995-461246, filed on 5 Jun 1995, ABANDONED Continuation-in-part
of Ser. No. WO 1994-US12880, filed on 7 Nov 1994, PENDING

PRAI US 2001-314381P 20010824 (60)
US 2001-278449P 20010326 (60)
US 2000-216879P 20000707 (60)
US 2000-180908P 20000208 (60)
US 1999-134067P 19990513 (60)
US 1999-132227P 19990503 (60)
US 1999-131963P 19990430 (60)
US 1998-74047P 19980209 (60)

DT Utility
FS APPLICATION
LN.CNT 13325
INCL INCLM: 424/145.100
NCL NCLM: 424/145.100
IC [7]
ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 158 OF 312 USPATFULL on STN
AN 2003:187348 USPATFULL
TI Method of monitoring neuroprotective treatment
IN Chenard, Bertrand L., Waterford, CT, UNITED STATES
Friedman, David L., Madison, CT, UNITED STATES
Kimmel, Lida, Chester, CT, UNITED STATES
Nelms, Linda F., Gales Ferry, CT, UNITED STATES
Silber, B. Michael, Madison, CT, UNITED STATES
Soares, Holly D., Noank, CT, UNITED STATES
Frost White, Walter, JR., Ledyard, CT, UNITED STATES
Pfizer Inc. (U.S. corporation)

PA
PI US 2003129134 A1 20030710
AI US 2002-268465 A1 20021010 (10)
PRAI US 2001-328890P 20011012 (60)
DT Utility
FS APPLICATION
LN.CNT 1218
INCL INCLM: 424/009.300
INCLS: 435/007.920
NCL NCLM: 424/009.300
NCLS: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 159 OF 312 USPATFULL on STN
AN 2003:181499 USPATFULL
TI Inhibitors of GSK-3 and crystal structures of GSK-3 protein and protein
complexes
IN Haar, Ernst ter, Roslindale, MA, UNITED STATES
Swenson, Lovorka, Belmont, MA, UNITED STATES
Green, Jeremy, Burlington, MA, UNITED STATES
Arnost, Michael J., North Andover, MA, UNITED STATES

PI US 2003125332 A1 20030703
AI US 2002-135255 A1 20020429 (10)
PRAI US 2001-287366P 20010430 (60)
US 2002-361899P 20020227 (60)
US 2001-297094P 20010608 (60)

DT Utility
FS APPLICATION
LN.CNT 4178
INCL INCLM: 514/248.000
INCLS: 544/236.000
NCL NCLM: 514/248.000
NCLS: 544/236.000
IC [7]
ICM: C07D487-02
ICS: A61K031-503

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 160 OF 312 USPATFULL on STN
AN 2003:180370 USPATFULL

IN passageways and cavities
 Signore, Pierre E., Vancouver, CANADA
 Machan, Lindsay S., Vancouver, CANADA
 PA University of British Columbia, Vancouver, CANADA (non-U.S. corporation)
 PI US 2003124197 A1 20030703
 AI US 2002-323401 A1 20021218 (10)
 RLI Continuation of Ser. No. US 2000-511570, filed on 23 Feb 2000, ABANDONED
 PRAI US 1999-121424P 19990223 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1939
 INCL INCLM: 424/499.000
 INCLS: 424/501.000; 514/449.000; 514/283.000; 514/054.000; 514/055.000
 NCL NCLM: 424/499.000
 NCLS: 424/501.000; 514/449.000; 514/283.000; 514/054.000; 514/055.000
 IC [7]
 ICM: A61K031-728
 ICS: A61K031-4745; A61K031-337; A61K009-14; A61K009-50
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 161 OF 312 USPATFULL on STN
 AN 2003:172702 USPATFULL
 TI Antibodies to tumor necrosis factor 5
 IN Wei, Ying-Fei, Berkeley, CA, UNITED STATES
 Ni, Jian, Rockville, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 PA Human Genome Sciences, Inc. (U.S. corporation)
 PI US 2003118546 A1 20030626
 AI US 2002-186643 A1 20020702 (10)
 RLI Division of Ser. No. US 2000-573986, filed on 18 May 2000, GRANTED, Pat.
 No. US 6455040 Division of Ser. No. US 1998-6353, filed on 13 Jan 1998,
 GRANTED, Pat. No. US 6261801
 PRAI US 1999-135164P 19990520 (60)
 US 1997-54885P 19970807 (60)
 US 1997-35496P 19970114 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9588
 INCL INCLM: 424/085.100
 INCLS: 424/146.100
 NCL NCLM: 424/085.100
 NCLS: 424/146.100
 IC [7]
 ICM: A61K039-395
 ICS: A61K038-19
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 162 OF 312 USPATFULL on STN
 AN 2003:166521 USPATFULL
 TI Methods of treating or preventing cell, tissue, and organ damage using
 human myeloid progenitor inhibitory factor-1 (MPIF-1)
 IN Li, Haodong, Gaithersburg, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 Grzegorzewski, Krzysztof J., Gaithersburg, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Patel, Vikram, Germantown, MD, UNITED STATES
 Gentz, Reinder L., Rockville, MD, UNITED STATES
 PA Human Genome Sciences, Inc. (U.S. corporation)
 PI US 2003114379 A1 20030619
 AI US 2002-261950 A1 20021002 (10)
 RLI Division of Ser. No. US 2000-689693, filed on 13 Oct 2000, GRANTED, Pat.
 No. US 6495129 Division of Ser. No. US 2000-571013, filed on 15 May
 2000, PENDING Division of Ser. No. US 1999-334951, filed on 17 Jun 1999,
 GRANTED, Pat. No. US 6451562 Continuation of Ser. No. US 1996-722723,
 filed on 30 Sep 1996, ABANDONED Continuation of Ser. No. US 1996-722719,
 filed on 30 Sep 1996, GRANTED, Pat. No. US 6001606 Continuation-in-part
 of Ser. No. US 1995-465682, filed on 6 Jun 1995, ABANDONED
 Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995,
 ABANDONED Continuation of Ser. No. US 1994-208339, filed on 8 Mar 1994,
 GRANTED, Pat. No. US 5504003
 PRAI US 1999-159362P 19991014 (60)
 US 1999-164059P 19991108 (60)
 US 1999-172063P 19991223 (60)
 US 2000-189048P 20000314 (60)

US 2000-211458P 20000613 (60)
US 2000-212658P 20000619 (60)
US 1996-27299P 19960930 (60)
US 1996-27300P 19960930 (60)

DT Utility
FS APPLICATION
LN.CNT 14465
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 163 OF 312 USPATFULL on STN
AN 2003:166515 USPATFULL
TI Polynucleotide encoding a novel cysteine protease of the calpain
superfamily, CAN-12, and variants thereof
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003114373 A1 20030619
AI US 2002-116519 A1 20020403 (10)
PRAI US 2001-281253P 20010403 (60)
US 2001-288768P 20010504 (60)
US 2001-296180P 20010606 (60)
US 2001-300620P 20010625 (60)

DT Utility
FS APPLICATION
LN.CNT 30149
INCL INCLM: 514/012.000
INCLS: 536/023.200; 530/350.000; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 514/012.000
NCLS: 536/023.200; 530/350.000; 435/069.100; 435/325.000; 435/320.100
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06; C07H021-04; C07K014-435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 164 OF 312 USPATFULL on STN
AN 2003:159830 USPATFULL
TI Methods and compositions for the treatment and prevention of parkinson's
disease
IN Rueger, David C., Southborough, MA, UNITED STATES
Sampath, Kuber T., Holliston, MA, UNITED STATES
Cohen, Charles M., Weston, MA, UNITED STATES
Oppermann, Hermann, Medway, MA, UNITED STATES
Pang, Roy H.L., Etna, NH, UNITED STATES

PI US 2003109445 A1 20030612
AI US 2002-272503 A1 20021016 (10)
RLI Continuation of Ser. No. US 1997-938622, filed on 25 Sep 1997, GRANTED,
Pat. No. US 6506729 Continuation-in-part of Ser. No. US 1994-260675,
filed on 16 Jun 1994, PENDING Continuation of Ser. No. US 1993-126100,
filed on 23 Sep 1993, ABANDONED Continuation of Ser. No. US 1992-922813,
filed on 31 Jul 1992, ABANDONED Continuation-in-part of Ser. No. US
1991-752764, filed on 30 Aug 1991, ABANDONED Continuation-in-part of
Ser. No. US 1991-753059, filed on 30 Aug 1991, ABANDONED
Continuation-in-part of Ser. No. US 1991-667274, filed on 11 Mar 1991,
ABANDONED

DT Utility
FS APPLICATION
LN.CNT 3035
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]
ICM: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 165 OF 312 USPATFULL on STN
AN 2003:159395 USPATFULL
TI Methods of making CDNA libraries
IN Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA

Baetge, E. Edward, Barrington, RI, UNITED STATES
 PI US 2003109008 A1 20030612
 AI US 2002-199830 A1 20020719 (10)
 RLI Continuation of Ser. No. US 1995-486313, filed on 7 Jun 1995, GRANTED, Pat. No. US 6497872 Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, ABANDONED Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation of Ser. No. US 1995-385404, filed on 7 Feb 1995, ABANDONED Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, ABANDONED Continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, ABANDONED Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 3873
 INCL INCLM: 435/091.100
 INCLS: 435/368.000
 NCL NCLM: 435/091.100
 NCLS: 435/368.000
 IC [7]
 ICM: C12P019-34
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 166 OF 312 USPATFULL on STN
 AN 2003:158903 USPATFULL
 TI Death domain containing receptor 4
 IN Ni, Jian, Rockville, MD, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Pan, James G., Belmont, CA, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
 PI US 2003108516 A1 20030612
 AI US 2002-175902 A1 20020621 (10)
 RLI Division of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Division of Ser. No. US 1998-13895, filed on 27 Jan 1998, GRANTED, Pat. No. US 6342363
 PRAI US 1999-132922P 19990506 (60)
 US 1997-37829P 19970205 (60)
 US 1997-35722P 19970128 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9230
 INCL INCLM: 424/085.100
 INCLS: 424/155.100; 514/012.000
 NCL NCLM: 424/085.100
 NCLS: 424/155.100; 514/012.000
 IC [7]
 ICM: A61K039-395
 ICS: A61K038-19; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 167 OF 312 USPATFULL on STN
 AN 2003:153422 USPATFULL
 TI Pyrazole compounds useful as protein kinase inhibitors
 IN Bebbington, David, Newbury, UNITED KINGDOM
 Charrier, Jean-Damien, Wantage, UNITED KINGDOM
 PI US 2003105090 A1 20030605
 AI US 2001-26966 A1 20011219 (10)
 PRAI US 2000-257887P 20001221 (60)
 US 2001-286949P 20010427 (60)
 DT Utility

LN.CNT 9063
INCL INCLM: 514/227.500
INCLS: 514/235.800; 514/252.190; 514/256.000; 544/060.000; 544/122.000;
544/295.000; 544/324.000; 544/317.000
NCL NCLM: 514/227.500
NCLS: 514/235.800; 514/252.190; 514/256.000; 544/060.000; 544/122.000;
544/295.000; 544/324.000; 544/317.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-506; A61K031-513; C07D417-14; C07D413-14;
C07D043-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 168 OF 312 USPATFULL on STN

AN 2003:152712 USPATFULL

TI Detection of RNA

IN Allawi, Hatim, Madison, WI, UNITED STATES
Bartholomay, Christian Tor, Madison, WI, UNITED STATES
Chehak, LuAnne, Janesville, WI, UNITED STATES
Curtis, Michelle L., Cottage Grove, WI, UNITED STATES
Eis, Peggy S., Madison, WI, UNITED STATES
Hall, Jeff G., Madison, WI, UNITED STATES
Ip, Hon S., Madison, WI, UNITED STATES
Kaiser, Michael, Madison, WI, UNITED STATES
Kwiatkowski, Robert W., JR., Verona, WI, UNITED STATES
Lukowiak, Andrew A., Madison, WI, UNITED STATES
Lyamichev, Victor, Madison, WI, UNITED STATES
Ma, WuPo, Madison, WI, UNITED STATES
Olson-Munoz, Marilyn C., Madison, WI, UNITED STATES
Olson, Sarah M., Cross Plains, WI, UNITED STATES
Schaefer, James J., Madison, WI, UNITED STATES
Skrzypczynski, Zbigniew, Verona, WI, UNITED STATES
Takova, Tsetska Y., Madison, WI, UNITED STATES
Vedvik, Kevin L., Madison, WI, UNITED STATES
Lyamichev, Natalie, Madison, WI, UNITED STATES
Neri, Burce P., Madison, WI, UNITED STATES
PA Third Wave Technologies, Inc., Madison, WI, 53719 (2)

PI US 2003104378 A1 20030605

AI US 2001-864636 A1 20010524 (9)

RLI Continuation-in-part of Ser. No. US 2000-577304, filed on 24 May 2000,
PENDING Continuation-in-part of Ser. No. US 1999-350309, filed on 9 Jul
1999, GRANTED, Pat. No. US 6348314 Continuation-in-part of Ser. No. US
1991-756386, filed on 9 Sep 1991, GRANTED, Pat. No. US 337472
Continuation-in-part of Ser. No. US 1995-381212, filed on 31 Jan 1995,
GRANTED, Pat. No. US 5608651 Continuation-in-part of Ser. No. US
1997-823516, filed on 24 Mar 1997, GRANTED, Pat. No. US 5994069
Continuation-in-part of Ser. No. US 1996-759038, filed on 2 Dec 1996,
GRANTED, Pat. No. US 6090543 Continuation-in-part of Ser. No. US
1996-682853, filed on 12 Jul 1996, GRANTED, Pat. No. US 6001567
Continuation-in-part of Ser. No. US 1996-599491, filed on 24 Jan 1996,
GRANTED, Pat. No. US 5846717 Continuation-in-part of Ser. No. US
2000-381212, filed on 8 Feb 2000, PENDING Continuation-in-part of Ser.
No. US 2001-758282, filed on 11 Jan 2001, PENDING

PRAI WO 1997-US1072 19970121

DT Utility

FS APPLICATION

LN.CNT 10869

INCL INCLM: 435/006.000

INCLS: 435/091.200

NCL NCLM: 435/006.000

NCLS: 435/091.200

IC [7]

ICM: C12Q001-68

ICS: C12P019-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 169 OF 312 USPATFULL on STN

AN 2003:140971 USPATFULL

TI Compositions useful as inhibitors of GSK-3

IN Cao, Jingrong, Newton, MA, UNITED STATES
Choquette, Debbie, Medford, MA, UNITED STATES
Davies, Robert, Arlington, MA, UNITED STATES
Forster, Cornelia, Pelham, NH, UNITED STATES
Lauffer, David, Stow, MA, UNITED STATES
Pierce, Albert, Somerville, MA, UNITED STATES

Wannamaker, Marion, Stow, MA, UNITED STATES
Metz, Natalie, Brighton, MA, UNITED STATES
PI US 2003096813 A1 20030522
AI US 2002-125885 A1 20020419 (10)
PRAI US 2001-285217P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 2547
INCL INCLM: 514/228.500
INCLS: 514/234.500; 514/252.160; 514/260.100; 514/265.100; 544/060.000;
544/117.000; 544/278.000; 544/280.000
NCL NCLM: 514/228.500
NCLS: 514/234.500; 514/252.160; 514/260.100; 514/265.100; 544/060.000;
544/117.000; 544/278.000; 544/280.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-519; C07D498-02; C07D487-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 170 OF 312 USPATFULL on STN
AN 2003:140116 USPATFULL
TI Methods of proliferating undifferentiated neural cells
IN Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES
PI US 2003095956 A1 20030522
AI US 2002-199918 A1 20020719 (10)
RLI Continuation of Ser. No. US 1995-486313, filed on 7 Jun 1995, PENDING
Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
ABANDONED Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991,
ABANDONED Continuation-in-part of Ser. No. US 1995-385404, filed on 7
Feb 1995, ABANDONED Continuation of Ser. No. US 1992-961813, filed on 16
Oct 1992, ABANDONED Continuation-in-part of Ser. No. US 1991-726812,
filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US
1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US
1994-221655, filed on 1 Apr 1994, ABANDONED Continuation of Ser. No. US
1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part of
Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED Continuation of
Ser. No. US 1993-10829, filed on 29 Jan 1993, ABANDONED
Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
ABANDONED Continuation-in-part of Ser. No. US 1993-149508, filed on 9
Nov 1993, ABANDONED Continuation-in-part of Ser. No. US 1991-726812,
filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser. No. US
1994-311099, filed on 23 Sep 1994, ABANDONED Continuation-in-part of
Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994,
ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8
Jul 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3838
INCL INCLM: 424/093.210
INCLS: 435/368.000
NCL NCLM: 424/093.210
NCLS: 435/368.000
IC [7]
ICM: A61K048-00
ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 171 OF 312 USPATFULL on STN
AN 2003:134060 USPATFULL
TI Viral vaccine composition, process, and methods of use
IN Jira, Vic, El Monte, CA, UNITED STATES
Jirathitikal, Vichai, Chachoengsao, THAILAND
PI US 2003092145 A1 20030515
AI US 2001-935344 A1 20010823 (9)
PRAI US 2000-227520P 20000824 (60)
DT Utility
FS APPLICATION
LN.CNT 3165
INCL INCLM: 435/173.300
INCLS: 435/236.000; 424/464.000; 424/204.100; 424/206.100; 424/207.100;
424/234.100; 424/208.100; 424/209.100; 424/211.100; 424/212.100;

NCL NCLM: 424/224.100; 424/225.100; 424/229.100; 424/232.100; 424/233.100
NCLS: 435/173.300
435/236.000; 424/464.000; 424/204.100; 424/206.100; 424/207.100;
424/234.100; 424/208.100; 424/209.100; 424/211.100; 424/212.100;
424/214.100; 424/215.100; 424/216.100; 424/217.100; 424/218.100;
424/224.100; 424/225.100; 424/229.100; 424/232.100; 424/233.100
IC [7]
ICM: C12N007-04
ICS: A61K039-165; A61K039-155; C12N013-00; A61K039-145; A61K039-17;
A61K039-125; A61K039-193; A61K039-245; A61K039-27; A61K039-23;
A61K009-20

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 172 OF 312 USPATFULL on STN
AN 2003:133480 USPATFULL
TI Binding polypeptides and methods based thereon
IN Beltzer, James P., Carlisle, MA, UNITED STATES
Potter, M. Daniel, UNITED STATES
Potter, Marilou, Acton, MA, UNITED STATES LR
Fleming, Tony J., Waltham, MA, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PI US 2003091565 A1 20030515
AI US 2001-932613 A1 20010817 (9)
PRAI US 2000-226700P 20000818 (60)
DT Utility
FS APPLICATION
LN.CNT 11834
INCL INCLM: 424/144.100
NCL NCLM: 424/144.100
IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 173 OF 312 USPATFULL on STN
AN 2003:120030 USPATFULL
TI Methods of screening biological agents
IN Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES
PI US 2003082515 A1 20030501
AI US 2002-199189 A1 20020719 (10)
RLI Continuation of Ser. No. US 1995-486313, filed on 7 Jun 1995, PENDING
Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
ABANDONED Continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991,
ABANDONED Continuation of Ser. No. US 1995-385404, filed on 7 Feb 1995,
ABANDONED Continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992,
ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8
Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-359945,
filed on 20 Dec 1994, ABANDONED Continuation of Ser. No. US 1994-221655,
filed on 1 Apr 1994, ABANDONED Continuation of Ser. No. US 1992-967622,
filed on 28 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US
1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser.
No. US 1995-376062, filed on 20 Jan 1995, ABANDONED Continuation of Ser.
No. US 1993-10829, filed on 29 Jan 1993, ABANDONED Continuation-in-part
of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
Continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993,
ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8
Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1994-311099,
filed on 23 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US
1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser.
No. US 1994-338730, filed on 14 Nov 1994, ABANDONED Continuation-in-part
of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3844
INCL INCLM: 435/004.000
INCLS: 435/368.000
NCL NCLM: 435/004.000
NCLS: 435/368.000
IC [7]
ICM: C12Q001-00
ICS: C12N005-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:112909 USPATFULL
TI Methods of suppressing microglial activation and systemic inflammatory responses
IN Laskowitz, Daniel T., Chapel Hill, NC, UNITED STATES
Matthew, William D., Durham, NC, UNITED STATES
McMillian, Michael, Rareton, NJ, UNITED STATES
PI US 2003077641 A1 20030424
AI US 2002-252120 A1 20020923 (10)
RLI Continuation-in-part of Ser. No. US 2001-957909, filed on 21 Sep 2001,
PENDING Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar
1999, ABANDONED
PRAI US 1998-77551P 19980311 (60)
DT Utility
FS APPLICATION
LN.CNT 3107
INCL INCLM: 435/006.000
INCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100
NCL NCLM: 435/006.000
NCLS: 514/013.000; 435/235.100; 435/325.000; 424/186.100
IC [7]
ICM: A61K038-17
ICS: A61K038-10; C12Q001-68; A61K038-00; C12N007-00; C12N007-01;
C12N005-00; C12N005-02; A61K039-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 175 OF 312 USPATFULL on STN
AN 2003:93621 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Davies, Robert, Arlington, MA, UNITED STATES
Li, Pan, Arlington, MA, UNITED STATES
PI US 2003064982 A1 20030403
AI US 2001-952875 A1 20010914 (9)
PRAI US 2000-232795P 20000915 (60)
US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8570
INCL INCLM: 514/227.800
INCLS: 514/235.800; 514/241.000; 514/252.020; 514/255.050; 514/275.000;
544/060.000; 544/122.000; 544/212.000; 544/238.000; 544/295.000;
544/296.000; 544/331.000
NCL NCLM: 514/227.800
NCLS: 514/235.800; 514/241.000; 514/252.020; 514/255.050; 514/275.000;
544/060.000; 544/122.000; 544/212.000; 544/238.000; 544/295.000;
544/296.000; 544/331.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-506; C07D417-14; C07D413-14; C07D043-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 176 OF 312 USPATFULL on STN
AN 2003:86331 USPATFULL
TI Antibodies that immunospecifically bind BlyS
IN Ruben, Steven M., Olney, MD, UNITED STATES
Barash, Steven C., Rockville, MD, UNITED STATES
Choi, Gil H., Rockville, MD, UNITED STATES
Vaughan, Tristan, Great Shelford, UNITED KINGDOM
Hilbert, David, Bethesda, MD, UNITED STATES
PI US 2003059937 A1 20030327
AI US 2001-880748 A1 20010615 (9)
PRAI US 2000-212210P 20000616 (60)
US 2000-240816P 20001017 (60)
US 2001-276248P 20010316 (60)
US 2001-277379P 20010321 (60)
US 2001-293499P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 17997
INCL INCLM: 435/345.000
INCLS: 530/350.000; 435/069.100; 530/300.000
NCL NCLM: 435/345.000
NCLS: 530/350.000; 435/069.100; 530/300.000
IC [7]
ICM: C07K001-00

C07K005-00; C07K007-00; C07K016-00; A61K038-00; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 177 OF 312 USPATFULL on STN
AN 2003:86257 USPATFULL
TI Antibodies against tumor necrosis factor delta (APRIL)
IN Ruben, Steven M., Brookeville, MD, UNITED STATES
PI US 2003059862 A1 20030327
AI US 2002-151882 A1 20020522 (10)
PRAI US 2001-293100P 20010524 (60)
DT Utility
FS APPLICATION
LN.CNT 8330
INCL INCLM: 435/007.230
INCLS: 530/388.230
NCL NCLM: 435/007.230
NCLS: 530/388.230
IC [7]
ICM: G01N033-574
ICS: C07K016-24

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 178 OF 312 USPATFULL on STN
AN 2003:86186 USPATFULL
TI Method for evaluating DNA probes position on substrate
IN Rokutan, Kazuhito, Osaka, JAPAN
Tomita, Hiroyuki, Tachikawa, JAPAN
Saito, Toshiro, Hatoyama, JAPAN
PI US 2003059791 A1 20030327
AI US 2002-83550 A1 20020227 (10)
PRAI JP 2001-53465 20010228
JP 2002-22682 20020131
DT Utility
FS APPLICATION
LN.CNT 2686
INCL INCLM: 435/006.000
INCLS: 435/287.200; 702/020.000
NCL NCLM: 435/006.000
NCLS: 435/287.200; 702/020.000
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C12M001-34

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 179 OF 312 USPATFULL on STN
AN 2003:79141 USPATFULL
TI Pyrazole compounds useful as protein kinase inhibitors
IN Bebbington, David, Newbury, UNITED KINGDOM
Charrier, Jean-Damien, Wantage, UNITED KINGDOM
Davies, Robert, Arlington, MA, UNITED STATES
Everitt, Simon, Beaconsfield, UNITED KINGDOM
Kay, David, Purton, UNITED KINGDOM
Knegtel, Ronald, Abingdon, UNITED KINGDOM
Patel, Sanjay, Abingdon, UNITED KINGDOM
PI US 2003055068 A1 20030320
AI US 2001-26967 A1 20011219 (10)
PRAI US 2000-257887P 20001221 (60)
US 2001-286949P 20010427 (60)
DT Utility
FS APPLICATION
LN.CNT 8979
INCL INCLM: 514/258.100
INCLS: 514/260.100; 514/262.100; 514/264.110; 514/266.230; 544/284.000;
544/278.000; 544/279.000
NCL NCLM: 514/258.100
NCLS: 514/260.100; 514/262.100; 514/264.110; 514/266.230; 544/284.000;
544/278.000; 544/279.000
IC [7]
ICM: A61K031-517
ICS: A61K031-519

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 180 OF 312 USPATFULL on STN
AN 2003:79071 USPATFULL
TI Characterization of GRP94-ligand interactions and purification,

IN Nicchittā, Christopher V., Durham, NC, UNITED STATES
Wassenberg, James J., Durham, NC, UNITED STATES
Rosser, Meredith F.N., Durham, NC, UNITED STATES
Reed, Robyn C., Durham, NC, UNITED STATES
PI US 2003054996 A1 20030320
AI US 2002-210333 A1 20020801 (10)
RLI Continuation of Ser. No. WO 2001-US9512, filed on 26 Mar 2001, PENDING
PRAI US 2000-192118P 20000324 (60)
DT Utility
FS APPLICATION
LN.CNT 5078
INCL INCLM: 514/012.000
INCLS: 435/199.000
NCL NCLM: 514/012.000
NCLS: 435/199.000
IC [7]
ICM: A61K038-17
ICS: C12N009-22
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 181 OF 312 USPATFULL on STN
AN 2003:71948 USPATFULL
TI Natural ligand for orphan G protein coupled receptor GPR86 and methods
of use
IN Communi, Didier, Dilbeek, BELGIUM
Suarez, Nathalie, Bruxelles, BELGIUM
Detheux, Michel, Mons, BELGIUM
Brezillion, Stephane, Bruxelles, BELGIUM
Lannoy, Vincent, Liernu, BELGIUM
Parmentier, Marc, Linebeek, BELGIUM
Boeynaems, Jean-Marie, Wemmel, BELGIUM
PI US 2003050235 A1 20030313
AI US 2001-924125 A1 20010807 (9)
DT Utility
FS APPLICATION
LN.CNT 3055
INCL INCLM: 514/012.000
INCLS: 435/007.210
NCL NCLM: 514/012.000
NCLS: 435/007.210
IC [7]
ICM: A61K038-17
ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 182 OF 312 USPATFULL on STN
AN 2003:71552 USPATFULL
TI In vitro and in vivo proliferation and use of multipotent neural stem
cells and their progeny
IN Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, UNITED STATES
Baetge, E. Edward, Barrington, RI, UNITED STATES
PI US 2003049837 A1 20030313
AI US 2001-925911 A1 20010809 (9)
RLI Continuation of Ser. No. US 1995-484203, filed on 7 Jun 1995, GRANTED,
Pat. No. US 6399369 Continuation-in-part of Ser. No. US 1994-270412,
filed on 5 Jul 1994, ABANDONED Continuation of Ser. No. US 1991-726812,
filed on 8 Jul 1991, ABANDONED Continuation of Ser. No. US 1995-385404,
filed on 7 Feb 1995, ABANDONED Continuation of Ser. No. US 1992-961813,
filed on 16 Oct 1992, ABANDONED Continuation-in-part of Ser. No. US
1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser.
No. US 1994-359945, filed on 20 Dec 1994, ABANDONED Continuation of Ser.
No. US 1994-221655, filed on 1 Apr 1994, ABANDONED Continuation of Ser.
No. US 1992-967622, filed on 28 Oct 1992, ABANDONED Continuation-in-part
of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995,
ABANDONED Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993,
ABANDONED Continuation-in-part of Ser. No. US 1991-726812, filed on 8
Jul 1991, ABANDONED Continuation-in-part of Ser. No. US 1993-149508,
filed on 9 Nov 1993, ABANDONED Continuation-in-part of Ser. No. US
1991-726812, filed on 8 Jul 1991, ABANDONED Continuation-in-part of Ser.
No. US 1994-311099, filed on 23 Sep 1994, ABANDONED Continuation-in-part
of Ser. No. US 1991-726812, filed on 8 Jul 1991, ABANDONED
Continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994,

Jul 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 4025
INCL INCLM: 435/368.000
INCLS: 435/384.000
NCL NCLM: 435/368.000
NCLS: 435/384.000
IC [7]
ICM: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 183 OF 312 USPATFULL on STN
AN 2003:45480 USPATFULL
TI Human 2-19 protein homologue, z219a
IN Conklin, Darrell C., Seattle, WA, UNITED STATES
Blumberg, Hal, Seattle, WA, UNITED STATES
PA ZymoGenetics, Inc. (U.S. corporation)
PI US 2003032792 A1 20030213
AI US 2001-39876 A1 20011026 (10)
RLI Continuation of Ser. No. US 1998-167513, filed on 6 Oct 1998, GRANTED,
Pat. No. US 6388064
PRAI US 1997-61712P 19971006 (60)
DT Utility
FS APPLICATION
LN.CNT 3262
INCL INCLM: 536/023.500
INCLS: 530/350.000; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 536/023.500
NCLS: 530/350.000; 435/069.100; 435/325.000; 435/320.100
IC [7]
ICM: C07H021-04
ICS: C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 184 OF 312 USPATFULL on STN
AN 2003:44759 USPATFULL
TI Evaluating neuropsychiatric diseases using a specimen-linked database
IN Muraca, Patrick J., Pittsfield, MA, UNITED STATES
PI US 2003032069 A1 20030213
AI US 2002-184671 A1 20020628 (10)
PRAI US 2001-302223P 20010629 (60)
DT Utility
FS APPLICATION
LN.CNT 3380
INCL INCLM: 435/007.210
INCLS: 702/019.000
NCL NCLM: 435/007.210
NCLS: 702/019.000
IC [7]
ICM: G01N033-567
ICS: G06F019-00; G01N033-48; G01N033-50

L5 ANSWER 185 OF 312 USPATFULL on STN
AN 2003:30380 USPATFULL
TI Dendritic enriched secreted lymphocyte activation molecule
IN Ruben, Steven M., Olney, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
PI US 2003022327 A1 20030130
AI US 2002-62523 A1 20020205 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US21130, filed on 3 Aug 2000,
UNKNOWN Continuation-in-part of Ser. No. US 1999-369248, filed on 5 Aug
1999, PENDING Continuation-in-part of Ser. No. WO 1999-US2415, filed on
4 Feb 1999, UNKNOWN Continuation-in-part of Ser. No. US 1999-244110,
filed on 4 Feb 1999, PENDING
PRAI US 2001-267523P 20010206 (60)
US 2000-190062P 20000317 (60)
US 1998-73962P 19980206 (60)
US 1998-78572P 19980319 (60)
DT Utility
FS APPLICATION
LN.CNT 12477
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/183.000

IC [7]
 ICM: C12N009-00
 ICS: C07H021-04; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 186 OF 312 USPATFULL on STN
 AN 2003:10656 USPATFULL
 TI Novel FGF homologs
 IN Deisher, Theresa A., Seattle, WA, UNITED STATES
 Conklin, Darrell C., Seattle, WA, UNITED STATES
 Raymond, Fenella C., Seattle, WA, UNITED STATES
 Bukowski, Thomas R., Seattle, WA, UNITED STATES
 Holderman, Susan D., Seattle, WA, UNITED STATES
 Sheppard, Paul O., Redmond, WA, UNITED STATES
 PA ZymoGenetics, Inc. (U.S. corporation)
 PI US 2003008351 A1 20030109
 AI US 2002-81347 A1 20020221 (10)
 RLI Continuation of Ser. No. US 1999-229947, filed on 13 Jan 1999, PENDING
 PRAI US 1996-28646P 19961016 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3583
 INCL INCLM: 435/069.100
 INCLS: 435/325.000; 435/320.100; 514/012.000; 530/350.000; 536/023.500
 NCL NCLM: 435/069.100
 NCLS: 435/325.000; 435/320.100; 514/012.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C07K017-00
 ICS: C07K014-00; C07K001-00; C12N005-02; C12N005-00; C12N015-74;
 C12N015-70; C12N015-63; C12N015-00; C12N015-09; C12P021-06; C07H021-04;
 A61K038-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 187 OF 312 USPATFULL on STN
 AN 2003:321515 USPATFULL
 TI Method and composition for modulating amyloidosis
 IN Reiner, Peter B., Vancouver, CANADA
 Lam, Fred Chiu-lai, Vancouver, CANADA
 PA The University of British Columbia, Vancouver, CANADA (non-U.S. corporation)
 PI US 6660725 B1 20031209
 AI US 2000-643511 20000822 (9)
 RLI Division of Ser. No. US 1998-177413, filed on 23 Oct 1998, now patented, Pat. No. US 6514688 Continuation-in-part of Ser. No. US 1998-67523, filed on 28 Apr 1998, now abandoned Continuation-in-part of Ser. No. US 1997-847616, filed on 28 Apr 1997, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 2468
 INCL INCLM: 514/169.000
 INCLS: 514/002.000; 514/009.000; 435/052.000; 552/502.000; 552/503.000;
 540/002.000
 NCL NCLM: 514/169.000
 NCLS: 435/052.000; 514/002.000; 514/009.000; 540/002.000; 552/502.000;
 552/503.000
 IC [7]
 ICM: A61K031-56
 ICS: C07J053-00
 EXF 514/2; 514/9; 514/169; 530/317; 530/322; 530/395; 552/502; 552/503;
 540/2; 435/52
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 188 OF 312 USPATFULL on STN
 AN 2003:279233 USPATFULL
 TI Apoptosis inducing molecule II and methods of use
 IN Ebner, Reinhard, Gaithersburg, MD, United States
 Yu, Guo-Liang, Berkeley, CA, United States
 Ruben, Steven M., Olney, MD, United States
 Ullrich, Stephen, Rockville, MD, United States
 Zhai, Yifan, Guilford, CT, United States
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 6635743 B1 20031021
 AI US 2000-523323 20000310 (9)
 RLI Continuation-in-part of Ser. No. US 1999-252656, filed on 19 Feb 1999,

1998-27287, filed on 20 Feb 1998, now patented, Pat. No. US 6479254
Continuation-in-part of Ser. No. US 1998-3886, filed on 7 Jan 1998, now
abandoned Continuation-in-part of Ser. No. US 1997-822953, filed on 21
Mar 1997, now abandoned

PRAI US 1999-168380P 19991202 (60)
US 1999-148326P 19990811 (60)
US 1999-142657P 19990706 (60)
US 1999-137457P 19990604 (60)
US 1999-124041P 19990311 (60)
US 1998-75409P 19980220 (60)
US 1996-30157P 19961031 (60)
US 1996-13923P 19960322 (60)
DT Utility
FS GRANTED
LN.CNT 11419
INCL INCLM: 530/388.230
INCLS: 530/387.300; 530/388.100; 530/389.100; 530/389.200; 530/387.100;
435/007.100; 930/144.000
NCL NCLM: 530/388.230
NCLS: 435/007.100; 530/387.100; 530/387.300; 530/388.100; 530/389.100;
530/389.200; 930/144.000
IC [7]
ICM: C07K016-00
ICS: C07K016-24; C07K014-525; G01N033-53
EXF 530/387.1; 530/387.3; 530/388.1; 530/388.23; 530/389.1; 530/389.2;
435/7.1; 930/144
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 189 OF 312 USPATFULL on STN
AN 2003:279119 USPATFULL
TI Monoclonal antibodies to membrane neutrokin-.alpha.
IN Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6635482 B1 20031021
AI US 2000-589286 20000608 (9)
RLI Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000
Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999
Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998
Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996
PRAI US 2000-176015P 20000114 (60)
US 1999-171626P 19991223 (60)
US 1999-171108P 19991216 (60)
US 1999-168624P 19991203 (60)
US 1999-167239P 19991124 (60)
US 1999-145824P 19990727 (60)
US 1999-142659P 19990706 (60)
US 1999-136784P 19990528 (60)
US 1999-131673P 19990429 (60)
US 1999-131278P 19990427 (60)
US 1999-130696P 19990423 (60)
US 1999-130412P 19990416 (60)
US 1999-127598P 19990402 (60)
US 1999-126599P 19990326 (60)
US 1999-124097P 19990312 (60)
US 1999-122388P 19990302 (60)
US 1997-36100P 19970114 (60)
DT Utility
FS GRANTED
LN.CNT 15413
INCL INCLM: 435/326.000
INCLS: 435/004.000; 435/328.000; 435/331.000; 530/387.100; 530/387.300;
530/387.900; 530/388.100; 530/388.150
NCL NCLM: 435/326.000
NCLS: 435/004.000; 435/328.000; 435/331.000; 530/387.100; 530/387.300;
530/387.900; 530/388.100; 530/388.150
IC [7]
ICM: C12N005-06
ICS: C12Q001-00; C07K016-00; C12P021-08
EXF 530/388.15; 530/350; 530/387.1; 530/387.9; 530/388.1; 530/391.1;
530/391.3; 530/387.3; 514/2; 514/4; 435/4; 435/7.1; 435/326; 435/331;
435/328; 435/334; 435/335; 435/336; 435/325; 424/130.1

L5 ANSWER 190 OF 312 USPATFULL on STN
AN 2003:253536 USPATFULL
TI Nucleic acids encoding human tumor necrosis factor TR20
IN Ruben, Steven M., Olney, MD, United States
Baker, Kevin P., Darnestown, MD, United States
Ni, Jian, Germantown, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6623941 B1 20030923
AI US 2001-848295 20010504 (9)
PRAI US 2000-202193P 20000505 (60)
DT Utility
FS GRANTED
LN.CNT 10960
INCL INCLM: 435/069.100
INCLS: 536/023.500; 530/350.000; 435/320.100; 435/252.300; 435/325.000
NCL NCLM: 435/069.100
NCLS: 435/252.300; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12N015-12
ICS: C07K014-705
EXF 536/23.5; 530/350; 435/320.1; 435/69.1; 435/252.3; 435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 191 OF 312 USPATFULL on STN
AN 2003:234803 USPATFULL
TI Carbocyclic and heterocyclic substituted semicarbazones and
thiosemicarbazones and the use thereof
IN Wang, Yan, San Diego, CA, United States
Cai, Sui Xiong, San Diego, CA, United States
Lan, Nancy C., S. Pasadena, CA, United States
Keana, John F. W., Eugene, OR, United States
Ilyin, Victor I., Irvine, CA, United States
Weber, Eckard, San Diego, CA, United States
PA Euro-Celtique S.A., LUXEMBOURG (non-U.S. corporation)
PI US 6613803 B1 20030902
AI US 1999-421403 19991021 (9)
RLI Continuation of Ser. No. WO 1998-US8004, filed on 22 Apr 1998
PRAI US 1997-62649P 19971022 (60)
US 1997-44530P 19970422 (60)
DT Utility
FS GRANTED
LN.CNT 2731
INCL INCLM: 514/583.000
INCLS: 514/237.500; 514/255.010; 514/274.000; 514/311.000; 514/327.000;
514/330.000; 514/351.000; 514/459.000; 514/466.000; 514/590.000
NCL NCLM: 514/583.000
NCLS: 514/237.500; 514/255.010; 514/274.000; 514/311.000; 514/327.000;
514/330.000; 514/351.000; 514/459.000; 514/466.000; 514/590.000
IC [7]
ICM: A61K031-17
ICS: A61K031-175
EXF 514/237.5; 514/255.01; 514/274; 514/311; 514/327; 514/330; 514/331;
514/459; 514/466; 514/583; 514/590
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 192 OF 312 USPATFULL on STN
AN 2003:197132 USPATFULL
TI S-adenosyl methionine regulation of metabolic pathways and its use in
diagnosis and therapy
IN Schwartz, Dennis E., Redmond, WA, United States
Vermeulen, Nicolaas M. J., Woodinville, WA, United States
O'Day, Christine L., Mountlake Terrace, WA, United States
PA MediQuest Therapeutics, Inc., Seattle, WA, United States (U.S.
corporation)
PI US 6596701 B1 20030722
WO 9633703 19961031
AI US 1998-930128 19980316 (8)
WO 1996-US5799 19960425
RLI Continuation-in-part of Ser. No. US 1995-476447, filed on 7 Jun 1995,
now abandoned Continuation-in-part of Ser. No. US 1995-428963, filed on
25 Apr 1995
DT Utility
FS GRANTED

INCL INCLM: 514/046.000
INCLS: 435/007.100; 528/338.000; 528/340.000
NCL NCLM: 514/046.000
NCLS: 435/007.100; 528/338.000; 528/340.000
IC [7]
ICM: A01N043-04
ICS: G01N033-53; C08G069-26
EXF 435/7.1; 514/46; 528/338; 528/340
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 193 OF 312 USPATFULL on STN
AN 2003:183970 USPATFULL
TI Method of detecting axonally-derived protein ***tau*** in patients
with traumatic CNS injury
IN Zemlan, Frank P., Cincinnati, OH, United States
PA University of Cincinnati, Cincinnati, OH, United States (U.S.
corporation)
PI US 6589746 B1 20030708
AI US 2000-694627 20001023 (9)
PRAI US 1999-160690P 19991021 (60)
DT Utility
FS GRANTED
LN.CNT 1568
INCL INCLM: 435/007.100
INCLS: 435/007.920; 435/007.940; 436/503.000; 424/130.100; 530/300.000
NCL NCLM: 435/007.100
NCLS: 424/130.100; 435/007.920; 435/007.940; 436/503.000; 530/300.000
IC [7]
ICM: G01N033-53
ICS: G01N033-533; G01N033-543; G01N033-567; A61K039-395
EXF 435/35; 435/69.1; 435/325; 435/7.1; 435/7.92; 530/300; 424/130.1;
424/184.1; 436/503
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 194 OF 312 USPATFULL on STN
AN 2003:137150 USPATFULL
TI Adipocyte-specific protein homologs
IN Sheppard, Paul O., Granite Falls, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6566499 B1 20030520
AI US 2000-506852 20000217 (9)
RLI Continuation-in-part of Ser. No. US 1998-118408, filed on 17 Jul 1998,
now patented, Pat. No. US 6265544
PRAI US 1997-53154P 19970718 (60)
DT Utility
FS GRANTED
LN.CNT 3609
INCL INCLM: 530/350.000
INCLS: 435/069.400; 435/325.000; 435/252.300; 435/320.100; 536/023.100
NCL NCLM: 530/350.000
NCLS: 435/069.400; 435/252.300; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: C07K017-00
ICS: C07H021-04; C12N015-09; C12N005-02; C12N001-20
EXF 435/69.4; 435/325; 435/252.3; 435/320.1; 530/350; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 195 OF 312 USPATFULL on STN
AN 2003:130038 USPATFULL
TI Transgenic mice over-expressing receptor for advanced glycation
endproduct (RAGE) and mutant APP in brain and uses thereof
IN Stern, David M., Great Neck, NY, United States
Schmidt, Ann Marie, Franklin Lakes, NJ, United States
Yan, Shi Du, New York, NY, United States
PA The Trustees of Columbia University in the City of New York, New York,
NY, United States (U.S. corporation)
PI US 6563015 B1 20030513
AI US 2000-638649 20000814 (9)
DT Utility
FS GRANTED
LN.CNT 1854
INCL INCLM: 800/003.000
INCLS: 800/012.000; 800/018.000
NCL NCLM: 800/003.000
NCLS: 800/012.000; 800/018.000

ICM: G01N033-00
EXF 800/12; 800/18; 800/3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 196 OF 312 USPATFULL on STN
AN 2003:129800 USPATFULL
TI Diagnostic methods using antibodies to Neutrokin-alpha
IN Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6562579 B1 20030513
AI US 2000-588947 20000608 (9)
RLI Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000
Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999
Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998
Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996
PRAI US 1997-36100P 19970114 (60)
US 1999-122388P 19990302 (60)
US 1999-124097P 19990312 (60)
US 1999-126599P 19990326 (60)
US 1999-127598P 19990402 (60)
US 1999-130412P 19990416 (60)
US 1999-130696P 19990423 (60)
US 1999-131278P 19990427 (60)
US 1999-131673P 19990429 (60)
US 1999-136784P 19990528 (60)
US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)
DT Utility
FS GRANTED
LN.CNT 15469
INCL INCLM: 435/007.100
INCLS: 435/007.200; 530/350.000; 530/387.900; 530/388.100; 530/388.230;
530/389.100; 530/391.300
NCL NCLM: 435/007.100
NCLS: 435/007.200; 530/350.000; 530/387.900; 530/388.100; 530/388.230;
530/389.100; 530/391.300
IC [7]
ICM: G01N033-53
ICS: C07K016-24
EXF 435/7.1; 435/7.23; 435/7.24; 435/7.7; 530/350; 530/351; 530/387.1;
530/388.1; 530/388.23; 514/2; 514/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 197 OF 312 USPATFULL on STN
AN 2003:47516 USPATFULL
TI Adipocyte complement related protein homolog zacrp3
IN Piddington, Christopher S., Thousand Oaks, CA, United States
Bishop, Paul D., Fall City, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6521233 B1 20030218
AI US 2000-552225 20000419 (9)
PRAI US 1999-130199P 19990420 (60)
DT Utility
FS GRANTED
LN.CNT 3334
INCL INCLM: 424/192.100
INCLS: 530/350.000; 530/402.000; 424/001.370; 424/193.100; 435/069.700
NCL NCLM: 424/192.100
NCLS: 424/001.370; 424/193.100; 435/069.700; 530/350.000; 530/402.000
IC [7]
ICM: C07K014-00
ICS: C07K014-47; C12N015-00
EXF 530/310; 530/402; 424/1.37; 424/192.1; 424/193.1; 435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 198 OF 312 USPATFULL on STN

TI FGF homologs
 IN Deisher, Theresa A., Seattle, WA, United States
 Conklin, Darrell C., Seattle, WA, United States
 Raymond, Fenella, Seattle, WA, United States
 Bukowski, Thomas R., Seattle, WA, United States
 Holderman, Susan D., Seattle, WA, United States
 Hansen, Birgit, Seattle, WA, United States
 Sheppard, Paul O., Redmond, WA, United States
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 6518236 B1 20030211
 AI US 1999-229947 19990113 (9)
 RLI Continuation-in-part of Ser. No. US 1997-951822, filed on 16 Oct 1997,
 now patented, Pat. No. US 5989866
 PRAI US 1996-28646P 19961016 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3301
 INCL INCLM: 514/002.000
 INCLS: 514/012.000; 530/350.000; 530/399.000; 435/069.700
 NCL NCLM: 514/002.000
 NCLS: 435/069.700; 514/012.000; 530/350.000; 530/399.000
 IC [7]
 ICM: C07K014-50
 ICS: A61K038-18
 EXF 514/2; 514/12; 530/399; 530/350; 435/69.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 199 OF 312 USPATFULL on STN
 AN 2003:13291 USPATFULL
 TI Methods and compositions for the treatment and prevention of Parkinson's
 disease
 IN Rueger, David C., Southborough, MA, United States
 Sampath, Kuber T., Holliston, MA, United States
 Cohen, Charles M., Weston, MA, United States
 Oppermann, Hermann, Medway, MA, United States
 Pang, Roy H. L., Etna, NH, United States
 PA Curis, Inc., Cambridge, MA, United States (U.S. corporation)
 PI US 6506729 B1 20030114
 AI US 1997-938622 19970925 (8)
 RLI Continuation-in-part of Ser. No. US 1994-260675, filed on 16 Jun 1994
 Continuation of Ser. No. US 1993-126100, filed on 23 Sep 1993, now
 abandoned Continuation of Ser. No. US 1992-922813, filed on 31 Jul 1992,
 now abandoned Continuation-in-part of Ser. No. US 1991-752764, filed on
 30 Aug 1991, now abandoned Continuation-in-part of Ser. No. US
 1991-753059, filed on 30 Aug 1991, now abandoned Continuation-in-part of
 Ser. No. US 1991-667274, filed on 8 Mar 1991, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 2995
 INCL INCLM: 514/012.000
 INCLS: 514/002.000; 530/350.000; 530/402.000
 NCL NCLM: 514/012.000
 NCLS: 514/002.000; 530/350.000; 530/402.000
 IC [7]
 ICM: A61K038-18
 EXF 514/2; 514/12; 530/350; 530/402
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 200 OF 312 USPATFULL on STN
 AN 2003:6434 USPATFULL
 TI Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and
 TR11SV2
 IN Ni, Jian, Rockville, MD, United States
 Ruben, Steven M., Olney, MD, United States
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
 corporation)
 PI US 6503184 B1 20030107
 AI US 2000-512363 20000223 (9)
 RLI Continuation-in-part of Ser. No. US 1998-176200, filed on 21 Oct 1998
 PRAI US 1999-121648P 19990224 (60)
 US 1999-134172P 19990513 (60)
 US 1999-144076P 19990716 (60)
 US 1997-63212P 19971021 (60)
 DT Utility
 FS GRANTED

INCL INCLM: 574/012.000
 INCLS: 514/002.000
 NCL NCLM: 514/012.000
 NCLS: 514/002.000
 IC [7]
 ICM: A61K038-00
 EXF 514/2; 514/12; 424/278.1; 424/283.1; 424/178.1; 424/184.1; 424/185.1;
 424/192.1; 424/198.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 201 OF 312 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 2003:1081437 SCISEARCH
 GA The Genuine Article (R) Number: 734RX
 TI Alterations in ***cerebrospinal*** ***fluid*** apolipoprotein E
 and amyloid beta-protein after traumatic brain injury
 AU Kay A D (Reprint); Petzold A; Kerr M; Keir G; Thompson E; Nicoll J A R
 CS Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, 1345 Govan Rd,
 Glasgow G51 4TF, Lanark, Scotland (Reprint); Univ Glasgow, So Gen Hosp,
 Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; Univ
 London, Inst Neurol & Neurosurg, Dept Neuroimmunol, London, England; Dept
 Neurosurg, Pittsburgh, PA USA; Ctr Nursing Res, Pittsburgh, PA USA; Univ
 Southampton, Southampton Gen Hosp, Div Clin Neurosci, Southampton, Hants,
 England
 CYA Scotland; England; USA
 SO JOURNAL OF NEUROTRAUMA, (OCT 2003) Vol. 20, No. 10, pp. 943-952.
 Publisher: MARY ANN LIEBERT INC PUBL, 2 MADISON AVENUE, LARCHMONT, NY
 10538 USA.
 ISSN: 0897-7151.
 DT Article; Journal
 LA English
 REC Reference Count: 71
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 202 OF 312 MEDLINE on STN
 AN 2003449861 MEDLINE
 DN PubMed ID: 14512714
 TI Decreased ***cerebrospinal*** ***fluid*** acetylcholinesterase in
 patients with subcortical ischemic vascular dementia.
 AU Wallin Anders; Sjogren Magnus; Blennow Kaj; Davidsson Pia
 CS Institute of Clinical Neuroscience, Sahlgrenska University Hospital,
 Molndal, Sweden.. anders.wallin@neuro.gu.se
 SO Dementia and geriatric cognitive disorders, (2003) 16 (4) 200-7.
 Journal code: 9705200. ISSN: 1420-8008.
 CY Switzerland
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200311
 ED Entered STN: 20030928
 Last Updated on STN: 20031107
 Entered Medline: 20031106

L5 ANSWER 203 OF 312 USPATFULL on STN DUPLICATE 19
 AN 2002:323155 USPATFULL
 TI Carbocyclic and heterocyclic substituted semicarbazones and
 thiosemicarbazones and the use thereof
 IN Wang, Yan, San Diego, CA, UNITED STATES
 Cai, Sui Xiong, San Diego, CA, UNITED STATES
 Lan, Nancy C., S. Pasadena, CA, UNITED STATES
 Keana, John F.W., Eugene, OR, UNITED STATES
 Ilyin, Victor I., Irvine, CA, UNITED STATES
 PI US 2002183321 A1 20021205
 US 6696442 B2 20040224
 AI US 2002-178477 A1 20020625 (10)
 RLI Division of Ser. No. US 1999-421403, filed on 21 Oct 1999, PENDING
 Continuation of Ser. No. WO 1998-US8004, filed on 22 Apr 1998, UNKNOWN
 PRAI US 1997-44530P 19970422 (60)
 US 1997-62649P 19971022 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2610
 INCL INCLM: 514/237.800
 INCLS: 514/255.010; 514/317.000; 514/582.000; 514/590.000
 NCL NCLM: 514/237.500

IC [7]
 ICM: A61K031-535
 ICS: A61K031-495; A61K031-445; A61K031-175
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 204 OF 312 USPATFULL on STN DUPLICATE 20
 AN 2002:280793 USPATFULL
 TI Adipocyte-specific protein homologs
 IN Sheppard, Paul O., Redmond, WA, UNITED STATES
 PA ZymoGenetics, Inc. (U.S. corporation)
 PI US 2002156243 A1 20021024
 US 6518403 B2 20030211
 AI US 2001-911176 A1 20010723 (9)
 RLI Division of Ser. No. US 1998-118408, filed on 17 Jul 1998, GRANTED, Pat.
 No. US 6265544
 PRAI US 1997-53154P 19970718 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3492
 INCL INCLM: 530/356.000
 INCLS: 435/183.000; 530/395.000
 NCL NCLM: 530/387.300
 NCLS: 530/387.900; 530/388.240; 530/389.200
 IC [7]
 ICM: C07K014-78
 ICS: C12N009-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 205 OF 312 USPATFULL on STN DUPLICATE 21
 AN 2002:267110 USPATFULL
 TI Methods of treating disorders related to apoE
 IN Huang, Yadong, San Francisco, CA, UNITED STATES
 Mahley, Robert W., San Francisco, CA, UNITED STATES
 PI US 2002147999 A1 20021010
 US 6787519 B2 20040907
 AI US 2001-33526 A1 20011102 (10)
 PRAI US 2000-245737P 20001103 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2672
 INCL INCLM: 800/012.000
 INCLS: 435/184.000; 514/012.000
 NCL NCLM: 514/002.000
 NCLS: 514/017.000; 514/018.000; 530/300.000; 530/329.000
 IC [7]
 ICM: A01K067-00
 ICS: C12N009-99; A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 206 OF 312 USPATFULL on STN DUPLICATE 22
 AN 2002:198576 USPATFULL
 TI Protein-protein interactions in neurodegenerative diseases
 IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
 Bartel, Paul L., Salt Lake City, UT, UNITED STATES
 Heichman, Karen, Salt Lake City, UT, UNITED STATES
 PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
 PI US 2002106676 A1 20020808
 US 6653102 B2 20031125
 AI US 2001-973963 A1 20011011 (9)
 PRAI US 2000-240790P 20001017 (60)
 US 2001-304775P 20010713 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3181
 INCL INCLM: 435/006.000
 INCLS: 435/368.000; 435/320.100; 435/069.100; 536/023.200; 435/226.000
 NCL NCLM: 435/069.100
 NCLS: 435/183.000; 435/252.300; 435/254.110; 435/254.200; 435/320.100;
 435/325.000; 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:185613 USPATFULL
 TI Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
 IN Ni, Jian, Germantown, MD, UNITED STATES
 Ruben, Steven M., Olney, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
 PI US 2002098525 A1 20020725
 US 6689607 B2 20040210
 AI US 2001-915593 A1 20010727 (9)
 RLI Continuation-in-part of Ser. No. US 2000-512363, filed on 23 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1998-176200, filed on 21 Oct 1998, PENDING
 PRAI US 2000-221577P 20000728 (60)
 US 1999-144076P 19990716 (60)
 US 1999-134172P 19990513 (60)
 US 1999-121648P 19990224 (60)
 US 1997-63212P 19971021 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 12618
 INCL INCLM: 435/007.900
 INCLS: 530/388.220
 NCL NCLM: 435/331.000
 NCLS: 435/007.100; 435/326.000; 435/328.000; 435/330.000; 435/334.000; 435/343.200; 435/344.100; 530/387.100; 530/387.300; 530/387.700; 530/387.900; 530/388.100; 530/388.150; 530/388.220; 530/388.750; 530/388.800; 530/388.850; 530/389.100; 530/389.700; 530/391.100; 530/391.300
 IC [7]
 ICM: G01N033-542
 ICS: G01N033-53; C07K016-28
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 208 OF 312 USPATFULL on STN DUPLICATE 24
 AN 2002:141109 USPATFULL
 TI Death domain containing receptor 5
 IN Ni, Jian, Rockville, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Rosen, Craig A., Laytonville, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, 20850 (U.S. corporation)
 PI US 2002072091 A1 20020613
 US 6743625 B2 20040601
 AI US 2001-874138 A1 20010606 (9)
 RLI Continuation of Ser. No. US 2000-565009, filed on 4 May 2000, PENDING Continuation of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
 PRAI US 1999-148939P 19990813 (60)
 US 1999-133238P 19990507 (60)
 US 1999-132498P 19990504 (60)
 US 1997-40846P 19970317 (60)
 US 1997-54021P 19970729 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8943
 INCL INCLM: 435/069.100
 INCLS: 435/325.000; 435/320.100; 536/023.500; 530/350.000
 NCL NCLM: 435/325.000
 NCLS: 435/069.100; 435/252.300; 435/254.110; 530/350.000; 536/023.100; 536/023.400; 536/023.500
 IC [7]
 ICM: C12P021-02
 ICS: C12N005-06; C07H021-04; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 209 OF 312 USPATFULL on STN DUPLICATE 25
 AN 2002:126317 USPATFULL
 TI Human tumor necrosis factor delta and epsilon
 IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 Dillon, Patrick J., Carlsbad, CA, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
 PI US 2002064829 A1 20020530
 US 6541224 B2 20030401

RLI Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997,
PENDING
PRAI US 1996-16812P 19960314 (60)
US 2001-293499P 20010525 (60)
US 2001-277978P 20010323 (60)
US 2001-276248P 20010316 (60)
US 2000-254875P 20001213 (60)
US 2000-241952P 20001023 (60)
US 2000-211537P 20000615 (60)
DT Utility
FS APPLICATION
LN.CNT 13531
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/351.000; 424/145.100; 530/388.230;
536/023.500
NCL NCLM: 435/069.500
NCLS: 435/007.710; 435/069.100; 435/069.700; 435/070.100; 514/002.000;
514/012.000; 530/350.000; 530/351.000
IC [7]
ICM: A61K039-395
ICS: C07K014-525; C07K016-24; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 210 OF 312 USPATFULL on STN DUPLICATE 26
AN 2002:119898 USPATFULL
TI Carbocyclic and heterocyclic substituted semicarbazones and
thiosemicarbazones and the use thereof
IN Wang, Yan, San Diego, CA, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Keana, John FW, Eugene, OR, UNITED STATES
PA CoCensys, Inc. (U.S. corporation)
PI US 2002061886 A1 20020523
US 6638947 B2 20031028
AI US 2001-3249 A1 20011206 (10)
RLI Division of Ser. No. US 1999-421403, filed on 21 Oct 1999, PENDING
Continuation of Ser. No. WO 1998-US8004, filed on 22 Apr 1998, UNKNOWN
PRAI US 1997-44530P 19970422 (60)
US 1997-62649P 19971022 (60)
DT Utility
FS APPLICATION
LN.CNT 2456
INCL INCLM: 514/235.500
INCLS: 514/255.010; 514/317.000; 514/330.000; 514/581.000; 514/590.000
NCL NCLM: 514/317.000
NCLS: 514/351.000; 514/459.000; 514/466.000; 514/583.000; 514/590.000;
546/221.000; 546/291.000; 549/419.000; 549/438.000; 564/020.000;
564/021.000; 564/036.000
IC [7]
ICM: A61K031-535
ICS: A61K031-495; A61K031-445; A61K031-175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 211 OF 312 USPATFULL on STN DUPLICATE 27
AN 2002:99506 USPATFULL
TI Compositions and methods for treatment of neurological disorders and
neurodegenerative diseases
IN Lee, Robert K.K., Boston, MA, UNITED STATES
Wurtman, Richard J., Boston, MA, UNITED STATES
PA Massachusetts Institute of Technology (U.S. corporation)
PI US 2002052407 A1 20020502
US 6469055 B2 20021022
AI US 2001-775809 A1 20010205 (9)
RLI Continuation of Ser. No. US 1999-435470, filed on 8 Nov 1999, PATENTED
Continuation-in-part of Ser. No. US 1997-924505, filed on 5 Sep 1997,
PATENTED
PRAI US 1996-25507P 19960905 (60)
US 1997-33765P 19970115 (60)
DT Utility
FS APPLICATION
LN.CNT 1807
INCL INCLM: 514/474.000
INCLS: 514/733.000
NCL NCLM: 514/474.000
NCLS: 514/733.000; 514/734.000
IC [7]

ICS: A61K031-05

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 212 OF 312 USPATFULL on STN DUPLICATE 28
AN 2002:99503 USPATFULL
TI Compositions and methods for treating or preventing diseases of body
passageways
IN Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
PI US 2002052404 A1 20020502
US 6759431 B2 20040706
AI US 2001-933652 A1 20010820 (9)
RLI Continuation of Ser. No. US 1996-653207, filed on 24 May 1996, UNKNOWN
DT Utility
FS APPLICATION
LN.CNT 4786
INCL INCLM: 514/449.000
INCLS: 424/486.000
NCL NCLM: 514/449.000
NCLS: 424/403.000; 424/426.000; 424/501.000
IC [7]
ICM: A61K031-337
ICS: A61K009-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 213 OF 312 USPATFULL on STN DUPLICATE 29
AN 2002:92635 USPATFULL
TI METHODS AND COMPOSITIONS FOR THE TREATMENT OF MOTOR NEURON INJURY AND
NEUROPATHY
IN RUEGER, DAVID C., SOUTHBOROUGH, MA, UNITED STATES
SAMPATH, KUBER T., HOLLISTON, MA, UNITED STATES
OPPERMANN, HERMAN, MEDWAY, MA, UNITED STATES
PANG, ROY H. L., NEW HAMPSHIRE, MA, UNITED STATES
COHEN, CHARLES M., WESTON, MA, UNITED STATES
PI US 2002049159 A1 20020425
US 6723698 B2 20040420
AI US 1997-937755 A1 19970925 (8)
RLI Continuation-in-part of Ser. No. US 1994-260675, filed on 16 Jun 1994,
PENDING Continuation of Ser. No. US 1993-126100, filed on 23 Sep 1993,
ABANDONED Continuation of Ser. No. US 1992-922813, filed on 31 Jul 1992,
ABANDONED Continuation-in-part of Ser. No. US 1991-752764, filed on 30
Aug 1991, ABANDONED Continuation-in-part of Ser. No. US 1991-753059,
filed on 30 Aug 1991, ABANDONED Continuation-in-part of Ser. No. US
1991-667274, filed on 11 Mar 1991, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 3688
INCL INCLM: 514/012.000
INCLS: 514/002.000
NCL NCLM: 514/012.000
NCLS: 530/351.000
IC [7]
ICM: A61K038-00
ICS: A01N037-18; C12N015-09

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 214 OF 312 USPATFULL on STN DUPLICATE 30
AN 2002:92229 USPATFULL
TI Model for alzheimer's disease and other neurodegenerative diseases
IN Lynch, Gary, Irvine, CA, UNITED STATES
Bi, Xiaoning, Irvine, CA, UNITED STATES
PI US 2002048746 A1 20020425
US 6803233 B2 20041012
AI US 2001-917789 A1 20010731 (9)
PRAI US 2001-283352P 20010413 (60)
US 2000-222060P 20000731 (60)
DT Utility
FS APPLICATION
LN.CNT 4252
INCL INCLM: 435/004.000
INCLS: 435/040.500; 435/007.200
NCL NCLM: 435/325.000
NCLS: 435/347.000; 435/352.000; 435/353.000; 435/354.000
IC [7]
ICM: C12Q001-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 215 OF 312 USPATFULL on STN DUPLICATE 31
AN 2002:67190 USPATFULL
TI METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS
IN REINER, PETER B., VANCOUVER, CANADA
LAM, FRED CHIU-LAI, VANCOUVER, CANADA
PI US 2002037843 A1 20020328
US 6514686 B2 20030204
AI US 1998-177413 A1 19981023 (9)
RLI Continuation-in-part of Ser. No. US 1998-67523, filed on 28 Apr 1998,
ABANDONED Continuation-in-part of Ser. No. US 1997-847616, filed on 28
Apr 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 2452
INCL INCLM: 514/011.000
INCLS: 530/317.000; 435/004.000; 435/007.100; 436/086.000; 530/324.000;
435/183.000
NCL NCLM: 435/004.000
NCLS: 435/007.400; 436/086.000; 530/324.000
IC [7]
ICM: C12Q001-00
ICS: G01N033-53; A61K038-00; G01N033-00; C12N009-00; C07K005-00;
C07K007-00; C07K016-00; C07K017-00; A61K038-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 216 OF 312 USPATFULL on STN DUPLICATE 32
AN 2002:22538 USPATFULL
TI METHOD OF TREATING NEURODEGENERATIVE DISORDERS VIA INHIBITION OF AMYLOID
BETA PEPTIDE BINDING
IN REITZ, ALLEN B., LANSDALE, PA, UNITED STATES
DEMETER, DAVID A., FISHERS, IN, UNITED STATES
LEE, DANIEL H.S., NORTHHAMPTON, PA, UNITED STATES
WANG, HOAU-YAN, PHILADELPHIA, PA, UNITED STATES
CHEN, ROBERT H., BELLE MEAD, NJ, UNITED STATES
ROSS, TINA MORGAN, AUDUBON, PA, UNITED STATES
SCOTT, MALCOLM K., LANSDALE, PA, UNITED STATES
PLATA-SALAMAN, CARLOS R., AMBLER, PA, UNITED STATES
PI US 2002013374 A1 20020131
US 6441049 B2 20020827
AI US 1999-320885 A1 19990527 (9)
PRAI US 1998-87577P 19980601 (60)
DT Utility
FS APPLICATION
LN.CNT 1507
INCL INCLM: 514/657.000
INCLS: 564/428.000; 564/429.000
NCL NCLM: 514/657.000
NCLS: 564/428.000; 564/429.000
IC [7]
ICM: A61K031-135
ICS: C07C211-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 217 OF 312 USPATFULL on STN DUPLICATE 33
AN 2002:283360 USPATFULL
TI Keratinocyte derived interferon
IN LaFleur, David W., Washington, DC, United States
Moore, Paul A., Germantown, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6472512 B1 20021029
US 2002187950 A1 20021212
AI US 2001-908594 20010720 (9)
RLI Continuation-in-part of Ser. No. US 2000-487792, filed on 20 Jan 2000
Continuation-in-part of Ser. No. WO 2000-US1239, filed on 20 Jan 2000
Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999
Continuation-in-part of Ser. No. WO 1999-US16424, filed on 21 Jul 1999
Continuation-in-part of Ser. No. US 2001-358587, filed on 24 May 2001,
now abandoned Continuation-in-part of Ser. No. WO 1998-US9916424, filed
on 21 Jul 1998, now abandoned
PRAI US 2001-292934P 20010524 (60)
US 2000-219621P 20000721 (60)

DT Utility
FS GRANTED
LN.CNT 14148
INCL INCLM: 530/388.200
INCLS: 530/388.150; 530/389.200; 530/391.300; 435/007.920; 435/331.000;
435/335.000
NCL NCLM: 530/388.200
NCLS: 435/007.920; 435/331.000; 435/335.000; 530/388.150; 530/389.200;
530/391.300
IC [7]
ICM: C07K016-00
ICS: C07K016-24; C12P021-08; G01N033-53
EXF 530/388.15; 530/388.2; 530/389.2; 530/391.3; 435/331; 435/335; 435/7.92
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 218 OF 312 USPATFULL on STN
AN 2002:339252 USPATFULL
TI Gene-targeted animal model of apolipoprotein E4 domain interaction and
uses thereof
IN Weisgraber, Karl H., Walnut Creek, CA, UNITED STATES
Farese, Robert V., San Francisco, CA, UNITED STATES
Raffai, Robert, San Francisco, CA, UNITED STATES
Dong, Li-Ming, Palo Alto, CA, UNITED STATES
PI US 2002194628 A1 20021219
AI US 2001-17718 A1 20011214 (10)
PRAI US 2001-276861P 20010316 (60)
DT Utility
FS APPLICATION
LN.CNT 2102
INCL INCLM: 800/008.000
INCLS: 435/325.000; 530/359.000; 800/018.000
NCL NCLM: 800/008.000
NCLS: 435/325.000; 530/359.000; 800/018.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027; C12N005-06; C07K014-775
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 219 OF 312 USPATFULL on STN
AN 2002:337940 USPATFULL
TI Cytokine receptor common gamma chain like
IN Ruben, Steven M., Olney, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
PI US 2002193305 A1 20021219
AI US 2002-78059 A1 20020220 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US22493, filed on 17 Aug 2000,
UNKNOWN Continuation-in-part of Ser. No. US 1999-376430, filed on 18 Aug
1999, PENDING Continuation-in-part of Ser. No. WO 1999-US5068, filed on
5 Mar 1999, UNKNOWN Continuation-in-part of Ser. No. US 1999-263626,
filed on 5 Mar 1999, PENDING
PRAI US 2001-269876P 20010221 (60)
US 1998-78563P 19980319 (60)
US 1998-86505P 19980522 (60)
DT Utility
FS APPLICATION
LN.CNT 13770
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/325.000; 435/320.100
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 220 OF 312 USPATFULL on STN
AN 2002:337920 USPATFULL
TI Neuroprotectants formulations and methods
IN Hesson, David P., Malvern, PA, UNITED STATES
Frazer, Glen D., Wynnewood, PA, UNITED STATES
Ross, Douglas, North wales, PA, UNITED STATES
PI US 2002193285 A1 20021219
AI US 2002-90441 A1 20020304 (10)
PRAI US 2001-331360P 20010302 (60)

FS APPLICATION
LN.CNT 870
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM: A61K031-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 221 OF 312 USPATFULL on STN
AN 2002:329846 USPATFULL
TI Neutrokin- α binding proteins and methods based thereon
IN Ruben, Steven M., Olney, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
Baker, Kevin, Darnestown, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002187526 A1 20021212
AI US 2002-84971 A1 20020301 (10)
RLI Continuation of Ser. No. US 2000-533822, filed on 24 Mar 2000, PENDING
PRAI US 1999-126599P 19990326 (60)
US 2000-188208P 20000310 (60)

DT Utility
FS APPLICATION

LN.CNT 13242
INCL INCLM: 435/069.500
INCLS: 435/320.100; 435/325.000; 536/023.500; 530/351.000
NCL NCLM: 435/069.500
NCLS: 435/320.100; 435/325.000; 536/023.500; 530/351.000
IC [7]

ICM: C12P021-02
ICS: C07H021-04; C07K014-52; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 222 OF 312 USPATFULL on STN
AN 2002:308385 USPATFULL
TI Serotonergic compositions and methods for treatment of mild cognitive impairment
IN Wurtman, Richard J., Boston, MA, UNITED STATES
Lee, Robert K. K., Boston, MA, UNITED STATES
PI US 2002173511 A1 20021121
AI US 2001-986469 A1 20011108 (9)
PRAI US 2000-246615P 20001108 (60)

DT Utility
FS APPLICATION

LN.CNT 1148
INCL INCLM: 514/252.120
INCLS: 514/254.020; 514/304.000; 514/255.030; 514/419.000; 514/321.000;
514/322.000; 514/438.000; 514/635.000; 514/456.000; 514/657.000
NCL NCLM: 514/252.120
NCLS: 514/254.020; 514/304.000; 514/255.030; 514/419.000; 514/321.000;
514/322.000; 514/438.000; 514/635.000; 514/456.000; 514/657.000
IC [7]

ICM: A61K031-496
ICS: A61K031-495; A61K031-454; A61K031-46; A61K031-4535; A61K031-353;
A61K031-405; A61K031-155; A61K031-135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 223 OF 312 USPATFULL on STN
AN 2002:301557 USPATFULL
TI Intranasal delivery of agents for regulating development of implanted cells in the CNS
IN Frey, William H., II, White Bear, MN, UNITED STATES
PI US 2002169102 A1 20021114
AI US 2002-114385 A1 20020402 (10)
PRAI US 2001-281062P 20010403 (60)

DT Utility
FS APPLICATION

LN.CNT 2177
INCL INCLM: 514/001.000
INCLS: 435/368.000
NCL NCLM: 514/001.000
NCLS: 435/368.000

IC [7]
ICM: A61K031-00
ICS: C12N005-08

L5 ANSWER 224 OF 312 USPATFULL on STN
 AN 2002:300816 USPATFULL
 TI Human tumor necrosis factor receptor TR9
 IN Ni, Jian, Germantown, MD, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Fan, Ping, Potomac, MD, UNITED STATES
 Gentz, Reiner L., Rockville, MD, UNITED STATES
 PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
 PI US 2002168359 A1 20021114
 AI US 2002-41574 A1 20020110 (10)
 RLI Division of Ser. No. US 2000-527236, filed on 16 Mar 2000, PATENTED
 Continuation-in-part of Ser. No. US 1998-95094, filed on 10 Jun 1998, PENDING
 PRAI US 1999-134220P 19990514 (60)
 US 1999-126019P 19990324 (60)
 US 1997-52991P 19970611 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 9755
 INCL INCLM: 424/139.100
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
 NCL NCLM: 424/139.100
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.200
 IC [7]
 ICM: A61K039-395
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-715
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 225 OF 312 USPATFULL on STN
 AN 2002:300807 USPATFULL
 TI Methods for treating disorders of neuronal deficiency with bone marrow-derived cells
 IN Brazelton, Timothy R., Cupertino, CA, UNITED STATES
 Blau, Helen M., Menlo Park, CA, UNITED STATES
 PI US 2002168350 A1 20021114
 AI US 2001-993045 A1 20011113 (9)
 PRAI US 2000-247128P 20001110 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1696
 INCL INCLM: 424/093.210
 INCLS: 424/093.700
 NCL NCLM: 424/093.210
 NCLS: 424/093.700
 IC [7]
 ICM: A61K048-00

L5 ANSWER 226 OF 312 USPATFULL on STN
 AN 2002:295110 USPATFULL
 TI Crystallization of IGF-1
 IN Schaffer, Michelle, Cambridge, UNITED KINGDOM
 Ultsch, Mark, Mill Valley, CA, UNITED STATES
 Vajdos, Felix, Ledyard, CT, UNITED STATES
 PA GENENTECH, INC. (non-U.S. corporation)
 PI US 2002165155 A1 20021107
 AI US 2002-66009 A1 20020201 (10)
 PRAI US 2001-287072P 20010427 (60)
 US 2001-267977P 20010209 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 2360
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 702/019.000
 NCL NCLM: 514/012.000
 NCLS: 530/350.000; 702/019.000
 IC [7]
 ICM: A61K038-18
 ICS: G06F019-00; G01N033-48; G01N033-50; C07K014-475
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 227 OF 312 USPATFULL on STN
 AN 2002:294746 USPATFULL
 TI Methods of suppressing microglial activation

Matthew, William D., Durham, NC, UNITED STATES
McMillian, Michael, Rareton, NJ, UNITED STATES
PI US 2002164789 A1 20021107
AI US 2001-957909 A1 20010921 (9)
RLI Continuation-in-part of Ser. No. US 1999-260430, filed on 1 Mar 1999,
PENDING
PRAI US 1998-77551P 19980311 (60)
DT Utility
FS APPLICATION
LN.CNT 1534
INCL INCLM: 435/343.000
INCLS: 514/012.000; 514/044.000; 435/005.000
NCL NCLM: 435/343.000
NCLS: 514/012.000; 514/044.000; 435/005.000
IC [7]
ICM: A61K038-17
ICS: C12Q001-70; A61K038-00; A61K031-70; A01N043-04; C12N005-06;
C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 228 OF 312 USPATFULL on STN
AN 2002:294612 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002164655 A1 20021107
AI US 2001-973941 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3277
INCL INCLM: 435/007.200
INCLS: 435/183.000; 530/388.260
NCL NCLM: 435/007.200
NCLS: 435/183.000; 530/388.260
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N009-00; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 229 OF 312 USPATFULL on STN
AN 2002:287633 USPATFULL
TI Isolated GRP94 ligand binding domain polypeptide and nucleic acid
encoding same, and screening methods employing same
IN Gewirth, Daniel T., Durham, NC, UNITED STATES
Nicchitta, Christopher V., Durham, NC, UNITED STATES
PI US 2002160496 A1 20021031
AI US 2001-968436 A1 20011001 (9)
RLI Continuation-in-part of Ser. No. WO 2001-US9512, filed on 26 Mar 2001,
UNKNOWN
PRAI US 2000-192118P 20000324 (60)
DT Utility
FS APPLICATION
LN.CNT 5917
INCL INCLM: 435/226.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 230 OF 312 USPATFULL on STN
AN 2002:287552 USPATFULL
TI Methods, pharmaceutical formulations and kits for identification of
subjects at risk for cancer and for the prevention of cancer in at- risk
subjects
IN Neely, Constance F., Raleigh, NC, UNITED STATES
PI US 2002160415 A1 20021031
AI US 2000-569394 A1 20000512 (9)
PRAI US 1999-134276P 19990514 (60)

FS APPLICATION
LN.CNT 1405
INCL INCLM: 435/007.100
INCLS: 424/009.100; 435/001.100; 435/004.000; 435/325.000; 435/007.230;
435/007.240; 530/350.000; 530/351.000
NCL NCLM: 435/007.100
NCLS: 424/009.100; 435/001.100; 435/004.000; 435/325.000; 435/007.230;
435/007.240; 530/350.000; 530/351.000
IC [7]
ICM: A01N001-00
ICS: A01N001-02; C12Q001-00; G01N033-53; G01N033-574; G01N033-555;
G01N033-567; A61K049-00; C12N005-00; C12N005-02; C07K001-00; C07K014-00;
C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 231 OF 312 USPATFULL on STN
AN 2002:273550 USPATFULL
TI Nucleic acids, proteins and antibodies
IN Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PI US 2002151681 A1 20021017
AI US 2001-925300 A1 20010810 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US5988, filed on 8 Mar 2000,
UNKNOWN

PRAI US 1999-124270P 19990312 (60)

DT Utility
FS APPLICATION

LN.CNT 29771
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/325.000; 435/320.100; 435/069.300
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/325.000; 435/320.100; 435/069.300
IC [7]

ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 232 OF 312 USPATFULL on STN
AN 2002:272419 USPATFULL
TI Tumor necrosis factor-gamma
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Zhang, Jun, Bethesda, MD, UNITED STATES
PI US 2002150534 A1 20021017
AI US 2001-899059 A1 20010706 (9)
RLI Continuation-in-part of Ser. No. WO 2000-US11689, filed on 28 Apr 2000,
UNKNOWN Continuation-in-part of Ser. No. US 1999-246129, filed on 8 Feb
1999, PENDING Continuation-in-part of Ser. No. US 1998-131237, filed on
7 Aug 1998, PENDING Continuation-in-part of Ser. No. US 1998-5020, filed
on 9 Jan 1998, ABANDONED Continuation-in-part of Ser. No. US
1995-461246, filed on 5 Jun 1995, ABANDONED Continuation-in-part of Ser.
No. WO 1994-US12880, filed on 7 Nov 1994, UNKNOWN

PRAI US 2001-278449P 20010326 (60)
US 2000-216879P 20000707 (60)
US 2000-180908P 20000208 (60)
US 1999-134067P 19990513 (60)
US 1999-132227P 19990503 (60)
US 1999-131963P 19990430 (60)
US 1998-74047P 19980209 (60)

DT Utility
FS APPLICATION

LN.CNT 12881
INCL INCLM: 424/001.490
INCLS: 424/145.100
NCL NCLM: 424/001.490
NCLS: 424/145.100
IC [7]

ICM: A61K051-00
ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 233 OF 312 USPATFULL on STN
AN 2002:258404 USPATFULL
TI Method for administering a cytokine to the central nervous system and

IN Frey, William H., II, North Oaks, MN, UNITED STATES
PA Chiron Corporation (U.S. corporation)
PI US 2002141971 A1 20021003
AI US 2002-102163 A1 20020320 (10)
RLI Continuation of Ser. No. US 2000-733168, filed on 8 Dec 2000, PENDING
PRAI US 1999-200708P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2947
INCL INCLM: 424/085.100
INCLS: 424/045.000; 424/085.500; 424/085.600; 424/085.700
NCL NCLM: 424/085.100
NCLS: 424/045.000; 424/085.500; 424/085.600; 424/085.700
IC [7]
ICM: A61K038-21
ICS: A61L009-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 234 OF 312 USPATFULL on STN
AN 2002:229107 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PI US 2002124273 A1 20020905
AI US 2001-973965 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3256
INCL INCLM: 800/003.000
INCLS: 435/007.930
NCL NCLM: 800/003.000
NCLS: 435/007.930
IC [7]
ICM: G01N033-00
ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 235 OF 312 USPATFULL on STN
AN 2002:222796 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002120947 A1 20020829
AI US 2001-949143 A1 20010910 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3104
INCL INCLM: 800/003.000
INCLS: 435/007.920
NCL NCLM: 800/003.000
NCLS: 435/007.920
IC [7]
ICM: A01K067-00
ICS: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 236 OF 312 USPATFULL on STN
AN 2002:221785 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002119927 A1 20020829
AI US 2001-972757 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility

LN.CNT 3204
INCL INCLM: 514/012.000
INCLS: 424/146.100
NCL NCLM: 514/012.000
NCLS: 424/146.100
IC [7]
ICM: A61K039-395
ICS: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 237 OF 312 USPATFULL on STN
AN 2002:221020 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PI US 2002119155 A1 20020829
AI US 2001-972038 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)

DT Utility
FS APPLICATION

LN.CNT 3081
INCL INCLM: 424/146.100
INCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000
NCL NCLM: 424/146.100
NCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000

IC [7]
ICM: A61K039-395
ICS: C12Q001-68; G01N033-53; C12N009-64; G01N033-567; C07K016-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 238 OF 312 USPATFULL on STN
AN 2002:214222 USPATFULL
TI Materials and methods for making improved micelle compositions
IN Onyuksel, Hayat, Western Springs, IL, UNITED STATES
Rubinstein, Israel, Highland Park, IL, UNITED STATES
PI US 2002115609 A1 20020822
AI US 2001-995403 A1 20011127 (9)
RLI Continuation-in-part of Ser. No. US 1999-239069, filed on 27 Jan 1999, GRANTED, Pat. No. US 6217886 Continuation-in-part of Ser. No. US 2000-462819, filed on 18 May 2000, GRANTED, Pat. No. US 6322810 A 371 of International Ser. No. WO 1998-US14316, filed on 9 Jul 1998, UNKNOWN

PRAI US 1997-52078P 19970714 (60)

DT Utility
FS APPLICATION

LN.CNT 2440
INCL INCLM: 514/012.000
INCLS: 424/450.000; 424/085.200
NCL NCLM: 514/012.000
NCLS: 424/450.000; 424/085.200

IC [7]
ICM: A61K038-20
ICS: A61K009-127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 239 OF 312 USPATFULL on STN
AN 2002:214220 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PI US 2002115607 A1 20020822
AI US 2001-975072 A1 20011012 (9)
PRAI US 2000-240790P 20001017 (60)

DT Utility
FS APPLICATION

LN.CNT 3574
INCL INCLM: 514/012.000
INCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000
NCL NCLM: 514/012.000
NCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000

ICM: A61K038-17
ICS: A61K039-395; C12N009-64; C07K014-435; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 240 OF 312 USPATFULL on STN
AN 2002:214219 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002115606 A1 20020822
AI US 2001-973964 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3354
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]

ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 241 OF 312 USPATFULL on STN
AN 2002:213743 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Mark, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc. (U.S. corporation)
PI US 2002115119 A1 20020822
AI US 2001-973063 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3133
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]

ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 242 OF 312 USPATFULL on STN
AN 2002:213736 USPATFULL
TI Neutrokin-alpha and Neutrokin-alpha splice variant
IN Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ullrich, Stephen, Rockville, MD, UNITED STATES
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 2002115112 A1 20020822
AI US 2001-929493 A1 20010815 (9)
RLI Continuation-in-part of Ser. No. US 2000-588947, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589285, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589286, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-589287, filed on 8 Jun 2000, PENDING Continuation-in-part of Ser. No. US 2000-586288, filed on 2 Jun 2000, PATENTED Continuation-in-part of Ser. No. US 2000-507968, filed on 22 Feb 2000, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999, PENDING
PRAI US 2000-225628P 20000815 (60)
US 2000-227008P 20000823 (60)
US 2000-234338P 20000922 (60)
US 2000-240806P 20001017 (60)
US 2000-250020P 20001130 (60)
US 2001-276248P 20010316 (60)
US 2001-293499P 20010525 (60)
US 2001-296122P 20010607 (60)
US 2001-304809P 20010713 (60)
US 1999-122388P 19990302 (60)

US 1999-126599P 19990326 (60)
US 1999-127598P 19990402 (60)
US 1999-130412P 19990416 (60)
US 1999-130696P 19990423 (60)
US 1999-131278P 19990427 (60)
US 1999-131673P 19990429 (60)
US 1999-136784P 19990528 (60)
US 1999-142659P 19990706 (60)
US 1999-145824P 19990727 (60)
US 1999-167239P 19991124 (60)
US 1999-168624P 19991203 (60)
US 1999-171108P 19991216 (60)
US 1999-171626P 19991223 (60)
US 2000-176015P 20000114 (60)

DT Utility
FS APPLICATION

LN.CNT 18178

INCL INCLM: 435/007.200

INCLS: 530/388.230; 424/145.100

NCL NCLM: 435/007.200

NCLS: 530/388.230; 424/145.100

IC [7]

ICM: C07K016-24

ICS: G01N033-567; G01N033-53; A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 243 OF 312 USPATFULL on STN

AN 2002:213426 USPATFULL

TI Protein-protein interactions in neurodegenerative diseases

IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES

Bartel, Paul L., Salt Lake City, UT, UNITED STATES

Heichman, Karen, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PI US 2002114799 A1 20020822

AI US 2001-973077 A1 20011010 (9)

PRAI US 2000-240790P 20001017 (60)

DT Utility

FS APPLICATION

LN.CNT 3207

INCL INCLM: 424/130.100

NCL NCLM: 424/130.100

IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 244 OF 312 USPATFULL on STN

AN 2002:198673 USPATFULL

TI Protein-protein interactions in neurodegenerative diseases

IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES

Bartel, Paul L., Salt Lake City, UT, UNITED STATES

Heichman, Karen, Salt Lake City, UT, UNITED STATES

PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)

PI US 2002106773 A1 20020808

AI US 2001-973064 A1 20011010 (9)

PRAI US 2000-240790P 20001017 (60)

DT Utility

FS APPLICATION

LN.CNT 3066

INCL INCLM: 435/196.000

INCLS: 435/007.100; 435/006.000; 530/388.260

NCL NCLM: 435/196.000

NCLS: 435/007.100; 435/006.000; 530/388.260

IC [7]

ICM: C12N009-16

ICS: C12Q001-68; G01N033-53; C07K016-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 245 OF 312 USPATFULL on STN

AN 2002:198636 USPATFULL

TI Human tumor necrosis factor receptor TR17

IN Ruben, Steven M., Olney, MD, UNITED STATES

Baker, Kevin P., Darnestown, MD, UNITED STATES

PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.)

PI US 2002106736 A1 20020808
AI US 2001-961376 A1 20010925 (9)
RLI Continuation-in-part of Ser. No. US 2000-533822, filed on 24 Mar 2000,
PENDING
PRAI US 2000-254874P 20001213 (60)
US 2000-235991P 20000926 (60)
US 2000-188208P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 13690
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 246 OF 312 USPATFULL on STN
AN 2002:191516 USPATFULL
TI Diagnostics and therapeutics for ocular disorders
IN Hageman, Gregory S., Coralville, IA, UNITED STATES
Mullins, Robert F., Coralville, IA, UNITED STATES
PI US 2002102581 A1 20020801
AI US 2001-949261 A1 20010906 (9)
RLI Continuation-in-part of Ser. No. US 2000-510230, filed on 22 Feb 2000,
PENDING Continuation-in-part of Ser. No. US 2001-845745, filed on 30 Apr
2001, PENDING
PRAI US 1999-120822P 19990219 (60)
US 1999-120668P 19990219 (60)
US 1999-123052P 19990305 (60)
US 2000-200698P 20000429 (60)
DT Utility
FS APPLICATION
LN.CNT 5644
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/040.500
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/040.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 247 OF 312 USPATFULL on STN
AN 2002:157602 USPATFULL
TI Novel polynucleotides from atherogenic cells and polypeptides encoded
thereby
IN Leach, Martin D., Madison, CT, UNITED STATES
Mehraban, Fuad, Trumbull, CT, UNITED STATES
Conley, Pamela B., Palo Alto, CA, UNITED STATES
Topper, James N., Los Altos, CA, UNITED STATES
Law, Debbie, San Francisco, CA, UNITED STATES
PI US 2002082206 A1 20020627
AI US 2001-867550 A1 20010530 (9)
PRAI US 2000-208427P 20000530 (60)
DT Utility
FS APPLICATION
LN.CNT 8166
INCL INCLM: 514/012.000
INCLS: 536/023.100; 435/069.100; 435/325.000; 435/320.100; 435/183.000;
530/350.000
NCL NCLM: 514/012.000
NCLS: 536/023.100; 435/069.100; 435/325.000; 435/320.100; 435/183.000;
530/350.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12N009-00; C12N005-06; C12P021-02; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 248 OF 312 USPATFULL on STN
AN 2002:149166 USPATFULL
TI Protection of neurons against glutamate-induced damage in glaucoma and
other conditions

PI US 2002077322 A1 20020620
AI US 2001-12938 A1 20011210 (10)
PRAI US 2000-256085P 20001215 (60)
DT Utility
FS APPLICATION
LN.CNT 1016
INCL INCLM: 514/233.800
INCLS: 514/266.300; 514/313.000; 514/416.000; 514/454.000; 514/627.000
NCL NCLM: 514/233.800
NCLS: 514/266.300; 514/313.000; 514/416.000; 514/454.000; 514/627.000
IC [7]
ICM: A61K031-5377
ICS: A61K031-47; A61K031-517; A61K031-353; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 249 OF 312 USPATFULL on STN
AN 2002:134563 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PI US 2002069424 A1 20020606
AI US 2001-971677 A1 20011009 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3101
INCL INCLM: 800/018.000
INCLS: 435/007.900; 800/003.000
NCL NCLM: 800/018.000
NCLS: 435/007.900; 800/003.000
IC [7]
ICM: A01K067-027
ICS: G01N033-00; G01N033-53; G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 250 OF 312 USPATFULL on STN
AN 2002:113904 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
PI US 2002059653 A1 20020516
AI US 2001-970666 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3084
INCL INCLM: 800/012.000
INCLS: 424/146.100; 514/012.000
NCL NCLM: 800/012.000
NCLS: 424/146.100; 514/012.000
IC [7]
ICM: A01K067-00
ICS: A61K039-395; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 251 OF 312 USPATFULL on STN
AN 2002:105674 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, 84108 (U.S. corporation)
PI US 2002054876 A1 20020509
AI US 2001-971675 A1 20011009 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)

FS APPLICATION
LN.CNT 3070
INCL INCLM: 424/146.100
NCL NCLM: 424/146.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 252 OF 312 USPATFULL on STN
AN 2002:92251 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT (U.S. corporation)
PI US 2002048769 A1 20020425
AI US 2001-970814 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)

DT Utility
FS APPLICATION
LN.CNT 3101
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/196.000; 530/388.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/196.000; 530/388.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C12N009-16; C07K016-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 253 OF 312 USPATFULL on STN
AN 2002:85161 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
PI US 2002045201 A1 20020418
AI US 2001-970898 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)

DT Utility
FS APPLICATION
LN.CNT 3090
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 254 OF 312 USPATFULL on STN
AN 2002:73343 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002040484 A1 20020404
AI US 2001-948904 A1 20010910 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)

DT Utility
FS APPLICATION
LN.CNT 3069
INCL INCLM: 800/008.000
INCLS: 514/012.000
NCL NCLM: 800/008.000
NCLS: 514/012.000
IC [7]

ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 255 OF 312 USPATFULL on STN
AN 2002:72885 USPATFULL
TI Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof
IN Hogenkamp, Derk J., Carlsbad, CA, UNITED STATES
Nguyen, Phong, Placentia, CA, UNITED STATES
Shao, Bin, Richboro, PA, UNITED STATES
PI US 2002040025 A1 20020404
AI US 2001-803659 A1 20010312 (9)
PRAI US 2000-188188P 20000310 (60)
DT Utility
FS APPLICATION
LN.CNT 2559
INCL INCLM: 514/241.000
INCLS: 514/242.000; 514/252.100; 514/256.000; 514/255.050; 514/340.000;
544/182.000; 544/211.000; 544/212.000; 544/333.000; 544/405.000;
546/272.100; 546/272.400; 546/275.400; 546/272.700
NCL NCLM: 514/241.000
NCLS: 514/242.000; 514/252.100; 514/256.000; 514/255.050; 514/340.000;
544/182.000; 544/211.000; 544/212.000; 544/333.000; 544/405.000;
546/272.100; 546/272.400; 546/275.400; 546/272.700
IC [7]
ICM: A61K031-53
ICS: C07D043-02; C07D041-02; A61K031-497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 256 OF 312 USPATFULL on STN
AN 2002:67273 USPATFULL
TI Sodium channel blocker compositions and the use thereof
IN Lan, Nancy C., Altadena, CA, UNITED STATES
PI US 2002037926 A1 20020328
AI US 2001-971007 A1 20011005 (9)
RLI Continuation of Ser. No. WO 2000-US9387, filed on 10 Apr 2000, UNKNOWN
PRAI US 1999-128543P 19990409 (60)
DT Utility
FS APPLICATION
LN.CNT 1130
INCL INCLM: 514/561.000
INCLS: 514/217.000
NCL NCLM: 514/561.000
NCLS: 514/217.000
IC [7]
ICM: A61K031-55
ICS: A61K031-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 257 OF 312 USPATFULL on STN
AN 2002:66639 USPATFULL
TI Compositions comprising heat shock proteins or alpha(2) macroglobulin, antigenic molecules and saponins, and methods of use thereof
IN Armen, Garo H., Manhasset, NY, UNITED STATES
PI US 2002037290 A1 20020328
AI US 2001-909778 A1 20010720 (9)
PRAI US 2000-223133P 20000807 (60)
DT Utility
FS APPLICATION
LN.CNT 4136
INCL INCLM: 424/178.100
INCLS: 514/012.000; 514/026.000
NCL NCLM: 424/178.100
NCLS: 514/012.000; 514/026.000
IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 258 OF 312 USPATFULL on STN
AN 2002:37339 USPATFULL
TI Composition and methods for improving integrity of compromised body passageways and cavities
IN Signore, Pierre E, Vancouver British Columbia, CANADA
PI US 2002022055 A1 20020221

PRAI US 1999-121424P 19990223 (60)
DT Utility
FS APPLICATION
LN.CNT 1938
INCL INCLM: 424/486.000
NCL NCLM: 424/486.000
IC [7]
ICM: A61K009-14

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 259 OF 312 USPATFULL on STN
AN 2002:27111 USPATFULL
TI Diagnostics and therapeutics for macular degeneration-related disorders
IN Hageman, Gregory S., Coralville, IA, UNITED STATES
Mullins, Robert F., Coralville, IA, UNITED STATES
PI US 2002015957 A1 20020207
AI US 2001-845745 A1 20010430 (9)
PRAI US 2000-200698P 20000429 (60)
DT Utility
FS APPLICATION
LN.CNT 3111
INCL INCLM: 435/006.000
INCLS: 351/200.000
NCL NCLM: 435/006.000
NCLS: 351/200.000
IC [7]
ICM: C12Q001-68
ICS: A61B003-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 260 OF 312 USPATFULL on STN
AN 2002:16563 USPATFULL
TI Compounds effecting neuron remodeling and assays for same
IN Mahley, Robert W., San Francisco, CA, UNITED STATES
Weisgraber, Karl H., Walnut Creek, CA, UNITED STATES
Pitas, Robert E., Albany, CA, UNITED STATES
PI US 2002009439 A1 20020124
AI US 2001-782757 A1 20010212 (9)
RLI Continuation-in-part of Ser. No. US 1998-70675, filed on 30 Apr 1998,
ABANDONED Continuation-in-part of Ser. No. US 1996-659785, filed on 19
Jan 1996, ABANDONED
PRAI US 1995-5550P 19951017 (60)
DT Utility
FS APPLICATION
LN.CNT 2749
INCL INCLM: 424/130.100
INCLS: 514/001.000
NCL NCLM: 424/130.100
NCLS: 514/001.000
IC [7]
ICM: A61K031-00
ICS: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 261 OF 312 USPATFULL on STN
AN 2002:12565 USPATFULL
TI Aryl substituted pyrazoles, triazoles, and tetrazoles, and the use
thereof
IN Hogenkamp, Derk J., Carlsbad, CA, UNITED STATES
Nguyen, Phong, Placentia, CA, UNITED STATES
Yang, Ji, Plainsboro, NJ, UNITED STATES
PI US 2002006947 A1 20020117
AI US 2001-814123 A1 20010322 (9)
PRAI US 2000-191757P 20000324 (60)
DT Utility
FS APPLICATION
LN.CNT 1234
INCL INCLM: 514/381.000
INCLS: 514/383.000; 514/398.000; 514/407.000; 548/316.400; 548/366.100;
548/263.200; 548/255.000; 548/251.000
NCL NCLM: 514/381.000
NCLS: 514/383.000; 514/398.000; 514/407.000; 548/316.400; 548/366.100;
548/263.200; 548/255.000; 548/251.000
IC [7]
ICM: C07D257-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 262 OF 312 USPATFULL on STN
AN 2002:340140 USPATFULL
TI Neural transplantation using proliferated multipotent neural stem cells
and their progeny
IN Weiss, Samuel, Alberta, CANADA
Reynolds, Brent, Alberta, CANADA
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PA NeuroSpheres Holdings Ltd., Calgary, CANADA (non-U.S. corporation)
PI US 6497872 B1 20021224
AI US 1995-486313 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
now abandoned Continuation of Ser. No. US 1991-726812, filed on 8 Jul
1991, now abandoned Continuation of Ser. No. US 486313
Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995,
now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct
1992, now abandoned Continuation-in-part of Ser. No. US 726812
Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser.
No. US 1994-359945, filed on 20 Dec 1994, now abandoned Continuation of
Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation
of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned
Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
now abandoned Continuation-in-part of Ser. No. US 486313
Continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995,
now abandoned Continuation of Ser. No. US 1993-10829, filed on 29 Jan
1993, now abandoned Continuation-in-part of Ser. No. US 726812
Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser.
No. US 1993-149508, filed on 9 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser.
No. US 486313 Continuation-in-part of Ser. No. US 1994-311099, filed on
23 Sep 1994, now abandoned Continuation-in-part of Ser. No. US 726812
Continuation-in-part of Ser. No. US 486313 Continuation-in-part of Ser.
No. US 1994-338730, filed on 14 Nov 1994, now abandoned
Continuation-in-part of Ser. No. US 726812
DT Utility
FS GRANTED
LN.CNT 4223
INCL INCLM: 424/093.100
INCLS: 424/093.200; 424/093.210
NCL NCLM: 424/093.100
NCLS: 424/093.200; 424/093.210
IC [7]
ICM: A01N063-00
ICS: A01N065-00; A61K048-00
EXF 424/93.1; 424/93.2; 424/93.21; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 263 OF 312 USPATFULL on STN
AN 2002:332463 USPATFULL
TI Methods of inhibiting hematopoietic stem cells using human myeloid
progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
IN Li, Haodong, Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6495129 B1 20021217
AI US 2000-689693 20001013 (9)
RLI Continuation of Ser. No. US 2000-571013, filed on 15 May 2000
Continuation-in-part of Ser. No. US 1999-334951, filed on 17 Jun 1999
Continuation of Ser. No. US 1997-941020, filed on 30 Sep 1997, now
abandoned Continuation-in-part of Ser. No. US 1996-722723, filed on 30
Sep 1996, now abandoned Continuation-in-part of Ser. No. US 1996-722719,
filed on 30 Sep 1996, now patented, Pat. No. US 6001606
Continuation-in-part of Ser. No. US 1995-468775, filed on 6 Jun 1995,
now abandoned Continuation-in-part of Ser. No. US 1995-465682, filed on
6 Jun 1995, now abandoned Continuation-in-part of Ser. No. US
1995-446881, filed on 5 May 1995, now abandoned Continuation-in-part of
Ser. No. US 468775 Continuation-in-part of Ser. No. US 465682
Continuation-in-part of Ser. No. US 446881 Continuation of Ser. No. US
446881 Continuation-in-part of Ser. No. US 1994-208339, filed on 8 Mar
1994, now patented, Pat. No. US 5504003 Continuation of Ser. No. US
446881 Continuation-in-part of Ser. No. US 208339 Continuation-in-part
of Ser. No. US 208339

US 2000-211458P 20000613 (60)
 US 2000-199142P 20000424 (60)
 US 2000-189048P 20000314 (60)
 US 1999-172063P 19991223 (60)
 US 1999-164059P 19991108 (60)
 US 1999-159362P 19991014 (60)
 DT Utility
 FS GRANTED
 LN.CNT 14198
 INCL INCLM: 424/085.100
 INCLS: 424/885.000; 514/002.000; 514/008.000; 514/012.000
 NCL NCLM: 424/085.100
 NCLS: 514/002.000; 514/008.000; 514/012.000
 IC [7]
 ICM: A61K038-19
 EXF 424/85.1; 424/885; 514/2; 514/8; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L5 ANSWER 264 OF 312 USPATFULL on STN
 AN 2002:303864 USPATFULL
 TI Adipocyte-specific protein homologs
 IN Sheppard, Paul O., Redmond, WA, United States
 Humes, Jacqueline M., Seattle, WA, United States
 PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
 PI US 6482612 B1 20021119
 AI US 2000-686838 20001010 (9)
 RLI Division of Ser. No. US 1998-140804, filed on 26 Aug 1998, now patented,
 Pat. No. US 6197930
 PRAI US 1997-56983P 19970826 (60)
 DT Utility
 FS GRANTED
 LN.CNT 3491
 INCL INCLM: 435/069.100
 INCLS: 435/006.000; 435/007.200; 435/007.210; 435/252.300; 435/320.100;
 530/350.000; 536/023.500; 436/501.000; 514/002.000
 NCL NCLM: 435/069.100
 NCLS: 435/006.000; 435/007.200; 435/007.210; 435/252.300; 435/320.100;
 436/501.000; 514/002.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C07H021-04
 ICS: C12P021-06; C07K001-00; G01N033-566; A61K038-00
 EXF 435/6; 435/7.2; 435/7.21; 435/69.1; 435/252.3; 435/320.1; 435/325;
 435/254.11; 530/350; 536/23.5; 536/23.1; 436/501; 514/2
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

 L5 ANSWER 265 OF 312 USPATFULL on STN
 AN 2002:254388 USPATFULL
 TI Carbocyclic and heterocyclic substituted semicarbazones and
 thiosemicarbazones and the use thereof
 IN Wang, Yan, San Diego, CA, United States
 Cai, Sui Xiong, San Diego, CA, United States
 Lan, Nancy C., S. Pasadena, CA, United States
 Keana, John F. W., Eugene, OR, United States
 Ilyin, Victor I., Irvine, CA, United States
 Weber, Eckard, San Diego, CA, United States
 PA Euro-Celtique S.A., LUXEMBOURG (non-U.S. corporation)
 PI US 6458843 B1 20021001
 AI US 1999-421403 19991021 (9)
 RLI Continuation of Ser. No. WO 1998-US8004, filed on 22 Apr 1998
 PRAI US 1997-62649P 19971022 (60)
 US 1997-44530P 19970422 (60)
 DT Utility
 FS GRANTED
 LN.CNT 2645
 INCL INCLM: 514/583.000
 INCLS: 514/237.500; 514/255.010; 514/274.000; 514/311.000; 514/327.000;
 514/330.000; 514/351.000; 514/459.000; 514/466.000; 514/590.000
 NCL NCLM: 514/583.000
 NCLS: 514/237.500; 514/255.010; 514/274.000; 514/311.000; 514/327.000;
 514/330.000; 514/351.000; 514/459.000; 514/466.000; 514/590.000
 IC [7]
 ICM: A61K031-17
 ICS: A61K031-175
 EXF 514/237.5; 514/255.01; 514/274; 514/311; 514/327; 514/330; 514/331;
 514/459; 514/466; 514/583; 514/590

L5 ANSWER 266 OF 312 USPATFULL on STN
 AN 2002:246365 USPATFULL
 TI Tumor necrosis factor receptor 5
 IN Wei, Ying-Fei, Berkeley, CA, United States
 Ni, Jian, Rockville, MD, United States
 Gentz, Reiner L., Rockville, MD, United States
 Ruben, Steven M., Odenton, MD, United States
 PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
 PI US 6455040 B1 20020924
 AI US 2000-573986 20000518 (9)
 RLI Continuation-in-part of Ser. No. US 1998-6353, filed on 13 Jan 1998, now patented, Pat. No. US 6261801
 PRAI US 1999-135164P 19990520 (60)
 US 1997-54885P 19970807 (60)
 US 1997-35496P 19970114 (60)
 DT Utility
 FS GRANTED
 LN.CNT 9119
 INCL INCLM: 424/134.100
 INCLS: 424/139.100; 424/178.100; 424/188.000; 424/143.100; 530/388.220; 530/387.300; 530/387.900; 435/007.210; 435/328.000; 435/334.000
 NCL NCLM: 424/134.100
 NCLS: 424/138.100; 424/139.100; 424/143.100; 424/178.100; 435/007.210; 435/328.000; 435/334.000; 530/387.300; 530/387.900; 530/388.220
 IC [7]
 ICM: A61K039-395
 EXF 530/387.3; 530/387.9; 530/388.22; 424/134.1; 424/139.1; 424/178.1; 424/188; 424/143.1; 435/7.21; 435/328; 435/334
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 267 OF 312 USPATFULL on STN
 AN 2002:224760 USPATFULL
 TI Methods for assessing the role of calcineurin immunosuppression and neurotoxicity
 IN Zhang, Wei, Stanford, CA, United States
 Seidman, Jonathan G., Milton, MA, United States
 Kagyali, Usamah S., Somerville, MA, United States
 Potter, Huntington, Boston, MA, United States
 PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
 PI US 6444870 B1 20020903
 AI US 1998-212868 19981216 (9)
 RLI Continuation of Ser. No. US 1995-433162, filed on 3 May 1995, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 3549
 INCL INCLM: 800/003.000
 INCLS: 800/018.000; 800/025.000; 435/455.000; 435/463.000; 435/320.100; 435/325.000
 NCL NCLM: 800/003.000
 NCLS: 435/320.100; 435/325.000; 435/455.000; 435/463.000; 800/018.000; 800/025.000
 IC [7]
 ICM: A01K067-027
 ICS: G01N033-00; C12N015-00; C12N015-63; C12N015-85
 EXF 800/3; 800/14; 800/18; 800/21; 800/22; 800/25; 800/12; 435/455; 435/463; 435/320.1; 435/325; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 268 OF 312 USPATFULL on STN
 AN 2002:224270 USPATFULL
 TI Methods of treating chronic inflammatory diseases using carbonyl trapping agents
 IN Shapiro, Howard K., 214 Price Ave., Apt. F-32, Narberth, PA, United States 19072
 PI US 6444221 B1 20020903
 AI US 1999-416120 19991012 (9)
 RLI Continuation-in-part of Ser. No. US 1995-473786, filed on 7 Jun 1995, now abandoned Continuation-in-part of Ser. No. US 1992-906909, filed on 30 Jun 1992, now abandoned
 DT Utility
 FS GRANTED

INCL INCLM: 424/451.000
INCLS: 424/457.000; 424/464.000; 424/468.000; 424/439.000; 424/442.000;
514/458.000; 514/055.000; 514/057.000
NCL NCLM: 424/451.000
NCLS: 424/439.000; 424/442.000; 424/457.000; 424/464.000; 424/468.000;
514/055.000; 514/057.000; 514/458.000
IC [7]
ICM: A61K009-48
EXF 424/451; 424/457; 424/464; 424/468; 424/439; 424/442; 514/55; 514/57;
514/458

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 269 OF 312 USPATFULL on STN
AN 2002:202241 USPATFULL
TI Death domain containing receptor-4
IN Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Pan, James G., Belmont, CA, United States
Gentz, Reiner L., Rockville, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
The Regents of the University of Michigan, Ann Arbor, MI, United States
(U.S. corporation)
PI US 6433147 B1 20020813
AI US 2000-565918 20000505 (9)
RLI Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998,
now patented, Pat. No. US 6342363
PRAI US 1999-132922P 19990506 (60)
US 1997-35722P 19970128 (60)
US 1997-37829P 19970205 (60)

DT Utility
FS GRANTED

LN.CNT 8675

INCL INCLM: 530/387.300
INCLS: 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500;
435/069.100; 435/325.000; 435/252.300; 435/254.110; 424/178.100
NCL NCLM: 530/387.300
NCLS: 424/178.100; 435/069.100; 435/252.300; 435/254.110; 435/325.000;
530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500

IC [7]

ICM: C07K014-705

EXF 530/300; 530/350; 530/402; 530/387.3; 536/23.1; 536/23.5; 536/23.4;
435/69.1; 435/375; 435/252.3; 435/254.11; 424/178.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 270 OF 312 USPATFULL on STN
AN 2002:202239 USPATFULL
TI Keratinocyte derived interferon
IN LaFleur, David W., Washington, DC, United States
Moore, Paul A., Germantown, MD, United States
Ruben, Steven M., Olney, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6433145 B1 20020813
AI US 2000-487792 20000120 (9)
RLI Continuation-in-part of Ser. No. US 1999-358587, filed on 21 Jul 1999,
now abandoned Continuation-in-part of Ser. No. WO 1999-US16424, filed on
21 Jul 1999

PRAI US 93643P (60)

DT Utility

FS GRANTED

LN.CNT 13514

INCL INCLM: 530/351.000
INCLS: 530/350.000; 424/085.400; 435/007.100
NCL NCLM: 530/351.000
NCLS: 424/085.400; 435/007.100; 530/350.000

IC [7]

ICM: C07K017-00

ICS: C07K014-00; A61K038-21; C12Q001-68

EXF 536/23.5; 536/23.52; 530/350; 530/351; 530/387.1; 435/69.1; 435/7.1;
424/85.4

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 271 OF 312 USPATFULL on STN

TI Aryl substituted pyrazoles, and pyrroles, and the use thereof
IN Hogenkamp, Derk, Carlsbad, CA, United States
Upasani, Ravindra, Foothill Ranch, CA, United States
Nguyen, Phong, Placentia, CA, United States
PA Euro-Celtique S.A., Luxembourg, LUXEMBOURG (non-U.S. corporation)
PI US 6414011 B1 20020702
AI US 2000-533864 20000324 (9)
PRAI US 1999-126553P 19990326 (60)
DT Utility
FS GRANTED
LN.CNT 3074
INCL INCLM: 514/406.000
INCLS: 514/403.000; 548/356.100; 548/373.100; 548/377.100
NCL NCLM: 514/406.000
NCLS: 514/403.000; 548/356.100; 548/373.100; 548/377.100
IC [7]
ICM: A61K031-415
ICS: C07D231-00; C07D231-02; C07D231-10
EXF 514/406; 514/403; 548/356.1; 548/373.1; 548/377.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 272 OF 312 USPATFULL on STN
AN 2002:137146 USPATFULL
TI Antibodies to neutrokin-alpha
IN Yu, Guo-Liang, Berkeley, CA, United States
Ebner, Reinhard, Gaithersburg, MD, United States
Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6403770 B1 20020611
AI US 2000-589287 20000608 (9)
RLI Continuation of Ser. No. US 2000-507968, filed on 22 Feb 2000
Continuation-in-part of Ser. No. US 1999-255794, filed on 23 Feb 1999
Continuation-in-part of Ser. No. US 1998-5874, filed on 12 Jan 1998
Continuation-in-part of Ser. No. WO 1996-US17957, filed on 25 Oct 1996
PRAI US 2000-176015P 20000114 (60)
US 1999-171626P 19991223 (60)
US 1999-171108P 19991216 (60)
US 1999-168624P 19991203 (60)
US 1999-167239P 19991124 (60)
US 1999-145824P 19990727 (60)
US 1999-142659P 19990706 (60)
US 1999-136784P 19990528 (60)
US 1999-131673P 19990429 (60)
US 1999-131278P 19990427 (60)
US 1999-130696P 19990423 (60)
US 1999-130412P 19990416 (60)
US 1999-127598P 19990402 (60)
US 1999-126599P 19990326 (60)
US 1999-124097P 19990312 (60)
US 1999-122388P 19990302 (60)
US 1997-36100P 19970114 (60)
DT Utility
FS GRANTED
LN.CNT 15430
INCL INCLM: 530/387.300
INCLS: 530/300.000; 530/324.000; 530/388.100; 530/388.230; 530/351.000;
435/069.500; 435/007.100
NCL NCLM: 530/387.300
NCLS: 435/007.100; 435/069.500; 530/300.000; 530/324.000; 530/351.000;
530/388.100; 530/388.230
IC [7]
ICM: C07K016-00
ICS: C12P021-08; C12P021-02; G01N035-53
EXF 530/387.1; 530/387.3; 530/387.9; 530/388.1; 530/388.23; 424/85.1;
536/23.1; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 273 OF 312 USPATFULL on STN
AN 2002:129781 USPATFULL
TI Multipotent neural stem cell cDNA libraries
IN Weiss, Samuel, Calgary, CANADA
Reynolds, Brent, Saltspring, CANADA
PA Neurospheres Holdings Ltd., Calgary, CANADA (non-U.S. corporation)

AI US 1995-484203 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
now abandoned Continuation of Ser. No. US 1991-726812, filed on 8 Jul
1991, now abandoned Continuation-in-part of Ser. No. US 1995-385404,
filed on 7 Feb 1995, now abandoned Continuation of Ser. No. US
1992-961813, filed on 16 Oct 1992, now abandoned Continuation-in-part of
Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned
Continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994,
now abandoned Continuation of Ser. No. US 1994-221655, filed on 1 Apr
1994, now abandoned Continuation of Ser. No. US 1992-967622, filed on 28
Oct 1992, now abandoned Continuation-in-part of Ser. No. US 1991-726812,
filed on 8 Jul 1991 Continuation-in-part of Ser. No. US 1995-376062,
filed on 20 Jan 1995, now abandoned Continuation of Ser. No. US
1993-10829, filed on 29 Jan 1993 Continuation-in-part of Ser. No. US
1991-726812, filed on 8 Jul 1991, now abandoned Continuation-in-part of
Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser.
No. US 1994-311099, filed on 23 Sep 1994, now abandoned
Continuation-in-part of Ser. No. US 726812 Continuation-in-part of Ser.
No. US 1994-338730, filed on 14 Nov 1994, now abandoned
Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
now abandoned
DT Utility
FS GRANTED
LN.CNT 3847
INCL INCLM: 435/320.100
INCLS: 536/023.500; 536/023.100; 435/368.000; 435/006.000; 435/091.100;
935/080.000
NCL NCLM: 435/320.100
NCLS: 435/006.000; 435/091.100; 435/368.000; 536/023.100; 536/023.500
IC [7]
ICM: C12N015-66
ICS: C12N015-12; C12Q001-68
EXF 536/23.1; 536/23.5; 435/320.1; 435/6; 435/91.1; 435/368; 935/80
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 274 OF 312 USPATFULL on STN
AN 2002:109176 USPATFULL
TI Human 2-19 protein homologue, z219a
IN Conklin, Darrell C., Seattle, WA, United States
Blumberg, Hal, Seattle, WA, United States
PA ZymoGenetics, Inc., Seattle, WA, United States (U.S. corporation)
PI US 6388064 B1 20020514
AI US 1998-167513 19981006 (9)
PRAI US 1997-61712P 19971006 (60)
DT Utility
FS GRANTED
LN.CNT 3127
INCL INCLM: 536/023.500
INCLS: 435/069.100; 435/069.800; 435/320.100; 435/325.000; 435/252.300;
435/254.110; 530/350.000
NCL NCLM: 536/023.500
NCLS: 435/069.100; 435/069.800; 435/252.300; 435/254.110; 435/320.100;
435/325.000; 530/350.000
IC [7]
ICM: C12N015-00
EXF 435/69.1; 435/325; 435/252.3; 435/254.11; 435/320.1; 435/69.8; 536/23.5;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 275 OF 312 USPATFULL on STN
AN 2002:81025 USPATFULL
TI Monoclonal antibodies to human CD6
IN Starling, Gary C., Lawrenceville, NJ, United States
Siadak, Anthony W., Seattle, WA, United States
Bowen, Michael A., Princeton, NJ, United States
Aruffo, Alejandro A., Belle Mead, NJ, United States
Bajorath, Jurgen, Lynnwood, WA, United States
Bodian, Dale L., Paoli, PA, United States
Skonier, John E., Seattle, WA, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S.
corporation)
PI US 6372215 B1 20020416
AI US 1998-30182 19980225 (9)
PRAI US 1997-40016P 19970303 (60)

FS GRANTED
LN.CNT 2170
INCL INCLM: 424/141.100
INCLS: 424/130.100; 424/133.100; 424/134.100; 424/178.100; 424/801.000;
435/070.100; 435/070.200; 435/070.250; 436/548.000; 532/350.000;
532/386.000; 532/387.100; 532/388.100; 532/391.100; 532/808.000;
532/864.000
NCL NCLM: 424/141.100
NCLS: 424/130.100; 424/133.100; 424/134.100; 424/178.100; 424/801.000;
435/007.100; 435/007.200; 435/007.250; 435/070.100; 435/070.200;
436/548.000; 530/350.000; 530/386.000; 530/387.100; 530/388.100;
530/391.100; 530/808.000; 530/864.000
IC [7]
ICM: A61K039-395
ICS: A61K039-00; C12P021-04; G01N033-53; C07K016-00
EXF 424/133.1; 424/141.1; 424/178.1; 424/801; 424/134.1; 424/130.1;
435/70.1; 435/70.2; 435/70.21; 436/548; 530/350; 530/386; 530/387.1;
530/388.1; 530/391.1; 530/808; 530/864
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 276 OF 312 USPATFULL on STN
AN 2002:57390 USPATFULL
TI Antibodies to human tumor necrosis factor receptor TR9
IN Ni, Jian, Rockville, MD, United States
Yu, Guo-Liang, Berkeley, CA, United States
Fan, Ping, Gaithersburg, MD, United States
Gentz, Reiner L., Rockville, MD, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
corporation)
PI US 6358508 B1 20020319
AI US 2000-527236 20000316 (9)
RLI Continuation-in-part of Ser. No. US 1998-95094, filed on 10 Jun 1998
PRAI US 1997-52991P 19970611 (60)
US 1999-126019P 19990324 (60)
US 1999-134220P 19990514 (60)
DT Utility
FS GRANTED
LN.CNT 8936
INCL INCLM: 424/139.100
INCLS: 424/178.100; 530/388.220; 530/389.100; 530/391.300; 530/391.700;
530/387.900
NCL NCLM: 424/139.100
NCLS: 424/178.100; 530/387.900; 530/388.220; 530/389.100; 530/391.300;
530/391.700
IC [7]
ICM: A61K039-395
EXF 530/388.22; 530/389.1; 530/391.3; 530/391.7; 530/387.9; 424/139.1;
424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 277 OF 312 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 34
AN 2002:196409 BIOSIS
DN PREV200200196409
TI Serum ****tau*** protein level as a marker of axonal damage in acute
ischemic stroke.
AU Bitsch, Andreas [Reprint author]; Horn, Claudia; Kemmling, Yvonne;
Seipelt, Maria; Hellenbrand, Uwe; Stiefel, Michael; Ciesielczyk, Barbara;
Cepek, Lukas; Bahn, Erik; Ratzka, Peter; Prange, Hilmar; Otto, Markus
CS Neurologische Klinik, Ruppiner Kliniken GmbH, Fehrbelliner Strasse 38,
D-16816, Neuruppin, Germany
abitsch@t-online.de
SO European Neurology, (January, 2002) Vol. 47, No. 1, pp. 45-51. print.
CODEN: EUNEAP. ISSN: 0014-3022.
DT Article
LA English
ED Entered STN: 13 Mar 2002
Last Updated on STN: 13 Mar 2002

L5 ANSWER 278 OF 312 USPATFULL on STN DUPLICATE 35
AN 2001:139289 USPATFULL
TI Serine protease specific monoclonal antibodies and their use
IN Kominami, Katsuya, Osaka, Japan
Okui, Akira, Yamatokoriyama-shi, Japan
Mitsui, Shinichi, Kyoto-shi, Japan

PI US 2001016331 A1 20010823
US 6645734 B2 20031111
AI US 2000-741171 A1 20001221 (9)
RLI Continuation-in-part of Ser. No. WO 1999-JP3578, filed on 2 Jul 1999,
UNKNOWN
PRAI JP 1998-187506 19980702
DT Utility
FS APPLICATION
LN.CNT 1613
INCL INCLM: 435/007.950
NCL NCLM: 435/007.920
NCLS: 435/007.100; 435/007.230; 435/007.400; 435/007.940; 435/007.950;
435/023.000; 435/040.520; 435/226.000; 435/332.000; 435/338.000;
435/960.000; 436/063.000; 436/164.000; 436/503.000; 436/518.000;
436/548.000; 436/811.000; 530/388.200; 530/388.260; 530/391.300

IC [7]
ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 279 OF 312 USPATFULL on STN DUPLICATE 36
AN 2001:123568 USPATFULL
TI COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING
CANCERS
IN SCHWARTZ, GARY K., BRIARCLIFF MANOR, NY, United States
ALBINO, ANTHONY P., NEW YORK, NY, United States
PI US 2001011076 A1 20010802
US 6444638 B2 20020903
AI US 1998-137442 A1 19980820 (9)
RLI Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, UNKNOWN
Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996,
ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20
Feb 1996, GRANTED, Pat. No. US 5821072
DT Utility
FS APPLICATION
LN.CNT 5287
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/091.100; 435/325.000; 435/375.000; 435/455.000;
424/094.100
NCL NCLM: 514/001.000
NCLS: 424/009.200; 514/090.000; 514/151.000; 514/183.000; 514/245.000;
514/449.000
IC [7]
ICM: A61K048-00
ICS: C12N015-85; C12N015-86; A61K038-43; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 280 OF 312 USPATFULL on STN DUPLICATE 37
AN 2001:109972 USPATFULL
TI AN IN VITRO ASSAY METHOD FOR THE STUDY OF BRAIN AGING
IN LYNCH, GARY S., IRVINE, CA, United States
BEDNARSKI, ERIC, IRVINE, CA, United States
RIBAK, CHARLES E., LAGUNA MIGUEL, CA, United States
GALL, CHRISTINE M., IRVINE, CA, United States
PI US 2001007854 A1 20010712
US 6447988 B2 20020910
AI US 1997-787784 A1 19970122 (8)
DT Utility
FS APPLICATION
LN.CNT 867
INCL INCLM: 514/006.000
INCLS: 514/002.000; 514/027.000; 435/001.100
NCL NCLM: 435/004.000
NCLS: 435/368.000; 435/375.000
IC [7]
ICM: A01N001-00
ICS: A01N001-02; A01N037-18; A61K038-00; A61K038-16; G01N033-53;
G01N033-537; G01N033-543; A61K031-70; A01N043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 281 OF 312 USPATFULL on STN
AN 2001:229649 USPATFULL
TI Methods for increasing ApoE levels for the treatment of
neurodegenerative disease
IN Poirier, Judes, Boisbriand, Canada
PI US 2001051602 A1 20011213

RLI Continuation of Ser. No. US 1998-160462, filed on 24 Sep 1998, GRANTED,
Pat. No. US 6274603
PRAI US 1997-59908P 19970924 (60)
DT Utility
FS APPLICATION
LN.CNT 1714
INCL INCLM: 514/002.000
INCLS: 514/031.000; 514/725.000; 435/006.000; 435/007.200
NCL NCLM: 514/002.000
NCLS: 514/031.000; 514/725.000; 435/006.000; 435/007.200
IC [7]
ICM: A01N037-18
ICS: A01N043-04; A61K031-07; C12Q001-68; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 282 OF 312 USPATFULL on STN
AN 2001:211923 USPATFULL
TI Method for administering a cytokine to the central nervous system and
the lymphatic system
IN Frey, William H., II, North Oaks, MN, United States
PA Chiron Corporation (U.S. corporation)
PI US 2001043915 A1 20011122
AI US 2000-733168 A1 20001208 (9)
PRAI US 1999-200708P 19991209 (60)
DT Utility
FS APPLICATION
LN.CNT 2997
INCL INCLM: 424/085.500
INCLS: 424/085.100; 424/043.000
NCL NCLM: 424/085.500
NCLS: 424/085.100; 424/043.000
IC [7]
ICM: A61K038-21
ICS: A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 283 OF 312 USPATFULL on STN
AN 2001:105021 USPATFULL
TI COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE
IN GRAINGER, DAVID J., CAMBRIDGE, Great Britain
TATALICK, LAUREN MARIE, REDMOND, WA, United States
PI US 2001006640 A1 20010705
AI US 1997-927939 A1 19970911 (8)
DT Utility
FS APPLICATION
LN.CNT 4174
INCL INCLM: 424/198.100
INCLS: 514/044.000; 514/025.000; 514/013.000; 536/023.500; 530/330.000
NCL NCLM: 424/198.100
NCLS: 514/044.000; 514/025.000; 514/013.000; 536/023.500; 530/330.000
IC [7]
ICM: A61K038-00
ICS: C07H021-04; A61K031-70; A01N043-04; A61K039-00; C07K005-00;
C07K007-00; C07K016-00; C07K017-00; A61K038-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 284 OF 312 USPATFULL on STN
AN 2001:191160 USPATFULL
TI Method of preventing neuronal death
IN Newcomb, Robert, Palo Alto, CA, United States
PA Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
corporation)
PI US 6310093 B1 20011030
AI US 1998-141881 19980827 (9)
PRAI US 1997-57220P 19970829 (60)
DT Utility
FS GRANTED
LN.CNT 1749
INCL INCLM: 514/496.000
INCLS: 514/492.000; 514/561.000
NCL NCLM: 514/496.000
NCLS: 514/492.000; 514/561.000
IC [7]
ICM: A61K031-195
ICS: A01N055-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 285 OF 312 USPATFULL on STN
AN 2001:163016 USPATFULL
TI Use of multipotent neural stem cells and their progeny for the screening
of drugs and other biological agents
IN Weiss, Samuel, Calgary, Canada
Reynolds, Brent, Calgary, Canada
Hammang, Joseph P., Barrington, RI, United States
Baetge, E. Edward, Barrington, RI, United States
PA Neurospheres Holdings, Ltd., Alberta, Canada (non-U.S. corporation)
PI US 6294346 B1 20010925
AI US 1995-484406 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995,
now abandoned, said Ser. No. US 484406 And Ser. No. US 1995-376062,
filed on 20 Jan 1995, now abandoned, said Ser. No. US 484406 And Ser.
No. US 1994-359945, filed on 20 Dec 1994, now abandoned, said Ser. No.
US 484406 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
abandoned, said Ser. No. US 484406 And Ser. No. US 1994-311099, filed
on 23 Sep 1994, now abandoned, said Ser. No. US 484406 And Ser. No. US
1994-270412, filed on 5 Jul 1994, now abandoned, said Ser. No. US
484406 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned
Continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
now abandoned Continuation of Ser. No. US 1992-961813, filed on 16 Oct
1992, now abandoned Continuation-in-part of Ser. No. US 726812
Continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now
abandoned Continuation-in-part of Ser. No. US 726812 Continuation of
Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned Continuation
of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned
Continuation-in-part of Ser. No. US 726812, said Ser. No. US 338730
Continuation-in-part of Ser. No. US 726812, said Ser. No. US 311099
Continuation-in-part of Ser. No. US 726812, said Ser. No. US 270412
Continuation-in-part of Ser. No. US 726812
DT Utility
FS GRANTED
LN.CNT 4153
INCL INCLM: 435/007.210
INCLS: 435/368.000; 435/377.000; 435/375.000
NCL NCLM: 435/007.210
NCLS: 435/368.000; 435/375.000; 435/377.000
IC [7]
ICM: G01N033-554
ICS: C12N005-00
EXF 435/7.21; 435/368; 435/378; 435/377; 435/375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 286 OF 312 USPATFULL on STN
AN 2001:147746 USPATFULL
TI Splice variants of the heregulin gene, nARIA and uses thereof
IN Role, Lorna W., New York, NY, United States
PA The Trustees of Columbia University in the City of New York, New York,
NY, United States (U.S. corporation)
PI US 6284535 B1 20010904
AI US 1996-697954 19960904 (8)
PRAI US 1995-3380P 19950907 (60)
DT Utility
FS GRANTED
LN.CNT 1833
INCL INCLM: 435/325.000
INCLS: 435/069.100; 435/320.100; 435/252.300; 536/023.100; 530/350.000
NCL NCLM: 435/325.000
NCLS: 435/069.100; 435/252.300; 435/320.100; 530/350.000; 536/023.100
IC [7]
ICM: C12N005-00
ICS: C12P021-06; C07H017-00; C07K014-00
EXF 330/350; 514/2; 435/69.1; 435/326.1; 435/325; 435/252.3; 536/23.1;
530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 287 OF 312 USPATFULL on STN
AN 2001:131318 USPATFULL
TI Methods for increasing ApoE levels for the treatment of
neurodegenerative disease
IN Poirier, Judes, Boisbriand, Canada
PA McGill University, Montreal, Canada (non-U.S. corporation)

AI US 1998-160462 19980924 (9)
PRAI US 1997-59908P 19970924 (60)
DT Utility
FS GRANTED
LN.CNT 1669
INCL INCLM: 514/330.000
INCLS: 514/451.000
NCL NCLM: 514/330.000
NCLS: 514/451.000
IC [7]
ICM: A61K031-445
ICS: A61K031-35
EXF 514/330; 514/451; 548/429
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 288 OF 312 USPATFULL on STN
AN 2001:22202 USPATFULL
TI Composition and methods for treatment of neurological disorders and neurodegenerative diseases
IN Lee, Robert K. K., Boston, MA, United States
Wurtman, Richard J., Boston, MA, United States
PA The Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6187756 B1 20010213
AI US 2000-493228 20000128 (9)
RLI Division of Ser. No. US 1997-924505, filed on 5 Sep 1997, now patented, Pat. No. US 6043224
PRAI US 1996-25507P 19960905 (60)
US 1997-33765P 19970115 (60)
DT Utility
FS Granted
LN.CNT 1695
INCL INCLM: 514/026.000
INCLS: 514/169.000; 514/182.000; 514/573.000; 514/878.000; 514/879.000
NCL NCLM: 514/026.000
NCLS: 514/169.000; 514/182.000; 514/573.000; 514/878.000; 514/879.000
IC [7]
ICM: A61K031-70
EXF 514/26; 514/182; 514/169; 514/573; 514/879; 514/878
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 289 OF 312 USPATFULL on STN
AN 2001:18494 USPATFULL
TI Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IN Lee, Robert K. K., 3 Union Park, Apt#1, Boston, MA, United States 02118
Wurtman, Richard J., Heritage on the Garden, 300 Boylston St., #1205, Boston, MA, United States 02116
PI US 6184248 B1 20010206
AI US 1999-435470 19991108 (9)
RLI Continuation-in-part of Ser. No. US 1997-924505, filed on 5 Sep 1997, now patented, Pat. No. US 6043224
PRAI US 1996-25507P 19960905 (60)
US 1997-33765P 19970115 (60)
DT Utility
FS Granted
LN.CNT 1830
INCL INCLM: 514/474.000
INCLS: 514/733.000; 514/734.000
NCL NCLM: 514/474.000
NCLS: 514/733.000; 514/734.000
IC [7]
ICM: A61K031-34
EXF 514/733; 514/734; 514/474
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 290 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 38
AN 2000:176025 CAPLUS
DN 132:191418
TI ***Tau*** factor as a marker for detection of early central nervous system damage
IN Hulstaert, Frank; Vanmechelen, Eugeen; Vanderstichele, Hugo
PA Innogenetics N.V., Belg.
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2

LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000014546	A1	20000316	WO 1999-EP6592	19990907
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2340433	AA	20000316	CA 1999-2340433	19990907
	AU 9959746	A1	20000327	AU 1999-59746	19990907
	AU 772151	B2	20040408		
	BR 9913112	A	20010508	BR 1999-13112	19990907
	EP 1112500	A1	20010704	EP 1999-968716	19990907
	EP 1112500	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002524740	T2	20020806	JP 2000-569239	19990907
	AT 277353	E	20041015	AT 1999-968716	19990907
PRAI	EP 1998-870190	A	19980908		
	WO 1999-EP6592	W	19990907		
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 291 OF 312 USPATFULL on STN
AN 2000:167749 USPATFULL
TI Method and compositions for treating and diagnosing tumors using adenosine receptor activated cells
IN Neely, Constance, Raleigh, NC, United States
PA Link Technology Incorporated, Raleigh, NC, United States (U.S. corporation)
PI US 6159701 20001212
AI US 1996-748559 19961108 (8)
DT Utility
FS Granted
LN.CNT 872
INCL INCLM: 435/007.230
INCLS: 435/007.100; 435/372.000; 530/300.000; 530/350.000
NCL NCLM: 435/007.230
NCLS: 435/007.100; 435/372.000; 530/300.000; 530/350.000
IC [7]
ICM: G01H033-53
EXF 435/372; 435/7.1; 435/7.23; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 292 OF 312 USPATFULL on STN
AN 2000:111069 USPATFULL
TI Non-invasive device and method for quantitative determination of oxidants and/or antioxidants in the skin
IN Kohen, Ron, Jerusalem, Israel
Fanberstein, David, Jerusalem, Israel
Tirosh, Oren, Holon, Israel
PA Yissum Research Development Company of the Hebrew University of Jerusalem, Israel (non-U.S. corporation)
PI US 6108570 20000822
WO 9613193 19960509
AI US 1997-817222 19970623 (8)
WO 1995-US13550 19951010
19970623 PCT 371 date
19970623 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 572
INCL INCLM: 600/345.000
INCLS: 600/354.000
NCL NCLM: 600/345.000
NCLS: 600/354.000
IC [7]
ICM: A61B005-05
EXF 600/345-348; 600/354; 600/363; 600/357; 600/365; 600/382; 600/309;

L5 ANSWER 293 OF 312 USPATFULL on STN
 AN 2000:70818 USPATFULL
 TI In vivo genetic modification of growth factor-responsive neural precursor cells
 IN Weiss, Samuel, Alberta, Canada
 Reynolds, Brent, Alberta, Canada
 Hammang, Joseph P., Barrington, RI, United States
 Baetge, E. Edward, Barrington, RI, United States
 PA NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
 PI US 6071889 20000606
 AI US 1995-479795 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned And a continuation-in-part of Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned And a continuation-in-part of Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned And a continuation-in-part of Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned And a continuation-in-part of Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned And a continuation-in-part of Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-270412, filed on 5 Jul 1994, now abandoned which is a continuation of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 4261
 INCL INCLM: 514/044.000
 INCLS: 424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
 NCL NCLM: 514/044.000
 NCLS: 424/093.100; 424/093.200; 424/093.210; 435/440.000; 435/455.000
 IC [7]
 ICM: A61K035-00
 ICS: A61K048-00
 EXF 514/44; 514/2; 536/23.1; 424/93.1; 424/93.2; 424/93.21; 435/455; 435/440
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 294 OF 312 USPATFULL on STN
 AN 2000:41226 USPATFULL
 TI Apolipoprotein E transgenic mice and assay methods
 IN Mucke, Lennart, Foster City, CA, United States
 Raber, Jacob, San Francisco, CA, United States
 Buttini, Manuel, Albany, CA, United States
 Mahley, Robert W., San Francisco, CA, United States
 Pitas, Robert E., Orinda, CA, United States
 PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
 PI US 6046381 20000404
 AI US 1998-70670 19980430 (9)
 DT Utility
 FS Granted
 LN.CNT 1700
 INCL INCLM: 800/018.000
 INCLS: 800/003.000; 800/013.000; 800/014.000; 435/325.000; 435/455.000
 NCL NCLM: 800/018.000
 NCLS: 435/325.000; 435/455.000; 800/003.000; 800/013.000; 800/014.000
 IC [7]

ICS: C12N015-00; C12N015-85
EXF 435/325; 435/455; 800/3; 800/13; 800/14; 800/18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 295 OF 312 USPATFULL on STN
AN 2000:37780 USPATFULL
TI Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IN Lee, Robert K. K., Boston, MA, United States
Wurtman, Richard J., Boston, MA, United States
PA The Massachusetts Institute of Technology, Cambridge, MA, United States (U.S. corporation)
PI US 6043224 20000328
AI US 1997-924505 19970905 (8)
PRAI US 1996-25507P 19960905 (60)
US 1997-33765P 19970115 (60)
DT Utility
FS Granted
LN.CNT 1651
INCL INCLM: 514/026.000
INCLS: 514/182.000; 514/169.000; 514/573.000
NCL NCLM: 514/026.000
NCLS: 514/169.000; 514/182.000; 514/573.000
IC [7]
ICM: A61K003-705
EXF 514/26; 514/182; 514/169; 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 296 OF 312 USPATFULL on STN
AN 2000:35495 USPATFULL
TI Drug delivery system and method
IN Walker, Jeffrey P., San Diego, CA, United States
Bernard, Robert M., Rancho Santa Fe, CA, United States
PA Ichor Medical Systems Inc., San Diego, CA, United States (U.S. corporation)
PI US 6041252 20000321
AI US 1995-476714 19950607 (8)
DT Utility
FS Granted
LN.CNT 2555
INCL INCLM: 604/020.000
INCLS: 604/021.000; 435/173.600; 435/285.200; 607/072.000
NCL NCLM: 604/020.000
NCLS: 435/173.600; 435/285.200; 604/021.000; 607/072.000
IC [7]
ICM: A61N001-30
EXF 604/20-21; 604/49; 935/52-53; 435/173.6; 435/285.2; 607/72

L5 ANSWER 297 OF 312 USPATFULL on STN
AN 2000:12602 USPATFULL
TI S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
IN Schwartz, Dennis E., Redmond, WA, United States
Vermeulen, Nicolaas M. J., Woodinville, WA, United States
O'Day, Christine L., Mountlake Terrace, WA, United States
PA Oridigm Corporation, Seattle, WA, United States (U.S. corporation)
PI US 6020139 20000201
AI US 1995-428963 19950425 (8)
DT Utility
FS Granted
LN.CNT 4367
INCL INCLM: 435/007.100
INCLS: 435/007.100; 435/192.000; 514/556.000
NCL NCLM: 435/007.100
NCLS: 435/192.000; 514/556.000
IC [6]
ICM: G01N033-53
ICS: C12N009-08; A01N037-30
EXF 435/7.1; 435/192; 514/556
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 298 OF 312 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 39
AN 2001:132124 BIOSIS
DN PREV200100132124

evaluated after acute ischemic stroke.

AU Hesse, Camilla [Reprint author]; Rosengren, Lars; Vanmechelen, Eugene;
 CS Vanderstichele, Hugo; Jensen, Christer; Davidsson, Pia; Blennow, Kaj
 Department of Clinical Neuroscience, Unit of Neurochemistry, University of
 Goteborg, Sahlgren's University Hospital/Molndal, S-431 80, Molndal,
 Sweden
 camilla.hesse@neuro.gu.se

SO Journal of Alzheimer's Disease, (November, 2000) Vol. 2, No. 3-4, pp.
 199-206. print.
 ISSN: 1387-2877.

DT Article
 LA English
 ED Entered STN: 14 Mar 2001
 Last Updated on STN: 15 Feb 2002

L5 ANSWER 299 OF 312 USPATFULL on STN
 AN 1999:141292 USPATFULL
 TI Growth factor-induced proliferation of neural precursor cells in vivo
 IN Weiss, Samuel, Alberta, Canada
 Reynolds, Brent, Alberta, Canada
 PA NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
 PI US 5980885 19991109
 AI US 1995-486307 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
 now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now
 abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now
 abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now
 abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now
 abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now
 abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
 abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
 filed on 8 Jul 1991, now abandoned, said Ser. No. US 270412 which is a
 continuation of Ser. No. US 726812, said Ser. No. US 385404 which is a
 continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now
 abandoned which is a continuation-in-part of Ser. No. US 726812, said
 Ser. No. US 359945 which is a continuation of Ser. No. US 1994-221655,
 filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No.
 US 1992-967622, filed on 28 Oct 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 726812, said Ser. No. US 376062
 which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993,
 now abandoned which is a continuation-in-part of Ser. No. US 726812,
 said Ser. No. US 149508 which is a continuation-in-part of Ser. No. US
 726812, said Ser. No. US 311099 which is a continuation-in-part of Ser.
 No. US 726812

DT Utility
 FS Granted
 LN.CNT 4215
 INCL INCLM: 424/093.210
 INCLS: 424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000;
 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000;
 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000

NCL NCLM: 424/093.210
 NCLS: 424/093.100; 424/093.200; 435/325.000; 435/360.000; 435/366.000;
 435/368.000; 435/377.000; 435/383.000; 435/384.000; 435/440.000;
 435/455.000; 435/456.000; 435/457.000; 514/002.000; 514/044.000

IC [6]
 ICM: A01N063-00
 ICS: A01N043-04; C12N005-00; C12N005-08

EXF 435/240.2; 435/325; 435/360; 435/366; 435/368; 435/377; 435/383;
 435/455; 435/456; 435/457; 514/2; 514/44; 424/93.1; 424/93.2; 424/93.21

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 300 OF 312 USPATFULL on STN
 AN 1998:159764 USPATFULL
 TI In vitro growth and proliferation of multipotent neural stem cells and
 their progeny
 IN Weiss, Samuel, Alberta, Canada
 Reynolds, Brent, Alberta, Canada
 Hammang, Joseph P., Barrington, RI, United States
 Baetge, E. Edward, Barrington, RI, United States
 PA Neurospheres, Ltd., Canada (non-U.S. corporation)
 PI US 5851832 19981222
 AI US 1995-486648 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
 now abandoned which is a continuation of Ser. No. US 1991-726812, filed

1995-385404, filed on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US 1992-961813, filed on 16 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-359945, filed on 20 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1992-967622, filed on 28 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991, now abandoned And Ser. No. US 1995-376062, filed on 20 Jan 1995, now abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1993-149508, filed on 9 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-311099, filed on 23 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812 And Ser. No. US 1994-338730, filed on 14 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 726812

DT Utility
FS Granted
LN.CNT 4487
INCL INCLM: 435/368.000
INCLS: 435/325.000; 435/366.000; 435/383.000; 435/384.000
NCL NCLM: 435/368.000
NCLS: 435/325.000; 435/366.000; 435/377.000; 435/383.000; 435/384.000
IC [6]
ICM: C12N005-06
ICS: C12N005-08; C12N005-02
EXF 435/240.2; 435/325; 435/366; 435/368; 435/377; 435/383; 435/384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 301 OF 312 USPATFULL on STN
AN 1998:135055 USPATFULL
TI Cytochalasins useful in providing protection against nerve cell injury associated with neurodegenerative disorders
IN Mattson, Mark P., Lexington, KY, United States
PA University of Kentucky Research Foundation, Lexington, KY, United States (U.S. corporation)
PI US 5830910 19981103
AI US 1995-546745 19951023 (8)
DT Utility
FS Granted
LN.CNT 1655
INCL INCLM: 514/411.000
NCL NCLM: 514/411.000
IC [6]
ICM: A61K031-40
EXF 514/411
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 302 OF 312 USPATFULL on STN
AN 1998:124583 USPATFULL
TI H.sub.3 -receptor agonists as therapeutic agents
IN Theoharides, Theoharis C., 14 Parkman St., #2, Brookline, MA, United States 02146
PI US 5821259 19981013
AI US 1995-524023 19950906 (8)
RLI Continuation of Ser. No. US 1994-284041, filed on 1 Aug 1994, now abandoned which is a continuation of Ser. No. US 1993-37697, filed on 24 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-790343, filed on 12 Nov 1991, now abandoned
DT Utility
FS Granted
LN.CNT 572
INCL INCLM: 514/396.000
INCLS: 514/397.000; 514/400.000
NCL NCLM: 514/396.000
NCLS: 514/397.000; 514/400.000
IC [6]
ICM: A61K031-415
EXF 514/396; 514/397; 514/400
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 303 OF 312 USPATFULL on STN
AN 1998:51459 USPATFULL
TI In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny

Reynolds, Brent, Alberta, Canada
 Hammang, Joseph P., Barrington, RI, United States
 Baetge, E. Edward, Barrington, RI, United States
 PA NeuroSpheres Holdings Ltd., Calgary, Canada (non-U.S. corporation)
 PI US 5750376 19980512
 AI US 1995-483122 19950607 (8)
 RLI Continuation-in-part of Ser. No. US 1994-270412, filed on 5 Jul 1994,
 now abandoned Ser. No. Ser. No. US 1995-385404, filed on 7 Feb 1995, now
 abandoned Ser. No. Ser. No. US 1994-359945, filed on 20 Dec 1994, now
 abandoned Ser. No. Ser. No. US 1995-376062, filed on 20 Jan 1995, now
 abandoned Ser. No. Ser. No. US 1993-149508, filed on 9 Nov 1993, now
 abandoned Ser. No. Ser. No. US 1994-311099, filed on 23 Sep 1994, now
 abandoned And Ser. No. US 1994-338730, filed on 14 Nov 1994, now
 abandoned which is a continuation-in-part of Ser. No. US 1991-726812,
 filed on 8 Jul 1991, now abandoned, said Ser. No. US 1995-385404, filed
 on 7 Feb 1995, now abandoned which is a continuation of Ser. No. US
 1992-961813, filed on 16 Oct 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
 now abandoned, said Ser. No. US 1994-359345, filed on 20 Dec 1994, now
 abandoned which is a continuation of Ser. No. US 1994-221655, filed on 1
 Apr 1994, now abandoned which is a continuation of Ser. No. US
 1992-967622, filed on 28 Oct 1992, now abandoned which is a
 continuation-in-part of Ser. No. US 1991-726812, filed on 8 Jul 1991,
 now abandoned, said Ser. No. US 1995-376062, filed on 20 Jan 1995, now
 abandoned which is a continuation of Ser. No. US 1993-10829, filed on 29
 Jan 1993, now abandoned which is a continuation-in-part of Ser. No. US
 1991-726812, filed on 8 Jul 1991, now abandoned, said Ser. No. US
 1994-270412, filed on 5 Jul 1994, now abandoned Ser. No. Ser. No. US
 1993-149508, filed on 9 Nov 1993, now abandoned And Ser. No. US
 1994-311099, filed on 23 Sep 1994, now abandoned, each Ser. No. US -
 which is a continuation-in-part of Ser. No. US 1991-726812, filed on 8
 Jul 1991, now abandoned
 DT Utility
 FS Granted
 LN.CNT 4339
 INCL INCLM: 435/069.520
 INCLS: 435/069.100; 435/172.300; 435/325.000; 435/368.000; 435/377.000;
 435/384.000; 435/392.000; 435/395.000
 NCL NCLM: 435/069.520
 NCLS: 435/069.100; 435/325.000; 435/368.000; 435/377.000; 435/384.000;
 435/392.000; 435/395.000; 435/455.000; 435/456.000; 435/458.000;
 435/461.000
 IC [6]
 ICM: C12N005-00
 ICS: C12N005-08; C12N005-10; C12P001-00
 EXF 435/240.2; 435/172.3; 435/69.1; 435/69.52; 435/325; 435/368; 435/377;
 435/384; 435/392; 435/395
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 304 OF 312 USPATFULL on STN
 AN 1998:30992 USPATFULL
 TI Method for treating Alzheimer's disease using glial line-derived
 neurotrophic factor (GDNF) protein product
 IN Williams, Lawrence R., Thousand Oaks, CA, United States
 PA Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
 PI US 5731284 19980324
 AI US 1995-535682 19950928 (8)
 DT Utility
 FS Granted
 LN.CNT 1677
 INCL INCLM: 514/008.000
 INCLS: 514/021.000
 NCL NCLM: 514/008.000
 NCLS: 514/021.000
 IC [6]
 ICM: A61F002-00
 ICS: A61K047-00; A61K031-685; A61K038-00
 EXF 514/8; 514/21
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5 ANSWER 305 OF 312 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 1998:230499 SCISEARCH
 GA The Genuine Article (R) Number: ZC115
 TI Does glutamate mediate brain damage in acute encephalitis?

CS UNIV HELSINKI, CENT HOSP, DEPT NEUROL, HAARTMANINKATU 4, FIN-00290
HELSINKI, FINLAND (Reprint); UNIV HELSINKI, CENT HOSP, DEPT CLIN CHEM,
FIN-00290 HELSINKI, FINLAND

CYA FINLAND

SO NEUROREPORT, (9 MAR 1998) Vol. 9, No. 4, pp. 577-581.
Publisher: RAPID SCIENCE PUBLISHERS, 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1
8NH.
ISSN: 0959-4965.

DT Article; Journal

FS LIFE

LA English

REC Reference Count: 34
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 306 OF 312 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN

AN 1998012830 EMBASE

TI Diagnosis of Alzheimer's disease with ***cerebrospinal***
fluid ***tau*** protein and aspartate aminotransferase
(multiple letters) [11].

AU Esmonde T.; Riemenschneider M.

CS T. Esmonde, Directorate of Neurosciences, Royal Victoria Hospital, Belfast
BT12 6BA, United Kingdom

SO Lancet, (3 Jan 1998) 351/9095 (63-64).
Refs: 0
ISSN: 0140-6736 CODEN: LANCAO

CY United Kingdom

DT Journal; Letter

FS 008 Neurology and Neurosurgery
032 Psychiatry

LA English

L5 ANSWER 307 OF 312 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 96:606451 PROMT

TITLE: Update and outlook in Alzheimer's disease

SOURCE: Drug Topics, (4 Nov 1996) pp. 118.
ISSN: 0012-6616.

LANGUAGE: English

WORD COUNT: 4677
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L5 ANSWER 308 OF 312 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN DUPLICATE 40

AN 96269862 EMBASE

DN 1996269862

TI High temporal resolution diffusion MRI of global cerebral ***ischemia***
and reperfusion.

AU Pierpaoli C.; Alger J.R.; Righini A.; Mattiello J.; Dickerson R.; Des Pres
D.; Barnett A.; Di Chiro G.

CS NIH, Bldg. 10, 9000 Rockville Pike, Bethesda, MD 20892, United States

SO Journal of Cerebral Blood Flow and Metabolism, (1996) 16/5 (892-905).
ISSN: 0271-678X CODEN: JCBMDN

CY United States

DT Journal; Article

FS 008 Neurology and Neurosurgery

LA English

SL English

L5 ANSWER 309 OF 312 USPATFULL on STN

AN 95:75952 USPATFULL

TI Method of treatment of neurodegeneration with calpain inhibitors

IN Bartus, Raymond T., Laguna Hills, CA, United States
Eveleth, David D., Irvine, CA, United States
Power, James C., Atlanta, GA, United States

PA Cortex Pharmaceuticals, Irvine, CA, United States (U.S. corporation)
Georgia Tech Research Corporation (GTRC), Atlanta, GA, United States
(U.S. corporation)

PI US 5444042 19950822

AI US 1994-207881 19940307 (8)

RLI Continuation of Ser. No. US 1991-816120, filed on 27 Dec 1991, now
abandoned which is a continuation-in-part of Ser. No. US 1991-682925,
filed on 9 Apr 1991, now abandoned which is a continuation of Ser. No.
US 1990-635952, filed on 28 Dec 1990

DT Utility

LN.CNT 4963
 INCL INCLM: 514/002.000
 INCLS: 514/016.000; 514/017.000; 514/018.000; 514/457.000; 435/023.000;
 435/184.000
 NCL NCLM: 514/002.000
 NCLS: 435/023.000; 435/184.000; 514/016.000; 514/017.000; 514/018.000;
 514/457.000
 IC [6]
 ICM: A61K037-00
 ICS: C12Q001-37; C12N009-99
 EXF 514/2; 514/16; 514/17; 514/18; 514/457; 514/460; 435/23; 435/184;
 435/219
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 310 OF 312 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 41
 AN 1995:77751 CAPLUS
 DN 122:4959
 TI Immunoassay for human ***Tau*** protein detection and central nerve
 cytopathy diagnosis
 IN Hosoda, Kenji; Eguchi, Hiroshi; Nakamoto, Tadakatsu; Kobayashi, Shinji;
 Kubota, Takaharu; Mori, Hiroshi
 PA Teijin Ltd., Japan
 SO PCT Int. Appl., 36 pp.
 CODEN: PIXXD2

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418560	A1	19940818	WO 1994-JP196	19940210
	W: AU, CA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 06239899	A2	19940830	JP 1993-46133	19930212
	AU 9460104	A1	19940829	AU 1994-60104	19940210
PRAI	JP 1993-46133		19930212		
	WO 1994-JP196		19940210		

L5 ANSWER 311 OF 312 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN DUPLICATE 42

AN 1986:173902 BIOSIS
 DN PREV198681084318; BA81:84318
 TI THE EFFECT OF PERINATAL ***ANOXIA*** ON AMINO-ACID METABOLISM IN THE
 DEVELOPING BRAIN PART II. THE EFFECT OF PERINATAL ***ANOXIA*** ON THE
 FREE AMINO-ACID PATTERNS IN ***CEREBROSPINAL*** ***FLUID*** OF
 INFANTS AND CHILDREN.
 AU KANEKO K [Reprint author]
 CS DEP OF PEDIATRICS, JUNTENDO UNIV, SCH OF MED, URAYASU HOSP, 2-1-1 TOMIOKA,
 URAYASU-SHI, CHIBA 272-01, JAPAN
 SO Brain and Development, (1985) Vol. 7, No. 4, pp. 400-407.
 ISSN: 0387-7604.
 DT Article
 FS BA
 LA ENGLISH
 ED Entered STN: 26 Apr 1986
 Last Updated on STN: 26 Apr 1986

L5 ANSWER 312 OF 312 FEDRIP COPYRIGHT 2004 NTIS on STN
 AN 2004:150685 FEDRIP
 NR CRISP 1Z01AG000139-04
 TI ***Cerebrospinal*** ***Fluid*** Markers Of Aging And Brain Disease
 SF Principal Investigator: RAPOPORT, STANLEY I
 CSS Supported By: NATIONAL INSTITUTE ON AGING
 FYR 2003
 FU Not Applicable
 FS National Institutes of Health
 STN INTERNATIONAL LOGOFF AT 17:33:57 ON 16 NOV 2004